{"name":"Biotech catalyst calendar","url":"https://julienwillard.com/calendar","license":"https://creativecommons.org/licenses/by/4.0/","attribution":"Julien Willard, julienwillard.com/calendar","methodology":"https://julienwillard.com/calendar/methodology","compiled":"2026-08-12T01:32:26.919Z","count":1312,"events":[{"id":"50cec356-20d2-40ed-a877-cc997031a24a","lane":"fda","event_type":"novel-approval","date":"2026-07-14","date_precision":"day","confidence":"confirmed","company":null,"ticker":null,"asset":"Revtorpyk (gedatolisib)","indication":"In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting","summary":"FDA approved Revtorpyk (gedatolisib) on 14 July 2026.","as_of":"2026-07-14","source":"novel-approvals","source_ref":"2026:Revtorpyk","source_url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/fda#e-50cec356-20d2-40ed-a877-cc997031a24a"},{"id":"da9dd90e-22b8-49b6-b5e7-4f2e35940c21","lane":"fda","event_type":"novel-approval","date":"2026-07-15","date_precision":"day","confidence":"confirmed","company":null,"ticker":null,"asset":"Lipfendra (enlicitide decanoate)","indication":"To reduce low-density lipoprotein cholesterol","summary":"FDA approved Lipfendra (enlicitide decanoate) on 15 July 2026 to reduce low-density lipoprotein cholesterol.","as_of":"2026-07-15","source":"novel-approvals","source_ref":"2026:Lipfendra","source_url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/fda#e-da9dd90e-22b8-49b6-b5e7-4f2e35940c21"},{"id":"eeab8d2d-afcf-4ada-be62-546024ae013e","lane":"fda","event_type":"approval","date":"2026-07-17","date_precision":"day","confidence":"confirmed","company":null,"ticker":null,"asset":"Lipfendra (enlicitide)","indication":null,"summary":"FDA approved Lipfendra (enlicitide) on 17 July 2026.","as_of":"2026-07-17","source":"fda-press","source_ref":"http://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol","source_url":"http://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/fda#e-eeab8d2d-afcf-4ada-be62-546024ae013e"},{"id":"a5907111-5575-4d6f-a658-0e8cb61d0f52","lane":"fda","event_type":"novel-approval","date":"2026-07-22","date_precision":"day","confidence":"confirmed","company":null,"ticker":null,"asset":"Jideytro (zidesamtinib)","indication":"To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor","summary":"FDA approved Jideytro (zidesamtinib) on 22 July 2026.","as_of":"2026-07-22","source":"novel-approvals","source_ref":"2026:Jideytro","source_url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/fda#e-a5907111-5575-4d6f-a658-0e8cb61d0f52"},{"id":"b9ce71ea-8e34-43de-a126-214844b5e9be","lane":"fda","event_type":"novel-approval","date":"2026-07-24","date_precision":"day","confidence":"confirmed","company":null,"ticker":null,"asset":"Lytenava (bevacizumab-vikg)","indication":"To treat patients with neovascular (wet) age-related macular degeneration","summary":"FDA approved Lytenava (bevacizumab-vikg) on 24 July 2026 to treat patients with neovascular (wet) age-related macular degeneration.","as_of":"2026-07-24","source":"novel-approvals","source_ref":"2026:Lytenava","source_url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/fda#e-b9ce71ea-8e34-43de-a126-214844b5e9be"},{"id":"53d54e75-86aa-4da5-bd6a-4b33867fa2f5","lane":"fda","event_type":"novel-approval","date":"2026-07-24","date_precision":"day","confidence":"confirmed","company":null,"ticker":null,"asset":"Simtriyo (centanafadine)","indication":"To treat attention-deficit hyperactivity disorder","summary":"FDA approved Simtriyo (centanafadine) on 24 July 2026 to treat attention-deficit hyperactivity disorder.","as_of":"2026-07-24","source":"novel-approvals","source_ref":"2026:Simtriyo","source_url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/fda#e-53d54e75-86aa-4da5-bd6a-4b33867fa2f5"},{"id":"1a29df3c-5dee-4eb5-8c2e-474d8af6f941","lane":"fda","event_type":"advisory-committee","date":"2026-07-29","date_precision":"day","confidence":"confirmed","company":"Capricor, Inc.","ticker":null,"asset":"BLA 125842","indication":null,"summary":"An FDA advisory committee meets on 29 July 2026 to review BLA 125842 from Capricor.","as_of":"2026-06-29","source":"federal-register","source_ref":"2026-13096","source_url":"https://www.federalregister.gov/documents/2026/06/29/2026-13096/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establishment-of-a-public","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/fda#e-1a29df3c-5dee-4eb5-8c2e-474d8af6f941"},{"id":"52de27db-fff8-46d3-b979-710dddc68d6f","lane":"fda","event_type":"advisory-committee","date":"2026-07-30","date_precision":"day","confidence":"confirmed","company":"Replimune, Inc.","ticker":null,"asset":"BLA 125827","indication":null,"summary":"An FDA advisory committee meets on 30 July 2026 to review BLA 125827 from Replimune.","as_of":"2026-07-08","source":"federal-register","source_ref":"2026-13810","source_url":"https://www.federalregister.gov/documents/2026/07/08/2026-13810/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establishment-of-a-public","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/fda#e-52de27db-fff8-46d3-b979-710dddc68d6f"},{"id":"c9ad4dcd-6920-4c83-892c-deac73484718","lane":"fda","event_type":"novel-approval","date":"2026-08-05","date_precision":"day","confidence":"confirmed","company":null,"ticker":null,"asset":"Orzeyful (oveporexton)","indication":"To treat narcolepsy type 1","summary":"FDA approved Orzeyful (oveporexton) on 5 August 2026 to treat narcolepsy type 1.","as_of":"2026-08-05","source":"novel-approvals","source_ref":"2026:Orzeyful","source_url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/fda#e-c9ad4dcd-6920-4c83-892c-deac73484718"},{"id":"b785043f-f6a6-47a4-90f7-494937e9a70e","lane":"fda","event_type":"accelerated-approval","date":"2026-08-06","date_precision":"day","confidence":"confirmed","company":null,"ticker":null,"asset":"Tudriqev (vusolimogene oderparepvec-wtpg)","indication":null,"summary":"FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) on 6 August 2026.","as_of":"2026-08-06","source":"fda-press","source_ref":"http://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma","source_url":"http://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/fda#e-b785043f-f6a6-47a4-90f7-494937e9a70e"},{"id":"1f2ff79d-6dc9-4d07-8c11-aa21e2a6061b","lane":"clinical","event_type":"primary-completion","date":"2026-08-12","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Enlicitide","indication":"Hyperlipidemia","summary":"As of 5 August 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in hyperlipidemia, on 12 August 2026.","as_of":"2026-08-05","source":"clinicaltrials","source_ref":"NCT07216482","source_url":"https://clinicaltrials.gov/study/NCT07216482","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1f2ff79d-6dc9-4d07-8c11-aa21e2a6061b"},{"id":"f5a34422-5d48-4c3f-b43d-78eed15182e6","lane":"clinical","event_type":"primary-completion","date":"2026-08-12","date_precision":"day","confidence":"estimated","company":"USWM CT, LLC","ticker":null,"asset":"Autologous genetically modified ADP-A2M4CD8 cells","indication":"Ovarian Cancer","summary":"As of 25 February 2026, USWM CT estimated primary completion of a Phase 2 trial in Ovarian Cancer, on 12 August 2026.","as_of":"2026-02-25","source":"clinicaltrials","source_ref":"NCT05601752","source_url":"https://clinicaltrials.gov/study/NCT05601752","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f5a34422-5d48-4c3f-b43d-78eed15182e6"},{"id":"dd73ce9d-509f-4c00-adc8-073a2ff6643d","lane":"clinical","event_type":"primary-completion","date":"2026-08-13","date_precision":"day","confidence":"estimated","company":"Hinova Pharmaceuticals Inc.","ticker":null,"asset":"HP515 10 mg Tablet","indication":"NAFLD (Non-alcoholic Fatty Liver Disease)","summary":"As of 29 December 2025, Hinova Pharmaceuticals estimated primary completion of a Phase 2 trial in NAFLD (Non-alcoholic Fatty Liver Disease), on 13 August 2026.","as_of":"2025-12-29","source":"clinicaltrials","source_ref":"NCT07308548","source_url":"https://clinicaltrials.gov/study/NCT07308548","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dd73ce9d-509f-4c00-adc8-073a2ff6643d"},{"id":"87bbcfdf-2050-43da-8769-a09f7b31db9a","lane":"clinical","event_type":"primary-completion","date":"2026-08-13","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Crovalimab","indication":"Paroxysmal Hemoglobinuria, Nocturnal","summary":"As of 5 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Paroxysmal Hemoglobinuria, Nocturnal, on 13 August 2026.","as_of":"2026-08-05","source":"clinicaltrials","source_ref":"NCT03157635","source_url":"https://clinicaltrials.gov/study/NCT03157635","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-87bbcfdf-2050-43da-8769-a09f7b31db9a"},{"id":"5095bad2-bd7f-4dcb-ba92-285ec5af0ca8","lane":"clinical","event_type":"primary-completion","date":"2026-08-13","date_precision":"day","confidence":"estimated","company":"Zealand Pharma","ticker":null,"asset":"Petrelintide","indication":"Overweight","summary":"As of 15 January 2026, Zealand Pharma estimated primary completion of a Phase 2 trial in overweight, on 13 August 2026.","as_of":"2026-01-15","source":"clinicaltrials","source_ref":"NCT06926842","source_url":"https://clinicaltrials.gov/study/NCT06926842","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5095bad2-bd7f-4dcb-ba92-285ec5af0ca8"},{"id":"3af7afd9-0c65-4edd-85ef-209170d94002","lane":"clinical","event_type":"primary-completion","date":"2026-08-13","date_precision":"day","confidence":"estimated","company":"pH-D Feminine Health LLC","ticker":null,"asset":"Boric acid","indication":"Vulvovaginal Candidiases","summary":"As of 3 August 2026, pH-D Feminine Health estimated primary completion of a Phase 3 trial in Vulvovaginal Candidiases, on 13 August 2026.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT07109869","source_url":"https://clinicaltrials.gov/study/NCT07109869","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3af7afd9-0c65-4edd-85ef-209170d94002"},{"id":"76656d53-61e7-4d7b-9b8d-191dfc38e1da","lane":"clinical","event_type":"primary-completion","date":"2026-08-14","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Nexium 20mg","indication":"Erosive Esophagitis","summary":"As of 27 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Erosive Esophagitis, on 14 August 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT05267613","source_url":"https://clinicaltrials.gov/study/NCT05267613","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-76656d53-61e7-4d7b-9b8d-191dfc38e1da"},{"id":"91c9e75f-44a9-4b68-a167-9e0c09854699","lane":"clinical","event_type":"primary-completion","date":"2026-08-15","date_precision":"day","confidence":"estimated","company":"Genzyme, a Sanofi Company","ticker":null,"asset":"Fitusiran","indication":"Hemophilia","summary":"As of 22 June 2026, Genzyme, a Sanofi estimated primary completion of a Phase 3 trial in hemophilia, on 15 August 2026.","as_of":"2026-06-22","source":"clinicaltrials","source_ref":"NCT03974113","source_url":"https://clinicaltrials.gov/study/NCT03974113","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-91c9e75f-44a9-4b68-a167-9e0c09854699"},{"id":"de17bf13-ea18-4bf2-87f0-1f05662bafa8","lane":"clinical","event_type":"primary-completion","date":"2026-08-15","date_precision":"day","confidence":"estimated","company":"PMV Pharmaceuticals, Inc","ticker":null,"asset":"rezatapopt","indication":"Advanced Solid Tumor","summary":"As of 10 August 2026, PMV Pharmaceuticals estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 15 August 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT04585750","source_url":"https://clinicaltrials.gov/study/NCT04585750","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-de17bf13-ea18-4bf2-87f0-1f05662bafa8"},{"id":"363340aa-7abc-4657-9444-51711aee3071","lane":"clinical","event_type":"primary-completion","date":"2026-08-16","date_precision":"day","confidence":"estimated","company":"JenKem Technology Co., Ltd.","ticker":null,"asset":"JK-1201I","indication":"Glioblastoma Multiforme (GBM)","summary":"As of 19 September 2024, JenKem Technology Co. estimated primary completion of a Phase 2 trial in Glioblastoma Multiforme (GBM), on 16 August 2026.","as_of":"2024-09-19","source":"clinicaltrials","source_ref":"NCT06595186","source_url":"https://clinicaltrials.gov/study/NCT06595186","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-363340aa-7abc-4657-9444-51711aee3071"},{"id":"e6909dfc-4e21-4670-8286-7853547d02c8","lane":"clinical","event_type":"primary-completion","date":"2026-08-17","date_precision":"day","confidence":"estimated","company":"BioArctic AB","ticker":null,"asset":"exidavnemab","indication":"Parkinson Disease","summary":"As of 10 March 2026, BioArctic estimated primary completion of a Phase 2 trial in Parkinson Disease, on 17 August 2026.","as_of":"2026-03-10","source":"clinicaltrials","source_ref":"NCT06671938","source_url":"https://clinicaltrials.gov/study/NCT06671938","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e6909dfc-4e21-4670-8286-7853547d02c8"},{"id":"fcb54160-2095-46e8-8cd1-e9aa5f95ad98","lane":"clinical","event_type":"primary-completion","date":"2026-08-17","date_precision":"day","confidence":"estimated","company":"Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA","ticker":null,"asset":"Ensifentrine 3 mg","indication":"Chronic Obstructive Pulmonary Disease","summary":"As of 23 July 2026, Verona Pharma estimated primary completion of a Phase 2 trial in Chronic Obstructive Pulmonary Disease, on 17 August 2026.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT07016412","source_url":"https://clinicaltrials.gov/study/NCT07016412","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fcb54160-2095-46e8-8cd1-e9aa5f95ad98"},{"id":"a2402c2c-2913-426f-a2dc-246eb02ba4f2","lane":"clinical","event_type":"primary-completion","date":"2026-08-18","date_precision":"day","confidence":"estimated","company":"Janssen Sciences Ireland UC","ticker":null,"asset":"Rilpivirine","indication":"Human Immunodeficiency Virus Type 1","summary":"As of 6 July 2026, Janssen Sciences Ireland UC estimated primary completion of a Phase 2 trial in Human Immunodeficiency Virus Type 1, on 18 August 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT02494986","source_url":"https://clinicaltrials.gov/study/NCT02494986","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a2402c2c-2913-426f-a2dc-246eb02ba4f2"},{"id":"85e14e21-740f-4ae5-9873-bc36b0ac2b8b","lane":"clinical","event_type":"primary-completion","date":"2026-08-18","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Raludotatug Deruxtecan (R-DXd)","indication":"Gastrointestinal Cancer","summary":"As of 23 April 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Gastrointestinal Cancer, on 18 August 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT06864169","source_url":"https://clinicaltrials.gov/study/NCT06864169","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-85e14e21-740f-4ae5-9873-bc36b0ac2b8b"},{"id":"7177f994-fd49-43fc-ad3e-2c3e6df04333","lane":"clinical","event_type":"primary-completion","date":"2026-08-18","date_precision":"day","confidence":"estimated","company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","ticker":null,"asset":"FDA018-ADC","indication":"Triple Negative Breast Cancer","summary":"As of 22 January 2026, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Triple Negative Breast Cancer, on 18 August 2026.","as_of":"2026-01-22","source":"clinicaltrials","source_ref":"NCT06519370","source_url":"https://clinicaltrials.gov/study/NCT06519370","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7177f994-fd49-43fc-ad3e-2c3e6df04333"},{"id":"bfde3181-61b3-4064-a2dc-2593030a29c2","lane":"clinical","event_type":"primary-completion","date":"2026-08-19","date_precision":"day","confidence":"estimated","company":"Amgen","ticker":null,"asset":"Dazodalibep","indication":"Sjogren's Syndrome","summary":"As of 16 January 2026, Amgen estimated primary completion of a Phase 3 trial in Sjogren's Syndrome, on 19 August 2026.","as_of":"2026-01-16","source":"clinicaltrials","source_ref":"NCT06104124","source_url":"https://clinicaltrials.gov/study/NCT06104124","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bfde3181-61b3-4064-a2dc-2593030a29c2"},{"id":"5c2353e5-aece-4d05-a220-0161de7d05b8","lane":"clinical","event_type":"primary-completion","date":"2026-08-19","date_precision":"day","confidence":"estimated","company":"ViiV Healthcare","ticker":null,"asset":"CAB LA + RPV LA","indication":"HIV Infections","summary":"As of 29 July 2026, ViiV Healthcare estimated primary completion of a Phase 3 trial in HIV Infections, on 19 August 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT06694805","source_url":"https://clinicaltrials.gov/study/NCT06694805","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5c2353e5-aece-4d05-a220-0161de7d05b8"},{"id":"ba865008-7340-4ee6-aefe-9f5c3433bbf8","lane":"clinical","event_type":"primary-completion","date":"2026-08-20","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD7798","indication":"Crohn's Disease","summary":"As of 1 June 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Crohn's Disease, on 20 August 2026.","as_of":"2026-06-01","source":"clinicaltrials","source_ref":"NCT06681324","source_url":"https://clinicaltrials.gov/study/NCT06681324","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ba865008-7340-4ee6-aefe-9f5c3433bbf8"},{"id":"914fab7e-2574-4549-b257-0c3eebde7e86","lane":"clinical","event_type":"primary-completion","date":"2026-08-20","date_precision":"day","confidence":"estimated","company":"Boehringer Ingelheim","ticker":null,"asset":"Vicadrostat","indication":"Chronic Kidney Disease","summary":"As of 7 August 2026, Boehringer Ingelheim estimated primary completion of a Phase 2 trial in Chronic Kidney Disease, on 20 August 2026.","as_of":"2026-08-07","source":"clinicaltrials","source_ref":"NCT06926660","source_url":"https://clinicaltrials.gov/study/NCT06926660","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-914fab7e-2574-4549-b257-0c3eebde7e86"},{"id":"4ed8317b-e7d0-4293-ab08-4ee2ca8e465d","lane":"clinical","event_type":"primary-completion","date":"2026-08-21","date_precision":"day","confidence":"estimated","company":"EMD Serono Research & Development Institute, Inc.","ticker":null,"asset":"Avelumab","indication":"Solid Tumors","summary":"As of 29 June 2026, EMD Serono Research & Development Institute estimated primary completion of a Phase 3 trial in Solid Tumors, on 21 August 2026.","as_of":"2026-06-29","source":"clinicaltrials","source_ref":"NCT03815643","source_url":"https://clinicaltrials.gov/study/NCT03815643","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4ed8317b-e7d0-4293-ab08-4ee2ca8e465d"},{"id":"24638210-ce49-47f4-9674-9fa6a6dbf0e2","lane":"clinical","event_type":"primary-completion","date":"2026-08-21","date_precision":"day","confidence":"estimated","company":"Longboard Pharmaceuticals","ticker":null,"asset":"LP352","indication":"Dravet Syndrome","summary":"As of 10 August 2026, Longboard Pharmaceuticals estimated primary completion of a Phase 3 trial in Dravet Syndrome, on 21 August 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT06660394","source_url":"https://clinicaltrials.gov/study/NCT06660394","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-24638210-ce49-47f4-9674-9fa6a6dbf0e2"},{"id":"1e068d0e-5490-4b8e-a888-cc82114f1ac7","lane":"clinical","event_type":"primary-completion","date":"2026-08-21","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Pembrolizumab","indication":"Carcinoma, Renal Cell","summary":"As of 30 July 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Carcinoma, Renal Cell, on 21 August 2026.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT04626479","source_url":"https://clinicaltrials.gov/study/NCT04626479","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1e068d0e-5490-4b8e-a888-cc82114f1ac7"},{"id":"e8a3a294-361f-445d-85e2-835ce8a658e2","lane":"clinical","event_type":"primary-completion","date":"2026-08-21","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Pembrolizumab","indication":"Carcinoma, Renal Cell","summary":"As of 30 July 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Carcinoma, Renal Cell, on 21 August 2026.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT04626518","source_url":"https://clinicaltrials.gov/study/NCT04626518","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e8a3a294-361f-445d-85e2-835ce8a658e2"},{"id":"52147299-60e2-4f60-947e-fdb4796d5b77","lane":"clinical","event_type":"primary-completion","date":"2026-08-21","date_precision":"day","confidence":"estimated","company":"NodThera Limited","ticker":null,"asset":"NT-0796","indication":"Obesity","summary":"As of 8 April 2026, NodThera estimated primary completion of a Phase 2 trial in obesity, on 21 August 2026.","as_of":"2026-04-08","source":"clinicaltrials","source_ref":"NCT07220629","source_url":"https://clinicaltrials.gov/study/NCT07220629","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-52147299-60e2-4f60-947e-fdb4796d5b77"},{"id":"7fb6260c-1dd9-4f2c-a9e3-210ca97171cc","lane":"clinical","event_type":"primary-completion","date":"2026-08-21","date_precision":"day","confidence":"estimated","company":"Novo Nordisk A/S","ticker":null,"asset":"CagriSema (Cagrilintide B and Semaglutide I)","indication":"Diabetes Mellitus, Type 2","summary":"As of 5 December 2025, Novo Nordisk estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, on 21 August 2026.","as_of":"2025-12-05","source":"clinicaltrials","source_ref":"NCT06797869","source_url":"https://clinicaltrials.gov/study/NCT06797869","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7fb6260c-1dd9-4f2c-a9e3-210ca97171cc"},{"id":"2e49ab15-afc7-4946-b977-4fb3adcb5c32","lane":"clinical","event_type":"primary-completion","date":"2026-08-22","date_precision":"day","confidence":"estimated","company":"Bazelet Nehushtan LtD.","ticker":null,"asset":"Oral CBD oil enriched with terpenes","indication":"Attention Deficit Hyperactivity Disorder (ADHD)","summary":"As of 23 August 2024, Bazelet Nehushtan estimated primary completion of a Phase 2 trial in Attention Deficit Hyperactivity Disorder (ADHD), on 22 August 2026.","as_of":"2024-08-23","source":"clinicaltrials","source_ref":"NCT06542445","source_url":"https://clinicaltrials.gov/study/NCT06542445","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2e49ab15-afc7-4946-b977-4fb3adcb5c32"},{"id":"6bc3f38f-34a7-4676-8263-dc9cd3725943","lane":"clinical","event_type":"primary-completion","date":"2026-08-22","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"RO7204239","indication":"Obesity","summary":"As of 11 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in obesity, on 22 August 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT06965413","source_url":"https://clinicaltrials.gov/study/NCT06965413","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6bc3f38f-34a7-4676-8263-dc9cd3725943"},{"id":"65ed8037-b0af-42c5-9219-96f8286766fd","lane":"clinical","event_type":"primary-completion","date":"2026-08-23","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"PF-07220060 + PF-07104091 combination dose escalation","indication":"Breast Cancer","summary":"As of 18 November 2024, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 23 August 2026.","as_of":"2024-11-18","source":"clinicaltrials","source_ref":"NCT05262400","source_url":"https://clinicaltrials.gov/study/NCT05262400","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-65ed8037-b0af-42c5-9219-96f8286766fd"},{"id":"9b7b1aa6-7add-4b76-b4a3-a5c6cd053621","lane":"clinical","event_type":"primary-completion","date":"2026-08-24","date_precision":"day","confidence":"estimated","company":"Alexion Pharmaceuticals, Inc.","ticker":null,"asset":"Danicopan","indication":"Paroxysmal Nocturnal Hemoglobinuria","summary":"As of 18 June 2026, Alexion Pharmaceuticals estimated primary completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria, on 24 August 2026.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT05389449","source_url":"https://clinicaltrials.gov/study/NCT05389449","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b7b1aa6-7add-4b76-b4a3-a5c6cd053621"},{"id":"9db0a6f8-a17b-4ec2-a78a-00e3b2dfb35a","lane":"clinical","event_type":"primary-completion","date":"2026-08-24","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD9833","indication":"ER-Positive HER2-Negative Breast Cancer","summary":"As of 14 October 2025, AstraZeneca estimated primary completion of a Phase 3 trial in ER-Positive HER2-Negative Breast Cancer, on 24 August 2026.","as_of":"2025-10-14","source":"clinicaltrials","source_ref":"NCT04711252","source_url":"https://clinicaltrials.gov/study/NCT04711252","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9db0a6f8-a17b-4ec2-a78a-00e3b2dfb35a"},{"id":"fa63b15c-3e09-4497-9831-5ba7ea3675ef","lane":"clinical","event_type":"primary-completion","date":"2026-08-24","date_precision":"day","confidence":"estimated","company":"Regeneron Pharmaceuticals","ticker":null,"asset":"Fianlimab","indication":"Resectable Non-small Cell Lung Cancer","summary":"As of 10 August 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Resectable Non-small Cell Lung Cancer, on 24 August 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT06161441","source_url":"https://clinicaltrials.gov/study/NCT06161441","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fa63b15c-3e09-4497-9831-5ba7ea3675ef"},{"id":"ef624489-1fcb-4dd9-8146-8b2e35d3d508","lane":"clinical","event_type":"primary-completion","date":"2026-08-24","date_precision":"day","confidence":"estimated","company":"Suzhou HepaThera Biotech Co., Ltd.","ticker":null,"asset":"HT-101","indication":"Chronic Hepatitis B","summary":"As of 19 September 2025, Suzhou HepaThera Biotech Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, on 24 August 2026.","as_of":"2025-09-19","source":"clinicaltrials","source_ref":"NCT07183306","source_url":"https://clinicaltrials.gov/study/NCT07183306","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ef624489-1fcb-4dd9-8146-8b2e35d3d508"},{"id":"2cdd138e-9feb-4cbc-9a4b-8f4e0cfe740f","lane":"clinical","event_type":"primary-completion","date":"2026-08-25","date_precision":"day","confidence":"estimated","company":"BPGbio","ticker":null,"asset":"BPM31510","indication":"Glioblastoma","summary":"As of 26 January 2026, BPGbio estimated primary completion of a Phase 2 trial in glioblastoma, on 25 August 2026.","as_of":"2026-01-26","source":"clinicaltrials","source_ref":"NCT04752813","source_url":"https://clinicaltrials.gov/study/NCT04752813","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2cdd138e-9feb-4cbc-9a4b-8f4e0cfe740f"},{"id":"0ee33319-9bce-4257-b5d6-382740518a80","lane":"clinical","event_type":"primary-completion","date":"2026-08-25","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"JDQ443","indication":"Non-Small Cell Lung Cancer","summary":"As of 25 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 25 August 2026.","as_of":"2026-06-25","source":"clinicaltrials","source_ref":"NCT05132075","source_url":"https://clinicaltrials.gov/study/NCT05132075","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0ee33319-9bce-4257-b5d6-382740518a80"},{"id":"cc3ac380-95ab-4f79-826f-b3764e18f845","lane":"clinical","event_type":"primary-completion","date":"2026-08-25","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"Rilzabrutinib dose 1","indication":"Graves' Disease","summary":"As of 7 July 2026, Sanofi estimated primary completion of a Phase 2 trial in Graves' Disease, on 25 August 2026.","as_of":"2026-07-07","source":"clinicaltrials","source_ref":"NCT06984627","source_url":"https://clinicaltrials.gov/study/NCT06984627","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cc3ac380-95ab-4f79-826f-b3764e18f845"},{"id":"ceb8b8d9-55c1-4bb3-8583-5d4e1b561e7a","lane":"clinical","event_type":"primary-completion","date":"2026-08-26","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Satralizumab","indication":"Duchenne Muscular Dystrophy","summary":"As of 15 May 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 26 August 2026.","as_of":"2026-05-15","source":"clinicaltrials","source_ref":"NCT06450639","source_url":"https://clinicaltrials.gov/study/NCT06450639","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ceb8b8d9-55c1-4bb3-8583-5d4e1b561e7a"},{"id":"03d8d111-5814-4bb1-983a-0cf234f259bf","lane":"clinical","event_type":"primary-completion","date":"2026-08-26","date_precision":"day","confidence":"estimated","company":"ParagonClinicals Inc.","ticker":null,"asset":"Paragon Novel Metabolic Regulator (PNMR)","indication":"Long COVID","summary":"As of 4 June 2026, ParagonClinicals estimated primary completion of a Phase 2 trial in Long COVID, on 26 August 2026.","as_of":"2026-06-04","source":"clinicaltrials","source_ref":"NCT07627815","source_url":"https://clinicaltrials.gov/study/NCT07627815","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-03d8d111-5814-4bb1-983a-0cf234f259bf"},{"id":"d4689a13-4811-427b-b5b2-d1f88eb27001","lane":"clinical","event_type":"primary-completion","date":"2026-08-27","date_precision":"day","confidence":"estimated","company":"Blue Earth Therapeutics Ltd","ticker":null,"asset":"Lutetium (177Lu) rhPSMA-10.1 Injection","indication":"Prostate Cancer","summary":"As of 14 May 2026, Blue Earth Therapeutics estimated primary completion of a Phase 2 trial in Prostate Cancer, on 27 August 2026.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT05413850","source_url":"https://clinicaltrials.gov/study/NCT05413850","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d4689a13-4811-427b-b5b2-d1f88eb27001"},{"id":"0f2b41f7-d0f1-4c66-8fcb-197e4aee99e9","lane":"clinical","event_type":"primary-completion","date":"2026-08-28","date_precision":"day","confidence":"estimated","company":"4Moving Biotech","ticker":null,"asset":"4P004","indication":"Knee Osteoarthritis","summary":"As of 27 July 2026, 4Moving Biotech estimated primary completion of a Phase 2 trial in Knee Osteoarthritis, on 28 August 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT07225829","source_url":"https://clinicaltrials.gov/study/NCT07225829","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0f2b41f7-d0f1-4c66-8fcb-197e4aee99e9"},{"id":"636761d3-0923-4a10-9230-9a41d512fa54","lane":"clinical","event_type":"primary-completion","date":"2026-08-28","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD2936","indication":"Non-Small-Cell Lung Carcinoma","summary":"As of 14 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Carcinoma, on 28 August 2026.","as_of":"2026-07-14","source":"clinicaltrials","source_ref":"NCT04995523","source_url":"https://clinicaltrials.gov/study/NCT04995523","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-636761d3-0923-4a10-9230-9a41d512fa54"},{"id":"4761b7ee-cd65-4a56-9c4b-8ff87b10ca13","lane":"clinical","event_type":"primary-completion","date":"2026-08-28","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Giredestrant","indication":"Endometrial Cancer","summary":"As of 10 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Endometrial Cancer, on 28 August 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT05634499","source_url":"https://clinicaltrials.gov/study/NCT05634499","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4761b7ee-cd65-4a56-9c4b-8ff87b10ca13"},{"id":"39c42e1d-1894-4c2c-bad7-e7aa1e687350","lane":"clinical","event_type":"primary-completion","date":"2026-08-28","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Alectinib","indication":"Non-Small Cell Lung Cancer","summary":"As of 2 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Non-Small Cell Lung Cancer, on 28 August 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT06624059","source_url":"https://clinicaltrials.gov/study/NCT06624059","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-39c42e1d-1894-4c2c-bad7-e7aa1e687350"},{"id":"4741d462-ab8c-4e8c-b67b-2cc5bba0fa0f","lane":"clinical","event_type":"primary-completion","date":"2026-08-29","date_precision":"day","confidence":"estimated","company":"Panbela Therapeutics, Inc.","ticker":null,"asset":"SBP-101","indication":"Pancreatic Cancer Metastatic","summary":"As of 6 November 2024, Panbela Therapeutics estimated primary completion of a Phase 3 trial in Pancreatic Cancer Metastatic, on 29 August 2026.","as_of":"2024-11-06","source":"clinicaltrials","source_ref":"NCT05254171","source_url":"https://clinicaltrials.gov/study/NCT05254171","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4741d462-ab8c-4e8c-b67b-2cc5bba0fa0f"},{"id":"c4c4d47b-b738-4046-8dee-aab6e400c3eb","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"Beletalent (Zhuhai) Pharmaceutical Co., Ltd","ticker":null,"asset":"TNTL","indication":"Non-Proliferative Diabetic Retinopathy","summary":"As of 24 August 2025, Beletalent (Zhuhai) Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Proliferative Diabetic Retinopathy, on 30 August 2026.","as_of":"2025-08-24","source":"clinicaltrials","source_ref":"NCT06817265","source_url":"https://clinicaltrials.gov/study/NCT06817265","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c4c4d47b-b738-4046-8dee-aab6e400c3eb"},{"id":"0579c1aa-4899-4194-b903-ebf0d9d07795","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"Fujian Haixi Pharmaceuticals Co., Ltd.","ticker":null,"asset":"C019199","indication":"Solid Tumor","summary":"As of 28 November 2025, Fujian Haixi Pharmaceuticals Co. estimated primary completion of a Phase 2 trial in Solid Tumor, on 30 August 2026.","as_of":"2025-11-28","source":"clinicaltrials","source_ref":"NCT06220318","source_url":"https://clinicaltrials.gov/study/NCT06220318","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0579c1aa-4899-4194-b903-ebf0d9d07795"},{"id":"405295c2-5c8a-462d-9ddb-b183f2938f51","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"asset":"HRS-5635 Injection","indication":"Chronic Hepatitis B","summary":"As of 17 November 2025, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, on 30 August 2026.","as_of":"2025-11-17","source":"clinicaltrials","source_ref":"NCT06425341","source_url":"https://clinicaltrials.gov/study/NCT06425341","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-405295c2-5c8a-462d-9ddb-b183f2938f51"},{"id":"fa58f912-8e88-43da-9591-05ee17e19329","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"HSK39004 Dry Powder Inhaler-0.75mg","indication":"Chronic Obstructive Pulmonary Disease (COPD)","summary":"As of 8 April 2026, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Chronic Obstructive Pulmonary Disease (COPD), on 30 August 2026.","as_of":"2026-04-08","source":"clinicaltrials","source_ref":"NCT07108699","source_url":"https://clinicaltrials.gov/study/NCT07108699","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fa58f912-8e88-43da-9591-05ee17e19329"},{"id":"343c8da1-3595-439d-8c74-cce5c083eee9","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"Il-Yang Pharm. Co., Ltd.","ticker":null,"asset":"Ilaprazole","indication":"Peptic Ulcer","summary":"As of 30 May 2025, Il-Yang Pharm. Co. estimated primary completion of a Phase 3 trial in Peptic Ulcer, on 30 August 2026.","as_of":"2025-05-30","source":"clinicaltrials","source_ref":"NCT06284876","source_url":"https://clinicaltrials.gov/study/NCT06284876","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-343c8da1-3595-439d-8c74-cce5c083eee9"},{"id":"96cef251-edb1-40a3-99c9-477996ad4506","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"Innovent Biologics Technology Limited (Shanghai R&D Center)","ticker":null,"asset":"IBI302 8mg dose","indication":"Neovascular Age-related Macular Degeneration","summary":"As of 8 January 2026, Innovent Biologics Technology estimated primary completion of a Phase 2 trial in Neovascular Age-related Macular Degeneration, on 30 August 2026.","as_of":"2026-01-08","source":"clinicaltrials","source_ref":"NCT07275840","source_url":"https://clinicaltrials.gov/study/NCT07275840","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-96cef251-edb1-40a3-99c9-477996ad4506"},{"id":"0e477219-6995-4d4a-b8df-9c888afd3565","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"Keymed Biosciences Co.Ltd","ticker":null,"asset":"CM310","indication":"Atopic Dermatitis","summary":"As of 2 October 2025, Keymed Biosciences Co. estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 30 August 2026.","as_of":"2025-10-02","source":"clinicaltrials","source_ref":"NCT06495229","source_url":"https://clinicaltrials.gov/study/NCT06495229","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0e477219-6995-4d4a-b8df-9c888afd3565"},{"id":"f05fe319-3a88-4ee5-831f-a577e1d03149","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"NeuroPro Therapeutics, Inc.","ticker":null,"asset":"NPT 2042","indication":"Epilepsy, Generalized","summary":"As of 29 May 2026, NeuroPro Therapeutics estimated primary completion of a Phase 2 trial in Epilepsy, Generalized, on 30 August 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT06769659","source_url":"https://clinicaltrials.gov/study/NCT06769659","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f05fe319-3a88-4ee5-831f-a577e1d03149"},{"id":"6451744c-5ed0-46f6-aff2-00aeb58d1ee8","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"OncoC4, Inc.","ticker":null,"asset":"ONC-392","indication":"Ovarian Cancer","summary":"As of 13 April 2026, OncoC4 estimated primary completion of a Phase 2 trial in Ovarian Cancer, on 30 August 2026.","as_of":"2026-04-13","source":"clinicaltrials","source_ref":"NCT05446298","source_url":"https://clinicaltrials.gov/study/NCT05446298","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6451744c-5ed0-46f6-aff2-00aeb58d1ee8"},{"id":"914463ff-6ec8-4da2-981a-cd4469404729","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"Elranatamab","indication":"Multiple Myeloma","summary":"As of 31 July 2026, Pfizer estimated primary completion of a Phase 3 trial in Multiple Myeloma, on 30 August 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT06152575","source_url":"https://clinicaltrials.gov/study/NCT06152575","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-914463ff-6ec8-4da2-981a-cd4469404729"},{"id":"e8ca3897-a034-4161-8a7f-7fad0880338c","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"ReCode Therapeutics","ticker":null,"asset":"RCT2100","indication":"Cystic Fibrosis","summary":"As of 16 January 2026, ReCode Therapeutics estimated primary completion of a Phase 2 trial in Cystic Fibrosis, on 30 August 2026.","as_of":"2026-01-16","source":"clinicaltrials","source_ref":"NCT06237335","source_url":"https://clinicaltrials.gov/study/NCT06237335","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e8ca3897-a034-4161-8a7f-7fad0880338c"},{"id":"363d628d-7cee-4bf4-b2a9-95c9a4c3a8b1","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"Satellos Bioscience, Inc.","ticker":null,"asset":"SAT-3247","indication":"Duchenne Muscular Dystrophy (DMD)","summary":"As of 23 April 2026, Satellos Bioscience estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy (DMD), on 30 August 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT06867107","source_url":"https://clinicaltrials.gov/study/NCT06867107","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-363d628d-7cee-4bf4-b2a9-95c9a4c3a8b1"},{"id":"821ace8e-729e-456f-abe1-9056293b86f2","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"TCM Biotech International Corp.","ticker":null,"asset":"PTX-9908 Injection","indication":"Carcinoma, Hepatocellular","summary":"As of 21 November 2024, TCM Biotech International estimated primary completion of a Phase 2 trial in Carcinoma, Hepatocellular, on 30 August 2026.","as_of":"2024-11-21","source":"clinicaltrials","source_ref":"NCT03812874","source_url":"https://clinicaltrials.gov/study/NCT03812874","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-821ace8e-729e-456f-abe1-9056293b86f2"},{"id":"8634e3e8-12a4-4750-8e31-6bb4c1a297ee","lane":"clinical","event_type":"primary-completion","date":"2026-08-30","date_precision":"day","confidence":"estimated","company":"TJ Biopharma Co., Ltd.","ticker":null,"asset":"Uliledlimab","indication":"Non Small Cell Lung Cancer","summary":"As of 30 January 2026, TJ Biopharma Co. estimated primary completion of a Phase 2 trial in Non Small Cell Lung Cancer, on 30 August 2026.","as_of":"2026-01-30","source":"clinicaltrials","source_ref":"NCT07005336","source_url":"https://clinicaltrials.gov/study/NCT07005336","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8634e3e8-12a4-4750-8e31-6bb4c1a297ee"},{"id":"89c3e12d-7793-40a7-a67f-5a6f94c18e2d","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"AMAG Pharmaceuticals, Inc.","ticker":null,"asset":"Ferumoxytol","indication":"Chronic Kidney Disease; Iron Deficiency Anemia","summary":"As of 17 April 2026, AMAG Pharmaceuticals estimated primary completion of a Phase 3 trial in Chronic Kidney Disease; Iron Deficiency Anemia, on 31 August 2026.","as_of":"2026-04-17","source":"clinicaltrials","source_ref":"NCT03619850","source_url":"https://clinicaltrials.gov/study/NCT03619850","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-89c3e12d-7793-40a7-a67f-5a6f94c18e2d"},{"id":"80b489f2-e5fd-46a4-9b07-1bf928d9b842","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Astellas Pharma Global Development, Inc.","ticker":null,"asset":"zolbetuximab","indication":"Pancreatic Cancer","summary":"As of 14 July 2026, Astellas Pharma Global Development estimated primary completion of a Phase 2 trial in Pancreatic Cancer, on 31 August 2026.","as_of":"2026-07-14","source":"clinicaltrials","source_ref":"NCT03816163","source_url":"https://clinicaltrials.gov/study/NCT03816163","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-80b489f2-e5fd-46a4-9b07-1bf928d9b842"},{"id":"5bff0428-a651-4d9a-ade9-66769b2d1fd9","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Bayer","ticker":null,"asset":"BAY3723113","indication":"Obstructive Hypertrophic Cardiomyopathy","summary":"As of 26 June 2026, Bayer estimated primary completion of a Phase 3 trial in Obstructive Hypertrophic Cardiomyopathy, on 31 August 2026.","as_of":"2026-06-26","source":"clinicaltrials","source_ref":"NCT07023341","source_url":"https://clinicaltrials.gov/study/NCT07023341","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5bff0428-a651-4d9a-ade9-66769b2d1fd9"},{"id":"27807f03-976a-4760-9dbb-e85c989d17e5","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Daewon Pharmaceutical Co., Ltd.","ticker":null,"asset":"Experimental","indication":"Perennial Allergic Rhinitis Accompanied by Asthma","summary":"As of 11 September 2025, Daewon Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Perennial Allergic Rhinitis Accompanied by Asthma, on 31 August 2026.","as_of":"2025-09-11","source":"clinicaltrials","source_ref":"NCT07168473","source_url":"https://clinicaltrials.gov/study/NCT07168473","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-27807f03-976a-4760-9dbb-e85c989d17e5"},{"id":"97ad74dc-a79f-4877-a160-afdd286d14b7","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Daiichi Sankyo","ticker":null,"asset":"Trastuzumab deruxtecan","indication":"Gastric Cancer, Adenocarcinoma","summary":"As of 27 May 2026, Daiichi Sankyo estimated primary completion of a Phase 3 trial in Gastric Cancer, Adenocarcinoma, on 31 August 2026.","as_of":"2026-05-27","source":"clinicaltrials","source_ref":"NCT04704934","source_url":"https://clinicaltrials.gov/study/NCT04704934","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-97ad74dc-a79f-4877-a160-afdd286d14b7"},{"id":"b53b20d2-0976-4106-b6aa-495a505b9977","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Galderma R&D","ticker":null,"asset":"Nemolizumab","indication":"Moderate-to-Severe Atopic Dermatitis","summary":"As of 30 October 2024, Galderma R&D estimated primary completion of a Phase 3 trial in Moderate-to-Severe Atopic Dermatitis, on 31 August 2026.","as_of":"2024-10-30","source":"clinicaltrials","source_ref":"NCT03989206","source_url":"https://clinicaltrials.gov/study/NCT03989206","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b53b20d2-0976-4106-b6aa-495a505b9977"},{"id":"48b463d7-2cf3-493d-aae9-ce89472af81f","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Hansoh BioMedical R&D Company","ticker":null,"asset":"HS-20093","indication":"Osteosarcoma","summary":"As of 9 April 2026, Hansoh BioMedical R&D estimated primary completion of a Phase 3 trial in osteosarcoma, on 31 August 2026.","as_of":"2026-04-09","source":"clinicaltrials","source_ref":"NCT06935409","source_url":"https://clinicaltrials.gov/study/NCT06935409","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-48b463d7-2cf3-493d-aae9-ce89472af81f"},{"id":"2214b51a-468d-4e20-bd12-a020585c1345","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Sefaxersen (RO7434656)","indication":"Primary IgA Nephropathy","summary":"As of 15 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Primary IgA Nephropathy, on 31 August 2026.","as_of":"2026-06-15","source":"clinicaltrials","source_ref":"NCT05797610","source_url":"https://clinicaltrials.gov/study/NCT05797610","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2214b51a-468d-4e20-bd12-a020585c1345"},{"id":"8160a161-f855-4420-b2b2-9f381d4d75d4","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Ipsen","ticker":null,"asset":"Corabotase","indication":"Moderate to Severe Upper Facial Lines","summary":"As of 28 July 2026, Ipsen estimated primary completion of a Phase 2 trial in Moderate to Severe Upper Facial Lines, on 31 August 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT04821089","source_url":"https://clinicaltrials.gov/study/NCT04821089","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8160a161-f855-4420-b2b2-9f381d4d75d4"},{"id":"3b3277d2-f761-4eba-8259-d14c1d879805","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Kyowa Kirin Co., Ltd.","ticker":null,"asset":"KHK4951","indication":"Diabetic Macular Edema (DME)","summary":"As of 30 October 2025, Kyowa Kirin Co. estimated primary completion of a Phase 2 trial in Diabetic Macular Edema (DME), on 31 August 2026.","as_of":"2025-10-30","source":"clinicaltrials","source_ref":"NCT06116916","source_url":"https://clinicaltrials.gov/study/NCT06116916","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3b3277d2-f761-4eba-8259-d14c1d879805"},{"id":"74ede089-ce15-49f7-8635-843fafc80f1a","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Kyowa Kirin Co., Ltd.","ticker":null,"asset":"KHK4951","indication":"Neovascular Age-Related Macular Degeneration (nAMD)","summary":"As of 30 October 2025, Kyowa Kirin Co. estimated primary completion of a Phase 2 trial in Neovascular Age-Related Macular Degeneration (nAMD), on 31 August 2026.","as_of":"2025-10-30","source":"clinicaltrials","source_ref":"NCT06116890","source_url":"https://clinicaltrials.gov/study/NCT06116890","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-74ede089-ce15-49f7-8635-843fafc80f1a"},{"id":"94a427d9-8c85-4e54-a69f-d64134766d80","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Lumen Bioscience, Inc.","ticker":null,"asset":"LMN-201","indication":"Clostridioides Difficile Infection","summary":"As of 30 July 2026, Lumen Bioscience estimated primary completion of a Phase 3 trial in Clostridioides Difficile Infection, on 31 August 2026.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT05330182","source_url":"https://clinicaltrials.gov/study/NCT05330182","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-94a427d9-8c85-4e54-a69f-d64134766d80"},{"id":"b0d7fbd0-319d-420f-af2e-1128a4de2c59","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"MediLink Therapeutics (Suzhou) Co., Ltd.","ticker":null,"asset":"YL202","indication":"Non Small Cell Lung Cancer","summary":"As of 9 March 2026, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Non Small Cell Lung Cancer, on 31 August 2026.","as_of":"2026-03-09","source":"clinicaltrials","source_ref":"NCT07202364","source_url":"https://clinicaltrials.gov/study/NCT07202364","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b0d7fbd0-319d-420f-af2e-1128a4de2c59"},{"id":"3c131065-1964-4545-8e70-9c6d427bcf83","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Myrtelle Inc.","ticker":null,"asset":"rAAV-Olig001-ASPA","indication":"Canavan Disease","summary":"As of 14 November 2025, Myrtelle estimated primary completion of a Phase 2 trial in Canavan Disease, on 31 August 2026.","as_of":"2025-11-14","source":"clinicaltrials","source_ref":"NCT04833907","source_url":"https://clinicaltrials.gov/study/NCT04833907","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3c131065-1964-4545-8e70-9c6d427bcf83"},{"id":"7acc24de-bce5-404d-9bee-c92f23468ae7","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Nantong Bencao Quadriga Medical Technology Co. Ltd.","ticker":null,"asset":"NBQ72S","indication":"Breast Cancer","summary":"As of 13 April 2026, Nantong Bencao Quadriga Medical Technology Co. estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 August 2026.","as_of":"2026-04-13","source":"clinicaltrials","source_ref":"NCT06810804","source_url":"https://clinicaltrials.gov/study/NCT06810804","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7acc24de-bce5-404d-9bee-c92f23468ae7"},{"id":"aad77804-cf5d-4268-8060-6743d36d5e01","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"RSVpreF","indication":"Respiratory Syncytial Virus (RSV)","summary":"As of 2 June 2026, Pfizer estimated primary completion of a Phase 3 trial in Respiratory Syncytial Virus (RSV), on 31 August 2026.","as_of":"2026-06-02","source":"clinicaltrials","source_ref":"NCT07543380","source_url":"https://clinicaltrials.gov/study/NCT07543380","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-aad77804-cf5d-4268-8060-6743d36d5e01"},{"id":"476a761b-bf9e-4f66-be67-93558640f802","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Santen Pharmaceutical Co., Ltd.","ticker":null,"asset":"DE-117B Eye Drops","indication":"Open Angle Glaucoma","summary":"As of 15 May 2026, Santen Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Open Angle Glaucoma, on 31 August 2026.","as_of":"2026-05-15","source":"clinicaltrials","source_ref":"NCT06666855","source_url":"https://clinicaltrials.gov/study/NCT06666855","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-476a761b-bf9e-4f66-be67-93558640f802"},{"id":"b602b066-bf86-4016-a045-10b39a373314","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Shenyang Sunshine Pharmaceutical Co., LTD.","ticker":null,"asset":"SSGJ-706","indication":"First-line Advanced NSCLC Patients","summary":"As of 18 December 2025, Shenyang Sunshine Pharmaceutical Co. estimated primary completion of a Phase 2 trial in First-line Advanced NSCLC Patients, on 31 August 2026.","as_of":"2025-12-18","source":"clinicaltrials","source_ref":"NCT07171606","source_url":"https://clinicaltrials.gov/study/NCT07171606","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b602b066-bf86-4016-a045-10b39a373314"},{"id":"b51529e4-274e-472e-95f7-971bf729651e","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Sichuan Jishengtang Pharmaceutical Co., Ltd.","ticker":null,"asset":"Wujia Yizhi granules","indication":"Alzheimer's Dementia","summary":"As of 29 December 2025, Sichuan Jishengtang Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Alzheimer's Dementia, on 31 August 2026.","as_of":"2025-12-29","source":"clinicaltrials","source_ref":"NCT06534723","source_url":"https://clinicaltrials.gov/study/NCT06534723","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b51529e4-274e-472e-95f7-971bf729651e"},{"id":"5589c40e-7e8f-4e28-a243-c5342f7c040c","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"asset":"SHR-1826；Adebrelimab；SHR-8068；Bevacizumab","indication":"NSCLC","summary":"As of 19 March 2025, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in nSCLC, on 31 August 2026.","as_of":"2025-03-19","source":"clinicaltrials","source_ref":"NCT06844474","source_url":"https://clinicaltrials.gov/study/NCT06844474","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5589c40e-7e8f-4e28-a243-c5342f7c040c"},{"id":"9974bf1c-5bda-4eea-bc9d-8de939cd0473","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Translational Sciences, Inc.","ticker":null,"asset":"TS23","indication":"Pulmonary Embolism","summary":"As of 1 July 2026, Translational Sciences estimated primary completion of a Phase 2 trial in Pulmonary Embolism, on 31 August 2026.","as_of":"2026-07-01","source":"clinicaltrials","source_ref":"NCT05408546","source_url":"https://clinicaltrials.gov/study/NCT05408546","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9974bf1c-5bda-4eea-bc9d-8de939cd0473"},{"id":"63bf0d6a-6835-4776-8606-810d4ad5ff3b","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"UCB Biopharma SRL","ticker":null,"asset":"Staccato alprazolam","indication":"Stereotypical Prolonged Seizures","summary":"As of 31 July 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Stereotypical Prolonged Seizures, on 31 August 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT05077904","source_url":"https://clinicaltrials.gov/study/NCT05077904","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-63bf0d6a-6835-4776-8606-810d4ad5ff3b"},{"id":"31c21610-fa8c-4397-a302-854ea9bc5b97","lane":"clinical","event_type":"primary-completion","date":"2026-08-31","date_precision":"day","confidence":"estimated","company":"Verastem, Inc.","ticker":null,"asset":"avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel","indication":"KRAS Activating Mutation","summary":"As of 2 September 2025, Verastem estimated primary completion of a Phase 2 trial in KRAS Activating Mutation, on 31 August 2026.","as_of":"2025-09-02","source":"clinicaltrials","source_ref":"NCT05669482","source_url":"https://clinicaltrials.gov/study/NCT05669482","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-31c21610-fa8c-4397-a302-854ea9bc5b97"},{"id":"9f79a263-42d1-4b85-8ce0-4bd3a48a58b1","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"Adalimumab","indication":"Juvenile Psoriatic Arthritis","summary":"As of 31 July 2026, AbbVie estimated primary completion of a Phase 3 trial in Juvenile Psoriatic Arthritis, in September 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT06100744","source_url":"https://clinicaltrials.gov/study/NCT06100744","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9f79a263-42d1-4b85-8ce0-4bd3a48a58b1"},{"id":"990bdf15-73ee-4d1e-8415-3abec52044a3","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Abscint NV/SA","ticker":null,"asset":"68Ga-NOTA-ABSCINT-HER2 PET/CT","indication":"Metastatic Breast Cancer","summary":"As of 2 June 2026, Abscint NV/SA estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in September 2026.","as_of":"2026-06-02","source":"clinicaltrials","source_ref":"NCT06369831","source_url":"https://clinicaltrials.gov/study/NCT06369831","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-990bdf15-73ee-4d1e-8415-3abec52044a3"},{"id":"47f3de3b-10d2-4d9b-af98-26580a04e2bf","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Agitated Solutions, Inc.","ticker":null,"asset":"Agitated Saline SoC","indication":"Right-To-Left Shunt","summary":"As of 6 July 2026, Agitated Solutions estimated primary completion of a Phase 3 trial in Right-To-Left Shunt, in September 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT06938347","source_url":"https://clinicaltrials.gov/study/NCT06938347","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-47f3de3b-10d2-4d9b-af98-26580a04e2bf"},{"id":"b0c9fcd0-163b-4114-92ba-e435ef93f959","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Alfasigma S.p.A.","ticker":null,"asset":"Filgotinib","indication":"Ulcerative Colitis","summary":"As of 22 May 2026, Alfasigma S.p.A. estimated primary completion of a Phase 3 trial in Ulcerative Colitis, in September 2026.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT02914535","source_url":"https://clinicaltrials.gov/study/NCT02914535","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b0c9fcd0-163b-4114-92ba-e435ef93f959"},{"id":"e7a1b847-ba7e-4baf-9ab6-cac599207cd2","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Alkermes, Inc.","ticker":null,"asset":"OLZ/SAM","indication":"Schizophrenia","summary":"As of 3 June 2026, Alkermes estimated primary completion of a Phase 3 trial in schizophrenia, in September 2026.","as_of":"2026-06-03","source":"clinicaltrials","source_ref":"NCT05303064","source_url":"https://clinicaltrials.gov/study/NCT05303064","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e7a1b847-ba7e-4baf-9ab6-cac599207cd2"},{"id":"40e91285-f886-4eb3-81fc-dbd98a077020","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Amydis Inc.","ticker":null,"asset":"AMDX-2011P","indication":"Alzheimer Disease","summary":"As of 13 February 2026, Amydis estimated primary completion of a Phase 2 trial in Alzheimer Disease, in September 2026.","as_of":"2026-02-13","source":"clinicaltrials","source_ref":"NCT06514001","source_url":"https://clinicaltrials.gov/study/NCT06514001","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-40e91285-f886-4eb3-81fc-dbd98a077020"},{"id":"f6b7fced-1c61-41c0-a060-402c40c27235","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"Ardelyx","ticker":null,"asset":"Tenapanor 50 MG","indication":"Irritable Bowel Syndrome With Constipation (IBS-C)","summary":"As of 4 June 2026, Ardelyx estimated primary completion of a Phase 3 trial in Irritable Bowel Syndrome With Constipation (IBS-C), on 1 September 2026.","as_of":"2026-06-04","source":"clinicaltrials","source_ref":"NCT05643534","source_url":"https://clinicaltrials.gov/study/NCT05643534","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f6b7fced-1c61-41c0-a060-402c40c27235"},{"id":"870ad692-9282-4d6b-96fc-548c8df1aaf0","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Arthrosi Therapeutics","ticker":null,"asset":"AR882 50 mg","indication":"Gout","summary":"As of 12 May 2026, Arthrosi Therapeutics estimated primary completion of a Phase 3 trial in gout, in September 2026.","as_of":"2026-05-12","source":"clinicaltrials","source_ref":"NCT06846515","source_url":"https://clinicaltrials.gov/study/NCT06846515","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-870ad692-9282-4d6b-96fc-548c8df1aaf0"},{"id":"600355db-d286-440b-ac6d-76980402b198","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Atea Pharmaceuticals, Inc.","ticker":null,"asset":"Bemnifosbuvir-Ruzasvir (BEM/RZR)","indication":"HEPATITIS C VIRUS CHRONIC INFECTION","summary":"As of 5 December 2025, Atea Pharmaceuticals estimated primary completion of a Phase 3 trial in HEPATITIS C VIRUS CHRONIC INFECTION, in September 2026.","as_of":"2025-12-05","source":"clinicaltrials","source_ref":"NCT06868264","source_url":"https://clinicaltrials.gov/study/NCT06868264","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-600355db-d286-440b-ac6d-76980402b198"},{"id":"2f20de4c-f0dd-432a-bc13-17970c9e31b8","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"Beijing Continent Pharmaceutical Co, Ltd.","ticker":null,"asset":"F573 for injection","indication":"Acute Liver Failure","summary":"As of 19 November 2025, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 2 trial in Acute Liver Failure, on 1 September 2026.","as_of":"2025-11-19","source":"clinicaltrials","source_ref":"NCT05689645","source_url":"https://clinicaltrials.gov/study/NCT05689645","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2f20de4c-f0dd-432a-bc13-17970c9e31b8"},{"id":"a8aaf6c5-2c09-4ab7-805a-a05a9bc3db15","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Bio-Thera Solutions","ticker":null,"asset":"Recombinant humanized anti-PD-1 monoclonal antibody injection","indication":"Cervical Cancer","summary":"As of 10 February 2025, Bio-Thera Solutions estimated primary completion of a Phase 3 trial in Cervical Cancer, in September 2026.","as_of":"2025-02-10","source":"clinicaltrials","source_ref":"NCT06123884","source_url":"https://clinicaltrials.gov/study/NCT06123884","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a8aaf6c5-2c09-4ab7-805a-a05a9bc3db15"},{"id":"c3bc70ad-ac96-42a4-a5ce-436693c75ab0","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Biohaven Therapeutics Ltd.","ticker":null,"asset":"Taldefgrobep Alfa","indication":"Obesity","summary":"As of 20 March 2026, Biohaven Therapeutics estimated primary completion of a Phase 2 trial in obesity, in September 2026.","as_of":"2026-03-20","source":"clinicaltrials","source_ref":"NCT07281495","source_url":"https://clinicaltrials.gov/study/NCT07281495","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c3bc70ad-ac96-42a4-a5ce-436693c75ab0"},{"id":"a045ef92-de23-4aeb-a71b-0cf62995ae07","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"TQB6411 Injection","indication":"Esophageal Cancer","summary":"As of 2 July 2026, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Esophageal Cancer, in September 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT07367516","source_url":"https://clinicaltrials.gov/study/NCT07367516","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a045ef92-de23-4aeb-a71b-0cf62995ae07"},{"id":"b5162a6d-921e-4b5c-bfde-0d5d625252e1","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","ticker":null,"asset":"TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy","indication":"Gastroesophageal Adenocarcinoma","summary":"As of 30 July 2025, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Gastroesophageal Adenocarcinoma, in September 2026.","as_of":"2025-07-30","source":"clinicaltrials","source_ref":"NCT06767800","source_url":"https://clinicaltrials.gov/study/NCT06767800","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b5162a6d-921e-4b5c-bfde-0d5d625252e1"},{"id":"0bb16fba-5c95-47c1-bb7d-3edbd0c06e7d","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Clarity Pharmaceuticals Ltd","ticker":null,"asset":"64Cu-SAR-bisPSMA","indication":"Prostatic Neoplasms, Castration-Resistant","summary":"As of 6 May 2026, Clarity Pharmaceuticals estimated primary completion of a Phase 2 trial in Prostatic Neoplasms, Castration-Resistant, in September 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT04868604","source_url":"https://clinicaltrials.gov/study/NCT04868604","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0bb16fba-5c95-47c1-bb7d-3edbd0c06e7d"},{"id":"47886e04-a60b-49d1-ae39-90a1151ae1e0","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Clarity Pharmaceuticals Ltd","ticker":null,"asset":"64Cu-SAR-bisPSMA","indication":"Prostate Cancer","summary":"As of 14 May 2026, Clarity Pharmaceuticals estimated primary completion of a Phase 3 trial in Prostate Cancer, in September 2026.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT06056830","source_url":"https://clinicaltrials.gov/study/NCT06056830","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-47886e04-a60b-49d1-ae39-90a1151ae1e0"},{"id":"29403a80-f156-46ae-9d35-66b2687de3dc","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Colgate Palmolive","ticker":null,"asset":"8% arginine + Zinc toothpaste","indication":"Dentinal Sensitivity","summary":"As of 7 August 2026, Colgate Palmolive estimated primary completion of a Phase 3 trial in Dentinal Sensitivity, in September 2026.","as_of":"2026-08-07","source":"clinicaltrials","source_ref":"NCT07664592","source_url":"https://clinicaltrials.gov/study/NCT07664592","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-29403a80-f156-46ae-9d35-66b2687de3dc"},{"id":"7c981518-d7e3-433b-baf0-db7282c18d91","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Cook MyoSite","ticker":null,"asset":"AMDC-USR (iltamiocel)","indication":"Stress Urinary Incontinence","summary":"As of 13 March 2026, Cook MyoSite estimated primary completion of a Phase 3 trial in Stress Urinary Incontinence, in September 2026.","as_of":"2026-03-13","source":"clinicaltrials","source_ref":"NCT03104517","source_url":"https://clinicaltrials.gov/study/NCT03104517","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7c981518-d7e3-433b-baf0-db7282c18d91"},{"id":"848592a1-000a-41af-b349-ebff5e0951e1","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Coordination Pharmaceuticals, Inc.","ticker":null,"asset":"RiMO-301","indication":"Head Neck Cancer","summary":"As of 17 September 2025, Coordination Pharmaceuticals estimated primary completion of a Phase 2 trial in Head Neck Cancer, in September 2026.","as_of":"2025-09-17","source":"clinicaltrials","source_ref":"NCT05838729","source_url":"https://clinicaltrials.gov/study/NCT05838729","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-848592a1-000a-41af-b349-ebff5e0951e1"},{"id":"8333350f-04a8-4c88-bcf6-ea93b2a73a15","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Corcept Therapeutics","ticker":null,"asset":"Miricorilant (Cohort A)","indication":"Nonalcoholic Steatohepatitis (NASH)","summary":"As of 8 May 2026, Corcept Therapeutics estimated primary completion of a Phase 2 trial in Nonalcoholic Steatohepatitis (NASH), in September 2026.","as_of":"2026-05-08","source":"clinicaltrials","source_ref":"NCT06108219","source_url":"https://clinicaltrials.gov/study/NCT06108219","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8333350f-04a8-4c88-bcf6-ea93b2a73a15"},{"id":"2d05d6d5-bbb1-49dc-b446-a18f88efa0e6","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Corcept Therapeutics","ticker":null,"asset":"Nenocorilant 200 mg","indication":"Neoplasms","summary":"As of 30 June 2026, Corcept Therapeutics estimated primary completion of a Phase 2 trial in neoplasms, in September 2026.","as_of":"2026-06-30","source":"clinicaltrials","source_ref":"NCT07276373","source_url":"https://clinicaltrials.gov/study/NCT07276373","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2d05d6d5-bbb1-49dc-b446-a18f88efa0e6"},{"id":"afc60bf1-493a-49dc-a806-53d5cdf8d8c9","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"CuraSen Therapeutics, Inc.","ticker":null,"asset":"CST-3056","indication":"Neurogenic Orthostatic Hypotension","summary":"As of 30 July 2026, CuraSen Therapeutics estimated primary completion of a Phase 2 trial in Neurogenic Orthostatic Hypotension, in September 2026.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT07089043","source_url":"https://clinicaltrials.gov/study/NCT07089043","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-afc60bf1-493a-49dc-a806-53d5cdf8d8c9"},{"id":"f9205a09-7463-43b9-a2f0-8f3260f4af82","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Curium US LLC","ticker":null,"asset":"Copper Cu 64 PSMA I&T","indication":"Prostate Cancer","summary":"As of 4 June 2026, Curium US estimated primary completion of a Phase 3 trial in Prostate Cancer, in September 2026.","as_of":"2026-06-04","source":"clinicaltrials","source_ref":"NCT06235151","source_url":"https://clinicaltrials.gov/study/NCT06235151","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f9205a09-7463-43b9-a2f0-8f3260f4af82"},{"id":"4c62df99-548b-49cc-b59e-ea4dbff8df77","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Cytokinetics","ticker":null,"asset":"CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)","indication":"Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)","summary":"As of 29 May 2026, Cytokinetics estimated primary completion of a Phase 2 trial in Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), in September 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT06793371","source_url":"https://clinicaltrials.gov/study/NCT06793371","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4c62df99-548b-49cc-b59e-ea4dbff8df77"},{"id":"9df7332e-33e6-47d2-a06d-c1566dbee32a","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Design Therapeutics, Inc.","ticker":null,"asset":"DT-168","indication":"Fuchs Endothelial Corneal Dystrophy","summary":"As of 29 December 2025, Design Therapeutics estimated primary completion of a Phase 2 trial in Fuchs Endothelial Corneal Dystrophy, in September 2026.","as_of":"2025-12-29","source":"clinicaltrials","source_ref":"NCT07024693","source_url":"https://clinicaltrials.gov/study/NCT07024693","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9df7332e-33e6-47d2-a06d-c1566dbee32a"},{"id":"549b1376-1e47-4af2-86c3-b22f2ad4bcce","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Disc Medicine, Inc","ticker":null,"asset":"DISC-1459","indication":"Erythropoietic Protoporphyria (EPP)","summary":"As of 3 August 2026, Disc Medicine estimated primary completion of a Phase 3 trial in Erythropoietic Protoporphyria (EPP), in September 2026.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT06910358","source_url":"https://clinicaltrials.gov/study/NCT06910358","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-549b1376-1e47-4af2-86c3-b22f2ad4bcce"},{"id":"b4a6e8ff-a757-4c65-b254-fb3320411a38","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"EIP Pharma Inc","ticker":null,"asset":"Neflamapimod","indication":"Nonfluent Variant Primary Progressive Aphasia (nfvPPA)","summary":"As of 6 July 2026, EIP Pharma estimated primary completion of a Phase 2 trial in Nonfluent Variant Primary Progressive Aphasia (nfvPPA), in September 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT07033481","source_url":"https://clinicaltrials.gov/study/NCT07033481","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b4a6e8ff-a757-4c65-b254-fb3320411a38"},{"id":"90585667-8ef4-4dca-a37a-4e75cc3be12b","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Edgewise Therapeutics, Inc.","ticker":null,"asset":"Sevasemten 10 mg","indication":"Becker Muscular Dystrophy","summary":"As of 31 July 2026, Edgewise Therapeutics estimated primary completion of a Phase 2 trial in Becker Muscular Dystrophy, in September 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT05291091","source_url":"https://clinicaltrials.gov/study/NCT05291091","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-90585667-8ef4-4dca-a37a-4e75cc3be12b"},{"id":"44d79db7-bb6e-428c-b8fd-f05b2b7092ea","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"Tirzepatide","indication":"Overweight","summary":"As of 8 May 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in overweight, in September 2026.","as_of":"2026-05-08","source":"clinicaltrials","source_ref":"NCT05536804","source_url":"https://clinicaltrials.gov/study/NCT05536804","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-44d79db7-bb6e-428c-b8fd-f05b2b7092ea"},{"id":"ed3c3a47-e48f-48ff-9a3a-f1becf3b8a08","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"LY3650150","indication":"Perennial Allergic Rhinitis (PAR)","summary":"As of 22 July 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Perennial Allergic Rhinitis (PAR), in September 2026.","as_of":"2026-07-22","source":"clinicaltrials","source_ref":"NCT06339008","source_url":"https://clinicaltrials.gov/study/NCT06339008","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ed3c3a47-e48f-48ff-9a3a-f1becf3b8a08"},{"id":"6359774f-d3fe-4f02-9530-06314947a44f","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"asset":"HRS-7249 Injection","indication":"Hyperlipidemia","summary":"As of 3 June 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in hyperlipidemia, in September 2026.","as_of":"2026-06-03","source":"clinicaltrials","source_ref":"NCT07100418","source_url":"https://clinicaltrials.gov/study/NCT07100418","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6359774f-d3fe-4f02-9530-06314947a44f"},{"id":"99d6d25e-d85a-4d3a-ac90-b640fdf53d00","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics","ticker":null,"asset":"Aleniglipron","indication":"Obese","summary":"As of 27 April 2026, Gasherbrum Bio estimated primary completion of a Phase 2 trial in obese, in September 2026.","as_of":"2026-04-27","source":"clinicaltrials","source_ref":"NCT07400588","source_url":"https://clinicaltrials.gov/study/NCT07400588","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-99d6d25e-d85a-4d3a-ac90-b640fdf53d00"},{"id":"04116947-3304-4346-bdd9-f32999871366","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Georgiamune Inc","ticker":null,"asset":"GIM122","indication":"Advanced Solid Malignancies","summary":"As of 11 July 2025, Georgiamune estimated primary completion of a Phase 2 trial in Advanced Solid Malignancies, in September 2026.","as_of":"2025-07-11","source":"clinicaltrials","source_ref":"NCT06028074","source_url":"https://clinicaltrials.gov/study/NCT06028074","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-04116947-3304-4346-bdd9-f32999871366"},{"id":"9ffe7e98-e640-46e4-a752-1b7f6a5e4f6d","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Gilead Sciences","ticker":null,"asset":"Sacituzumab Govitecan-hziy (SG)","indication":"Non-small Cell Lung Cancer","summary":"As of 11 February 2026, Gilead Sciences estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in September 2026.","as_of":"2026-02-11","source":"clinicaltrials","source_ref":"NCT05186974","source_url":"https://clinicaltrials.gov/study/NCT05186974","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9ffe7e98-e640-46e4-a752-1b7f6a5e4f6d"},{"id":"8e7e5cfe-658f-4f30-9000-1f9dd4cc9ce9","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Gilead Sciences","ticker":null,"asset":"TAF","indication":"Chronic Hepatitis B","summary":"As of 18 June 2026, Gilead Sciences estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, in September 2026.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT02932150","source_url":"https://clinicaltrials.gov/study/NCT02932150","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8e7e5cfe-658f-4f30-9000-1f9dd4cc9ce9"},{"id":"f8d55dcf-f9d3-49ee-bf02-c5a7356cb0b5","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Glaukos Corporation","ticker":null,"asset":"GLK-321 low dose BID","indication":"Demodex Blepharitis","summary":"As of 27 February 2026, Glaukos estimated primary completion of a Phase 2 trial in Demodex Blepharitis, in September 2026.","as_of":"2026-02-27","source":"clinicaltrials","source_ref":"NCT07400965","source_url":"https://clinicaltrials.gov/study/NCT07400965","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f8d55dcf-f9d3-49ee-bf02-c5a7356cb0b5"},{"id":"e48c0421-939b-4eb7-b671-106d30e710f6","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Dostarlimab","indication":"Neoplasms, Head and Neck","summary":"As of 24 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Neoplasms, Head and Neck, on 1 September 2026.","as_of":"2026-06-24","source":"clinicaltrials","source_ref":"NCT06062420","source_url":"https://clinicaltrials.gov/study/NCT06062420","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e48c0421-939b-4eb7-b671-106d30e710f6"},{"id":"53133ee0-7753-4514-aca1-4d9bf2112561","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Guangdong Hengrui Pharmaceutical Co., Ltd","ticker":null,"asset":"SHR-1905 Injection","indication":"Moderate-to-severe Atopic Dermatitis","summary":"As of 8 April 2026, Guangdong Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Moderate-to-severe Atopic Dermatitis, in September 2026.","as_of":"2026-04-08","source":"clinicaltrials","source_ref":"NCT07211542","source_url":"https://clinicaltrials.gov/study/NCT07211542","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-53133ee0-7753-4514-aca1-4d9bf2112561"},{"id":"f1fc0763-3ff0-4ef3-9bd4-f496fdb99b91","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Hexaell Biotech Co., Ltd.","ticker":null,"asset":"HepaCure","indication":"Acute on Chronic Hepatic Failure","summary":"As of 25 February 2025, Hexaell Biotech Co. estimated primary completion of a Phase 2 trial in Acute on Chronic Hepatic Failure, in September 2026.","as_of":"2025-02-25","source":"clinicaltrials","source_ref":"NCT05989958","source_url":"https://clinicaltrials.gov/study/NCT05989958","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f1fc0763-3ff0-4ef3-9bd4-f496fdb99b91"},{"id":"9189900f-0c04-4ae1-92d3-dd464a01bd59","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"Incyte Corporation","ticker":null,"asset":"Tafasitamab","indication":"Diffuse Large B-cell Lymphoma","summary":"As of 1 April 2026, Incyte estimated primary completion of a Phase 3 trial in Diffuse Large B-cell Lymphoma, on 1 September 2026.","as_of":"2026-04-01","source":"clinicaltrials","source_ref":"NCT04824092","source_url":"https://clinicaltrials.gov/study/NCT04824092","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9189900f-0c04-4ae1-92d3-dd464a01bd59"},{"id":"9536023d-43b9-42c1-9ed3-4574d9e53845","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"Initiator Pharma","ticker":null,"asset":"Pudafensine","indication":"Vulvodynia","summary":"As of 5 February 2026, Initiator Pharma estimated primary completion of a Phase 2 trial in vulvodynia, on 1 September 2026.","as_of":"2026-02-05","source":"clinicaltrials","source_ref":"NCT07391241","source_url":"https://clinicaltrials.gov/study/NCT07391241","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9536023d-43b9-42c1-9ed3-4574d9e53845"},{"id":"902ce75c-c07e-40d0-8e10-4314368ac847","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Jiangsu BioJeTay Biotechnology Co., Ltd.","ticker":null,"asset":"STSP-0601 for Injection","indication":"Hemophilia","summary":"As of 23 April 2026, Jiangsu BioJeTay Biotechnology Co. estimated primary completion of a Phase 3 trial in hemophilia, in September 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT06922045","source_url":"https://clinicaltrials.gov/study/NCT06922045","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-902ce75c-c07e-40d0-8e10-4314368ac847"},{"id":"32f8ea52-dae7-48ed-973e-4108efc60600","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Karyopharm Therapeutics Inc","ticker":null,"asset":"Selinexor","indication":"Myelofibrosis","summary":"As of 2 July 2026, Karyopharm Therapeutics estimated primary completion of a Phase 2 trial in myelofibrosis, in September 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT04562870","source_url":"https://clinicaltrials.gov/study/NCT04562870","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-32f8ea52-dae7-48ed-973e-4108efc60600"},{"id":"40eccffb-426d-4ed0-8895-43d2888c66dc","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Lubris Bio Pty Ltd","ticker":null,"asset":"rhPRG4 450ug/ml","indication":"Ocular Graft Versus Host Disease","summary":"As of 20 January 2026, Lubris Bio Pty estimated primary completion of a Phase 2 trial in Ocular Graft Versus Host Disease, in September 2026.","as_of":"2026-01-20","source":"clinicaltrials","source_ref":"NCT07118254","source_url":"https://clinicaltrials.gov/study/NCT07118254","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-40eccffb-426d-4ed0-8895-43d2888c66dc"},{"id":"940bba22-dd2b-4795-854c-69dfbeb2006d","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Mabwell (Shanghai) Bioscience Co., Ltd.","ticker":null,"asset":"9MW2821","indication":"Advanced Urothelial Carcinoma","summary":"As of 13 April 2025, Mabwell (Shanghai) Bioscience Co. estimated primary completion of a Phase 3 trial in Advanced Urothelial Carcinoma, in September 2026.","as_of":"2025-04-13","source":"clinicaltrials","source_ref":"NCT06196736","source_url":"https://clinicaltrials.gov/study/NCT06196736","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-940bba22-dd2b-4795-854c-69dfbeb2006d"},{"id":"866d83e4-700f-4565-9cb8-afcb07371124","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"Mabwell (Shanghai) Bioscience Co., Ltd.","ticker":null,"asset":"9MW2921","indication":"Advanced Solid Tumor","summary":"As of 21 November 2024, Mabwell (Shanghai) Bioscience Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 1 September 2026.","as_of":"2024-11-21","source":"clinicaltrials","source_ref":"NCT05990452","source_url":"https://clinicaltrials.gov/study/NCT05990452","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-866d83e4-700f-4565-9cb8-afcb07371124"},{"id":"42913b59-7905-484d-939e-c244ff287762","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Maze Therapeutics","ticker":null,"asset":"MZE829","indication":"Proteinuric Kidney Disease","summary":"As of 27 July 2026, Maze Therapeutics estimated primary completion of a Phase 2 trial in Proteinuric Kidney Disease, in September 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT06830629","source_url":"https://clinicaltrials.gov/study/NCT06830629","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-42913b59-7905-484d-939e-c244ff287762"},{"id":"e2a5b335-8c36-4132-8b1e-3377b0832194","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"MediLink Therapeutics (Suzhou) Co., Ltd.","ticker":null,"asset":"YL202 for injection; Toripalimab injection","indication":"Advanced Solid Tumors","summary":"As of 12 September 2025, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 1 September 2026.","as_of":"2025-09-12","source":"clinicaltrials","source_ref":"NCT07169994","source_url":"https://clinicaltrials.gov/study/NCT07169994","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e2a5b335-8c36-4132-8b1e-3377b0832194"},{"id":"d09f9c8d-6255-4c0c-bf87-7718a2e3f791","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Nacuity Pharmaceuticals, Inc.","ticker":null,"asset":"NPI-002 Intravitreal Implant","indication":"Cataract","summary":"As of 13 April 2026, Nacuity Pharmaceuticals estimated primary completion of a Phase 2 trial in cataract, in September 2026.","as_of":"2026-04-13","source":"clinicaltrials","source_ref":"NCT05026632","source_url":"https://clinicaltrials.gov/study/NCT05026632","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d09f9c8d-6255-4c0c-bf87-7718a2e3f791"},{"id":"90510ce2-db6a-4583-953e-8dc37e7ec9b2","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"NewAmsterdam Pharma","ticker":null,"asset":"Obicetrapib 10mg","indication":"Antioxidant Absorption","summary":"As of 20 October 2025, NewAmsterdam Pharma estimated primary completion of a Phase 2 trial in Antioxidant Absorption, in September 2026.","as_of":"2025-10-20","source":"clinicaltrials","source_ref":"NCT06982508","source_url":"https://clinicaltrials.gov/study/NCT06982508","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-90510ce2-db6a-4583-953e-8dc37e7ec9b2"},{"id":"0f7addd0-dd46-4049-9e08-203a31463b5c","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"Novo Nordisk A/S","ticker":null,"asset":"NNC0519-0130","indication":"Chronic Kidney Disease","summary":"As of 11 March 2026, Novo Nordisk estimated primary completion of a Phase 2 trial in Chronic Kidney Disease, on 1 September 2026.","as_of":"2026-03-11","source":"clinicaltrials","source_ref":"NCT06717698","source_url":"https://clinicaltrials.gov/study/NCT06717698","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0f7addd0-dd46-4049-9e08-203a31463b5c"},{"id":"357d338b-e9a6-4656-a97e-c176b91248ed","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"ORIC Pharmaceuticals","ticker":null,"asset":"ORIC-114","indication":"Solid Tumors","summary":"As of 5 August 2025, ORIC Pharmaceuticals estimated primary completion of a Phase 2 trial in Solid Tumors, in September 2026.","as_of":"2025-08-05","source":"clinicaltrials","source_ref":"NCT05315700","source_url":"https://clinicaltrials.gov/study/NCT05315700","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-357d338b-e9a6-4656-a97e-c176b91248ed"},{"id":"ea0bd0e6-c702-4b6c-a51c-237bb32ad5cd","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Octapharma","ticker":null,"asset":"Newnorm","indication":"Primary Immune Deficiency","summary":"As of 6 August 2026, Octapharma estimated primary completion of a Phase 3 trial in Primary Immune Deficiency, in September 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT04640142","source_url":"https://clinicaltrials.gov/study/NCT04640142","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ea0bd0e6-c702-4b6c-a51c-237bb32ad5cd"},{"id":"d6a8d5e8-8dba-4950-973b-04416d12ddc2","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"ARV-471","indication":"Breast Cancer","summary":"As of 10 February 2026, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 1 September 2026.","as_of":"2026-02-10","source":"clinicaltrials","source_ref":"NCT05548127","source_url":"https://clinicaltrials.gov/study/NCT05548127","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d6a8d5e8-8dba-4950-973b-04416d12ddc2"},{"id":"f949be40-de4b-45f4-8216-a4363837ae26","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Pharmazz, Inc.","ticker":null,"asset":"Drug: Normal Saline","indication":"Acute Ischemic Stroke","summary":"As of 24 June 2026, Pharmazz estimated primary completion of a Phase 3 trial in Acute Ischemic Stroke, in September 2026.","as_of":"2026-06-24","source":"clinicaltrials","source_ref":"NCT05691244","source_url":"https://clinicaltrials.gov/study/NCT05691244","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f949be40-de4b-45f4-8216-a4363837ae26"},{"id":"517baf7a-11b2-4279-af64-b302cba54597","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Processa Pharmaceuticals","ticker":null,"asset":"PCS6422 and capecitabine","indication":"Breast Cancer","summary":"As of 19 June 2025, Processa Pharmaceuticals estimated primary completion of a Phase 2 trial in Breast Cancer, in September 2026.","as_of":"2025-06-19","source":"clinicaltrials","source_ref":"NCT06568692","source_url":"https://clinicaltrials.gov/study/NCT06568692","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-517baf7a-11b2-4279-af64-b302cba54597"},{"id":"37f14cb3-4910-4bad-bc65-0c347e9c6c14","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"asset":"GM1","indication":"Chemotherapy-induced Peripheral Neuropathy (CIPN)","summary":"As of 6 August 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Chemotherapy-induced Peripheral Neuropathy (CIPN), in September 2026.","as_of":"2025-08-06","source":"clinicaltrials","source_ref":"NCT06994507","source_url":"https://clinicaltrials.gov/study/NCT06994507","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-37f14cb3-4910-4bad-bc65-0c347e9c6c14"},{"id":"1f33554d-c342-49a2-897a-92405a8c7d7d","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Qlaris Bio, Inc.","ticker":null,"asset":"QLS-111 Ophthalmic Solution (0.015%)","indication":"Non-proliferative Diabetic Retinopathy (NPDR)","summary":"As of 6 July 2026, Qlaris Bio estimated primary completion of a Phase 2 trial in Non-proliferative Diabetic Retinopathy (NPDR), in September 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT07354477","source_url":"https://clinicaltrials.gov/study/NCT07354477","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1f33554d-c342-49a2-897a-92405a8c7d7d"},{"id":"6b4a3a06-fd13-4423-b173-9dfe93e744c0","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"R-Pharm International, LLC","ticker":null,"asset":"OKZ q4w","indication":"Juvenile Idiopathic Arthritis","summary":"As of 8 April 2026, R-Pharm International estimated primary completion of a Phase 2 trial in Juvenile Idiopathic Arthritis, in September 2026.","as_of":"2026-04-08","source":"clinicaltrials","source_ref":"NCT07517575","source_url":"https://clinicaltrials.gov/study/NCT07517575","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6b4a3a06-fd13-4423-b173-9dfe93e744c0"},{"id":"e2454f18-ca8f-4199-af3a-2d8ba7c4aa66","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"REGENXBIO Inc.","ticker":null,"asset":"RGX-202","indication":"Duchenne Muscular Dystrophy","summary":"As of 21 July 2026, REGENXBIO estimated primary completion of a Phase 3 trial in Duchenne Muscular Dystrophy, in September 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT05693142","source_url":"https://clinicaltrials.gov/study/NCT05693142","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e2454f18-ca8f-4199-af3a-2d8ba7c4aa66"},{"id":"a2268ab3-74b3-4280-b7a4-00b3dfe1a853","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Repurposed Therapeutics, Inc.","ticker":null,"asset":"DPI-386 Nasal Gel","indication":"Motion Sickness, Space","summary":"As of 16 May 2024, Repurposed Therapeutics estimated primary completion of a Phase 2 trial in Motion Sickness, Space, in September 2026.","as_of":"2024-05-16","source":"clinicaltrials","source_ref":"NCT05852730","source_url":"https://clinicaltrials.gov/study/NCT05852730","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a2268ab3-74b3-4280-b7a4-00b3dfe1a853"},{"id":"28f45400-f51f-493d-b17c-eba931f35dd2","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Ribocure Pharmaceuticals AB","ticker":null,"asset":"RBD1016","indication":"Chronic Hepatitis D","summary":"As of 3 February 2026, Ribocure Pharmaceuticals estimated primary completion of a Phase 2 trial in Chronic Hepatitis D, in September 2026.","as_of":"2026-02-03","source":"clinicaltrials","source_ref":"NCT06649266","source_url":"https://clinicaltrials.gov/study/NCT06649266","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-28f45400-f51f-493d-b17c-eba931f35dd2"},{"id":"51505ee8-9ee1-45ad-9d79-5a9f0fec4ed4","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"ScandiBio Therapeutics AB","ticker":null,"asset":"Combined metabolic activators","indication":"Alzheimer Disease","summary":"As of 6 February 2026, ScandiBio Therapeutics estimated primary completion of a Phase 3 trial in Alzheimer Disease, in September 2026.","as_of":"2026-02-06","source":"clinicaltrials","source_ref":"NCT07062198","source_url":"https://clinicaltrials.gov/study/NCT07062198","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-51505ee8-9ee1-45ad-9d79-5a9f0fec4ed4"},{"id":"a40301b5-8d8c-4b0b-965a-1b0803a1de79","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"asset":"HRS-1893 Tablets","indication":"Obstructive Hypertrophic Cardiomyopathy","summary":"As of 20 August 2025, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 3 trial in Obstructive Hypertrophic Cardiomyopathy, in September 2026.","as_of":"2025-08-20","source":"clinicaltrials","source_ref":"NCT07021976","source_url":"https://clinicaltrials.gov/study/NCT07021976","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a40301b5-8d8c-4b0b-965a-1b0803a1de79"},{"id":"9b77a3ad-59d6-49b3-b133-b2c581929ca7","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Shanghai HyaMab Biotech Co.,Ltd.","ticker":null,"asset":"PE0116&PE0105","indication":"Locally Advanced/Metastatic Solid Tumors","summary":"As of 15 December 2023, Shanghai HyaMab Biotech Co. estimated primary completion of a Phase 2 trial in Locally Advanced/Metastatic Solid Tumors, in September 2026.","as_of":"2023-12-15","source":"clinicaltrials","source_ref":"NCT05801237","source_url":"https://clinicaltrials.gov/study/NCT05801237","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b77a3ad-59d6-49b3-b133-b2c581929ca7"},{"id":"3d0a06cf-eb34-458a-b55c-49148ae3ac05","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","ticker":null,"asset":"PRT-064040 nasal spray","indication":"Migraine","summary":"As of 29 January 2026, Sichuan Purity Pharmaceutical Technology Co. estimated primary completion of a Phase 2 trial in migraine, in September 2026.","as_of":"2026-01-29","source":"clinicaltrials","source_ref":"NCT07304518","source_url":"https://clinicaltrials.gov/study/NCT07304518","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3d0a06cf-eb34-458a-b55c-49148ae3ac05"},{"id":"93aaf15a-3a6c-4d6b-99eb-dc3105a93e69","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Silence Therapeutics plc","ticker":null,"asset":"SLN124","indication":"Polycythemia Vera","summary":"As of 19 December 2025, Silence Therapeutics estimated primary completion of a Phase 2 trial in Polycythemia Vera, in September 2026.","as_of":"2025-12-19","source":"clinicaltrials","source_ref":"NCT05499013","source_url":"https://clinicaltrials.gov/study/NCT05499013","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-93aaf15a-3a6c-4d6b-99eb-dc3105a93e69"},{"id":"5c2391c3-c77c-4b97-b260-3d69c1b9ecf6","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Sinovac Life Sciences Co., Ltd.","ticker":null,"asset":"Sinovac PCV24","indication":"Pneumococcal Infectious Disease","summary":"As of 24 December 2025, Sinovac Life Sciences Co. estimated primary completion of a Phase 2 trial in Pneumococcal Infectious Disease, in September 2026.","as_of":"2025-12-24","source":"clinicaltrials","source_ref":"NCT07300644","source_url":"https://clinicaltrials.gov/study/NCT07300644","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5c2391c3-c77c-4b97-b260-3d69c1b9ecf6"},{"id":"e020ca85-b22f-4c0b-b6a0-08a2fdae7817","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Supernus Pharmaceuticals, Inc.","ticker":null,"asset":"SPN-812","indication":"Attention-Deficit/Hyperactivity Disorder","summary":"As of 15 July 2026, Supernus Pharmaceuticals estimated primary completion of a Phase 3 trial in Attention-Deficit/Hyperactivity Disorder, in September 2026.","as_of":"2026-07-15","source":"clinicaltrials","source_ref":"NCT02736656","source_url":"https://clinicaltrials.gov/study/NCT02736656","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e020ca85-b22f-4c0b-b6a0-08a2fdae7817"},{"id":"de89aeaa-0b76-4f71-ab36-f97e63f07ca4","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"asset":"SHR-8068","indication":"Advanced Hepatocellular Carcinoma","summary":"As of 4 May 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 3 trial in Advanced Hepatocellular Carcinoma, in September 2026.","as_of":"2026-05-04","source":"clinicaltrials","source_ref":"NCT06618664","source_url":"https://clinicaltrials.gov/study/NCT06618664","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-de89aeaa-0b76-4f71-ab36-f97e63f07ca4"},{"id":"ba7097d1-a32a-4296-93c5-f6ca11eb6b7a","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","ticker":null,"asset":"ZG005 for Injection","indication":"Hepatocellular Carcinoma","summary":"As of 16 December 2024, Suzhou Zelgen Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, in September 2026.","as_of":"2024-12-16","source":"clinicaltrials","source_ref":"NCT06558227","source_url":"https://clinicaltrials.gov/study/NCT06558227","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ba7097d1-a32a-4296-93c5-f6ca11eb6b7a"},{"id":"994f1236-cd7a-421b-8cce-bcc4c7642f46","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","ticker":null,"asset":"ZG006","indication":"Small Cell Lung Cancer","summary":"As of 5 January 2026, Suzhou Zelgen Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Small Cell Lung Cancer, in September 2026.","as_of":"2026-01-05","source":"clinicaltrials","source_ref":"NCT05978284","source_url":"https://clinicaltrials.gov/study/NCT05978284","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-994f1236-cd7a-421b-8cce-bcc4c7642f46"},{"id":"0beb6e20-3120-47d9-8376-050ee834de58","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Syndax Pharmaceuticals","ticker":null,"asset":"Axatilimab","indication":"Idiopathic Pulmonary Fibrosis","summary":"As of 27 March 2026, Syndax Pharmaceuticals estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in September 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT06132256","source_url":"https://clinicaltrials.gov/study/NCT06132256","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0beb6e20-3120-47d9-8376-050ee834de58"},{"id":"965679d2-4260-4f88-8346-e46ef690b35e","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"TYK Medicines, Inc","ticker":null,"asset":"TYK-00540","indication":"HR-positive, HER2-negative Advanced Breast Cancer","summary":"As of 29 April 2025, TYK Medicines estimated primary completion of a Phase 2 trial in HR-positive, HER2-negative Advanced Breast Cancer, in September 2026.","as_of":"2025-04-29","source":"clinicaltrials","source_ref":"NCT06950086","source_url":"https://clinicaltrials.gov/study/NCT06950086","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-965679d2-4260-4f88-8346-e46ef690b35e"},{"id":"b2f2874d-0156-490f-9aa6-6fe4a7f9c6ac","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Tango Therapeutics, Inc.","ticker":null,"asset":"TNG260","indication":"Non Small Cell Lung Cancer","summary":"As of 6 July 2026, Tango Therapeutics estimated primary completion of a Phase 2 trial in Non Small Cell Lung Cancer, in September 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT05887492","source_url":"https://clinicaltrials.gov/study/NCT05887492","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b2f2874d-0156-490f-9aa6-6fe4a7f9c6ac"},{"id":"1f863553-b8de-4283-a6f6-fe95be3d0694","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"Tarian Pharma","ticker":null,"asset":"Brimonidine tartrate Gel","indication":"EGFR Inhibitor-associated Rash","summary":"As of 10 February 2025, Tarian Pharma estimated primary completion of a Phase 2 trial in EGFR Inhibitor-associated Rash, on 1 September 2026.","as_of":"2025-02-10","source":"clinicaltrials","source_ref":"NCT06818058","source_url":"https://clinicaltrials.gov/study/NCT06818058","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1f863553-b8de-4283-a6f6-fe95be3d0694"},{"id":"95abf599-931b-451f-b00a-90eb733da072","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Tiziana Life Sciences LTD","ticker":null,"asset":"Foralumab","indication":"Secondary Progressive Multiple Sclerosis","summary":"As of 2 July 2026, Tiziana Life Sciences estimated primary completion of a Phase 2 trial in Secondary Progressive Multiple Sclerosis, in September 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT06292923","source_url":"https://clinicaltrials.gov/study/NCT06292923","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-95abf599-931b-451f-b00a-90eb733da072"},{"id":"0038f6e1-85cd-4648-a33a-7d1d13b9cd40","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Tourmaline Bio, Inc., a Novartis Company","ticker":null,"asset":"TOUR006 - 20 MG","indication":"Thyroid Eye Disease","summary":"As of 23 April 2026, Tourmaline Bio, Inc., a Novartis estimated primary completion of a Phase 2 trial in Thyroid Eye Disease, in September 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT06088979","source_url":"https://clinicaltrials.gov/study/NCT06088979","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0038f6e1-85cd-4648-a33a-7d1d13b9cd40"},{"id":"84fc94cb-29d1-443e-9f26-c91bee96c038","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"UCB BIOSCIENCES, Inc.","ticker":null,"asset":"fenfluramine","indication":"Dravet Syndrome","summary":"As of 7 August 2026, UCB BIOSCIENCES estimated primary completion of a Phase 3 trial in Dravet Syndrome, on 1 September 2026.","as_of":"2026-08-07","source":"clinicaltrials","source_ref":"NCT06118255","source_url":"https://clinicaltrials.gov/study/NCT06118255","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-84fc94cb-29d1-443e-9f26-c91bee96c038"},{"id":"fc629019-e63d-4c0f-a05c-a93a352bd39f","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Vanda Pharmaceuticals","ticker":null,"asset":"Trichostatin A","indication":"Onychomycosis of Toenail","summary":"As of 4 February 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 2 trial in Onychomycosis of Toenail, in September 2026.","as_of":"2026-02-04","source":"clinicaltrials","source_ref":"NCT07065773","source_url":"https://clinicaltrials.gov/study/NCT07065773","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fc629019-e63d-4c0f-a05c-a93a352bd39f"},{"id":"93866912-df05-47a9-bc5d-d070bb8b46b6","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Vanda Pharmaceuticals","ticker":null,"asset":"Tasimelteon","indication":"Sleep Wake Disorders","summary":"As of 27 July 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 3 trial in Sleep Wake Disorders, in September 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT04652882","source_url":"https://clinicaltrials.gov/study/NCT04652882","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-93866912-df05-47a9-bc5d-d070bb8b46b6"},{"id":"46666be3-0932-4090-9f14-c381d9113bad","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Vanda Pharmaceuticals","ticker":null,"asset":"VSJ-110","indication":"Dry Eye","summary":"As of 17 September 2025, Vanda Pharmaceuticals estimated primary completion of a Phase 2 trial in Dry Eye, in September 2026.","as_of":"2025-09-17","source":"clinicaltrials","source_ref":"NCT07179055","source_url":"https://clinicaltrials.gov/study/NCT07179055","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-46666be3-0932-4090-9f14-c381d9113bad"},{"id":"4dd3b391-a999-447a-b355-05f6f0ef30e9","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Vera Therapeutics, Inc.","ticker":null,"asset":"Atacicept","indication":"IgA Nephropathy (IgAN)","summary":"As of 13 April 2026, Vera Therapeutics estimated primary completion of a Phase 2 trial in IgA Nephropathy (IgAN), in September 2026.","as_of":"2026-04-13","source":"clinicaltrials","source_ref":"NCT07020923","source_url":"https://clinicaltrials.gov/study/NCT07020923","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4dd3b391-a999-447a-b355-05f6f0ef30e9"},{"id":"a696ace5-6ed2-423e-be78-feac3fde47b9","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"day","confidence":"estimated","company":"Vigonvita Life Sciences","ticker":null,"asset":"LV232 40mg","indication":"MDD","summary":"As of 20 May 2026, Vigonvita Life Sciences estimated primary completion of a Phase 2 trial in mDD, on 1 September 2026.","as_of":"2026-05-20","source":"clinicaltrials","source_ref":"NCT06828887","source_url":"https://clinicaltrials.gov/study/NCT06828887","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a696ace5-6ed2-423e-be78-feac3fde47b9"},{"id":"ca91509b-7cab-45b6-906f-7df29c7f24b4","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"Wave Life Sciences USA, Inc.","ticker":null,"asset":"WVE-006","indication":"Alpha-1 Antitrypsin Deficiency","summary":"As of 14 April 2026, Wave Life Sciences USA estimated primary completion of a Phase 2 trial in Alpha-1 Antitrypsin Deficiency, in September 2026.","as_of":"2026-04-14","source":"clinicaltrials","source_ref":"NCT06405633","source_url":"https://clinicaltrials.gov/study/NCT06405633","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ca91509b-7cab-45b6-906f-7df29c7f24b4"},{"id":"5f51c131-e892-46f2-9419-4734596e4e36","lane":"clinical","event_type":"primary-completion","date":"2026-09-01","date_precision":"month","confidence":"estimated","company":"argenx","ticker":null,"asset":"Empasiprubart","indication":"Multifocal Motor Neuropathy (MMN)","summary":"As of 20 May 2026, argenx estimated primary completion of a Phase 3 trial in Multifocal Motor Neuropathy (MMN), in September 2026.","as_of":"2026-05-20","source":"clinicaltrials","source_ref":"NCT06742190","source_url":"https://clinicaltrials.gov/study/NCT06742190","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5f51c131-e892-46f2-9419-4734596e4e36"},{"id":"9469afb5-5b24-494d-a586-948907655840","lane":"clinical","event_type":"primary-completion","date":"2026-09-02","date_precision":"day","confidence":"estimated","company":"Boehringer Ingelheim","ticker":null,"asset":"zongertinib","indication":"Lung Cancer, Non-squamous, Non-small Cell","summary":"As of 23 July 2026, Boehringer Ingelheim estimated primary completion of a Phase 3 trial in Lung Cancer, Non-squamous, Non-small Cell, on 2 September 2026.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT06151574","source_url":"https://clinicaltrials.gov/study/NCT06151574","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9469afb5-5b24-494d-a586-948907655840"},{"id":"ce00beff-f312-47a8-a668-08a753e6ca90","lane":"clinical","event_type":"primary-completion","date":"2026-09-02","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"PF-07868489","indication":"Pulmonary Arterial Hypertension","summary":"As of 19 May 2026, Pfizer estimated primary completion of a Phase 2 trial in Pulmonary Arterial Hypertension, on 2 September 2026.","as_of":"2026-05-19","source":"clinicaltrials","source_ref":"NCT06137742","source_url":"https://clinicaltrials.gov/study/NCT06137742","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ce00beff-f312-47a8-a668-08a753e6ca90"},{"id":"299641f1-792c-494a-a7c7-67bc330a4eeb","lane":"clinical","event_type":"primary-completion","date":"2026-09-03","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"SAR441344 IV","indication":"Systemic Lupus Erythematosus","summary":"As of 6 August 2026, Sanofi estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus, on 3 September 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT05039840","source_url":"https://clinicaltrials.gov/study/NCT05039840","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-299641f1-792c-494a-a7c7-67bc330a4eeb"},{"id":"4f5ec661-e942-4843-b686-5a905fe03fb2","lane":"clinical","event_type":"primary-completion","date":"2026-09-04","date_precision":"day","confidence":"estimated","company":"Clear Scientific, Inc.","ticker":null,"asset":"Methamphetamine","indication":"Methamphetamine Intoxication","summary":"As of 7 July 2026, Clear Scientific estimated primary completion of a Phase 2 trial in Methamphetamine Intoxication, on 4 September 2026.","as_of":"2026-07-07","source":"clinicaltrials","source_ref":"NCT06721494","source_url":"https://clinicaltrials.gov/study/NCT06721494","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4f5ec661-e942-4843-b686-5a905fe03fb2"},{"id":"ba884bb6-bf17-43c7-baab-df2a05f398dc","lane":"clinical","event_type":"primary-completion","date":"2026-09-05","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"BMS-986490","indication":"Advanced Solid Tumors","summary":"As of 2 July 2026, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 5 September 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT06730750","source_url":"https://clinicaltrials.gov/study/NCT06730750","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ba884bb6-bf17-43c7-baab-df2a05f398dc"},{"id":"3855f930-9047-4d2b-ad79-882d7cb6dfb0","lane":"clinical","event_type":"primary-completion","date":"2026-09-05","date_precision":"day","confidence":"estimated","company":"H. Lundbeck A/S","ticker":null,"asset":"Eptinezumab","indication":"Chronic Migraine in Children","summary":"As of 14 July 2026, H. Lundbeck estimated primary completion of a Phase 3 trial in Chronic Migraine in Children, on 5 September 2026.","as_of":"2026-07-14","source":"clinicaltrials","source_ref":"NCT04965675","source_url":"https://clinicaltrials.gov/study/NCT04965675","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3855f930-9047-4d2b-ad79-882d7cb6dfb0"},{"id":"8b203be6-b683-46f0-8e46-d2f10417adbb","lane":"clinical","event_type":"primary-completion","date":"2026-09-05","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Tulisokibart","indication":"Arthritis, Rheumatoid","summary":"As of 12 June 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Arthritis, Rheumatoid, on 5 September 2026.","as_of":"2026-06-12","source":"clinicaltrials","source_ref":"NCT07176390","source_url":"https://clinicaltrials.gov/study/NCT07176390","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8b203be6-b683-46f0-8e46-d2f10417adbb"},{"id":"dadef6fe-d31b-4da7-9606-c35ecf9dead0","lane":"clinical","event_type":"primary-completion","date":"2026-09-06","date_precision":"day","confidence":"estimated","company":"ALK-Abelló A/S","ticker":null,"asset":"HDM SLIT-tablet (12 SQ-HDM)","indication":"Allergic Rhinoconjunctivitis","summary":"As of 20 July 2026, ALK-Abelló estimated primary completion of a Phase 3 trial in Allergic Rhinoconjunctivitis, on 6 September 2026.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT07060885","source_url":"https://clinicaltrials.gov/study/NCT07060885","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dadef6fe-d31b-4da7-9606-c35ecf9dead0"},{"id":"0b4e6485-e4a1-4eb3-bb7c-1cac408ef35a","lane":"clinical","event_type":"primary-completion","date":"2026-09-06","date_precision":"day","confidence":"estimated","company":"CastleVax Inc.","ticker":null,"asset":"NDV-HXP-S-KP.2","indication":"COVID-19","summary":"As of 22 July 2026, CastleVax estimated primary completion of a Phase 2 trial in cOVID-19, on 6 September 2026.","as_of":"2026-07-22","source":"clinicaltrials","source_ref":"NCT07215520","source_url":"https://clinicaltrials.gov/study/NCT07215520","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0b4e6485-e4a1-4eb3-bb7c-1cac408ef35a"},{"id":"c4b1b7b3-d344-4aa7-8afb-72d7643e3cd2","lane":"clinical","event_type":"primary-completion","date":"2026-09-06","date_precision":"day","confidence":"estimated","company":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"asset":"IBI306","indication":"Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia","summary":"As of 14 April 2026, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia, on 6 September 2026.","as_of":"2026-04-14","source":"clinicaltrials","source_ref":"NCT07473960","source_url":"https://clinicaltrials.gov/study/NCT07473960","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c4b1b7b3-d344-4aa7-8afb-72d7643e3cd2"},{"id":"0785b9d7-a0da-4d88-8204-cc69a4778b92","lane":"clinical","event_type":"primary-completion","date":"2026-09-09","date_precision":"day","confidence":"estimated","company":"ViiV Healthcare","ticker":null,"asset":"CAB LA","indication":"HIV Infections","summary":"As of 18 November 2025, ViiV Healthcare estimated primary completion of a Phase 2 trial in HIV Infections, on 9 September 2026.","as_of":"2025-11-18","source":"clinicaltrials","source_ref":"NCT06741397","source_url":"https://clinicaltrials.gov/study/NCT06741397","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0785b9d7-a0da-4d88-8204-cc69a4778b92"},{"id":"e42ec202-3fad-440d-8545-2d89376cf44d","lane":"clinical","event_type":"primary-completion","date":"2026-09-10","date_precision":"day","confidence":"estimated","company":"Galaxy Therapeutics INC","ticker":null,"asset":"The SEAL™ Saccular Endovascular Aneurysm Lattice System","indication":"Intracranial Aneurysm","summary":"As of 16 January 2026, Galaxy Therapeutics estimated primary completion of a Phase 3 trial in Intracranial Aneurysm, on 10 September 2026.","as_of":"2026-01-16","source":"clinicaltrials","source_ref":"NCT05831202","source_url":"https://clinicaltrials.gov/study/NCT05831202","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e42ec202-3fad-440d-8545-2d89376cf44d"},{"id":"a864708a-ff35-4a11-b17c-1ee610a472d1","lane":"clinical","event_type":"primary-completion","date":"2026-09-10","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Candidate varicella vaccine","indication":"Chickenpox","summary":"As of 29 May 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in chickenpox, on 10 September 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT06855160","source_url":"https://clinicaltrials.gov/study/NCT06855160","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a864708a-ff35-4a11-b17c-1ee610a472d1"},{"id":"09c931ed-0351-41ae-aec8-99e9ff44b49e","lane":"clinical","event_type":"primary-completion","date":"2026-09-10","date_precision":"day","confidence":"estimated","company":"Shanghai Vitalgen BioPharma Co., Ltd.","ticker":null,"asset":"VGN-R09b","indication":"Parkinson's Disease","summary":"As of 31 March 2026, Shanghai Vitalgen BioPharma Co. estimated primary completion of a Phase 2 trial in Parkinson's Disease, on 10 September 2026.","as_of":"2026-03-31","source":"clinicaltrials","source_ref":"NCT06480461","source_url":"https://clinicaltrials.gov/study/NCT06480461","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-09c931ed-0351-41ae-aec8-99e9ff44b49e"},{"id":"53052be4-cec8-44b5-9cc7-0f54baad0174","lane":"clinical","event_type":"primary-completion","date":"2026-09-11","date_precision":"day","confidence":"estimated","company":"NS Pharma, Inc.","ticker":null,"asset":"NS-089/NCNP-02","indication":"Duchenne Muscular Dystrophy","summary":"As of 6 March 2026, NS Pharma estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 11 September 2026.","as_of":"2026-03-06","source":"clinicaltrials","source_ref":"NCT05996003","source_url":"https://clinicaltrials.gov/study/NCT05996003","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-53052be4-cec8-44b5-9cc7-0f54baad0174"},{"id":"e02199fb-e070-4a7f-9b4b-ea4ebc96d9aa","lane":"clinical","event_type":"primary-completion","date":"2026-09-11","date_precision":"day","confidence":"estimated","company":"Priovant Therapeutics, Inc.","ticker":null,"asset":"Brepocitinib PO QD","indication":"Uveitis, Posterior","summary":"As of 12 January 2026, Priovant Therapeutics estimated primary completion of a Phase 3 trial in Uveitis, Posterior, on 11 September 2026.","as_of":"2026-01-12","source":"clinicaltrials","source_ref":"NCT06431373","source_url":"https://clinicaltrials.gov/study/NCT06431373","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e02199fb-e070-4a7f-9b4b-ea4ebc96d9aa"},{"id":"de7986fb-2501-4573-921b-3a23c8221933","lane":"clinical","event_type":"primary-completion","date":"2026-09-13","date_precision":"day","confidence":"estimated","company":"Grit Biotechnology","ticker":null,"asset":"GT201","indication":"Solid Tumor, Adult","summary":"As of 27 April 2026, Grit Biotechnology estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 13 September 2026.","as_of":"2026-04-27","source":"clinicaltrials","source_ref":"NCT06144671","source_url":"https://clinicaltrials.gov/study/NCT06144671","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-de7986fb-2501-4573-921b-3a23c8221933"},{"id":"920a51ec-5306-4b17-bd49-549d45ec1d17","lane":"clinical","event_type":"primary-completion","date":"2026-09-15","date_precision":"day","confidence":"estimated","company":"Bayer","ticker":null,"asset":"BAY2599023 (DTX201)","indication":"Hemophilia A","summary":"As of 6 July 2026, Bayer estimated primary completion of a Phase 2 trial in Hemophilia A, on 15 September 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT03588299","source_url":"https://clinicaltrials.gov/study/NCT03588299","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-920a51ec-5306-4b17-bd49-549d45ec1d17"},{"id":"a16d6929-f645-4f9a-ab17-b5cc70b2431d","lane":"clinical","event_type":"primary-completion","date":"2026-09-15","date_precision":"day","confidence":"estimated","company":"H. Lundbeck A/S","ticker":null,"asset":"Lu AG13909","indication":"Cushing's Disease","summary":"As of 12 June 2026, H. Lundbeck estimated primary completion of a Phase 2 trial in Cushing's Disease, on 15 September 2026.","as_of":"2026-06-12","source":"clinicaltrials","source_ref":"NCT06471829","source_url":"https://clinicaltrials.gov/study/NCT06471829","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a16d6929-f645-4f9a-ab17-b5cc70b2431d"},{"id":"0b76581c-2457-450d-9be4-a48cb6518bd6","lane":"clinical","event_type":"primary-completion","date":"2026-09-15","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Pembrolizumab","indication":"Endometrial Neoplasms","summary":"As of 24 July 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Endometrial Neoplasms, on 15 September 2026.","as_of":"2026-07-24","source":"clinicaltrials","source_ref":"NCT04634877","source_url":"https://clinicaltrials.gov/study/NCT04634877","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0b76581c-2457-450d-9be4-a48cb6518bd6"},{"id":"479a7dab-a21e-468a-973e-f0c4a23eb0f5","lane":"clinical","event_type":"primary-completion","date":"2026-09-15","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"MET233 and MET097","indication":"Obesity and Obesity-related Medical Conditions","summary":"As of 1 June 2026, Pfizer estimated primary completion of a Phase 2 trial in Obesity and Obesity-related Medical Conditions, on 15 September 2026.","as_of":"2026-06-01","source":"clinicaltrials","source_ref":"NCT06924320","source_url":"https://clinicaltrials.gov/study/NCT06924320","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-479a7dab-a21e-468a-973e-f0c4a23eb0f5"},{"id":"ba5c190e-a25e-49b6-97f4-3f084c7847aa","lane":"clinical","event_type":"primary-completion","date":"2026-09-15","date_precision":"day","confidence":"estimated","company":"Teva Branded Pharmaceutical Products R&D LLC","ticker":null,"asset":"TEV-53408","indication":"Celiac Disease","summary":"As of 27 July 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 2 trial in Celiac Disease, on 15 September 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT06807463","source_url":"https://clinicaltrials.gov/study/NCT06807463","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ba5c190e-a25e-49b6-97f4-3f084c7847aa"},{"id":"160602a3-e0d8-46e1-976b-905b6dd12633","lane":"clinical","event_type":"primary-completion","date":"2026-09-15","date_precision":"day","confidence":"estimated","company":"Thirty Respiratory Limited","ticker":null,"asset":"RESP30TB","indication":"Pulmonary Tuberculoses","summary":"As of 12 January 2026, Thirty Respiratory estimated primary completion of a Phase 2 trial in Pulmonary Tuberculoses, on 15 September 2026.","as_of":"2026-01-12","source":"clinicaltrials","source_ref":"NCT07073638","source_url":"https://clinicaltrials.gov/study/NCT07073638","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-160602a3-e0d8-46e1-976b-905b6dd12633"},{"id":"ac19a949-c3fd-4515-ab64-d5ca29915051","lane":"clinical","event_type":"primary-completion","date":"2026-09-15","date_precision":"day","confidence":"estimated","company":"Wuhan YZY Biopharma Co., Ltd.","ticker":null,"asset":"M701 pleural infusion","indication":"Malignant Pleural Effusions","summary":"As of 8 July 2026, Wuhan YZY Biopharma Co. estimated primary completion of a Phase 2 trial in Malignant Pleural Effusions, on 15 September 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT05543330","source_url":"https://clinicaltrials.gov/study/NCT05543330","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ac19a949-c3fd-4515-ab64-d5ca29915051"},{"id":"edfb3628-a340-4a85-a4c0-7750366db5e8","lane":"clinical","event_type":"primary-completion","date":"2026-09-17","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Ocrelizumab Test Formulation","indication":"Multiple Sclerosis","summary":"As of 6 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Multiple Sclerosis, on 17 September 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT07074886","source_url":"https://clinicaltrials.gov/study/NCT07074886","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-edfb3628-a340-4a85-a4c0-7750366db5e8"},{"id":"7db638fc-2ee4-4839-a070-db182e0bb612","lane":"clinical","event_type":"primary-completion","date":"2026-09-17","date_precision":"day","confidence":"estimated","company":"Vertex Pharmaceuticals Incorporated","ticker":null,"asset":"Biological/Vaccine","indication":"Type 1 Diabetes","summary":"As of 23 March 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 3 trial in Type 1 Diabetes, on 17 September 2026.","as_of":"2026-03-23","source":"clinicaltrials","source_ref":"NCT06832410","source_url":"https://clinicaltrials.gov/study/NCT06832410","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7db638fc-2ee4-4839-a070-db182e0bb612"},{"id":"2fc039e3-a724-4c6b-be60-671794547cf9","lane":"clinical","event_type":"primary-completion","date":"2026-09-18","date_precision":"day","confidence":"estimated","company":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","ticker":null,"asset":"Topotecan - usual","indication":"SCLC","summary":"As of 8 September 2025, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair estimated primary completion of a Phase 3 trial in sCLC, on 18 September 2026.","as_of":"2025-09-08","source":"clinicaltrials","source_ref":"NCT07145333","source_url":"https://clinicaltrials.gov/study/NCT07145333","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2fc039e3-a724-4c6b-be60-671794547cf9"},{"id":"079fa468-0276-4e15-9a2f-f008ebb6b7d6","lane":"clinical","event_type":"primary-completion","date":"2026-09-18","date_precision":"day","confidence":"estimated","company":"Takeda","ticker":null,"asset":"TAK-279","indication":"Crohn's Disease","summary":"As of 6 July 2026, Takeda estimated primary completion of a Phase 2 trial in Crohn's Disease, on 18 September 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT06233461","source_url":"https://clinicaltrials.gov/study/NCT06233461","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-079fa468-0276-4e15-9a2f-f008ebb6b7d6"},{"id":"19c1ed51-52e4-419b-8612-749059af3143","lane":"clinical","event_type":"primary-completion","date":"2026-09-19","date_precision":"day","confidence":"estimated","company":"Teva Branded Pharmaceutical Products R&D LLC","ticker":null,"asset":"Fp/ABS","indication":"Asthma","summary":"As of 25 June 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 3 trial in asthma, on 19 September 2026.","as_of":"2026-06-25","source":"clinicaltrials","source_ref":"NCT06664619","source_url":"https://clinicaltrials.gov/study/NCT06664619","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-19c1ed51-52e4-419b-8612-749059af3143"},{"id":"80082423-e616-485b-97e3-8a9a8d5de32d","lane":"clinical","event_type":"primary-completion","date":"2026-09-20","date_precision":"day","confidence":"estimated","company":"Bharat Biotech International Limited","ticker":null,"asset":"BBV87 Chikungunya vaccine","indication":"Active Immunisation for Chikungunya Virus Infection","summary":"As of 29 April 2026, Bharat Biotech International estimated primary completion of a Phase 3 trial in Active Immunisation for Chikungunya Virus Infection, on 20 September 2026.","as_of":"2026-04-29","source":"clinicaltrials","source_ref":"NCT07555392","source_url":"https://clinicaltrials.gov/study/NCT07555392","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-80082423-e616-485b-97e3-8a9a8d5de32d"},{"id":"cb2bc70e-68a8-4d5e-9492-d82c077bd07e","lane":"clinical","event_type":"primary-completion","date":"2026-09-20","date_precision":"day","confidence":"estimated","company":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","ticker":null,"asset":"HDM1005 1","indication":"Obesity & Overweight","summary":"As of 12 December 2025, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Obesity & Overweight, on 20 September 2026.","as_of":"2025-12-12","source":"clinicaltrials","source_ref":"NCT07279194","source_url":"https://clinicaltrials.gov/study/NCT07279194","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cb2bc70e-68a8-4d5e-9492-d82c077bd07e"},{"id":"ff0f6c13-bd7b-436d-a851-4980cdbfd626","lane":"clinical","event_type":"primary-completion","date":"2026-09-21","date_precision":"day","confidence":"estimated","company":"Cardiol Therapeutics Inc.","ticker":null,"asset":"CardiolRx","indication":"Recurrent Pericarditis","summary":"As of 23 July 2026, Cardiol Therapeutics estimated primary completion of a Phase 3 trial in Recurrent Pericarditis, on 21 September 2026.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT06708299","source_url":"https://clinicaltrials.gov/study/NCT06708299","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ff0f6c13-bd7b-436d-a851-4980cdbfd626"},{"id":"72761681-3d5b-4184-bbf9-ebcac632e36f","lane":"clinical","event_type":"primary-completion","date":"2026-09-22","date_precision":"day","confidence":"estimated","company":"BeOne Medicines","ticker":null,"asset":"Sonrotoclax","indication":"Waldenstrom Macroglobulinemia","summary":"As of 2 January 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Waldenstrom Macroglobulinemia, on 22 September 2026.","as_of":"2026-01-02","source":"clinicaltrials","source_ref":"NCT05952037","source_url":"https://clinicaltrials.gov/study/NCT05952037","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-72761681-3d5b-4184-bbf9-ebcac632e36f"},{"id":"a3be4b30-5ef2-410d-8fb5-2d6e0fb641e4","lane":"clinical","event_type":"primary-completion","date":"2026-09-22","date_precision":"day","confidence":"estimated","company":"ImmVira Pharma Co. Ltd","ticker":null,"asset":"T3011","indication":"Solid Tumor","summary":"As of 8 October 2025, ImmVira Pharma Co. estimated primary completion of a Phase 2 trial in Solid Tumor, on 22 September 2026.","as_of":"2025-10-08","source":"clinicaltrials","source_ref":"NCT04370587","source_url":"https://clinicaltrials.gov/study/NCT04370587","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a3be4b30-5ef2-410d-8fb5-2d6e0fb641e4"},{"id":"91ffcf0c-21fc-44c5-bc40-68af0b1fb55a","lane":"clinical","event_type":"primary-completion","date":"2026-09-22","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Belzutifan","indication":"Renal Cell Carcinoma","summary":"As of 22 July 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 22 September 2026.","as_of":"2026-07-22","source":"clinicaltrials","source_ref":"NCT05468697","source_url":"https://clinicaltrials.gov/study/NCT05468697","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-91ffcf0c-21fc-44c5-bc40-68af0b1fb55a"},{"id":"734deea5-55aa-46dd-acf7-caff7b1a405b","lane":"clinical","event_type":"primary-completion","date":"2026-09-22","date_precision":"day","confidence":"estimated","company":"ModernaTX, Inc.","ticker":null,"asset":"mRNA-1403","indication":"Norovirus Acute Gastroenteritis","summary":"As of 3 April 2026, ModernaTX estimated primary completion of a Phase 2 trial in Norovirus Acute Gastroenteritis, on 22 September 2026.","as_of":"2026-04-03","source":"clinicaltrials","source_ref":"NCT05992935","source_url":"https://clinicaltrials.gov/study/NCT05992935","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-734deea5-55aa-46dd-acf7-caff7b1a405b"},{"id":"7219cdb1-140c-4a6e-9b36-2ffe593c0958","lane":"clinical","event_type":"primary-completion","date":"2026-09-23","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"PF-07220060","indication":"Liposarcoma","summary":"As of 1 October 2025, Pfizer estimated primary completion of a Phase 2 trial in liposarcoma, on 23 September 2026.","as_of":"2025-10-01","source":"clinicaltrials","source_ref":"NCT04557449","source_url":"https://clinicaltrials.gov/study/NCT04557449","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7219cdb1-140c-4a6e-9b36-2ffe593c0958"},{"id":"2fe2f14f-6f50-4848-a0af-f42c21d1b2fc","lane":"clinical","event_type":"primary-completion","date":"2026-09-23","date_precision":"day","confidence":"estimated","company":"Sinocelltech Ltd.","ticker":null,"asset":"SCT520FF","indication":"nAMD","summary":"As of 4 September 2025, Sinocelltech estimated primary completion of a Phase 2 trial in nAMD, on 23 September 2026.","as_of":"2025-09-04","source":"clinicaltrials","source_ref":"NCT06672536","source_url":"https://clinicaltrials.gov/study/NCT06672536","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2fe2f14f-6f50-4848-a0af-f42c21d1b2fc"},{"id":"4a2a0538-f40f-41cb-9e48-a08d275ecb7d","lane":"clinical","event_type":"primary-completion","date":"2026-09-24","date_precision":"day","confidence":"estimated","company":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"asset":"IBI362","indication":"Obesity","summary":"As of 11 July 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in obesity, on 24 September 2026.","as_of":"2025-07-11","source":"clinicaltrials","source_ref":"NCT06862908","source_url":"https://clinicaltrials.gov/study/NCT06862908","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4a2a0538-f40f-41cb-9e48-a08d275ecb7d"},{"id":"4084e37b-3ea7-4ca9-b2d8-666d01ce6aee","lane":"clinical","event_type":"primary-completion","date":"2026-09-24","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"YTB323","indication":"Systemic Lupus Erythematosus","summary":"As of 24 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus, on 24 September 2026.","as_of":"2026-07-24","source":"clinicaltrials","source_ref":"NCT05798117","source_url":"https://clinicaltrials.gov/study/NCT05798117","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4084e37b-3ea7-4ca9-b2d8-666d01ce6aee"},{"id":"654ced0a-9fa8-4c92-8dab-c9cfc962b31d","lane":"clinical","event_type":"primary-completion","date":"2026-09-27","date_precision":"day","confidence":"estimated","company":"Biogen","ticker":null,"asset":"Litifilimab","indication":"Lupus Erythematosus, Systemic","summary":"As of 29 January 2026, Biogen estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 27 September 2026.","as_of":"2026-01-29","source":"clinicaltrials","source_ref":"NCT04961567","source_url":"https://clinicaltrials.gov/study/NCT04961567","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-654ced0a-9fa8-4c92-8dab-c9cfc962b31d"},{"id":"c7e981f3-853d-4237-9ca7-32fcc583a8a0","lane":"clinical","event_type":"primary-completion","date":"2026-09-28","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD0901","indication":"Gastric Cancer","summary":"As of 17 June 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Gastric Cancer, on 28 September 2026.","as_of":"2026-06-17","source":"clinicaltrials","source_ref":"NCT07143604","source_url":"https://clinicaltrials.gov/study/NCT07143604","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c7e981f3-853d-4237-9ca7-32fcc583a8a0"},{"id":"de9bc696-4f4d-4d89-9142-83f2a9f18c73","lane":"clinical","event_type":"primary-completion","date":"2026-09-28","date_precision":"day","confidence":"estimated","company":"Attralus, Inc.","ticker":null,"asset":"AT02","indication":"Amyloidosis; Systemic","summary":"As of 6 May 2026, Attralus estimated primary completion of a Phase 2 trial in Amyloidosis; Systemic, on 28 September 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT05951049","source_url":"https://clinicaltrials.gov/study/NCT05951049","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-de9bc696-4f4d-4d89-9142-83f2a9f18c73"},{"id":"6ddf070a-d10e-443c-8be3-09510344e73b","lane":"clinical","event_type":"primary-completion","date":"2026-09-28","date_precision":"day","confidence":"estimated","company":"Incyte Corporation","ticker":null,"asset":"INCB099280","indication":"Cutaneous Squamous Cell Carcinoma","summary":"As of 24 February 2026, Incyte estimated primary completion of a Phase 2 trial in Cutaneous Squamous Cell Carcinoma, on 28 September 2026.","as_of":"2026-02-24","source":"clinicaltrials","source_ref":"NCT05888844","source_url":"https://clinicaltrials.gov/study/NCT05888844","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6ddf070a-d10e-443c-8be3-09510344e73b"},{"id":"1fd76975-4438-495d-957f-703621596517","lane":"clinical","event_type":"primary-completion","date":"2026-09-28","date_precision":"day","confidence":"estimated","company":"MoonLake Immunotherapeutics AG","ticker":null,"asset":"Sonelokimab","indication":"Hidradenitis Suppurativa","summary":"As of 6 May 2026, MoonLake Immunotherapeutics estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 28 September 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT06768671","source_url":"https://clinicaltrials.gov/study/NCT06768671","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1fd76975-4438-495d-957f-703621596517"},{"id":"74c31712-dff2-4df7-894d-08a357a91b4a","lane":"clinical","event_type":"primary-completion","date":"2026-09-28","date_precision":"day","confidence":"estimated","company":"Ocugen","ticker":null,"asset":"OCU410ST","indication":"Stargardt Disease","summary":"As of 31 July 2026, Ocugen estimated primary completion of a Phase 3 trial in Stargardt Disease, on 28 September 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT05956626","source_url":"https://clinicaltrials.gov/study/NCT05956626","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-74c31712-dff2-4df7-894d-08a357a91b4a"},{"id":"5197167a-b665-40f6-9ec9-ba497b432320","lane":"clinical","event_type":"primary-completion","date":"2026-09-29","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Depemokimab","indication":"Eosinophilic Granulomatosis With Polyangiitis","summary":"As of 8 July 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Eosinophilic Granulomatosis With Polyangiitis, on 29 September 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT05263934","source_url":"https://clinicaltrials.gov/study/NCT05263934","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5197167a-b665-40f6-9ec9-ba497b432320"},{"id":"f87eb617-8338-4ffb-b4c7-c7fed771fec9","lane":"clinical","event_type":"primary-completion","date":"2026-09-29","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"Amlitelimab","indication":"Asthma","summary":"As of 20 May 2026, Sanofi estimated primary completion of a Phase 2 trial in asthma, on 29 September 2026.","as_of":"2026-05-20","source":"clinicaltrials","source_ref":"NCT06033833","source_url":"https://clinicaltrials.gov/study/NCT06033833","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f87eb617-8338-4ffb-b4c7-c7fed771fec9"},{"id":"8c45cef4-a375-4e12-94e5-b1aab801413c","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Accro Bioscience (Suzhou) Limited","ticker":null,"asset":"AC-101","indication":"Ulcerative Colitis","summary":"As of 24 July 2025, Accro Bioscience (Suzhou) estimated primary completion of a Phase 2 trial in Ulcerative Colitis, on 30 September 2026.","as_of":"2025-07-24","source":"clinicaltrials","source_ref":"NCT07083193","source_url":"https://clinicaltrials.gov/study/NCT07083193","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8c45cef4-a375-4e12-94e5-b1aab801413c"},{"id":"819497d4-79ac-4e8e-8a63-0910c3bcf73b","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Allist Pharmaceuticals, Inc.","ticker":null,"asset":"JAB-21822","indication":"Advanced Non-squamous Non-small-cell Lung Cancer","summary":"As of 4 April 2025, Allist Pharmaceuticals estimated primary completion of a Phase 3 trial in Advanced Non-squamous Non-small-cell Lung Cancer, on 30 September 2026.","as_of":"2025-04-04","source":"clinicaltrials","source_ref":"NCT06416410","source_url":"https://clinicaltrials.gov/study/NCT06416410","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-819497d4-79ac-4e8e-8a63-0910c3bcf73b"},{"id":"4b543849-368b-4422-88ca-09b8e5eeeb8c","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Arrowhead Pharmaceuticals","ticker":null,"asset":"ARO-DIMERPA","indication":"Hyperlipidemia; Mixed","summary":"As of 13 July 2026, Arrowhead Pharmaceuticals estimated primary completion of a Phase 2 trial in Hyperlipidemia; Mixed, on 30 September 2026.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT07223658","source_url":"https://clinicaltrials.gov/study/NCT07223658","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4b543849-368b-4422-88ca-09b8e5eeeb8c"},{"id":"de2674c0-7fe9-4084-837b-c199cb4b798e","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Dato-DXd","indication":"Metastatic Non-small Cell Lung Cancer","summary":"As of 14 May 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Metastatic Non-small Cell Lung Cancer, on 30 September 2026.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT06417814","source_url":"https://clinicaltrials.gov/study/NCT06417814","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-de2674c0-7fe9-4084-837b-c199cb4b798e"},{"id":"f630bbd7-8f31-4b1e-9cf2-bde8a3d75890","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Durvalumab","indication":"Non-Small Cell Lung Cancer","summary":"As of 18 June 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 30 September 2026.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT05221840","source_url":"https://clinicaltrials.gov/study/NCT05221840","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f630bbd7-8f31-4b1e-9cf2-bde8a3d75890"},{"id":"ec83ff2f-695b-4655-85e0-dbeefb66a049","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD0780","indication":"Dyslipidaemia","summary":"As of 4 June 2026, AstraZeneca estimated primary completion of a Phase 2 trial in dyslipidaemia, on 30 September 2026.","as_of":"2026-06-04","source":"clinicaltrials","source_ref":"NCT07218900","source_url":"https://clinicaltrials.gov/study/NCT07218900","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ec83ff2f-695b-4655-85e0-dbeefb66a049"},{"id":"d4aa02bb-3629-422a-8f6b-96ea57468444","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Durvalumab","indication":"Hepatocellular Carcinoma","summary":"As of 26 June 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Hepatocellular Carcinoma, on 30 September 2026.","as_of":"2026-06-26","source":"clinicaltrials","source_ref":"NCT05557838","source_url":"https://clinicaltrials.gov/study/NCT05557838","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d4aa02bb-3629-422a-8f6b-96ea57468444"},{"id":"bd2bd318-4b87-448a-aba8-ea5ae9e1807d","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Beijing Continent Pharmaceutical Co, Ltd.","ticker":null,"asset":"Pirfenidone Capsules","indication":"Pneumoconiosis","summary":"As of 24 November 2025, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 3 trial in pneumoconiosis, on 30 September 2026.","as_of":"2025-11-24","source":"clinicaltrials","source_ref":"NCT05288179","source_url":"https://clinicaltrials.gov/study/NCT05288179","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bd2bd318-4b87-448a-aba8-ea5ae9e1807d"},{"id":"1279046f-7527-4a00-9b3c-8c1ae4a85782","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Beijing Pearl Biotechnology Limited Liability Company","ticker":null,"asset":"PLB1001","indication":"Non-small Cell Lung Cancer","summary":"As of 29 June 2025, Beijing Pearl Biotechnology Limited Liability estimated primary completion of a Phase 3 trial in Non-small Cell Lung Cancer, on 30 September 2026.","as_of":"2025-06-29","source":"clinicaltrials","source_ref":"NCT05989542","source_url":"https://clinicaltrials.gov/study/NCT05989542","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1279046f-7527-4a00-9b3c-8c1ae4a85782"},{"id":"8f8dd207-e7ba-437c-8ddb-dcb19048b52d","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"BioInvent International AB","ticker":null,"asset":"BI-1206","indication":"Indolent B-Cell Non-Hodgkin Lymphoma","summary":"As of 24 April 2025, BioInvent International estimated primary completion of a Phase 2 trial in Indolent B-Cell Non-Hodgkin Lymphoma, on 30 September 2026.","as_of":"2025-04-24","source":"clinicaltrials","source_ref":"NCT03571568","source_url":"https://clinicaltrials.gov/study/NCT03571568","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8f8dd207-e7ba-437c-8ddb-dcb19048b52d"},{"id":"767d46ad-90a6-4968-9394-67082fab6695","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Biogen","ticker":null,"asset":"Litifilimab","indication":"Lupus Erythematosus, Systemic","summary":"As of 10 February 2026, Biogen estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 30 September 2026.","as_of":"2026-02-10","source":"clinicaltrials","source_ref":"NCT04895241","source_url":"https://clinicaltrials.gov/study/NCT04895241","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-767d46ad-90a6-4968-9394-67082fab6695"},{"id":"ce0f33dd-2a59-41e9-9a58-85870deed00c","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"BMS-986449","indication":"Advanced Solid Tumors","summary":"As of 11 June 2025, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 30 September 2026.","as_of":"2025-06-11","source":"clinicaltrials","source_ref":"NCT05888831","source_url":"https://clinicaltrials.gov/study/NCT05888831","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ce0f33dd-2a59-41e9-9a58-85870deed00c"},{"id":"a54741ac-94b3-47db-811e-4a59a58e7ed2","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"CSPC Ouyi Pharmaceutical Co., Ltd.","ticker":null,"asset":"Dextromethorphan and Bupropion Sustained-Release Tablets","indication":"Major Depressive Disorder (MDD)","summary":"As of 6 May 2025, CSPC Ouyi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Major Depressive Disorder (MDD), on 30 September 2026.","as_of":"2025-05-06","source":"clinicaltrials","source_ref":"NCT06958692","source_url":"https://clinicaltrials.gov/study/NCT06958692","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a54741ac-94b3-47db-811e-4a59a58e7ed2"},{"id":"5a781452-c2f1-453f-b109-17476f8bcb11","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Cantex Pharmaceuticals","ticker":null,"asset":"Azeliragon","indication":"Glioblastoma","summary":"As of 31 March 2026, Cantex Pharmaceuticals estimated primary completion of a Phase 2 trial in glioblastoma, on 30 September 2026.","as_of":"2026-03-31","source":"clinicaltrials","source_ref":"NCT05986851","source_url":"https://clinicaltrials.gov/study/NCT05986851","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5a781452-c2f1-453f-b109-17476f8bcb11"},{"id":"ab86ed83-1c03-4610-b027-80489b14d888","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Chongqing Claruvis Pharmaceutical Co., Ltd.","ticker":null,"asset":"Recombinant Botulinum Toxin Type A for injection (YY001)","indication":"Upper Limb Spasticity","summary":"As of 22 January 2026, Chongqing Claruvis Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Upper Limb Spasticity, on 30 September 2026.","as_of":"2026-01-22","source":"clinicaltrials","source_ref":"NCT06783114","source_url":"https://clinicaltrials.gov/study/NCT06783114","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ab86ed83-1c03-4610-b027-80489b14d888"},{"id":"24b2c55e-1753-4b1f-8b99-9c4806f1bb4b","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Daiichi Sankyo","ticker":null,"asset":"Ifinatamab deruxtecan","indication":"Extensive Stage-small Cell Lung Cancer","summary":"As of 6 February 2026, Daiichi Sankyo estimated primary completion of a Phase 2 trial in Extensive Stage-small Cell Lung Cancer, on 30 September 2026.","as_of":"2026-02-06","source":"clinicaltrials","source_ref":"NCT06362252","source_url":"https://clinicaltrials.gov/study/NCT06362252","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-24b2c55e-1753-4b1f-8b99-9c4806f1bb4b"},{"id":"02479a36-72c1-4ccb-9db9-f33a32182005","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"EIP Pharma Inc","ticker":null,"asset":"Neflamapimod","indication":"Moderate to Severe Acute Ischaemic Stroke","summary":"As of 8 July 2026, EIP Pharma estimated primary completion of a Phase 2 trial in Moderate to Severe Acute Ischaemic Stroke, on 30 September 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT06987643","source_url":"https://clinicaltrials.gov/study/NCT06987643","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-02479a36-72c1-4ccb-9db9-f33a32182005"},{"id":"977b870d-a925-42ac-a941-47ff071e9cc4","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"EMD Serono Research & Development Institute, Inc.","ticker":null,"asset":"M1774","indication":"Non-Small Cell Lung Cancer","summary":"As of 28 May 2026, EMD Serono Research & Development Institute estimated primary completion of a Phase 2 trial in Non-Small Cell Lung Cancer, on 30 September 2026.","as_of":"2026-05-28","source":"clinicaltrials","source_ref":"NCT05882734","source_url":"https://clinicaltrials.gov/study/NCT05882734","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-977b870d-a925-42ac-a941-47ff071e9cc4"},{"id":"a98ec382-50e5-4b9f-a0ec-951f4e43ba18","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"EveryONE Medicines Inc.","ticker":null,"asset":"Individualized ASO","indication":"Pediatric SDLT CNS Disorders","summary":"As of 17 March 2026, EveryONE Medicines estimated primary completion of a Phase 2 trial in Pediatric SDLT CNS Disorders, on 30 September 2026.","as_of":"2026-03-17","source":"clinicaltrials","source_ref":"NCT07410143","source_url":"https://clinicaltrials.gov/study/NCT07410143","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a98ec382-50e5-4b9f-a0ec-951f4e43ba18"},{"id":"953b666b-3a86-48cc-b391-efd37fc69056","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"EyeBiotech Ltd.","ticker":null,"asset":"Ranibizumab","indication":"Diabetic Macular Edema (DME)","summary":"As of 26 June 2026, EyeBiotech estimated primary completion of a Phase 3 trial in Diabetic Macular Edema (DME), on 30 September 2026.","as_of":"2026-06-26","source":"clinicaltrials","source_ref":"NCT06571045","source_url":"https://clinicaltrials.gov/study/NCT06571045","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-953b666b-3a86-48cc-b391-efd37fc69056"},{"id":"48ab605e-69f7-4279-b4a1-9b0863ae7b27","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"GSK4527226","indication":"Alzheimer's Disease","summary":"As of 14 November 2025, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Alzheimer's Disease, on 30 September 2026.","as_of":"2025-11-14","source":"clinicaltrials","source_ref":"NCT06079190","source_url":"https://clinicaltrials.gov/study/NCT06079190","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-48ab605e-69f7-4279-b4a1-9b0863ae7b27"},{"id":"960b06ba-873a-4698-a263-54172eee94e7","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"RSVPreF3 OA vaccine","indication":"Respiratory Syncytial Virus Infections","summary":"As of 29 July 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Respiratory Syncytial Virus Infections, on 30 September 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT06534892","source_url":"https://clinicaltrials.gov/study/NCT06534892","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-960b06ba-873a-4698-a263-54172eee94e7"},{"id":"dd23850e-e08f-4354-96de-1c8a23ffd3d9","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Linerixibat","indication":"Cholestasis","summary":"As of 22 June 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in cholestasis, on 30 September 2026.","as_of":"2026-06-22","source":"clinicaltrials","source_ref":"NCT04167358","source_url":"https://clinicaltrials.gov/study/NCT04167358","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dd23850e-e08f-4354-96de-1c8a23ffd3d9"},{"id":"b333e321-fdd7-4ba1-9e0d-aa3dee6b9e54","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"iNTS-GMMA Dose C","indication":"Salmonella Infections","summary":"As of 19 May 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Salmonella Infections, on 30 September 2026.","as_of":"2026-05-19","source":"clinicaltrials","source_ref":"NCT06213506","source_url":"https://clinicaltrials.gov/study/NCT06213506","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b333e321-fdd7-4ba1-9e0d-aa3dee6b9e54"},{"id":"c6a16d68-d430-4aa1-8d3b-348376a5fe07","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Glycomine, Inc.","ticker":null,"asset":"GLM101 (Part A, Double-blind)","indication":"Phosphomannomutase 2 Deficiency","summary":"As of 27 February 2026, Glycomine estimated primary completion of a Phase 3 trial in Phosphomannomutase 2 Deficiency, on 30 September 2026.","as_of":"2026-02-27","source":"clinicaltrials","source_ref":"NCT06892288","source_url":"https://clinicaltrials.gov/study/NCT06892288","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c6a16d68-d430-4aa1-8d3b-348376a5fe07"},{"id":"9982b39b-4461-440c-b43d-232ce180a153","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Graegis Pharmaceuticals Ltd","ticker":null,"asset":"GR1014-CG 2.4%","indication":"Radiodermatitis; Acute","summary":"As of 25 September 2025, Graegis Pharmaceuticals estimated primary completion of a Phase 2 trial in Radiodermatitis; Acute, on 30 September 2026.","as_of":"2025-09-25","source":"clinicaltrials","source_ref":"NCT07192588","source_url":"https://clinicaltrials.gov/study/NCT07192588","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9982b39b-4461-440c-b43d-232ce180a153"},{"id":"eaafaaae-753f-4e85-ab6d-279addb708b8","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"H. Lundbeck A/S","ticker":null,"asset":"Lu AG13909","indication":"Congenital Adrenal Hyperplasia","summary":"As of 9 March 2026, H. Lundbeck estimated primary completion of a Phase 2 trial in Congenital Adrenal Hyperplasia, on 30 September 2026.","as_of":"2026-03-09","source":"clinicaltrials","source_ref":"NCT05669950","source_url":"https://clinicaltrials.gov/study/NCT05669950","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-eaafaaae-753f-4e85-ab6d-279addb708b8"},{"id":"1422d13c-53d1-4982-a689-4c92e8e9b798","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Hansoh BioMedical R&D Company","ticker":null,"asset":"HS-20093","indication":"Small Cell Lung Cancer","summary":"As of 16 October 2024, Hansoh BioMedical R&D estimated primary completion of a Phase 3 trial in Small Cell Lung Cancer, on 30 September 2026.","as_of":"2024-10-16","source":"clinicaltrials","source_ref":"NCT06498479","source_url":"https://clinicaltrials.gov/study/NCT06498479","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1422d13c-53d1-4982-a689-4c92e8e9b798"},{"id":"77e89eed-7e9a-421d-9017-c67cbe129af6","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Glofitamab","indication":"Lymphoma","summary":"As of 17 February 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in lymphoma, on 30 September 2026.","as_of":"2026-02-17","source":"clinicaltrials","source_ref":"NCT04980222","source_url":"https://clinicaltrials.gov/study/NCT04980222","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-77e89eed-7e9a-421d-9017-c67cbe129af6"},{"id":"dd4a79ed-8bd5-414b-966e-66a3816174a9","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"ImmunityBio, Inc.","ticker":null,"asset":"BCG (50mg/instillation) + N-803 (400 μg/instillation)","indication":"Non-muscle Invasive Bladder Cancer","summary":"As of 31 March 2026, ImmunityBio estimated primary completion of a Phase 2 trial in Non-muscle Invasive Bladder Cancer, on 30 September 2026.","as_of":"2026-03-31","source":"clinicaltrials","source_ref":"NCT02138734","source_url":"https://clinicaltrials.gov/study/NCT02138734","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dd4a79ed-8bd5-414b-966e-66a3816174a9"},{"id":"dac0016f-b338-434a-8c6d-9a404c4694d5","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"asset":"Tirzepatide","indication":"Obesity","summary":"As of 15 December 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in obesity, on 30 September 2026.","as_of":"2025-12-15","source":"clinicaltrials","source_ref":"NCT07000955","source_url":"https://clinicaltrials.gov/study/NCT07000955","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dac0016f-b338-434a-8c6d-9a404c4694d5"},{"id":"f76cdc31-315e-4b6a-9378-cca280bb6649","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"asset":"Pemetrexed","indication":"Non-Small Cell Lung Cancer","summary":"As of 26 June 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 30 September 2026.","as_of":"2025-06-26","source":"clinicaltrials","source_ref":"NCT05116462","source_url":"https://clinicaltrials.gov/study/NCT05116462","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f76cdc31-315e-4b6a-9378-cca280bb6649"},{"id":"1d027b74-950f-4f9f-a322-5c6ce63931d9","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","ticker":null,"asset":"IBI112","indication":"Psoriasis","summary":"As of 22 December 2025, Innovent Biopharmaceutical Technology (Hangzhou) Co. estimated primary completion of a Phase 3 trial in psoriasis, on 30 September 2026.","as_of":"2025-12-22","source":"clinicaltrials","source_ref":"NCT07265284","source_url":"https://clinicaltrials.gov/study/NCT07265284","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1d027b74-950f-4f9f-a322-5c6ce63931d9"},{"id":"232c2e21-ccce-430d-a381-363faa5ef8bf","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"J Ints Bio","ticker":null,"asset":"JIN-A02","indication":"EGFR Mutant Advanced Non-small Cell Lung Cancer","summary":"As of 16 May 2025, J Ints Bio estimated primary completion of a Phase 2 trial in EGFR Mutant Advanced Non-small Cell Lung Cancer, on 30 September 2026.","as_of":"2025-05-16","source":"clinicaltrials","source_ref":"NCT05394831","source_url":"https://clinicaltrials.gov/study/NCT05394831","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-232c2e21-ccce-430d-a381-363faa5ef8bf"},{"id":"cbe99c7b-5115-4a2d-b120-95380040cbf3","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Joincare Pharmaceutical Group Industry Co., Ltd","ticker":null,"asset":"JKN2403 Tablets","indication":"COPD (Chronic Obstructive Pulmonary Disease)","summary":"As of 20 January 2026, Joincare Pharmaceutical Group Industry Co. estimated primary completion of a Phase 2 trial in COPD (Chronic Obstructive Pulmonary Disease), on 30 September 2026.","as_of":"2026-01-20","source":"clinicaltrials","source_ref":"NCT07351734","source_url":"https://clinicaltrials.gov/study/NCT07351734","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cbe99c7b-5115-4a2d-b120-95380040cbf3"},{"id":"b0494a03-2242-48bf-8097-525cbb83a14f","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Kahr Bio Australia Pty Ltd","ticker":null,"asset":"DSP107 + Atezolizumab","indication":"Colorectal Cancer","summary":"As of 8 June 2026, Kahr Bio Australia Pty estimated primary completion of a Phase 2 trial in Colorectal Cancer, on 30 September 2026.","as_of":"2026-06-08","source":"clinicaltrials","source_ref":"NCT07235293","source_url":"https://clinicaltrials.gov/study/NCT07235293","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b0494a03-2242-48bf-8097-525cbb83a14f"},{"id":"4a2afe4d-144f-4f42-b59b-fe6481b1f66d","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Mirati Therapeutics Inc.","ticker":null,"asset":"Adagrasib oral dose of 400 mg twice daily tablets","indication":"Advanced NSCLC","summary":"As of 23 June 2026, Mirati Therapeutics estimated primary completion of a Phase 2 trial in Advanced NSCLC, on 30 September 2026.","as_of":"2026-06-23","source":"clinicaltrials","source_ref":"NCT05609578","source_url":"https://clinicaltrials.gov/study/NCT05609578","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4a2afe4d-144f-4f42-b59b-fe6481b1f66d"},{"id":"a00d00fb-c3cb-4cff-8fc6-6d1bc33fc830","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"JDQ443","indication":"KRAS G12C Mutant Solid Tumors","summary":"As of 15 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in KRAS G12C Mutant Solid Tumors, on 30 September 2026.","as_of":"2026-06-15","source":"clinicaltrials","source_ref":"NCT05358249","source_url":"https://clinicaltrials.gov/study/NCT05358249","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a00d00fb-c3cb-4cff-8fc6-6d1bc33fc830"},{"id":"ed7a0628-5114-4511-adbf-cbb5ec697394","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"OM Pharma SA","ticker":null,"asset":"OM-85","indication":"Recurrent Wheezing","summary":"As of 23 February 2026, OM Pharma SA estimated primary completion of a Phase 2 trial in Recurrent Wheezing, on 30 September 2026.","as_of":"2026-02-23","source":"clinicaltrials","source_ref":"NCT05857930","source_url":"https://clinicaltrials.gov/study/NCT05857930","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ed7a0628-5114-4511-adbf-cbb5ec697394"},{"id":"623f3cdd-8fad-475e-a614-d71755ab9d30","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Shanghai JMT-Bio Inc.","ticker":null,"asset":"JMT101","indication":"Locally Advanced or Metastatic Non-squamous NSCLC","summary":"As of 16 December 2024, Shanghai JMT-Bio estimated primary completion of a Phase 3 trial in Locally Advanced or Metastatic Non-squamous NSCLC, on 30 September 2026.","as_of":"2024-12-16","source":"clinicaltrials","source_ref":"NCT06735391","source_url":"https://clinicaltrials.gov/study/NCT06735391","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-623f3cdd-8fad-475e-a614-d71755ab9d30"},{"id":"6df63655-0bdc-4282-a8d8-40159160d0df","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"asset":"T3011","indication":"Advanced Melanoma","summary":"As of 6 August 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Advanced Melanoma, on 30 September 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT06214156","source_url":"https://clinicaltrials.gov/study/NCT06214156","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6df63655-0bdc-4282-a8d8-40159160d0df"},{"id":"929871b1-79cd-40f3-b229-b2c47db050cf","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Stamford Pharmaceuticals, Inc.","ticker":null,"asset":"SP-002","indication":"Basal Cell Carcinoma","summary":"As of 20 September 2024, Stamford Pharmaceuticals estimated primary completion of a Phase 2 trial in Basal Cell Carcinoma, on 30 September 2026.","as_of":"2024-09-20","source":"clinicaltrials","source_ref":"NCT06344052","source_url":"https://clinicaltrials.gov/study/NCT06344052","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-929871b1-79cd-40f3-b229-b2c47db050cf"},{"id":"c8093021-cb8f-40e2-b541-1a663e9cd6ea","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"SyneuRx International (Taiwan) Corp","ticker":null,"asset":"NaBen®","indication":"Refractory Schizophrenia","summary":"As of 13 September 2021, SyneuRx International (Taiwan) estimated primary completion of a Phase 3 trial in Refractory Schizophrenia, on 30 September 2026.","as_of":"2021-09-13","source":"clinicaltrials","source_ref":"NCT03094429","source_url":"https://clinicaltrials.gov/study/NCT03094429","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c8093021-cb8f-40e2-b541-1a663e9cd6ea"},{"id":"20aa88a1-d672-4dff-a809-45bbb37d76ae","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Takeda","ticker":null,"asset":"TAK-279","indication":"Ulcerative Colitis","summary":"As of 6 May 2026, Takeda estimated primary completion of a Phase 2 trial in Ulcerative Colitis, on 30 September 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT06254950","source_url":"https://clinicaltrials.gov/study/NCT06254950","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-20aa88a1-d672-4dff-a809-45bbb37d76ae"},{"id":"d19c51d8-df2d-42ee-8b20-889ea39c103f","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Turning Point Therapeutics, Inc.","ticker":null,"asset":"Oral repotrectinib (TPX-0005)","indication":"Locally Advanced Solid Tumors","summary":"As of 19 November 2025, Turning Point Therapeutics estimated primary completion of a Phase 2 trial in Locally Advanced Solid Tumors, on 30 September 2026.","as_of":"2025-11-19","source":"clinicaltrials","source_ref":"NCT04094610","source_url":"https://clinicaltrials.gov/study/NCT04094610","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d19c51d8-df2d-42ee-8b20-889ea39c103f"},{"id":"1eb1dc89-24a3-40d4-b1c5-ee9784ed046d","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Umecrine Cognition AB","ticker":null,"asset":"golexanolone","indication":"Primary Biliary Cholangitis (PBC)","summary":"As of 26 June 2026, Umecrine Cognition estimated primary completion of a Phase 2 trial in Primary Biliary Cholangitis (PBC), on 30 September 2026.","as_of":"2026-06-26","source":"clinicaltrials","source_ref":"NCT07304843","source_url":"https://clinicaltrials.gov/study/NCT07304843","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1eb1dc89-24a3-40d4-b1c5-ee9784ed046d"},{"id":"0b255b16-09ed-4579-aafb-e35b801dd5a0","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"UniQure Biopharma B.V.","ticker":null,"asset":"AMT-162","indication":"Amyotrophic Lateral Sclerosis","summary":"As of 22 October 2025, UniQure Biopharma B.V. estimated primary completion of a Phase 2 trial in Amyotrophic Lateral Sclerosis, on 30 September 2026.","as_of":"2025-10-22","source":"clinicaltrials","source_ref":"NCT06100276","source_url":"https://clinicaltrials.gov/study/NCT06100276","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0b255b16-09ed-4579-aafb-e35b801dd5a0"},{"id":"fdce55a4-1e64-4381-a6fc-cbb3d7946116","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"Uniquity One (UNI)","ticker":null,"asset":"Biological: Solrikitug low dose","indication":"COPD","summary":"As of 11 August 2026, Uniquity One estimated primary completion of a Phase 2 trial in cOPD, on 30 September 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT06496620","source_url":"https://clinicaltrials.gov/study/NCT06496620","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fdce55a4-1e64-4381-a6fc-cbb3d7946116"},{"id":"907477be-afe3-4e45-ae1a-e824760975f3","lane":"clinical","event_type":"primary-completion","date":"2026-09-30","date_precision":"day","confidence":"estimated","company":"argenx","ticker":null,"asset":"Efgartigimod PH20 SC","indication":"Generalized Myasthenia Gravis","summary":"As of 4 June 2026, argenx estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 30 September 2026.","as_of":"2026-06-04","source":"clinicaltrials","source_ref":"NCT06392386","source_url":"https://clinicaltrials.gov/study/NCT06392386","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-907477be-afe3-4e45-ae1a-e824760975f3"},{"id":"9248bf53-6bf4-49de-873d-cf8717cf8d1f","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"ABBV-RGX-314 Dose 1","indication":"AMD","summary":"As of 3 August 2026, AbbVie estimated primary completion of a Phase 3 trial in aMD, in October 2026.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT05407636","source_url":"https://clinicaltrials.gov/study/NCT05407636","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9248bf53-6bf4-49de-873d-cf8717cf8d1f"},{"id":"d34353fa-2d6c-41a9-a5d8-8cf14b44a0d0","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Actinogen Medical","ticker":null,"asset":"Xanamem","indication":"Dementia Moderate","summary":"As of 21 July 2026, Actinogen Medical estimated primary completion of a Phase 3 trial in Dementia Moderate, in October 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT06125951","source_url":"https://clinicaltrials.gov/study/NCT06125951","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d34353fa-2d6c-41a9-a5d8-8cf14b44a0d0"},{"id":"5716d844-0177-4d25-ac79-dd8900f0894b","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Acumen Pharmaceuticals","ticker":null,"asset":"sabirnetug","indication":"Alzheimer Disease","summary":"As of 27 October 2025, Acumen Pharmaceuticals estimated primary completion of a Phase 2 trial in Alzheimer Disease, in October 2026.","as_of":"2025-10-27","source":"clinicaltrials","source_ref":"NCT06335173","source_url":"https://clinicaltrials.gov/study/NCT06335173","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5716d844-0177-4d25-ac79-dd8900f0894b"},{"id":"41864eca-a2b9-4ff1-8f07-6a2fac0ac265","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Akeso","ticker":null,"asset":"AK112, Gemcitabine, Cisplatin","indication":"Biliary Tract Cancer","summary":"As of 21 January 2026, Akeso estimated primary completion of a Phase 3 trial in Biliary Tract Cancer, in October 2026.","as_of":"2026-01-21","source":"clinicaltrials","source_ref":"NCT06591520","source_url":"https://clinicaltrials.gov/study/NCT06591520","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-41864eca-a2b9-4ff1-8f07-6a2fac0ac265"},{"id":"2201fefa-add1-4c4f-9553-35c482af0910","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Aldena Therapeutics","ticker":null,"asset":"ALD-102 Solution","indication":"Alopecia Areata (AA)","summary":"As of 4 March 2026, Aldena Therapeutics estimated primary completion of a Phase 2 trial in Alopecia Areata (AA), in October 2026.","as_of":"2026-03-04","source":"clinicaltrials","source_ref":"NCT06826196","source_url":"https://clinicaltrials.gov/study/NCT06826196","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2201fefa-add1-4c4f-9553-35c482af0910"},{"id":"4763ca26-ffc2-4f60-917f-80186c8d48a3","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Aramis Biotechnologies Inc.","ticker":null,"asset":"Recombinant Influenza vaccine candidate","indication":"Influenza","summary":"As of 4 August 2026, Aramis Biotechnologies estimated primary completion of a Phase 2 trial in influenza, in October 2026.","as_of":"2026-08-04","source":"clinicaltrials","source_ref":"NCT07291635","source_url":"https://clinicaltrials.gov/study/NCT07291635","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4763ca26-ffc2-4f60-917f-80186c8d48a3"},{"id":"e74431e9-61fb-4d00-bbe4-aa844cd9e6ed","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"Beijing Dongfang Biotech Co., Ltd.","ticker":null,"asset":"Exendin-4 Fc fusion protein injection(1.2mg）","indication":"Type2 Diabetes Mellitus","summary":"As of 17 September 2025, Beijing Dongfang Biotech Co. estimated primary completion of a Phase 3 trial in Type2 Diabetes Mellitus, on 1 October 2026.","as_of":"2025-09-17","source":"clinicaltrials","source_ref":"NCT06257966","source_url":"https://clinicaltrials.gov/study/NCT06257966","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e74431e9-61fb-4d00-bbe4-aa844cd9e6ed"},{"id":"391fa434-058c-4611-80b2-2f6ad6b8a3f5","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Beijing InnoCare Pharma Tech Co., Ltd.","ticker":null,"asset":"ICP-332 Tablets","indication":"Plaque Psoriasis","summary":"As of 31 December 2025, Beijing InnoCare Pharma Tech Co. estimated primary completion of a Phase 2 trial in Plaque Psoriasis, in October 2026.","as_of":"2025-12-31","source":"clinicaltrials","source_ref":"NCT07251998","source_url":"https://clinicaltrials.gov/study/NCT07251998","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-391fa434-058c-4611-80b2-2f6ad6b8a3f5"},{"id":"c968a932-0493-450a-92ec-8c148c738559","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"BioAegis Therapeutics Inc.","ticker":null,"asset":"Rhu-pGSN","indication":"Acute Respiratory Distress Syndrome","summary":"As of 15 June 2026, BioAegis Therapeutics estimated primary completion of a Phase 2 trial in Acute Respiratory Distress Syndrome, on 1 October 2026.","as_of":"2026-06-15","source":"clinicaltrials","source_ref":"NCT05947955","source_url":"https://clinicaltrials.gov/study/NCT05947955","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c968a932-0493-450a-92ec-8c148c738559"},{"id":"7094eb30-951d-4f15-8ac9-c5e29dccd329","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Biohaven Therapeutics Ltd.","ticker":null,"asset":"BHV-7000","indication":"Focal Epilepsy","summary":"As of 1 July 2026, Biohaven Therapeutics estimated primary completion of a Phase 3 trial in Focal Epilepsy, in October 2026.","as_of":"2026-07-01","source":"clinicaltrials","source_ref":"NCT06309966","source_url":"https://clinicaltrials.gov/study/NCT06309966","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7094eb30-951d-4f15-8ac9-c5e29dccd329"},{"id":"235b53c3-a64c-4e23-8185-4f7c37654d07","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"CanSino Biologics Inc.","ticker":null,"asset":"Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose","indication":"Poliomyelitis","summary":"As of 6 August 2026, CanSino Biologics estimated primary completion of a Phase 2 trial in poliomyelitis, in October 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT06577298","source_url":"https://clinicaltrials.gov/study/NCT06577298","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-235b53c3-a64c-4e23-8185-4f7c37654d07"},{"id":"6e4d3989-5880-4eb4-a0e1-da6c1b0d3d12","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Celldex Therapeutics","ticker":null,"asset":"barzolvolimab","indication":"Chronic Spontaneous Urticaria","summary":"As of 25 March 2026, Celldex Therapeutics estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria, in October 2026.","as_of":"2026-03-25","source":"clinicaltrials","source_ref":"NCT06445023","source_url":"https://clinicaltrials.gov/study/NCT06445023","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6e4d3989-5880-4eb4-a0e1-da6c1b0d3d12"},{"id":"75e1bb2d-8f6c-4ae8-93e9-02cb7ab7bb39","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Celldex Therapeutics","ticker":null,"asset":"barzolvolimab","indication":"Chronic Spontaneous Urticaria","summary":"As of 25 March 2026, Celldex Therapeutics estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria, in October 2026.","as_of":"2026-03-25","source":"clinicaltrials","source_ref":"NCT06455202","source_url":"https://clinicaltrials.gov/study/NCT06455202","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-75e1bb2d-8f6c-4ae8-93e9-02cb7ab7bb39"},{"id":"3adff6cf-6d93-4009-92f8-8e1b87a9f292","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"D-1553 Tablet","indication":"Non Small Cell Lung Cancer","summary":"As of 26 April 2024, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Non Small Cell Lung Cancer, in October 2026.","as_of":"2024-04-26","source":"clinicaltrials","source_ref":"NCT06300177","source_url":"https://clinicaltrials.gov/study/NCT06300177","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3adff6cf-6d93-4009-92f8-8e1b87a9f292"},{"id":"bebf15e7-02fc-47bd-9c3b-23bab383c45b","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"Citryll BV","ticker":null,"asset":"[89Zr]Zr-CIT","indication":"RA","summary":"As of 30 January 2026, Citryll BV estimated primary completion of a Phase 2 trial in rA, on 1 October 2026.","as_of":"2026-01-30","source":"clinicaltrials","source_ref":"NCT07147959","source_url":"https://clinicaltrials.gov/study/NCT07147959","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bebf15e7-02fc-47bd-9c3b-23bab383c45b"},{"id":"a6db2b8a-d4e4-4828-9ffc-61a5dcc06fc3","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"Cocrystal Pharma, Inc.","ticker":null,"asset":"CDI-988","indication":"Norovirus","summary":"As of 17 February 2026, Cocrystal Pharma estimated primary completion of a Phase 2 trial in norovirus, on 1 October 2026.","as_of":"2026-02-17","source":"clinicaltrials","source_ref":"NCT07198139","source_url":"https://clinicaltrials.gov/study/NCT07198139","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a6db2b8a-d4e4-4828-9ffc-61a5dcc06fc3"},{"id":"4a09b3d8-2426-4d60-9112-def4ad6b0c38","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Corcept Therapeutics","ticker":null,"asset":"Dazucorilant 300 mg","indication":"Amyotrophic Lateral Sclerosis","summary":"As of 16 June 2026, Corcept Therapeutics estimated primary completion of a Phase 2 trial in Amyotrophic Lateral Sclerosis, in October 2026.","as_of":"2026-06-16","source":"clinicaltrials","source_ref":"NCT05407324","source_url":"https://clinicaltrials.gov/study/NCT05407324","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4a09b3d8-2426-4d60-9112-def4ad6b0c38"},{"id":"628acd57-2f43-4ed3-a0c6-254233829a77","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Crinetics Pharmaceuticals Inc.","ticker":null,"asset":"atumelnant","indication":"Cushing Syndrome","summary":"As of 4 June 2026, Crinetics Pharmaceuticals estimated primary completion of a Phase 2 trial in Cushing Syndrome, in October 2026.","as_of":"2026-06-04","source":"clinicaltrials","source_ref":"NCT05804669","source_url":"https://clinicaltrials.gov/study/NCT05804669","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-628acd57-2f43-4ed3-a0c6-254233829a77"},{"id":"97c71c98-a440-4409-b995-f349774a60f6","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Debiopharm International SA","ticker":null,"asset":"Debio 4326","indication":"Central Precocious Puberty","summary":"As of 27 July 2026, Debiopharm International SA estimated primary completion of a Phase 3 trial in Central Precocious Puberty, in October 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT06129539","source_url":"https://clinicaltrials.gov/study/NCT06129539","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-97c71c98-a440-4409-b995-f349774a60f6"},{"id":"0cd4ee89-62c8-4293-9ee3-79661e46b005","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Disc Medicine, Inc","ticker":null,"asset":"DISC-0974","indication":"Inflammatory Bowel Disease (IBD)","summary":"As of 3 August 2026, Disc Medicine estimated primary completion of a Phase 2 trial in Inflammatory Bowel Disease (IBD), in October 2026.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT07368972","source_url":"https://clinicaltrials.gov/study/NCT07368972","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0cd4ee89-62c8-4293-9ee3-79661e46b005"},{"id":"73132fa8-bb40-453c-afca-636323357274","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"Retatrutide","indication":"Type 2 Diabetes","summary":"As of 20 July 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 2 Diabetes, in October 2026.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT06297603","source_url":"https://clinicaltrials.gov/study/NCT06297603","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-73132fa8-bb40-453c-afca-636323357274"},{"id":"e2c1f9a7-d882-4e61-81a2-6ffe0bbc4333","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"Baricitinib","indication":"Systemic Juvenile Idiopathic Arthritis","summary":"As of 11 August 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Systemic Juvenile Idiopathic Arthritis, in October 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT04088396","source_url":"https://clinicaltrials.gov/study/NCT04088396","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e2c1f9a7-d882-4e61-81a2-6ffe0bbc4333"},{"id":"4a90e7ac-3c77-4b1f-8e2c-f9fac6edd721","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Endeavor Biomedicines, Inc.","ticker":null,"asset":"ENV-101","indication":"Idiopathic Pulmonary Fibrosis","summary":"As of 24 February 2026, Endeavor Biomedicines estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in October 2026.","as_of":"2026-02-24","source":"clinicaltrials","source_ref":"NCT06422884","source_url":"https://clinicaltrials.gov/study/NCT06422884","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4a90e7ac-3c77-4b1f-8e2c-f9fac6edd721"},{"id":"94c6937d-1ba6-4015-a269-620b18f05fbe","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"EyePoint Pharmaceuticals, Inc.","ticker":null,"asset":"EYP-1901","indication":"Wet Age Related Macular Degeneration","summary":"As of 4 August 2026, EyePoint Pharmaceuticals estimated primary completion of a Phase 3 trial in Wet Age Related Macular Degeneration, in October 2026.","as_of":"2026-08-04","source":"clinicaltrials","source_ref":"NCT06683742","source_url":"https://clinicaltrials.gov/study/NCT06683742","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-94c6937d-1ba6-4015-a269-620b18f05fbe"},{"id":"1dab9e44-d0bd-4dbe-99b7-9a231d2b931c","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"Fujian Akeylink Biotechnology Co., Ltd.","ticker":null,"asset":"GST-HG141","indication":"Chronic Hepatitis B","summary":"As of 17 July 2026, Fujian Akeylink Biotechnology Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, on 1 October 2026.","as_of":"2026-07-17","source":"clinicaltrials","source_ref":"NCT07709520","source_url":"https://clinicaltrials.gov/study/NCT07709520","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1dab9e44-d0bd-4dbe-99b7-9a231d2b931c"},{"id":"d591b859-ecef-4a3f-9523-d1fadfa18887","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"asset":"HRS-7450 Injection","indication":"Acute Ischemic Stroke","summary":"As of 29 June 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, in October 2026.","as_of":"2026-06-29","source":"clinicaltrials","source_ref":"NCT07233070","source_url":"https://clinicaltrials.gov/study/NCT07233070","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d591b859-ecef-4a3f-9523-d1fadfa18887"},{"id":"c8db5a41-3a8c-4592-9e97-c4a3ca456d55","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"GEn1E Lifesciences","ticker":null,"asset":"GEn-1124","indication":"Respiratory Distress Syndrome, Acute","summary":"As of 23 June 2026, GEn1E Lifesciences estimated primary completion of a Phase 2 trial in Respiratory Distress Syndrome, Acute, in October 2026.","as_of":"2026-06-23","source":"clinicaltrials","source_ref":"NCT05795465","source_url":"https://clinicaltrials.gov/study/NCT05795465","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c8db5a41-3a8c-4592-9e97-c4a3ca456d55"},{"id":"c6e0afc9-e522-4712-9949-8f5802a183fe","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"GIE Medical","ticker":null,"asset":"GIE Medical ProTractX3 TTS DCB","indication":"Esophageal Stricture","summary":"As of 25 June 2025, GIE Medical estimated primary completion of a Phase 3 trial in Esophageal Stricture, in October 2026.","as_of":"2025-06-25","source":"clinicaltrials","source_ref":"NCT05561114","source_url":"https://clinicaltrials.gov/study/NCT05561114","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c6e0afc9-e522-4712-9949-8f5802a183fe"},{"id":"4553864c-94df-4fd1-82e0-cf5670a898a8","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Gilead Sciences","ticker":null,"asset":"Sacituzumab Govitecan-hziy","indication":"Solid Tumor","summary":"As of 17 November 2025, Gilead Sciences estimated primary completion of a Phase 2 trial in Solid Tumor, in October 2026.","as_of":"2025-11-17","source":"clinicaltrials","source_ref":"NCT05119907","source_url":"https://clinicaltrials.gov/study/NCT05119907","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4553864c-94df-4fd1-82e0-cf5670a898a8"},{"id":"279fe174-e326-40a5-89ad-8ca62b25bf59","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Gilgamesh Pharmaceuticals","ticker":null,"asset":"GM-2505","indication":"Major Depressive Disorder","summary":"As of 9 February 2026, Gilgamesh Pharmaceuticals estimated primary completion of a Phase 2 trial in Major Depressive Disorder, in October 2026.","as_of":"2026-02-09","source":"clinicaltrials","source_ref":"NCT06236880","source_url":"https://clinicaltrials.gov/study/NCT06236880","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-279fe174-e326-40a5-89ad-8ca62b25bf59"},{"id":"2fac5eed-e2a0-46fc-aa2d-c2bc8ce2c993","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Housey Healthcare ULC","ticker":null,"asset":"HP-211","indication":"Type 2 Diabetes","summary":"As of 23 April 2026, Housey Healthcare ULC estimated primary completion of a Phase 2 trial in Type 2 Diabetes, in October 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT07546929","source_url":"https://clinicaltrials.gov/study/NCT07546929","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2fac5eed-e2a0-46fc-aa2d-c2bc8ce2c993"},{"id":"01e27a68-b37b-481c-8b05-72a8f4227bbe","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"ImmunityBio, Inc.","ticker":null,"asset":"N-803 (IL-15 Superagonist)","indication":"Long COVID","summary":"As of 11 May 2026, ImmunityBio estimated primary completion of a Phase 2 trial in Long COVID, in October 2026.","as_of":"2026-05-11","source":"clinicaltrials","source_ref":"NCT07108036","source_url":"https://clinicaltrials.gov/study/NCT07108036","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-01e27a68-b37b-481c-8b05-72a8f4227bbe"},{"id":"d9713d47-67c1-4381-886c-cc13768965b5","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Immunocore Ltd","ticker":null,"asset":"Brenetafusp","indication":"Select Advanced Solid Tumors","summary":"As of 6 March 2026, Immunocore estimated primary completion of a Phase 2 trial in Select Advanced Solid Tumors, in October 2026.","as_of":"2026-03-06","source":"clinicaltrials","source_ref":"NCT04262466","source_url":"https://clinicaltrials.gov/study/NCT04262466","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d9713d47-67c1-4381-886c-cc13768965b5"},{"id":"b000b4f7-8196-4a33-a605-1acfcd27ed0a","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Immunovant Sciences GmbH","ticker":null,"asset":"IMVT-1402","indication":"Subacute Cutaneous Lupus Erythematosus","summary":"As of 10 July 2026, Immunovant Sciences estimated primary completion of a Phase 2 trial in Subacute Cutaneous Lupus Erythematosus, in October 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT06980805","source_url":"https://clinicaltrials.gov/study/NCT06980805","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b000b4f7-8196-4a33-a605-1acfcd27ed0a"},{"id":"69a406d2-eaa6-4a50-b972-b8c9f8a2280f","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Industrial Farmacéutica Cantabria, S.A.","ticker":null,"asset":"Minoxidil Tablets","indication":"Androgenetic Alopecia","summary":"As of 12 May 2026, Industrial Farmacéutica Cantabria estimated primary completion of a Phase 3 trial in Androgenetic Alopecia, in October 2026.","as_of":"2026-05-12","source":"clinicaltrials","source_ref":"NCT05888922","source_url":"https://clinicaltrials.gov/study/NCT05888922","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-69a406d2-eaa6-4a50-b972-b8c9f8a2280f"},{"id":"a35b7e4d-5e2f-443e-9f7e-9ee6616856ca","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Ingenia Therapeutics INC","ticker":null,"asset":"IGT-303","indication":"Healthy Volunteers","summary":"As of 18 May 2026, Ingenia Therapeutics estimated primary completion of a Phase 2 trial in Healthy Volunteers, in October 2026.","as_of":"2026-05-18","source":"clinicaltrials","source_ref":"NCT07231679","source_url":"https://clinicaltrials.gov/study/NCT07231679","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a35b7e4d-5e2f-443e-9f7e-9ee6616856ca"},{"id":"3109f92e-9919-4fea-91a7-e5af1e840e3e","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"Inhatarget Therapeutics","ticker":null,"asset":"CIS-DPI","indication":"NSCLC (advanced Non-small Cell Lung Cancer)","summary":"As of 26 March 2025, Inhatarget Therapeutics estimated primary completion of a Phase 2 trial in NSCLC (advanced Non-small Cell Lung Cancer), on 1 October 2026.","as_of":"2025-03-26","source":"clinicaltrials","source_ref":"NCT06896890","source_url":"https://clinicaltrials.gov/study/NCT06896890","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3109f92e-9919-4fea-91a7-e5af1e840e3e"},{"id":"f279807f-7e38-43a1-b22e-7bd2506b4ef5","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Inmunotek S.L.","ticker":null,"asset":"10,000 MG01 +10,000 T521","indication":"Rhinitis, Allergic","summary":"As of 13 May 2025, Inmunotek S.L. estimated primary completion of a Phase 3 trial in Rhinitis, Allergic, in October 2026.","as_of":"2025-05-13","source":"clinicaltrials","source_ref":"NCT04898283","source_url":"https://clinicaltrials.gov/study/NCT04898283","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f279807f-7e38-43a1-b22e-7bd2506b4ef5"},{"id":"9066dbe2-c0be-4d48-8bca-214b48e75966","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Kynexis B.V.","ticker":null,"asset":"KYN-5356 low dose","indication":"Cognitive Impairment Associated With Schizophrenia (CIAS)","summary":"As of 23 June 2026, Kynexis B.V. estimated primary completion of a Phase 2 trial in Cognitive Impairment Associated With Schizophrenia (CIAS), in October 2026.","as_of":"2026-06-23","source":"clinicaltrials","source_ref":"NCT07191483","source_url":"https://clinicaltrials.gov/study/NCT07191483","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9066dbe2-c0be-4d48-8bca-214b48e75966"},{"id":"c999de34-3006-4a41-9180-f7e42fdd3ba3","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Lallemand Health Solutions","ticker":null,"asset":"Probiotic Formula 1","indication":"Focus is on Healthy Subjects","summary":"As of 18 June 2026, Lallemand Health Solutions estimated primary completion of a Phase 2 trial in Focus is on Healthy Subjects, in October 2026.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT07246161","source_url":"https://clinicaltrials.gov/study/NCT07246161","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c999de34-3006-4a41-9180-f7e42fdd3ba3"},{"id":"c033133d-0ace-497d-b014-8b1edeaa1d56","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Laminar Pharmaceuticals","ticker":null,"asset":"LAM561","indication":"High-grade Glioma","summary":"As of 20 November 2025, Laminar Pharmaceuticals estimated primary completion of a Phase 2 trial in High-grade Glioma, in October 2026.","as_of":"2025-11-20","source":"clinicaltrials","source_ref":"NCT04299191","source_url":"https://clinicaltrials.gov/study/NCT04299191","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c033133d-0ace-497d-b014-8b1edeaa1d56"},{"id":"22cc60a3-1a35-4e17-9a4c-47880d7f5bbe","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Loxo Oncology, Inc.","ticker":null,"asset":"Pirtobrutinib","indication":"Chronic Lymphocytic Leukemia","summary":"As of 29 January 2026, Loxo Oncology estimated primary completion of a Phase 3 trial in Chronic Lymphocytic Leukemia, in October 2026.","as_of":"2026-01-29","source":"clinicaltrials","source_ref":"NCT04965493","source_url":"https://clinicaltrials.gov/study/NCT04965493","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-22cc60a3-1a35-4e17-9a4c-47880d7f5bbe"},{"id":"f2b8698e-7bd0-4def-9be6-825b242b28dc","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"MedTrace Pharma A/S","ticker":null,"asset":"[O-15]-Water PET Myocardial Perfusion Imaging (MPI)","indication":"Coronary Artery Disease","summary":"As of 10 August 2026, MedTrace Pharma estimated primary completion of a Phase 3 trial in Coronary Artery Disease, in October 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT05134012","source_url":"https://clinicaltrials.gov/study/NCT05134012","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f2b8698e-7bd0-4def-9be6-825b242b28dc"},{"id":"99e9a7f9-6b15-473f-a2b7-8ead0362fc57","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"MediLink Therapeutics (Suzhou) Co., Ltd.","ticker":null,"asset":"YL201 for Injection","indication":"Advanced Solid Tumor","summary":"As of 12 March 2026, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in October 2026.","as_of":"2026-03-12","source":"clinicaltrials","source_ref":"NCT06057922","source_url":"https://clinicaltrials.gov/study/NCT06057922","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-99e9a7f9-6b15-473f-a2b7-8ead0362fc57"},{"id":"5fe650a6-1075-42d1-bb6d-9827f35a4cc9","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Merz North America, Inc.","ticker":null,"asset":"NT 201","indication":"Neuromuscular Agents","summary":"As of 22 May 2026, Merz North America estimated primary completion of a Phase 3 trial in Neuromuscular Agents, in October 2026.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT07122193","source_url":"https://clinicaltrials.gov/study/NCT07122193","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5fe650a6-1075-42d1-bb6d-9827f35a4cc9"},{"id":"46b650b7-6520-4862-b56a-7b2bb9b97039","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Mirum Pharmaceuticals, Inc.","ticker":null,"asset":"Maralixibat","indication":"Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)","summary":"As of 11 August 2026, Mirum Pharmaceuticals estimated primary completion of a Phase 3 trial in October 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT06553768","source_url":"https://clinicaltrials.gov/study/NCT06553768","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-46b650b7-6520-4862-b56a-7b2bb9b97039"},{"id":"42064e6d-e7bb-4bb1-85dd-6cd9cc5e34cc","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Novadip Biosciences","ticker":null,"asset":"NVD003","indication":"Congenital Pseudarthrosis of Tibia","summary":"As of 1 April 2026, Novadip Biosciences estimated primary completion of a Phase 3 trial in Congenital Pseudarthrosis of Tibia, in October 2026.","as_of":"2026-04-01","source":"clinicaltrials","source_ref":"NCT07112443","source_url":"https://clinicaltrials.gov/study/NCT07112443","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-42064e6d-e7bb-4bb1-85dd-6cd9cc5e34cc"},{"id":"6352e766-665e-4ffc-8f7d-ca008acffd55","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Novaliq GmbH","ticker":null,"asset":"Tacrolimus ophthalmic solution","indication":"Non-infectious Anterior Uveitis","summary":"As of 28 July 2026, Novaliq estimated primary completion of a Phase 2 trial in Non-infectious Anterior Uveitis, in October 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT07285070","source_url":"https://clinicaltrials.gov/study/NCT07285070","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6352e766-665e-4ffc-8f7d-ca008acffd55"},{"id":"a06e0bd6-1a64-4d04-9a17-4a0dca1e5d7c","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"Iptacopan (LNP023)","indication":"Age-Related Macular Degeneration","summary":"As of 3 July 2025, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Age-Related Macular Degeneration, on 1 October 2026.","as_of":"2025-07-03","source":"clinicaltrials","source_ref":"NCT05230537","source_url":"https://clinicaltrials.gov/study/NCT05230537","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a06e0bd6-1a64-4d04-9a17-4a0dca1e5d7c"},{"id":"405cb4a4-e23b-4df3-8241-3d5964330361","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"Novo Nordisk A/S","ticker":null,"asset":"Ziltivekimab","indication":"Heart Failure","summary":"As of 31 July 2026, Novo Nordisk estimated primary completion of a Phase 3 trial in Heart Failure, on 1 October 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT06200207","source_url":"https://clinicaltrials.gov/study/NCT06200207","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-405cb4a4-e23b-4df3-8241-3d5964330361"},{"id":"2e033cbc-e197-41cc-b42b-8ad4b2d061ea","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Organon and Co","ticker":null,"asset":"tapinarof cream, 1%","indication":"Plaque Psoriasis","summary":"As of 17 April 2026, Organon and estimated primary completion of a Phase 3 trial in Plaque Psoriasis, in October 2026.","as_of":"2026-04-17","source":"clinicaltrials","source_ref":"NCT05172726","source_url":"https://clinicaltrials.gov/study/NCT05172726","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2e033cbc-e197-41cc-b42b-8ad4b2d061ea"},{"id":"10b7d25a-96c4-4b3f-b8d6-1311b1fbf745","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","ticker":null,"asset":"T cell injection targeting CD7 chimeric antigen receptor","indication":"CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma","summary":"As of 6 July 2026, PersonGen BioTherapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma, on 1 October 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT07188610","source_url":"https://clinicaltrials.gov/study/NCT07188610","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-10b7d25a-96c4-4b3f-b8d6-1311b1fbf745"},{"id":"70cc416d-f94e-4e65-b113-4c50730bed09","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Pharming Technologies B.V.","ticker":null,"asset":"Leniolisib","indication":"Common Variable Immunodeficiency (CVID)","summary":"As of 12 February 2026, Pharming Technologies B.V. estimated primary completion of a Phase 2 trial in Common Variable Immunodeficiency (CVID), in October 2026.","as_of":"2026-02-12","source":"clinicaltrials","source_ref":"NCT06897358","source_url":"https://clinicaltrials.gov/study/NCT06897358","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-70cc416d-f94e-4e65-b113-4c50730bed09"},{"id":"6ed3f88d-a8da-4497-8f27-5690655caad5","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Phathom Pharmaceuticals, Inc.","ticker":null,"asset":"Vonoprazan","indication":"Eosinophilic Esophagitis","summary":"As of 29 June 2026, Phathom Pharmaceuticals estimated primary completion of a Phase 2 trial in Eosinophilic Esophagitis, in October 2026.","as_of":"2026-06-29","source":"clinicaltrials","source_ref":"NCT06851559","source_url":"https://clinicaltrials.gov/study/NCT06851559","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6ed3f88d-a8da-4497-8f27-5690655caad5"},{"id":"444ac3fd-b5c7-4db7-8647-0182e55e10d5","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Philogen S.p.A.","ticker":null,"asset":"Onfekafusp alfa","indication":"Glioblastoma","summary":"As of 10 October 2023, Philogen S.p.A. estimated primary completion of a Phase 2 trial in glioblastoma, in October 2026.","as_of":"2023-10-10","source":"clinicaltrials","source_ref":"NCT04443010","source_url":"https://clinicaltrials.gov/study/NCT04443010","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-444ac3fd-b5c7-4db7-8647-0182e55e10d5"},{"id":"bfcd60e7-2c02-41bc-a49d-3ac64a53bf7f","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"Prana Therapies Inc","ticker":null,"asset":"PRA-216","indication":"Mild to Moderate Asthma","summary":"As of 6 August 2026, Prana Therapies estimated primary completion of a Phase 2 trial in Mild to Moderate Asthma, on 1 October 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT07245368","source_url":"https://clinicaltrials.gov/study/NCT07245368","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bfcd60e7-2c02-41bc-a49d-3ac64a53bf7f"},{"id":"d8c36ec2-15ba-4658-9f8a-0cdca280c881","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Privo Technologies","ticker":null,"asset":"PRV211 (Intraoperative Cisplatin System)","indication":"Oral Squamous Cell Carcinoma","summary":"As of 23 April 2026, Privo Technologies estimated primary completion of a Phase 3 trial in Oral Squamous Cell Carcinoma, in October 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT05893888","source_url":"https://clinicaltrials.gov/study/NCT05893888","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d8c36ec2-15ba-4658-9f8a-0cdca280c881"},{"id":"4db54792-de78-49a4-851d-2302eee83bd0","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"asset":"QLC5508","indication":"Advanced Solid Tumor","summary":"As of 1 December 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in October 2026.","as_of":"2025-12-01","source":"clinicaltrials","source_ref":"NCT07256782","source_url":"https://clinicaltrials.gov/study/NCT07256782","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4db54792-de78-49a4-851d-2302eee83bd0"},{"id":"3f2ef42c-33f7-45af-8fed-349b7601c6d3","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"RemeGen Co., Ltd.","ticker":null,"asset":"Disitamab Vedotin","indication":"Breast Cancer","summary":"As of 17 February 2025, RemeGen Co. estimated primary completion of a Phase 2 trial in Breast Cancer, on 1 October 2026.","as_of":"2025-02-17","source":"clinicaltrials","source_ref":"NCT06642545","source_url":"https://clinicaltrials.gov/study/NCT06642545","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3f2ef42c-33f7-45af-8fed-349b7601c6d3"},{"id":"f9500368-095e-4a5b-bdaf-118654bedf3c","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"Research Institute of Geroprotective Technologies","ticker":null,"asset":"Aroxxen","indication":"Coronary Artery Disease","summary":"As of 6 May 2026, Research Institute of Geroprotective Technologies estimated primary completion of a Phase 2 trial in Coronary Artery Disease, on 1 October 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT07397351","source_url":"https://clinicaltrials.gov/study/NCT07397351","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f9500368-095e-4a5b-bdaf-118654bedf3c"},{"id":"84e3067d-32b1-41da-8949-acba3fcefa52","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Retension Pharmaceuticals. Inc.","ticker":null,"asset":"RTN-001","indication":"Uncontrolled Hypertension","summary":"As of 29 June 2026, Retension Pharmaceuticals. estimated primary completion of a Phase 2 trial in Uncontrolled Hypertension, in October 2026.","as_of":"2026-06-29","source":"clinicaltrials","source_ref":"NCT07142356","source_url":"https://clinicaltrials.gov/study/NCT07142356","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-84e3067d-32b1-41da-8949-acba3fcefa52"},{"id":"1fb05ab2-56f9-4901-ac16-f69dc8755f6a","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Senseye, Inc.","ticker":null,"asset":"Senseye Diagnostic Tool (DT)","indication":"PTSD - Post Traumatic Stress Disorder","summary":"As of 29 April 2026, Senseye estimated primary completion of a Phase 3 trial in PTSD - Post Traumatic Stress Disorder, in October 2026.","as_of":"2026-04-29","source":"clinicaltrials","source_ref":"NCT07280065","source_url":"https://clinicaltrials.gov/study/NCT07280065","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1fb05ab2-56f9-4901-ac16-f69dc8755f6a"},{"id":"8affc756-1ee4-4b4d-8d94-6b06baec326f","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Sernova Biotherapeutics Inc.","ticker":null,"asset":"Sernova Cell Pouch","indication":"Type 1 Diabetes Mellitus","summary":"As of 25 February 2026, Sernova Biotherapeutics estimated primary completion of a Phase 2 trial in Type 1 Diabetes Mellitus, in October 2026.","as_of":"2026-02-25","source":"clinicaltrials","source_ref":"NCT03513939","source_url":"https://clinicaltrials.gov/study/NCT03513939","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8affc756-1ee4-4b4d-8d94-6b06baec326f"},{"id":"6ebaccc7-7734-4cac-a310-d20a416c1d53","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Shanghai Hengrui Pharmaceutical Co., Ltd.","ticker":null,"asset":"SHR-A2102；Adebrelimab；Cisplatin","indication":"Advanced or Metastatic Esophageal Cancer","summary":"As of 3 January 2025, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced or Metastatic Esophageal Cancer, in October 2026.","as_of":"2025-01-03","source":"clinicaltrials","source_ref":"NCT06474468","source_url":"https://clinicaltrials.gov/study/NCT06474468","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6ebaccc7-7734-4cac-a310-d20a416c1d53"},{"id":"870bbae1-f1d8-4bda-92e5-37fab71fd901","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Shanghai Hengrui Pharmaceutical Co., Ltd.","ticker":null,"asset":"SHR-A2102","indication":"Non-small Cell Lung Cancer","summary":"As of 1 December 2025, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in October 2026.","as_of":"2025-12-01","source":"clinicaltrials","source_ref":"NCT07229729","source_url":"https://clinicaltrials.gov/study/NCT07229729","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-870bbae1-f1d8-4bda-92e5-37fab71fd901"},{"id":"9e3032e1-77f5-4188-ab6d-17b23eb09868","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Shanghai Hengrui Pharmaceutical Co., Ltd.","ticker":null,"asset":"SHR-A2102 for Injection","indication":"Advanced or Metastatic Non-small Cell Lung Cancer","summary":"As of 23 December 2025, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced or Metastatic Non-small Cell Lung Cancer, in October 2026.","as_of":"2025-12-23","source":"clinicaltrials","source_ref":"NCT06512051","source_url":"https://clinicaltrials.gov/study/NCT06512051","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9e3032e1-77f5-4188-ab6d-17b23eb09868"},{"id":"0fe483a0-798a-4a6c-b7dd-67bdd1e5a51d","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Shanghai Huilun Pharmaceutical Co., Ltd.","ticker":null,"asset":"HL-1186","indication":"Postoperative Pain","summary":"As of 16 July 2026, Shanghai Huilun Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Postoperative Pain, in October 2026.","as_of":"2026-07-16","source":"clinicaltrials","source_ref":"NCT07709598","source_url":"https://clinicaltrials.gov/study/NCT07709598","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0fe483a0-798a-4a6c-b7dd-67bdd1e5a51d"},{"id":"983383e8-0a53-43a3-9686-ed5ad40fb125","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Shanghai Huilun Pharmaceutical Co., Ltd.","ticker":null,"asset":"HL-1186","indication":"Postoperative Pain","summary":"As of 13 July 2026, Shanghai Huilun Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Postoperative Pain, in October 2026.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT07699601","source_url":"https://clinicaltrials.gov/study/NCT07699601","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-983383e8-0a53-43a3-9686-ed5ad40fb125"},{"id":"cbcb10e9-c290-4602-87a7-1a7501fb967a","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Shanghai Shengdi Pharmaceutical Co., Ltd","ticker":null,"asset":"SHR-4610 Injection","indication":"Solid Tumors","summary":"As of 24 July 2026, Shanghai Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Solid Tumors, in October 2026.","as_of":"2026-07-24","source":"clinicaltrials","source_ref":"NCT07231211","source_url":"https://clinicaltrials.gov/study/NCT07231211","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cbcb10e9-c290-4602-87a7-1a7501fb967a"},{"id":"de4ecc60-0054-4bb6-9335-1fee49efadaf","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1 for Injection","indication":"Recurrent Glioblastoma","summary":"As of 7 May 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Recurrent Glioblastoma, in October 2026.","as_of":"2025-05-07","source":"clinicaltrials","source_ref":"NCT06598787","source_url":"https://clinicaltrials.gov/study/NCT06598787","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-de4ecc60-0054-4bb6-9335-1fee49efadaf"},{"id":"255a4627-f70a-4a5f-bfdd-fc55660038a8","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-M07D1","indication":"HER2-positive Breast Cancer","summary":"As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in HER2-positive Breast Cancer, in October 2026.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT06316531","source_url":"https://clinicaltrials.gov/study/NCT06316531","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-255a4627-f70a-4a5f-bfdd-fc55660038a8"},{"id":"73437507-08b8-48e5-9086-a8b41d935e7a","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-M07D1","indication":"HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma","summary":"As of 6 August 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma, in October 2026.","as_of":"2025-08-06","source":"clinicaltrials","source_ref":"NCT06423885","source_url":"https://clinicaltrials.gov/study/NCT06423885","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-73437507-08b8-48e5-9086-a8b41d935e7a"},{"id":"cf3b0b32-bb83-4169-9f71-f5202bb10df9","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Sol-Gel Technologies, Ltd.","ticker":null,"asset":"Patidegib Topical Gel","indication":"Gorlin Syndrome","summary":"As of 11 August 2026, Sol-Gel Technologies estimated primary completion of a Phase 3 trial in Gorlin Syndrome, in October 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT06050122","source_url":"https://clinicaltrials.gov/study/NCT06050122","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cf3b0b32-bb83-4169-9f71-f5202bb10df9"},{"id":"2df9e832-dc53-4d82-87f0-0943f329cea9","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"asset":"SHR-A1811","indication":"Recurrent or Metastatic Cervical Cancer","summary":"As of 6 June 2025, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Recurrent or Metastatic Cervical Cancer, in October 2026.","as_of":"2025-06-06","source":"clinicaltrials","source_ref":"NCT06859775","source_url":"https://clinicaltrials.gov/study/NCT06859775","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2df9e832-dc53-4d82-87f0-0943f329cea9"},{"id":"cb8b0a6d-348f-45a8-bdc5-fe64da542c70","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Suzhou Teligene Ltd.","ticker":null,"asset":"TL938 Capsules","indication":"Colorectal Cancer Metastatic","summary":"As of 28 April 2026, Suzhou Teligene estimated primary completion of a Phase 2 trial in Colorectal Cancer Metastatic, in October 2026.","as_of":"2026-04-28","source":"clinicaltrials","source_ref":"NCT06589830","source_url":"https://clinicaltrials.gov/study/NCT06589830","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cb8b0a6d-348f-45a8-bdc5-fe64da542c70"},{"id":"e21945d5-eae0-4296-ab28-189375655715","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Triveni Bio","ticker":null,"asset":"TRIV-509","indication":"Atopic Dermatitis","summary":"As of 27 April 2026, Triveni Bio estimated primary completion of a Phase 2 trial in Atopic Dermatitis, in October 2026.","as_of":"2026-04-27","source":"clinicaltrials","source_ref":"NCT07167758","source_url":"https://clinicaltrials.gov/study/NCT07167758","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e21945d5-eae0-4296-ab28-189375655715"},{"id":"d15d24aa-753a-48ef-bedc-9391b4f716df","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"USWM CT, LLC","ticker":null,"asset":"Afamitresgene autoleucel","indication":"Synovial Sarcoma","summary":"As of 11 August 2026, USWM CT estimated primary completion of a Phase 2 trial in Synovial Sarcoma, on 1 October 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT05642455","source_url":"https://clinicaltrials.gov/study/NCT05642455","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d15d24aa-753a-48ef-bedc-9391b4f716df"},{"id":"94543c03-fe99-4934-aa02-f483bf7c4f25","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Vanda Pharmaceuticals","ticker":null,"asset":"iloperidone","indication":"Hypertension","summary":"As of 27 February 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 2 trial in hypertension, in October 2026.","as_of":"2026-02-27","source":"clinicaltrials","source_ref":"NCT07090161","source_url":"https://clinicaltrials.gov/study/NCT07090161","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-94543c03-fe99-4934-aa02-f483bf7c4f25"},{"id":"40634e9f-c046-4d0c-bdc9-e4d0c5f30eae","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Vyriad, Inc.","ticker":null,"asset":"VV1","indication":"Melanoma","summary":"As of 8 July 2026, Vyriad estimated primary completion of a Phase 2 trial in melanoma, in October 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT04291105","source_url":"https://clinicaltrials.gov/study/NCT04291105","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-40634e9f-c046-4d0c-bdc9-e4d0c5f30eae"},{"id":"7b8d912c-4c16-4bab-aa9b-64f314e055c8","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Xenon Pharmaceuticals Inc.","ticker":null,"asset":"XEN1101","indication":"Focal Onset Seizures","summary":"As of 14 May 2026, Xenon Pharmaceuticals estimated primary completion of a Phase 3 trial in Focal Onset Seizures, in October 2026.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT05716100","source_url":"https://clinicaltrials.gov/study/NCT05716100","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7b8d912c-4c16-4bab-aa9b-64f314e055c8"},{"id":"58144f8a-7c3c-4bc3-bffc-f86d6b9115d2","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"month","confidence":"estimated","company":"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.","ticker":null,"asset":"Clascoterone","indication":"Acne Vulgaris","summary":"As of 9 July 2025, Zhejiang Sunshine Mandi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Acne Vulgaris, in October 2026.","as_of":"2025-07-09","source":"clinicaltrials","source_ref":"NCT06403501","source_url":"https://clinicaltrials.gov/study/NCT06403501","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-58144f8a-7c3c-4bc3-bffc-f86d6b9115d2"},{"id":"677a81da-b7ab-4d65-b217-0ff6979a701e","lane":"clinical","event_type":"primary-completion","date":"2026-10-01","date_precision":"day","confidence":"estimated","company":"argenx","ticker":null,"asset":"efgartigimod PH20 SC","indication":"Primary Immune Thrombocytopenia","summary":"As of 12 January 2026, argenx estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia, on 1 October 2026.","as_of":"2026-01-12","source":"clinicaltrials","source_ref":"NCT04812925","source_url":"https://clinicaltrials.gov/study/NCT04812925","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-677a81da-b7ab-4d65-b217-0ff6979a701e"},{"id":"6eb3f14c-b320-4672-86ae-681f4c95d642","lane":"clinical","event_type":"primary-completion","date":"2026-10-02","date_precision":"day","confidence":"estimated","company":"PEACHES BIOTECH","ticker":null,"asset":"PRS CK STORM","indication":"SARS-CoV-2","summary":"As of 10 June 2026, PEACHES BIOTECH estimated primary completion of a Phase 2 trial in sARS-CoV-2, on 2 October 2026.","as_of":"2026-06-10","source":"clinicaltrials","source_ref":"NCT06684379","source_url":"https://clinicaltrials.gov/study/NCT06684379","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6eb3f14c-b320-4672-86ae-681f4c95d642"},{"id":"2dad0c77-8c4d-416f-9520-3081297b25e0","lane":"clinical","event_type":"primary-completion","date":"2026-10-02","date_precision":"day","confidence":"estimated","company":"Takeda","ticker":null,"asset":"TAK-861","indication":"Narcolepsy Type 1 (NT1)","summary":"As of 8 July 2026, Takeda estimated primary completion of a Phase 3 trial in Narcolepsy Type 1 (NT1), on 2 October 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT07363720","source_url":"https://clinicaltrials.gov/study/NCT07363720","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2dad0c77-8c4d-416f-9520-3081297b25e0"},{"id":"967112c7-3a72-4f8f-b498-0a47373cd178","lane":"clinical","event_type":"primary-completion","date":"2026-10-04","date_precision":"day","confidence":"estimated","company":"Eddingpharm (Zhuhai) Co., Ltd.","ticker":null,"asset":"EDP167","indication":"Homozygous Familial Hypercholesterolemia (HoFH)","summary":"As of 20 May 2026, Eddingpharm (Zhuhai) Co. estimated primary completion of a Phase 2 trial in Homozygous Familial Hypercholesterolemia (HoFH), on 4 October 2026.","as_of":"2026-05-20","source":"clinicaltrials","source_ref":"NCT07489209","source_url":"https://clinicaltrials.gov/study/NCT07489209","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-967112c7-3a72-4f8f-b498-0a47373cd178"},{"id":"1edad944-9a1a-4d70-806e-e8a575313cc6","lane":"clinical","event_type":"primary-completion","date":"2026-10-05","date_precision":"day","confidence":"estimated","company":"ModernaTX, Inc.","ticker":null,"asset":"mRNA-1189","indication":"Epstein-Barr Virus Infection","summary":"As of 6 May 2026, ModernaTX estimated primary completion of a Phase 2 trial in Epstein-Barr Virus Infection, on 5 October 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT05164094","source_url":"https://clinicaltrials.gov/study/NCT05164094","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1edad944-9a1a-4d70-806e-e8a575313cc6"},{"id":"93d03545-22e2-4265-8d96-08c86afabb1a","lane":"clinical","event_type":"primary-completion","date":"2026-10-05","date_precision":"day","confidence":"estimated","company":"Swedish Orphan Biovitrum","ticker":null,"asset":"Pacritinib","indication":"Primary Myelofibrosis","summary":"As of 30 April 2026, Swedish Orphan Biovitrum estimated primary completion of a Phase 3 trial in Primary Myelofibrosis, on 5 October 2026.","as_of":"2026-04-30","source":"clinicaltrials","source_ref":"NCT03165734","source_url":"https://clinicaltrials.gov/study/NCT03165734","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-93d03545-22e2-4265-8d96-08c86afabb1a"},{"id":"3e4911e9-eb9c-4f3c-bac3-f22b0f4e34ae","lane":"clinical","event_type":"primary-completion","date":"2026-10-06","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"BMS-986278","indication":"Idiopathic Pulmonary Fibrosis","summary":"As of 24 March 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Idiopathic Pulmonary Fibrosis, on 6 October 2026.","as_of":"2026-03-24","source":"clinicaltrials","source_ref":"NCT06003426","source_url":"https://clinicaltrials.gov/study/NCT06003426","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3e4911e9-eb9c-4f3c-bac3-f22b0f4e34ae"},{"id":"a6fd0a42-bc0a-4482-82f5-39f3629cc44d","lane":"clinical","event_type":"primary-completion","date":"2026-10-07","date_precision":"day","confidence":"estimated","company":"Regeneron Pharmaceuticals","ticker":null,"asset":"Dupilumab","indication":"Atopic Dermatitis","summary":"As of 29 May 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 7 October 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT02612454","source_url":"https://clinicaltrials.gov/study/NCT02612454","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a6fd0a42-bc0a-4482-82f5-39f3629cc44d"},{"id":"c9ab3114-6a1e-44a6-ac19-48b48df61bfd","lane":"clinical","event_type":"primary-completion","date":"2026-10-08","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Tobemstomig","indication":"Renal Cell Carcinoma","summary":"As of 10 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 8 October 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT05805501","source_url":"https://clinicaltrials.gov/study/NCT05805501","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c9ab3114-6a1e-44a6-ac19-48b48df61bfd"},{"id":"0848fcbc-bf25-4ea5-a3b8-07b7804f76a3","lane":"clinical","event_type":"primary-completion","date":"2026-10-09","date_precision":"day","confidence":"estimated","company":"Incyte Corporation","ticker":null,"asset":"Ruxolitinib Cream","indication":"Hidradenitis Suppurativa","summary":"As of 28 July 2026, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 9 October 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT06959225","source_url":"https://clinicaltrials.gov/study/NCT06959225","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0848fcbc-bf25-4ea5-a3b8-07b7804f76a3"},{"id":"696757ab-0ba8-4594-a85b-3a977869cf9c","lane":"clinical","event_type":"primary-completion","date":"2026-10-09","date_precision":"day","confidence":"estimated","company":"Incyte Corporation","ticker":null,"asset":"Ruxolitinib Cream","indication":"Hidradenitis Suppurativa","summary":"As of 8 July 2026, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 9 October 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT06958211","source_url":"https://clinicaltrials.gov/study/NCT06958211","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-696757ab-0ba8-4594-a85b-3a977869cf9c"},{"id":"9438196a-6a93-4c98-bf20-0f0d53896cf7","lane":"clinical","event_type":"primary-completion","date":"2026-10-10","date_precision":"day","confidence":"estimated","company":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","ticker":null,"asset":"HDM1002 200 mg","indication":"Type 2 Diabetes","summary":"As of 25 September 2025, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Type 2 Diabetes, on 10 October 2026.","as_of":"2025-09-25","source":"clinicaltrials","source_ref":"NCT07193459","source_url":"https://clinicaltrials.gov/study/NCT07193459","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9438196a-6a93-4c98-bf20-0f0d53896cf7"},{"id":"3ac9bd6b-276f-420f-81d9-f58251c77372","lane":"clinical","event_type":"primary-completion","date":"2026-10-10","date_precision":"day","confidence":"estimated","company":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","ticker":null,"asset":"MC2-01 cream","indication":"Plaque Psoriasis","summary":"As of 23 June 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Plaque Psoriasis, on 10 October 2026.","as_of":"2026-06-23","source":"clinicaltrials","source_ref":"NCT07357831","source_url":"https://clinicaltrials.gov/study/NCT07357831","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3ac9bd6b-276f-420f-81d9-f58251c77372"},{"id":"f20aa1c3-49c4-405e-8422-6d0e3f19afe8","lane":"clinical","event_type":"primary-completion","date":"2026-10-11","date_precision":"day","confidence":"estimated","company":"Biocodex","ticker":null,"asset":"Saccharomyces Boulardii 250 MG","indication":"IBS (Irritable Bowel Syndrome)","summary":"As of 18 November 2025, Biocodex estimated primary completion of a Phase 3 trial in IBS (Irritable Bowel Syndrome), on 11 October 2026.","as_of":"2025-11-18","source":"clinicaltrials","source_ref":"NCT07168434","source_url":"https://clinicaltrials.gov/study/NCT07168434","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f20aa1c3-49c4-405e-8422-6d0e3f19afe8"},{"id":"b4bdd40c-d5b0-4e4d-8903-cf0c132d8705","lane":"clinical","event_type":"primary-completion","date":"2026-10-12","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"CC-92480","indication":"Multiple Myeloma","summary":"As of 5 September 2025, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 12 October 2026.","as_of":"2025-09-05","source":"clinicaltrials","source_ref":"NCT05372354","source_url":"https://clinicaltrials.gov/study/NCT05372354","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b4bdd40c-d5b0-4e4d-8903-cf0c132d8705"},{"id":"f5763113-6400-4d82-b8c1-3dded6c3c054","lane":"clinical","event_type":"primary-completion","date":"2026-10-12","date_precision":"day","confidence":"estimated","company":"Janssen Research & Development, LLC","ticker":null,"asset":"Apalutamide","indication":"Metastatic Castrate-sensitive Prostate Cancer","summary":"As of 31 July 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Metastatic Castrate-sensitive Prostate Cancer, on 12 October 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT05884398","source_url":"https://clinicaltrials.gov/study/NCT05884398","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f5763113-6400-4d82-b8c1-3dded6c3c054"},{"id":"4ad0607b-73e7-422a-95ba-d68d1fb6b544","lane":"clinical","event_type":"primary-completion","date":"2026-10-12","date_precision":"day","confidence":"estimated","company":"Regeneron Pharmaceuticals","ticker":null,"asset":"Ravulizumab","indication":"Paroxysmal Nocturnal Hemoglobinuria","summary":"As of 30 April 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria, on 12 October 2026.","as_of":"2026-04-30","source":"clinicaltrials","source_ref":"NCT05133531","source_url":"https://clinicaltrials.gov/study/NCT05133531","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4ad0607b-73e7-422a-95ba-d68d1fb6b544"},{"id":"ec82c6c3-ae18-433c-aeda-6c7f715a6d8a","lane":"clinical","event_type":"primary-completion","date":"2026-10-13","date_precision":"day","confidence":"estimated","company":"Aspa Therapeutics","ticker":null,"asset":"AAV9 BBP-812","indication":"Canavan Disease","summary":"As of 17 April 2026, Aspa Therapeutics estimated primary completion of a Phase 2 trial in Canavan Disease, on 13 October 2026.","as_of":"2026-04-17","source":"clinicaltrials","source_ref":"NCT04998396","source_url":"https://clinicaltrials.gov/study/NCT04998396","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ec82c6c3-ae18-433c-aeda-6c7f715a6d8a"},{"id":"cb4ac794-eee0-4360-bc6e-27d731879491","lane":"clinical","event_type":"primary-completion","date":"2026-10-13","date_precision":"day","confidence":"estimated","company":"Daewoong Pharmaceutical Co. LTD.","ticker":null,"asset":"DWN12088","indication":"Idiopathic Pulmonary Fibrosis","summary":"As of 16 July 2026, Daewoong Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, on 13 October 2026.","as_of":"2026-07-16","source":"clinicaltrials","source_ref":"NCT05389215","source_url":"https://clinicaltrials.gov/study/NCT05389215","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cb4ac794-eee0-4360-bc6e-27d731879491"},{"id":"3d0aa4ca-9c81-4f8e-875f-aa4f3d65c0c9","lane":"clinical","event_type":"primary-completion","date":"2026-10-13","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Cobolimab","indication":"Melanoma","summary":"As of 12 November 2025, GlaxoSmithKline estimated primary completion of a Phase 2 trial in melanoma, on 13 October 2026.","as_of":"2025-11-12","source":"clinicaltrials","source_ref":"NCT06521567","source_url":"https://clinicaltrials.gov/study/NCT06521567","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3d0aa4ca-9c81-4f8e-875f-aa4f3d65c0c9"},{"id":"82c2aa36-9d23-4191-aabb-41d64f293f9d","lane":"clinical","event_type":"primary-completion","date":"2026-10-13","date_precision":"day","confidence":"estimated","company":"Shanghai JMT-Bio Inc.","ticker":null,"asset":"JSKN003","indication":"Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants","summary":"As of 24 March 2025, Shanghai JMT-Bio estimated primary completion of a Phase 3 trial on 13 October 2026.","as_of":"2025-03-24","source":"clinicaltrials","source_ref":"NCT06846437","source_url":"https://clinicaltrials.gov/study/NCT06846437","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-82c2aa36-9d23-4191-aabb-41d64f293f9d"},{"id":"2577d3a0-febf-4a69-9309-0ebce738abf2","lane":"clinical","event_type":"primary-completion","date":"2026-10-14","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"dTpa vaccine","indication":"Diphtheria-Tetanus-acellular Pertussis Vaccines","summary":"As of 28 July 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines, on 14 October 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT07596173","source_url":"https://clinicaltrials.gov/study/NCT07596173","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2577d3a0-febf-4a69-9309-0ebce738abf2"},{"id":"ef5c6eec-4e3f-4c9d-a5ce-fc597bfaa42b","lane":"clinical","event_type":"primary-completion","date":"2026-10-14","date_precision":"day","confidence":"estimated","company":"Inozyme Pharma","ticker":null,"asset":"INZ-701","indication":"Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency","summary":"As of 10 August 2026, Inozyme Pharma estimated primary completion of a Phase 3 trial in Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, on 14 October 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT07473973","source_url":"https://clinicaltrials.gov/study/NCT07473973","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ef5c6eec-4e3f-4c9d-a5ce-fc597bfaa42b"},{"id":"87057dbc-e791-46f0-815a-09ec76d3e2ba","lane":"clinical","event_type":"primary-completion","date":"2026-10-14","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"Itepekimab (SAR440340)","indication":"Chronic Rhinosinusitis With Nasal Polyps","summary":"As of 20 May 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Rhinosinusitis With Nasal Polyps, on 14 October 2026.","as_of":"2026-05-20","source":"clinicaltrials","source_ref":"NCT06834347","source_url":"https://clinicaltrials.gov/study/NCT06834347","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-87057dbc-e791-46f0-815a-09ec76d3e2ba"},{"id":"aae500ad-36c5-4db6-b3e7-3c6f2c493dc6","lane":"clinical","event_type":"primary-completion","date":"2026-10-15","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD6489","indication":"RSV Respiratory Syncytial Virus","summary":"As of 21 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in RSV Respiratory Syncytial Virus, on 15 October 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT07717840","source_url":"https://clinicaltrials.gov/study/NCT07717840","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-aae500ad-36c5-4db6-b3e7-3c6f2c493dc6"},{"id":"ed6f6fb7-6b23-4291-86e3-5bd815232ae3","lane":"clinical","event_type":"primary-completion","date":"2026-10-15","date_precision":"day","confidence":"estimated","company":"Birch BioMed Inc","ticker":null,"asset":"IP1 control cream (Vehicle base)","indication":"Burn Scar","summary":"As of 4 May 2026, Birch BioMed estimated primary completion of a Phase 3 trial in Burn Scar, on 15 October 2026.","as_of":"2026-05-04","source":"clinicaltrials","source_ref":"NCT06807021","source_url":"https://clinicaltrials.gov/study/NCT06807021","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ed6f6fb7-6b23-4291-86e3-5bd815232ae3"},{"id":"b522359a-556c-454f-b6b3-3ce967d7abca","lane":"clinical","event_type":"primary-completion","date":"2026-10-15","date_precision":"day","confidence":"estimated","company":"CanariaBio Inc.","ticker":null,"asset":"Oregovomab","indication":"Ovarian Neoplasm Epithelial","summary":"As of 1 April 2026, CanariaBio estimated primary completion of a Phase 2 trial in Ovarian Neoplasm Epithelial, on 15 October 2026.","as_of":"2026-04-01","source":"clinicaltrials","source_ref":"NCT05605535","source_url":"https://clinicaltrials.gov/study/NCT05605535","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b522359a-556c-454f-b6b3-3ce967d7abca"},{"id":"c00bd783-658f-42f1-86ab-b1d0559508fd","lane":"clinical","event_type":"primary-completion","date":"2026-10-15","date_precision":"day","confidence":"estimated","company":"Eccogene","ticker":null,"asset":"ECC4703","indication":"Adult Obesity","summary":"As of 25 June 2026, Eccogene estimated primary completion of a Phase 2 trial in Adult Obesity, on 15 October 2026.","as_of":"2026-06-25","source":"clinicaltrials","source_ref":"NCT07505303","source_url":"https://clinicaltrials.gov/study/NCT07505303","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c00bd783-658f-42f1-86ab-b1d0559508fd"},{"id":"43aaa1f4-6424-4494-995f-b204fb12b731","lane":"clinical","event_type":"primary-completion","date":"2026-10-15","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"AAA617","indication":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","summary":"As of 1 May 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Metastatic Castration Resistant Prostate Cancer (mCRPC), on 15 October 2026.","as_of":"2026-05-01","source":"clinicaltrials","source_ref":"NCT06894511","source_url":"https://clinicaltrials.gov/study/NCT06894511","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-43aaa1f4-6424-4494-995f-b204fb12b731"},{"id":"25e134f3-7550-48b0-a254-996ed32e4daa","lane":"clinical","event_type":"primary-completion","date":"2026-10-15","date_precision":"day","confidence":"estimated","company":"Solid Biosciences Inc.","ticker":null,"asset":"SGT-001","indication":"Duchenne Muscular Dystrophy","summary":"As of 10 August 2026, Solid Biosciences estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 15 October 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT03368742","source_url":"https://clinicaltrials.gov/study/NCT03368742","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-25e134f3-7550-48b0-a254-996ed32e4daa"},{"id":"a0480eb2-4001-402f-a375-6e779e00c158","lane":"clinical","event_type":"primary-completion","date":"2026-10-15","date_precision":"day","confidence":"estimated","company":"Suzhou Alphamab Co., Ltd.","ticker":null,"asset":"KN057","indication":"Hemophilia A Without Inhibitor","summary":"As of 17 September 2025, Suzhou Alphamab Co. estimated primary completion of a Phase 3 trial in Hemophilia A Without Inhibitor, on 15 October 2026.","as_of":"2025-09-17","source":"clinicaltrials","source_ref":"NCT06569108","source_url":"https://clinicaltrials.gov/study/NCT06569108","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a0480eb2-4001-402f-a375-6e779e00c158"},{"id":"6e4f1309-fded-4e40-8d18-b62e34c1a662","lane":"clinical","event_type":"primary-completion","date":"2026-10-16","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Glofitamab","indication":"Non-Hodgkins Lymphoma","summary":"As of 6 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Non-Hodgkins Lymphoma, on 16 October 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT03533283","source_url":"https://clinicaltrials.gov/study/NCT03533283","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6e4f1309-fded-4e40-8d18-b62e34c1a662"},{"id":"2c0e45c8-d8ad-4178-bf99-9d3fe271dff4","lane":"clinical","event_type":"primary-completion","date":"2026-10-18","date_precision":"day","confidence":"estimated","company":"Kunming Pharmaceuticals, Inc.","ticker":null,"asset":"The KPCXM18 injection","indication":"Acute Ischemic Stroke","summary":"As of 12 December 2025, Kunming Pharmaceuticals estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 18 October 2026.","as_of":"2025-12-12","source":"clinicaltrials","source_ref":"NCT07279493","source_url":"https://clinicaltrials.gov/study/NCT07279493","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2c0e45c8-d8ad-4178-bf99-9d3fe271dff4"},{"id":"9030cf52-85a4-482a-ae85-e4f9c7a8c7cc","lane":"clinical","event_type":"primary-completion","date":"2026-10-19","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"Deucravacitinib","indication":"Systemic Lupus Erythematosus","summary":"As of 2 December 2025, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Systemic Lupus Erythematosus, on 19 October 2026.","as_of":"2025-12-02","source":"clinicaltrials","source_ref":"NCT05620407","source_url":"https://clinicaltrials.gov/study/NCT05620407","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9030cf52-85a4-482a-ae85-e4f9c7a8c7cc"},{"id":"a249c50c-5e39-43e1-b657-ea2332ab5d75","lane":"clinical","event_type":"primary-completion","date":"2026-10-19","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"Deucravacitinib","indication":"Systemic Lupus Erythematosus","summary":"As of 3 December 2025, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Systemic Lupus Erythematosus, on 19 October 2026.","as_of":"2025-12-03","source":"clinicaltrials","source_ref":"NCT05617677","source_url":"https://clinicaltrials.gov/study/NCT05617677","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a249c50c-5e39-43e1-b657-ea2332ab5d75"},{"id":"2430b772-ad86-459d-a491-577785beae19","lane":"clinical","event_type":"primary-completion","date":"2026-10-19","date_precision":"day","confidence":"estimated","company":"Incyte Corporation","ticker":null,"asset":"Povorcitinib","indication":"Prurigo Nodularis","summary":"As of 14 April 2026, Incyte estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 19 October 2026.","as_of":"2026-04-14","source":"clinicaltrials","source_ref":"NCT06516965","source_url":"https://clinicaltrials.gov/study/NCT06516965","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2430b772-ad86-459d-a491-577785beae19"},{"id":"ff572c41-60e2-41a0-a50f-f7f4eee14fa5","lane":"clinical","event_type":"primary-completion","date":"2026-10-19","date_precision":"day","confidence":"estimated","company":"Incyte Corporation","ticker":null,"asset":"Povorcitinib","indication":"Prurigo Nodularis","summary":"As of 28 May 2026, Incyte estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 19 October 2026.","as_of":"2026-05-28","source":"clinicaltrials","source_ref":"NCT06516952","source_url":"https://clinicaltrials.gov/study/NCT06516952","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ff572c41-60e2-41a0-a50f-f7f4eee14fa5"},{"id":"fc7b618e-df27-4bba-8221-e1c4ade7ad38","lane":"clinical","event_type":"primary-completion","date":"2026-10-19","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"PF-07275315","indication":"Atopic Dermatitis","summary":"As of 4 May 2026, Pfizer estimated primary completion of a Phase 2 trial in Atopic Dermatitis, on 19 October 2026.","as_of":"2026-05-04","source":"clinicaltrials","source_ref":"NCT05995964","source_url":"https://clinicaltrials.gov/study/NCT05995964","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fc7b618e-df27-4bba-8221-e1c4ade7ad38"},{"id":"4fd8c923-af51-4dca-91ff-d35818ea2ff9","lane":"clinical","event_type":"primary-completion","date":"2026-10-20","date_precision":"day","confidence":"estimated","company":"Biogen","ticker":null,"asset":"Litifilimab","indication":"Subacute Cutaneous Lupus Erythematosus","summary":"As of 31 July 2026, Biogen estimated primary completion of a Phase 3 trial in Subacute Cutaneous Lupus Erythematosus, on 20 October 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT05531565","source_url":"https://clinicaltrials.gov/study/NCT05531565","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4fd8c923-af51-4dca-91ff-d35818ea2ff9"},{"id":"6d231794-652f-4ec7-ac8b-378a0dd07cf9","lane":"clinical","event_type":"primary-completion","date":"2026-10-20","date_precision":"day","confidence":"estimated","company":"Bioray Laboratories","ticker":null,"asset":"BRL-101","indication":"Beta-Thalassemia","summary":"As of 21 July 2026, Bioray Laboratories estimated primary completion of a Phase 2 trial in beta-Thalassemia, on 20 October 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT05577312","source_url":"https://clinicaltrials.gov/study/NCT05577312","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6d231794-652f-4ec7-ac8b-378a0dd07cf9"},{"id":"bb48bb3a-e815-4653-baa4-52d15ebe46db","lane":"clinical","event_type":"primary-completion","date":"2026-10-20","date_precision":"day","confidence":"estimated","company":"Daiichi Sankyo","ticker":null,"asset":"DS-3939a","indication":"Advanced Solid Tumor","summary":"As of 17 July 2026, Daiichi Sankyo estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 20 October 2026.","as_of":"2026-07-17","source":"clinicaltrials","source_ref":"NCT05875168","source_url":"https://clinicaltrials.gov/study/NCT05875168","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bb48bb3a-e815-4653-baa4-52d15ebe46db"},{"id":"17471488-0813-4cf0-9eaa-6dc43d25a0dd","lane":"clinical","event_type":"primary-completion","date":"2026-10-20","date_precision":"day","confidence":"estimated","company":"LEO Pharma","ticker":null,"asset":"Tralokinumab + TCS","indication":"Atopic Dermatitis","summary":"As of 7 July 2026, LEO Pharma estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 20 October 2026.","as_of":"2026-07-07","source":"clinicaltrials","source_ref":"NCT06311682","source_url":"https://clinicaltrials.gov/study/NCT06311682","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-17471488-0813-4cf0-9eaa-6dc43d25a0dd"},{"id":"da6c2e92-f49d-4cbe-bac1-4f21a123c841","lane":"clinical","event_type":"primary-completion","date":"2026-10-20","date_precision":"day","confidence":"estimated","company":"Nanjing Leads Biolabs Co.,Ltd","ticker":null,"asset":"LBL-034 for Injection","indication":"Relapsed/Refractory Multiple Myeloma","summary":"As of 4 December 2025, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Relapsed/Refractory Multiple Myeloma, on 20 October 2026.","as_of":"2025-12-04","source":"clinicaltrials","source_ref":"NCT06049290","source_url":"https://clinicaltrials.gov/study/NCT06049290","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-da6c2e92-f49d-4cbe-bac1-4f21a123c841"},{"id":"5347e614-e6bf-4383-8a52-e156e4168402","lane":"clinical","event_type":"primary-completion","date":"2026-10-20","date_precision":"day","confidence":"estimated","company":"Otsuka Pharmaceutical Development & Commercialization, Inc.","ticker":null,"asset":"SEP-363856","indication":"Schizophrenia","summary":"As of 31 July 2026, Otsuka Pharmaceutical Development & Commercialization estimated primary completion of a Phase 3 trial in schizophrenia, on 20 October 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT06894212","source_url":"https://clinicaltrials.gov/study/NCT06894212","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5347e614-e6bf-4383-8a52-e156e4168402"},{"id":"107290a7-c64c-42c6-808f-3b0619df31c3","lane":"clinical","event_type":"primary-completion","date":"2026-10-22","date_precision":"day","confidence":"estimated","company":"Amgen","ticker":null,"asset":"Dazodalibep","indication":"Sjögren's Syndrome (SS)","summary":"As of 8 January 2026, Amgen estimated primary completion of a Phase 3 trial in Sjögren's Syndrome (SS), on 22 October 2026.","as_of":"2026-01-08","source":"clinicaltrials","source_ref":"NCT06245408","source_url":"https://clinicaltrials.gov/study/NCT06245408","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-107290a7-c64c-42c6-808f-3b0619df31c3"},{"id":"d25250be-6bdd-4970-baed-2951219e22dd","lane":"clinical","event_type":"primary-completion","date":"2026-10-22","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Ocrelizumab","indication":"Progressive Multiple Sclerosis (PMS)","summary":"As of 23 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Progressive Multiple Sclerosis (PMS), on 22 October 2026.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT03523858","source_url":"https://clinicaltrials.gov/study/NCT03523858","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d25250be-6bdd-4970-baed-2951219e22dd"},{"id":"750242ae-f622-4d3a-9246-4d7dc5c4583c","lane":"clinical","event_type":"primary-completion","date":"2026-10-22","date_precision":"day","confidence":"estimated","company":"Shanghai Henlius Biotech","ticker":null,"asset":"HLX10+chemo","indication":"SCLC, Extensive Stage","summary":"As of 20 May 2026, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in SCLC, Extensive Stage, on 22 October 2026.","as_of":"2026-05-20","source":"clinicaltrials","source_ref":"NCT06812260","source_url":"https://clinicaltrials.gov/study/NCT06812260","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-750242ae-f622-4d3a-9246-4d7dc5c4583c"},{"id":"44ea339b-88fc-40bd-b2c9-b5ff89758338","lane":"clinical","event_type":"primary-completion","date":"2026-10-23","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Durvalumab","indication":"Carcinoma, Non-Small-Cell Lung","summary":"As of 2 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung, on 23 October 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT06008093","source_url":"https://clinicaltrials.gov/study/NCT06008093","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-44ea339b-88fc-40bd-b2c9-b5ff89758338"},{"id":"f4ed4283-04ca-4841-94b9-ead74ad96f2c","lane":"clinical","event_type":"primary-completion","date":"2026-10-26","date_precision":"day","confidence":"estimated","company":"CSL Behring","ticker":null,"asset":"Recombinant single-chain factor VIII (rVIII-SingleChain)","indication":"Congenital Hemophilia A","summary":"As of 23 April 2026, CSL Behring estimated primary completion of a Phase 3 trial in Congenital Hemophilia A, on 26 October 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT06738485","source_url":"https://clinicaltrials.gov/study/NCT06738485","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f4ed4283-04ca-4841-94b9-ead74ad96f2c"},{"id":"eecbe5ea-b568-4827-8000-2ca1c6c239bd","lane":"clinical","event_type":"primary-completion","date":"2026-10-26","date_precision":"day","confidence":"estimated","company":"Galderma R&D","ticker":null,"asset":"Nemolizumab","indication":"Prurigo Nodularis","summary":"As of 12 November 2025, Galderma R&D estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 26 October 2026.","as_of":"2025-11-12","source":"clinicaltrials","source_ref":"NCT04204616","source_url":"https://clinicaltrials.gov/study/NCT04204616","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-eecbe5ea-b568-4827-8000-2ca1c6c239bd"},{"id":"3c5c5b55-ffce-4286-9661-01a34992cbc7","lane":"clinical","event_type":"primary-completion","date":"2026-10-26","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"Inclisiran sodium 300 mg","indication":"Coronary Artery Disease","summary":"As of 13 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Coronary Artery Disease, on 26 October 2026.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT05360446","source_url":"https://clinicaltrials.gov/study/NCT05360446","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3c5c5b55-ffce-4286-9661-01a34992cbc7"},{"id":"e02a9c94-f4ba-458f-b8c0-a1a3b9a925f6","lane":"clinical","event_type":"primary-completion","date":"2026-10-27","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Volrustomig","indication":"Hepatocellular Carcinoma","summary":"As of 2 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 27 October 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT05775159","source_url":"https://clinicaltrials.gov/study/NCT05775159","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e02a9c94-f4ba-458f-b8c0-a1a3b9a925f6"},{"id":"51e732b4-e292-4424-a107-86720956ddda","lane":"clinical","event_type":"primary-completion","date":"2026-10-28","date_precision":"day","confidence":"estimated","company":"Akeso","ticker":null,"asset":"Cadonilimab (AK104)","indication":"NSCLC (Non-small Cell Lung Cancer)","summary":"As of 12 March 2025, Akeso estimated primary completion of a Phase 3 trial in NSCLC (Non-small Cell Lung Cancer), on 28 October 2026.","as_of":"2025-03-12","source":"clinicaltrials","source_ref":"NCT06617416","source_url":"https://clinicaltrials.gov/study/NCT06617416","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-51e732b4-e292-4424-a107-86720956ddda"},{"id":"24d44034-83d8-46b9-8fdb-aa4db1a8d80b","lane":"clinical","event_type":"primary-completion","date":"2026-10-28","date_precision":"day","confidence":"estimated","company":"Boehringer Ingelheim","ticker":null,"asset":"BI 771716","indication":"Macular Degeneration, Age-related","summary":"As of 14 May 2026, Boehringer Ingelheim estimated primary completion of a Phase 2 trial in Macular Degeneration, Age-related, on 28 October 2026.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT06722157","source_url":"https://clinicaltrials.gov/study/NCT06722157","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-24d44034-83d8-46b9-8fdb-aa4db1a8d80b"},{"id":"5698d867-0bbf-4d94-b20a-82c326dccff7","lane":"clinical","event_type":"primary-completion","date":"2026-10-28","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"RO7204239","indication":"Spinal Muscular Atrophy (SMA)","summary":"As of 11 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Spinal Muscular Atrophy (SMA), on 28 October 2026.","as_of":"2026-06-11","source":"clinicaltrials","source_ref":"NCT05115110","source_url":"https://clinicaltrials.gov/study/NCT05115110","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5698d867-0bbf-4d94-b20a-82c326dccff7"},{"id":"43d4546e-7d3e-48e9-8f1d-52984c3761c1","lane":"clinical","event_type":"primary-completion","date":"2026-10-28","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Belzutifan","indication":"Carcinoma, Renal Cell","summary":"As of 15 May 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Carcinoma, Renal Cell, on 28 October 2026.","as_of":"2026-05-15","source":"clinicaltrials","source_ref":"NCT05239728","source_url":"https://clinicaltrials.gov/study/NCT05239728","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-43d4546e-7d3e-48e9-8f1d-52984c3761c1"},{"id":"6845d0f1-2ef0-4ca8-a3ae-b0eac5ba3bdd","lane":"clinical","event_type":"primary-completion","date":"2026-10-29","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Pembrolizumab","indication":"Carcinoma, Renal Cell","summary":"As of 6 May 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Carcinoma, Renal Cell, on 29 October 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT04736706","source_url":"https://clinicaltrials.gov/study/NCT04736706","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6845d0f1-2ef0-4ca8-a3ae-b0eac5ba3bdd"},{"id":"4a77f705-fbea-4f84-8150-191596fde54f","lane":"clinical","event_type":"primary-completion","date":"2026-10-29","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"Ianalumab","indication":"Primary Immune Thrombocytopenia (ITP)","summary":"As of 15 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia (ITP), on 29 October 2026.","as_of":"2026-06-15","source":"clinicaltrials","source_ref":"NCT05653349","source_url":"https://clinicaltrials.gov/study/NCT05653349","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4a77f705-fbea-4f84-8150-191596fde54f"},{"id":"587c42c7-b630-43fd-ac7f-e053fc39b61d","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Abbisko Therapeutics Co, Ltd","ticker":null,"asset":"ABSK021","indication":"cGvHD","summary":"As of 12 August 2024, Abbisko Therapeutics Co estimated primary completion of a Phase 2 trial in cGvHD, on 30 October 2026.","as_of":"2024-08-12","source":"clinicaltrials","source_ref":"NCT06186804","source_url":"https://clinicaltrials.gov/study/NCT06186804","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-587c42c7-b630-43fd-ac7f-e053fc39b61d"},{"id":"bcec8e7a-af4c-40e0-a5ae-6270c258167a","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Antelope Surgical Solutions, Inc","ticker":null,"asset":"AS1986NS","indication":"Prostate Cancer","summary":"As of 9 July 2026, Antelope Surgical Solutions estimated primary completion of a Phase 2 trial in Prostate Cancer, on 30 October 2026.","as_of":"2026-07-09","source":"clinicaltrials","source_ref":"NCT06906471","source_url":"https://clinicaltrials.gov/study/NCT06906471","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bcec8e7a-af4c-40e0-a5ae-6270c258167a"},{"id":"d9de27ba-9885-4e5c-b4e4-cefa1ffed506","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Beijing Continent Pharmaceutical Co, Ltd.","ticker":null,"asset":"Hydronidone Capsules","indication":"Chronic Hepatitis B With Hepatic Fibrosis","summary":"As of 31 March 2026, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 3 trial in Chronic Hepatitis B With Hepatic Fibrosis, on 30 October 2026.","as_of":"2026-03-31","source":"clinicaltrials","source_ref":"NCT07343778","source_url":"https://clinicaltrials.gov/study/NCT07343778","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d9de27ba-9885-4e5c-b4e4-cefa1ffed506"},{"id":"3d3b20df-adc7-4372-971b-5f198ee2f5bf","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Biotheus Inc.","ticker":null,"asset":"PM8002","indication":"TNBC","summary":"As of 11 March 2025, Biotheus estimated primary completion of a Phase 2 trial in tNBC, on 30 October 2026.","as_of":"2025-03-11","source":"clinicaltrials","source_ref":"NCT05918133","source_url":"https://clinicaltrials.gov/study/NCT05918133","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3d3b20df-adc7-4372-971b-5f198ee2f5bf"},{"id":"60b7075d-daf9-4928-bdfe-0211f332d1fe","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"CSPC Ouyi Pharmaceutical Co., Ltd.","ticker":null,"asset":"Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR","indication":"Type 2 Diabetes","summary":"As of 6 April 2026, CSPC Ouyi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Type 2 Diabetes, on 30 October 2026.","as_of":"2026-04-06","source":"clinicaltrials","source_ref":"NCT07026968","source_url":"https://clinicaltrials.gov/study/NCT07026968","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-60b7075d-daf9-4928-bdfe-0211f332d1fe"},{"id":"4d87bfee-1002-4486-b462-fab790375496","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Genzyme, a Sanofi Company","ticker":null,"asset":"venglustat (GZ402671)","indication":"Gaucher Disease Type 1","summary":"As of 10 July 2026, Genzyme, a Sanofi estimated primary completion of a Phase 2 trial in Gaucher Disease Type 1, on 30 October 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT02843035","source_url":"https://clinicaltrials.gov/study/NCT02843035","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4d87bfee-1002-4486-b462-fab790375496"},{"id":"88995124-28c6-4c16-a8e9-0495eb93864f","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","ticker":null,"asset":"18F-MFBG","indication":"Parkinson Disease (PD)","summary":"As of 1 July 2026, Innervate Radiopharmaceuticals estimated primary completion of a Phase 2 trial in Parkinson Disease (PD), on 30 October 2026.","as_of":"2026-07-01","source":"clinicaltrials","source_ref":"NCT07176286","source_url":"https://clinicaltrials.gov/study/NCT07176286","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-88995124-28c6-4c16-a8e9-0495eb93864f"},{"id":"bb42612f-4112-45c5-a826-a338ef9d0436","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","ticker":null,"asset":"18F-metaFluorobenzylguanidine","indication":"Heart Failure","summary":"As of 1 July 2026, Innervate Radiopharmaceuticals estimated primary completion of a Phase 2 trial in Heart Failure, on 30 October 2026.","as_of":"2026-07-01","source":"clinicaltrials","source_ref":"NCT06965621","source_url":"https://clinicaltrials.gov/study/NCT06965621","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bb42612f-4112-45c5-a826-a338ef9d0436"},{"id":"38a27d04-36cf-4240-8a9f-39a319fbc865","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Kind Pharmaceuticals LLC","ticker":null,"asset":"AND017 capsules","indication":"Anemia Due to Chronic Kidney Disease","summary":"As of 27 March 2026, Kind Pharmaceuticals estimated primary completion of a Phase 3 trial in Anemia Due to Chronic Kidney Disease, on 30 October 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT07494409","source_url":"https://clinicaltrials.gov/study/NCT07494409","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-38a27d04-36cf-4240-8a9f-39a319fbc865"},{"id":"02d891c7-92d2-4a82-a7a1-42865140d967","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Laekna Limited","ticker":null,"asset":"Afuresertib","indication":"Breast Cancer","summary":"As of 2 April 2026, Laekna estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 October 2026.","as_of":"2026-04-02","source":"clinicaltrials","source_ref":"NCT04851613","source_url":"https://clinicaltrials.gov/study/NCT04851613","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-02d891c7-92d2-4a82-a7a1-42865140d967"},{"id":"326a05cd-06c7-47d0-8b7b-cbb763a17776","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Natureceuticals Sdn Bhd","ticker":null,"asset":"Nuvastatic 300","indication":"Fatigue Related to Cancer Treatment","summary":"As of 25 June 2026, Natureceuticals Sdn Bhd estimated primary completion of a Phase 3 trial in Fatigue Related to Cancer Treatment, on 30 October 2026.","as_of":"2026-06-25","source":"clinicaltrials","source_ref":"NCT07669467","source_url":"https://clinicaltrials.gov/study/NCT07669467","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-326a05cd-06c7-47d0-8b7b-cbb763a17776"},{"id":"8f86c6ff-3ceb-408d-9596-b5ebf67691d8","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Nouscom SRL","ticker":null,"asset":"GAd-209-FSP low dose","indication":"Solid Tumor, Adult","summary":"As of 13 February 2026, Nouscom SRL estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 30 October 2026.","as_of":"2026-02-13","source":"clinicaltrials","source_ref":"NCT04041310","source_url":"https://clinicaltrials.gov/study/NCT04041310","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8f86c6ff-3ceb-408d-9596-b5ebf67691d8"},{"id":"e9c43eb6-e987-48e1-a06a-0c59c2e58dc0","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"asset":"HRS-2189","indication":"Advanced Unresectable or Metastatic Breast Cancer","summary":"As of 2 March 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Advanced Unresectable or Metastatic Breast Cancer, on 30 October 2026.","as_of":"2026-03-02","source":"clinicaltrials","source_ref":"NCT06679036","source_url":"https://clinicaltrials.gov/study/NCT06679036","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e9c43eb6-e987-48e1-a06a-0c59c2e58dc0"},{"id":"f0bb9129-4706-4d8e-8368-9bdbac67cae0","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Shanghai Henlius Biotech","ticker":null,"asset":"HLX43 dose 1","indication":"Solid Tumor Cancer","summary":"As of 17 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Solid Tumor Cancer, on 30 October 2026.","as_of":"2025-11-17","source":"clinicaltrials","source_ref":"NCT06848699","source_url":"https://clinicaltrials.gov/study/NCT06848699","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f0bb9129-4706-4d8e-8368-9bdbac67cae0"},{"id":"f97d64ac-e9f2-4292-9e0a-a559d97bdf62","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Tyligand Pharmaceuticals (Suzhou) Limited","ticker":null,"asset":"TSN1611","indication":"Malignant Neoplasm","summary":"As of 24 April 2026, Tyligand Pharmaceuticals (Suzhou) estimated primary completion of a Phase 2 trial in Malignant Neoplasm, on 30 October 2026.","as_of":"2026-04-24","source":"clinicaltrials","source_ref":"NCT06385925","source_url":"https://clinicaltrials.gov/study/NCT06385925","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f97d64ac-e9f2-4292-9e0a-a559d97bdf62"},{"id":"267ff3d3-5aa6-48e7-bb8d-2dfe0d8c486a","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Vertex Pharmaceuticals Incorporated","ticker":null,"asset":"VX-121/TEZ/D-IVA","indication":"Cystic Fibrosis","summary":"As of 21 July 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 3 trial in Cystic Fibrosis, on 30 October 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT05444257","source_url":"https://clinicaltrials.gov/study/NCT05444257","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-267ff3d3-5aa6-48e7-bb8d-2dfe0d8c486a"},{"id":"beac1b75-3f34-48a9-b41b-37cd1e3b3828","lane":"clinical","event_type":"primary-completion","date":"2026-10-30","date_precision":"day","confidence":"estimated","company":"Vidya Therapeutics Inc","ticker":null,"asset":"VT7208","indication":"Multiple Sclerosis","summary":"As of 21 July 2026, Vidya Therapeutics estimated primary completion of a Phase 2 trial in Multiple Sclerosis, on 30 October 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT07085507","source_url":"https://clinicaltrials.gov/study/NCT07085507","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-beac1b75-3f34-48a9-b41b-37cd1e3b3828"},{"id":"9b218c1d-3043-4530-bede-db6d9b343877","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Adagene Inc","ticker":null,"asset":"ADG126","indication":"Advanced/Metastatic Solid Tumors","summary":"As of 7 January 2026, Adagene estimated primary completion of a Phase 2 trial in Advanced/Metastatic Solid Tumors, on 31 October 2026.","as_of":"2026-01-07","source":"clinicaltrials","source_ref":"NCT05405595","source_url":"https://clinicaltrials.gov/study/NCT05405595","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b218c1d-3043-4530-bede-db6d9b343877"},{"id":"f18ec4a6-23fd-48bb-a6f6-2dcfea286583","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Amgen","ticker":null,"asset":"anvumetostat","indication":"MTAP-deleted NSCLC","summary":"As of 28 May 2026, Amgen estimated primary completion of a Phase 2 trial in MTAP-deleted NSCLC, on 31 October 2026.","as_of":"2026-05-28","source":"clinicaltrials","source_ref":"NCT06593522","source_url":"https://clinicaltrials.gov/study/NCT06593522","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f18ec4a6-23fd-48bb-a6f6-2dcfea286583"},{"id":"b690014f-f415-4bae-868c-6a179a1fc92a","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Animuscure Inc.","ticker":null,"asset":"AMC6156 0.1mg","indication":"Sarcopenia in Elderly","summary":"As of 3 August 2026, Animuscure estimated primary completion of a Phase 2 trial in Sarcopenia in Elderly, on 31 October 2026.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT07072195","source_url":"https://clinicaltrials.gov/study/NCT07072195","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b690014f-f415-4bae-868c-6a179a1fc92a"},{"id":"43c0284e-3aba-4cac-a103-326f4e0e2383","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Annexon, Inc.","ticker":null,"asset":"Vonaprument","indication":"Geographic Atrophy","summary":"As of 4 May 2026, Annexon estimated primary completion of a Phase 3 trial in Geographic Atrophy, on 31 October 2026.","as_of":"2026-05-04","source":"clinicaltrials","source_ref":"NCT06510816","source_url":"https://clinicaltrials.gov/study/NCT06510816","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-43c0284e-3aba-4cac-a103-326f4e0e2383"},{"id":"64786fb8-0d27-49b5-b70f-2b1c2fd5456a","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"AskBio Inc","ticker":null,"asset":"AB-1002","indication":"Congestive Heart Failure","summary":"As of 3 December 2025, AskBio estimated primary completion of a Phase 2 trial in Congestive Heart Failure, on 31 October 2026.","as_of":"2025-12-03","source":"clinicaltrials","source_ref":"NCT05598333","source_url":"https://clinicaltrials.gov/study/NCT05598333","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-64786fb8-0d27-49b5-b70f-2b1c2fd5456a"},{"id":"13f3877b-5df3-4e18-a18c-8451ba903373","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Capivasertib","indication":"Breast Cancer","summary":"As of 27 March 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Breast Cancer, on 31 October 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT06635447","source_url":"https://clinicaltrials.gov/study/NCT06635447","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-13f3877b-5df3-4e18-a18c-8451ba903373"},{"id":"5050b46b-9681-43be-b6f7-a2e29b614848","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Avistone Biotechnology Co., Ltd.","ticker":null,"asset":"Vebreltinib","indication":"Non-Small-Cell Lung Cancer","summary":"As of 21 May 2025, Avistone Biotechnology Co. estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer, on 31 October 2026.","as_of":"2025-05-21","source":"clinicaltrials","source_ref":"NCT06574347","source_url":"https://clinicaltrials.gov/study/NCT06574347","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5050b46b-9681-43be-b6f7-a2e29b614848"},{"id":"2f35cbeb-d957-43e4-aaca-d84f177cdcf5","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Changzhou Qianhong Bio-pharma Co., Ltd.","ticker":null,"asset":"QHRD106 Injection (Low-dose group)","indication":"Acute Ischemic Stroke","summary":"As of 9 February 2026, Changzhou Qianhong Bio-pharma Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 31 October 2026.","as_of":"2026-02-09","source":"clinicaltrials","source_ref":"NCT07396337","source_url":"https://clinicaltrials.gov/study/NCT07396337","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2f35cbeb-d957-43e4-aaca-d84f177cdcf5"},{"id":"35c4f604-2850-4751-bc0e-09e10c3b6f2c","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Genentech, Inc.","ticker":null,"asset":"Venetoclax","indication":"Chronic Lymphocytic Leukemia","summary":"As of 25 February 2026, Genentech estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, on 31 October 2026.","as_of":"2026-02-25","source":"clinicaltrials","source_ref":"NCT06524375","source_url":"https://clinicaltrials.gov/study/NCT06524375","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-35c4f604-2850-4751-bc0e-09e10c3b6f2c"},{"id":"be159fc5-75cd-4aec-914f-28d7a4a1179c","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Alectinib","indication":"Non-Small Cell Lung Cancer","summary":"As of 5 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 31 October 2026.","as_of":"2026-06-05","source":"clinicaltrials","source_ref":"NCT03178552","source_url":"https://clinicaltrials.gov/study/NCT03178552","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-be159fc5-75cd-4aec-914f-28d7a4a1179c"},{"id":"6403d0a4-9f7e-4730-a77f-5e119e622058","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Tobemstomig","indication":"Breast Cancer","summary":"As of 11 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 October 2026.","as_of":"2026-06-11","source":"clinicaltrials","source_ref":"NCT05852691","source_url":"https://clinicaltrials.gov/study/NCT05852691","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6403d0a4-9f7e-4730-a77f-5e119e622058"},{"id":"598849fa-3767-4291-8795-58356bdb4606","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"asset":"IBI3003","indication":"Multiple Myeloma","summary":"As of 13 December 2024, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 31 October 2026.","as_of":"2024-12-13","source":"clinicaltrials","source_ref":"NCT06083207","source_url":"https://clinicaltrials.gov/study/NCT06083207","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-598849fa-3767-4291-8795-58356bdb4606"},{"id":"a739643a-df7c-4f7e-849c-3fc9a5fa190e","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Janssen Research & Development, LLC","ticker":null,"asset":"Milvexian","indication":"Atrial Fibrillation","summary":"As of 6 July 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Atrial Fibrillation, on 31 October 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT05757869","source_url":"https://clinicaltrials.gov/study/NCT05757869","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a739643a-df7c-4f7e-849c-3fc9a5fa190e"},{"id":"05d2bafd-8fbf-489c-ab66-2c5df645dde9","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"SHR6390","indication":"Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk...","summary":"As of 1 August 2024, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial on 31 October 2026.","as_of":"2024-08-01","source":"clinicaltrials","source_ref":"NCT04842617","source_url":"https://clinicaltrials.gov/study/NCT04842617","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-05d2bafd-8fbf-489c-ab66-2c5df645dde9"},{"id":"4de6d9cf-465d-45fe-9edc-5ec4f59a7eae","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Longboard Pharmaceuticals","ticker":null,"asset":"LP352","indication":"Developmental and Epileptic Encephalopathy","summary":"As of 17 July 2026, Longboard Pharmaceuticals estimated primary completion of a Phase 3 trial in Developmental and Epileptic Encephalopathy, on 31 October 2026.","as_of":"2026-07-17","source":"clinicaltrials","source_ref":"NCT06719141","source_url":"https://clinicaltrials.gov/study/NCT06719141","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4de6d9cf-465d-45fe-9edc-5ec4f59a7eae"},{"id":"896eaf58-a29a-48d2-989a-97baf0c917f1","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"MaaT Pharma","ticker":null,"asset":"Pooled allogeneic fecal microbiotherapy","indication":"Transplant Complication","summary":"As of 27 December 2024, MaaT Pharma estimated primary completion of a Phase 2 trial in Transplant Complication, on 31 October 2026.","as_of":"2024-12-27","source":"clinicaltrials","source_ref":"NCT05762211","source_url":"https://clinicaltrials.gov/study/NCT05762211","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-896eaf58-a29a-48d2-989a-97baf0c917f1"},{"id":"41560feb-5c94-4bcc-8dc3-b3b759a94758","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Myosin Therapeutics Inc.","ticker":null,"asset":"MT-125","indication":"Glioblastoma (GBM)","summary":"As of 14 April 2026, Myosin Therapeutics estimated primary completion of a Phase 2 trial in glioblastoma (GBM), on 31 October 2026.","as_of":"2026-04-14","source":"clinicaltrials","source_ref":"NCT07185880","source_url":"https://clinicaltrials.gov/study/NCT07185880","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-41560feb-5c94-4bcc-8dc3-b3b759a94758"},{"id":"4cdc74fc-ee61-4a2b-b049-05c36e128a55","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"NEXTGEN Bioscience","ticker":null,"asset":"NXC736","indication":"Alopecia Areata","summary":"As of 13 April 2026, NEXTGEN Bioscience estimated primary completion of a Phase 2 trial in Alopecia Areata, on 31 October 2026.","as_of":"2026-04-13","source":"clinicaltrials","source_ref":"NCT06104839","source_url":"https://clinicaltrials.gov/study/NCT06104839","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4cdc74fc-ee61-4a2b-b049-05c36e128a55"},{"id":"68871dff-4e46-46a9-bac1-963a878b0060","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Natureceuticals Sdn Bhd","ticker":null,"asset":"Nuvastatic 300","indication":"Fatigue Related to Cancer Treatment","summary":"As of 25 June 2026, Natureceuticals Sdn Bhd estimated primary completion of a Phase 3 trial in Fatigue Related to Cancer Treatment, on 31 October 2026.","as_of":"2026-06-25","source":"clinicaltrials","source_ref":"NCT07669454","source_url":"https://clinicaltrials.gov/study/NCT07669454","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-68871dff-4e46-46a9-bac1-963a878b0060"},{"id":"e6c9a764-be6d-47e7-a019-7e89d99efbf9","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Neurimmune AG","ticker":null,"asset":"ALXN2220","indication":"Amyloid Transthyretin Cardiomyopathy","summary":"As of 19 December 2025, Neurimmune estimated primary completion of a Phase 2 trial in Amyloid Transthyretin Cardiomyopathy, on 31 October 2026.","as_of":"2025-12-19","source":"clinicaltrials","source_ref":"NCT07213583","source_url":"https://clinicaltrials.gov/study/NCT07213583","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e6c9a764-be6d-47e7-a019-7e89d99efbf9"},{"id":"fc56adf6-d12e-4ecf-955f-86885c27a01c","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Rhythm Pharmaceuticals, Inc.","ticker":null,"asset":"Setmelanotide","indication":"Prader-Willi Syndrome","summary":"As of 12 February 2026, Rhythm Pharmaceuticals estimated primary completion of a Phase 2 trial in Prader-Willi Syndrome, on 31 October 2026.","as_of":"2026-02-12","source":"clinicaltrials","source_ref":"NCT06772597","source_url":"https://clinicaltrials.gov/study/NCT06772597","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fc56adf6-d12e-4ecf-955f-86885c27a01c"},{"id":"19b435d9-042f-4fd8-91ed-f501223a5d09","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Salubris Biotherapeutics Inc","ticker":null,"asset":"JK07","indication":"Heart Failure With Reduced Ejection Fraction","summary":"As of 22 May 2026, Salubris Biotherapeutics estimated primary completion of a Phase 2 trial in Heart Failure With Reduced Ejection Fraction, on 31 October 2026.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT06369298","source_url":"https://clinicaltrials.gov/study/NCT06369298","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-19b435d9-042f-4fd8-91ed-f501223a5d09"},{"id":"20cca7b3-4a19-40a0-adb7-7b9c881d8150","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Sarepta Therapeutics, Inc.","ticker":null,"asset":"Eteplirsen","indication":"Muscular Dystrophy, Duchenne","summary":"As of 27 February 2026, Sarepta Therapeutics estimated primary completion of a Phase 3 trial in Muscular Dystrophy, Duchenne, on 31 October 2026.","as_of":"2026-02-27","source":"clinicaltrials","source_ref":"NCT03992430","source_url":"https://clinicaltrials.gov/study/NCT03992430","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-20cca7b3-4a19-40a0-adb7-7b9c881d8150"},{"id":"12aec0b0-2e3d-4648-91b7-264c6c649683","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"asset":"HRS-8080; SHR-A1811","indication":"Breast Cancer","summary":"As of 25 November 2024, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 October 2026.","as_of":"2024-11-25","source":"clinicaltrials","source_ref":"NCT06222879","source_url":"https://clinicaltrials.gov/study/NCT06222879","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-12aec0b0-2e3d-4648-91b7-264c6c649683"},{"id":"ddd6c460-f178-4bae-a884-bf7ced8860d2","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Shanghai Henlius Biotech","ticker":null,"asset":"HLX43 DOSE 1","indication":"Carcinoma, Hepatocellular","summary":"As of 10 March 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Carcinoma, Hepatocellular, on 31 October 2026.","as_of":"2025-03-10","source":"clinicaltrials","source_ref":"NCT06742892","source_url":"https://clinicaltrials.gov/study/NCT06742892","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ddd6c460-f178-4bae-a884-bf7ced8860d2"},{"id":"61753490-66a9-44da-a408-884ea0ceac1e","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Shanghai Henlius Biotech","ticker":null,"asset":"HLX43","indication":"Esophageal Cancer","summary":"As of 18 May 2026, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Esophageal Cancer, on 31 October 2026.","as_of":"2026-05-18","source":"clinicaltrials","source_ref":"NCT06769113","source_url":"https://clinicaltrials.gov/study/NCT06769113","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-61753490-66a9-44da-a408-884ea0ceac1e"},{"id":"b7e53e02-5f8b-4c86-b95a-781c97b8dbb9","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Spyre Therapeutics, Inc.","ticker":null,"asset":"SPY002-072","indication":"Rheumatoid Arthritis","summary":"As of 5 June 2026, Spyre Therapeutics estimated primary completion of a Phase 2 trial in Rheumatoid Arthritis, on 31 October 2026.","as_of":"2026-06-05","source":"clinicaltrials","source_ref":"NCT07148414","source_url":"https://clinicaltrials.gov/study/NCT07148414","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b7e53e02-5f8b-4c86-b95a-781c97b8dbb9"},{"id":"be54f910-59e5-4ff3-8d13-c91373db37a8","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"TG Therapeutics, Inc.","ticker":null,"asset":"Ublituximab","indication":"Relapsing Multiple Sclerosis","summary":"As of 17 July 2026, TG Therapeutics estimated primary completion of a Phase 3 trial in Relapsing Multiple Sclerosis, on 31 October 2026.","as_of":"2026-07-17","source":"clinicaltrials","source_ref":"NCT07211633","source_url":"https://clinicaltrials.gov/study/NCT07211633","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-be54f910-59e5-4ff3-8d13-c91373db37a8"},{"id":"04fba133-5d41-4d71-b3a9-efeea2052159","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Takeda","ticker":null,"asset":"TAK-788","indication":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","summary":"As of 30 March 2026, Takeda estimated primary completion of a Phase 3 trial in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), on 31 October 2026.","as_of":"2026-03-30","source":"clinicaltrials","source_ref":"NCT04129502","source_url":"https://clinicaltrials.gov/study/NCT04129502","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-04fba133-5d41-4d71-b3a9-efeea2052159"},{"id":"a2c3606e-2b41-479a-abd0-8aff5386865b","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Takeda","ticker":null,"asset":"TAK-788","indication":"Carcinoma, Non-Small-Cell Lung","summary":"As of 25 February 2026, Takeda estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung, on 31 October 2026.","as_of":"2026-02-25","source":"clinicaltrials","source_ref":"NCT02716116","source_url":"https://clinicaltrials.gov/study/NCT02716116","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a2c3606e-2b41-479a-abd0-8aff5386865b"},{"id":"0df23a84-7bf8-4610-b23f-b5dda1094cb2","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Teva Branded Pharmaceutical Products R&D LLC","ticker":null,"asset":"TEV-56248","indication":"Asthma","summary":"As of 24 July 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 3 trial in asthma, on 31 October 2026.","as_of":"2026-07-24","source":"clinicaltrials","source_ref":"NCT06052267","source_url":"https://clinicaltrials.gov/study/NCT06052267","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0df23a84-7bf8-4610-b23f-b5dda1094cb2"},{"id":"786457ba-c2d3-46a7-b1a0-a2f31cc1c4b9","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Topadur Pharma AG","ticker":null,"asset":"TOP-N53","indication":"Digital Ulcers in Systemic Sclerosis","summary":"As of 15 June 2026, Topadur Pharma estimated primary completion of a Phase 2 trial in Digital Ulcers in Systemic Sclerosis, on 31 October 2026.","as_of":"2026-06-15","source":"clinicaltrials","source_ref":"NCT06954597","source_url":"https://clinicaltrials.gov/study/NCT06954597","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-786457ba-c2d3-46a7-b1a0-a2f31cc1c4b9"},{"id":"bdfe2864-1852-40fb-89c0-c98569b07528","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Viatris Innovation GmbH","ticker":null,"asset":"Cenerimod","indication":"Lupus Erythematosus, Systemic","summary":"As of 28 July 2026, Viatris Innovation estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 31 October 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT05648500","source_url":"https://clinicaltrials.gov/study/NCT05648500","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bdfe2864-1852-40fb-89c0-c98569b07528"},{"id":"cf887eba-fcae-4899-bb55-ed2c33bb568a","lane":"clinical","event_type":"primary-completion","date":"2026-10-31","date_precision":"day","confidence":"estimated","company":"Viatris Innovation GmbH","ticker":null,"asset":"Cenerimod","indication":"Lupus Erythematosus, Systemic","summary":"As of 28 July 2026, Viatris Innovation estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 31 October 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT05672576","source_url":"https://clinicaltrials.gov/study/NCT05672576","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cf887eba-fcae-4899-bb55-ed2c33bb568a"},{"id":"d89bcee9-f5fd-40f6-93fa-d33921765143","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"Mirvetuximab soravtansine","indication":"High Grade Ovarian Cancer","summary":"As of 28 October 2025, AbbVie estimated primary completion of a Phase 2 trial in High Grade Ovarian Cancer, in November 2026.","as_of":"2025-10-28","source":"clinicaltrials","source_ref":"NCT05456685","source_url":"https://clinicaltrials.gov/study/NCT05456685","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d89bcee9-f5fd-40f6-93fa-d33921765143"},{"id":"f5d4f311-10c5-4a6c-b5c6-2a5bd3f75029","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"ABBV-932","indication":"Generalized Anxiety Disorder (GAD)","summary":"As of 17 June 2026, AbbVie estimated primary completion of a Phase 2 trial in Generalized Anxiety Disorder (GAD), in November 2026.","as_of":"2026-06-17","source":"clinicaltrials","source_ref":"NCT06846320","source_url":"https://clinicaltrials.gov/study/NCT06846320","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f5d4f311-10c5-4a6c-b5c6-2a5bd3f75029"},{"id":"9c778da3-e70e-4394-8eab-95ad181edee9","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"Venetoclax","indication":"Chronic Lymphocytic Leukemia (CLL)","summary":"As of 9 February 2026, AbbVie estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia (CLL), in November 2026.","as_of":"2026-02-09","source":"clinicaltrials","source_ref":"NCT04895436","source_url":"https://clinicaltrials.gov/study/NCT04895436","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9c778da3-e70e-4394-8eab-95ad181edee9"},{"id":"9c648010-50d4-4bbe-97ce-382cbb7c0592","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"Budigalimab","indication":"Hepatocellular Carcinoma","summary":"As of 14 August 2025, AbbVie estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, in November 2026.","as_of":"2025-08-14","source":"clinicaltrials","source_ref":"NCT05822752","source_url":"https://clinicaltrials.gov/study/NCT05822752","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9c648010-50d4-4bbe-97ce-382cbb7c0592"},{"id":"7470a3c9-5571-4ac5-be41-4c59453eb8e3","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Acesion Pharma","ticker":null,"asset":"AP31969","indication":"Atrial Fibrillation (AF)","summary":"As of 12 June 2026, Acesion Pharma estimated primary completion of a Phase 2 trial in Atrial Fibrillation (AF), in November 2026.","as_of":"2026-06-12","source":"clinicaltrials","source_ref":"NCT07267949","source_url":"https://clinicaltrials.gov/study/NCT07267949","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7470a3c9-5571-4ac5-be41-4c59453eb8e3"},{"id":"b72234f8-c3bb-446c-9e0d-3c432e638180","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Admetsys Corporation","ticker":null,"asset":"glucose and insulin infusions","indication":"Hyperglycemia","summary":"As of 30 July 2024, Admetsys estimated primary completion of a Phase 2 trial in hyperglycemia, in November 2026.","as_of":"2024-07-30","source":"clinicaltrials","source_ref":"NCT01291719","source_url":"https://clinicaltrials.gov/study/NCT01291719","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b72234f8-c3bb-446c-9e0d-3c432e638180"},{"id":"f9091d3a-be96-4c7f-8a58-964e3a8d272f","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Akeso","ticker":null,"asset":"cadonilimab","indication":"Gastric and Gastroesophageal Junction Adenocarcinoma","summary":"As of 24 June 2024, Akeso estimated primary completion of a Phase 3 trial in Gastric and Gastroesophageal Junction Adenocarcinoma, in November 2026.","as_of":"2024-06-24","source":"clinicaltrials","source_ref":"NCT06341335","source_url":"https://clinicaltrials.gov/study/NCT06341335","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f9091d3a-be96-4c7f-8a58-964e3a8d272f"},{"id":"95af9072-a81b-4b15-b4e6-affec8c851b2","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Alkermes, Inc.","ticker":null,"asset":"ALKS 2680","indication":"Idiopathic Hypersomnia","summary":"As of 24 June 2026, Alkermes estimated primary completion of a Phase 2 trial in Idiopathic Hypersomnia, in November 2026.","as_of":"2026-06-24","source":"clinicaltrials","source_ref":"NCT06843590","source_url":"https://clinicaltrials.gov/study/NCT06843590","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-95af9072-a81b-4b15-b4e6-affec8c851b2"},{"id":"64fff16e-382d-45e1-a975-f12cdf3d9991","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Anbogen Therapeutics, Inc.","ticker":null,"asset":"ABT-101","indication":"Advanced Solid Tumor","summary":"As of 24 June 2024, Anbogen Therapeutics estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in November 2026.","as_of":"2024-06-24","source":"clinicaltrials","source_ref":"NCT05532696","source_url":"https://clinicaltrials.gov/study/NCT05532696","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-64fff16e-382d-45e1-a975-f12cdf3d9991"},{"id":"a77bf3f8-e144-4273-8d40-3e8727f55d9c","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Apogee Therapeutics, Inc.","ticker":null,"asset":"APG777","indication":"Atopic Dermatitis","summary":"As of 22 July 2026, Apogee Therapeutics estimated primary completion of a Phase 2 trial in Atopic Dermatitis, in November 2026.","as_of":"2026-07-22","source":"clinicaltrials","source_ref":"NCT06395948","source_url":"https://clinicaltrials.gov/study/NCT06395948","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a77bf3f8-e144-4273-8d40-3e8727f55d9c"},{"id":"0a9e6539-4c4b-4aa6-9d67-da06c5520a6d","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Aptose Biosciences Inc.","ticker":null,"asset":"Tuspetinib","indication":"Leukemia, Myeloid, Acute","summary":"As of 26 August 2025, Aptose Biosciences estimated primary completion of a Phase 2 trial in Leukemia, Myeloid, Acute, in November 2026.","as_of":"2025-08-26","source":"clinicaltrials","source_ref":"NCT03850574","source_url":"https://clinicaltrials.gov/study/NCT03850574","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0a9e6539-4c4b-4aa6-9d67-da06c5520a6d"},{"id":"58a02d37-5e4b-4336-9acf-3b7814ac9941","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Arthrosi Therapeutics","ticker":null,"asset":"AR882 75 mg","indication":"Gout","summary":"As of 15 May 2026, Arthrosi Therapeutics estimated primary completion of a Phase 2 trial in gout, in November 2026.","as_of":"2026-05-15","source":"clinicaltrials","source_ref":"NCT07116746","source_url":"https://clinicaltrials.gov/study/NCT07116746","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-58a02d37-5e4b-4336-9acf-3b7814ac9941"},{"id":"20987765-473a-4e68-bbe0-21ce0575590f","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Atossa Therapeutics, Inc.","ticker":null,"asset":"(Z)-endoxifen","indication":"Breast Neoplasms","summary":"As of 8 July 2026, Atossa Therapeutics estimated primary completion of a Phase 2 trial in Breast Neoplasms, in November 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT05607004","source_url":"https://clinicaltrials.gov/study/NCT05607004","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-20987765-473a-4e68-bbe0-21ce0575590f"},{"id":"72dde625-d3f4-4175-8280-360e39be9248","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Avistone Biotechnology Co., Ltd.","ticker":null,"asset":"PLB1004","indication":"Non-Small-Cell Lung Cancer","summary":"As of 20 March 2026, Avistone Biotechnology Co. estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer, in November 2026.","as_of":"2026-03-20","source":"clinicaltrials","source_ref":"NCT07336732","source_url":"https://clinicaltrials.gov/study/NCT07336732","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-72dde625-d3f4-4175-8280-360e39be9248"},{"id":"984335fc-3b5c-48c7-9fd4-82e090718012","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"BeOne Medicines","ticker":null,"asset":"Sonrotoclax","indication":"Relapsed/Refractory Multiple Myeloma","summary":"As of 7 August 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Relapsed/Refractory Multiple Myeloma, in November 2026.","as_of":"2026-08-07","source":"clinicaltrials","source_ref":"NCT04973605","source_url":"https://clinicaltrials.gov/study/NCT04973605","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-984335fc-3b5c-48c7-9fd4-82e090718012"},{"id":"d65a8098-5ef4-47ba-a21c-6d4cd0fe3c6c","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"BeOne Medicines","ticker":null,"asset":"Sonrotoclax","indication":"Chronic Lymphocytic Leukemia","summary":"As of 9 July 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, in November 2026.","as_of":"2026-07-09","source":"clinicaltrials","source_ref":"NCT06637501","source_url":"https://clinicaltrials.gov/study/NCT06637501","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d65a8098-5ef4-47ba-a21c-6d4cd0fe3c6c"},{"id":"7965bdc5-7562-4a1b-9f6e-d9052b673b33","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"BeOne Medicines","ticker":null,"asset":"BGB-16673","indication":"B-cell Malignancy","summary":"As of 6 August 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in B-cell Malignancy, in November 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT05006716","source_url":"https://clinicaltrials.gov/study/NCT05006716","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7965bdc5-7562-4a1b-9f6e-d9052b673b33"},{"id":"1cf556e7-116d-46cf-b195-75f64adc1c49","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Beckley Psytech Limited","ticker":null,"asset":"BPL-003","indication":"Treatment Resistant Depression","summary":"As of 6 July 2026, Beckley Psytech estimated primary completion of a Phase 2 trial in Treatment Resistant Depression, in November 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT05660642","source_url":"https://clinicaltrials.gov/study/NCT05660642","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1cf556e7-116d-46cf-b195-75f64adc1c49"},{"id":"1b74b6ab-d284-4ca8-9fd4-31637bed7ab8","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"BeiGene","ticker":null,"asset":"Tislelizumab (BGB-A317)","indication":"MSI-H/dMMR Solid Tumors","summary":"As of 10 July 2026, BeiGene estimated primary completion of a Phase 2 trial in MSI-H/dMMR Solid Tumors, in November 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT03736889","source_url":"https://clinicaltrials.gov/study/NCT03736889","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1b74b6ab-d284-4ca8-9fd4-31637bed7ab8"},{"id":"17fad844-a3b9-491b-84f7-32374572043f","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"BioNTech SE","ticker":null,"asset":"RO7198457 intravenous (IV)","indication":"Colorectal Cancer Stage II","summary":"As of 15 July 2026, BioNTech SE estimated primary completion of a Phase 2 trial in Colorectal Cancer Stage II, in November 2026.","as_of":"2026-07-15","source":"clinicaltrials","source_ref":"NCT04486378","source_url":"https://clinicaltrials.gov/study/NCT04486378","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-17fad844-a3b9-491b-84f7-32374572043f"},{"id":"948df9e4-9ea5-4196-a228-ca76d00c66ff","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"KarXT","indication":"Bipolar-I Disorder With Mania or Mania With Mixed Features","summary":"As of 27 July 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial on 1 November 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT06951698","source_url":"https://clinicaltrials.gov/study/NCT06951698","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-948df9e4-9ea5-4196-a228-ca76d00c66ff"},{"id":"82e60e1d-63a6-4fe6-8894-5d600b9a03c9","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"CG Oncology, Inc.","ticker":null,"asset":"Cretostimogene Grenadenorepvec","indication":"Non Muscle Invasive Bladder Cancer","summary":"As of 1 July 2026, CG Oncology estimated primary completion of a Phase 3 trial in Non Muscle Invasive Bladder Cancer, in November 2026.","as_of":"2026-07-01","source":"clinicaltrials","source_ref":"NCT06111235","source_url":"https://clinicaltrials.gov/study/NCT06111235","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-82e60e1d-63a6-4fe6-8894-5d600b9a03c9"},{"id":"4b676def-3056-420f-ab62-78a4ff5d9d12","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Calluna Pharma AS","ticker":null,"asset":"CAL101","indication":"Idiopathic Pulmonary Fibrosis","summary":"As of 27 April 2026, Calluna Pharma AS estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in November 2026.","as_of":"2026-04-27","source":"clinicaltrials","source_ref":"NCT06736990","source_url":"https://clinicaltrials.gov/study/NCT06736990","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4b676def-3056-420f-ab62-78a4ff5d9d12"},{"id":"3aea50ce-5f2d-4638-9fde-0db4c984e1bd","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Camurus AB","ticker":null,"asset":"CAM2029","indication":"Gastro-enteropancreatic Neuroendocrine Tumor","summary":"As of 28 July 2026, Camurus estimated primary completion of a Phase 3 trial in Gastro-enteropancreatic Neuroendocrine Tumor, in November 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT05050942","source_url":"https://clinicaltrials.gov/study/NCT05050942","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3aea50ce-5f2d-4638-9fde-0db4c984e1bd"},{"id":"df3dd1ce-4701-47b1-bb85-1bec28f3f8a4","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Cardiff Oncology","ticker":null,"asset":"Onvansertib","indication":"Metastatic Colorectal Cancer","summary":"As of 16 June 2026, Cardiff Oncology estimated primary completion of a Phase 2 trial in Metastatic Colorectal Cancer, in November 2026.","as_of":"2026-06-16","source":"clinicaltrials","source_ref":"NCT06106308","source_url":"https://clinicaltrials.gov/study/NCT06106308","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-df3dd1ce-4701-47b1-bb85-1bec28f3f8a4"},{"id":"d2dc154e-acbe-4a14-b586-a830df01b750","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","ticker":null,"asset":"TQB2868 injection","indication":"Pancreatic Neoplasms","summary":"As of 19 September 2025, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Pancreatic Neoplasms, in November 2026.","as_of":"2025-09-19","source":"clinicaltrials","source_ref":"NCT06767813","source_url":"https://clinicaltrials.gov/study/NCT06767813","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d2dc154e-acbe-4a14-b586-a830df01b750"},{"id":"1886bd65-7ecf-4595-b80a-4f096bc2d32d","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Colgate Palmolive","ticker":null,"asset":"Colgate SNaP Total 10/10, 1.5 Taurate","indication":"Plaque, Dental","summary":"As of 27 May 2026, Colgate Palmolive estimated primary completion of a Phase 3 trial in Plaque, Dental, in November 2026.","as_of":"2026-05-27","source":"clinicaltrials","source_ref":"NCT07605338","source_url":"https://clinicaltrials.gov/study/NCT07605338","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1886bd65-7ecf-4595-b80a-4f096bc2d32d"},{"id":"f868ee3c-12e5-4902-bb02-c0de22548aa1","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"day","confidence":"estimated","company":"Corbus Pharmaceuticals Inc.","ticker":null,"asset":"CRB-601 monoclonal antibody","indication":"Solid Tumor","summary":"As of 3 June 2025, Corbus Pharmaceuticals estimated primary completion of a Phase 2 trial in Solid Tumor, on 1 November 2026.","as_of":"2025-06-03","source":"clinicaltrials","source_ref":"NCT06603844","source_url":"https://clinicaltrials.gov/study/NCT06603844","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f868ee3c-12e5-4902-bb02-c0de22548aa1"},{"id":"8f1c6c2f-2565-40e3-9272-af2c82808ab9","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"DBV Technologies","ticker":null,"asset":"DBV712 250 mcg","indication":"Allergy","summary":"As of 22 July 2026, DBV Technologies estimated primary completion of a Phase 3 trial in allergy, in November 2026.","as_of":"2026-07-22","source":"clinicaltrials","source_ref":"NCT07003919","source_url":"https://clinicaltrials.gov/study/NCT07003919","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8f1c6c2f-2565-40e3-9272-af2c82808ab9"},{"id":"dfb1728a-2d7d-49da-9da1-1a5cbfe49a12","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"LY4515100","indication":"Acute Pain","summary":"As of 1 May 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Acute Pain, in November 2026.","as_of":"2026-05-01","source":"clinicaltrials","source_ref":"NCT07511816","source_url":"https://clinicaltrials.gov/study/NCT07511816","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dfb1728a-2d7d-49da-9da1-1a5cbfe49a12"},{"id":"100584e9-0c45-49f6-9ce2-fd35c567686c","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"Tirzepatide","indication":"Type 1 Diabetes","summary":"As of 17 February 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 1 Diabetes, in November 2026.","as_of":"2026-02-17","source":"clinicaltrials","source_ref":"NCT06962280","source_url":"https://clinicaltrials.gov/study/NCT06962280","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-100584e9-0c45-49f6-9ce2-fd35c567686c"},{"id":"ac7d928b-5587-4794-99a9-375a3a83b9a9","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"Tirzepatide","indication":"Type 1 Diabetes","summary":"As of 12 May 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 1 Diabetes, in November 2026.","as_of":"2026-05-12","source":"clinicaltrials","source_ref":"NCT06914895","source_url":"https://clinicaltrials.gov/study/NCT06914895","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ac7d928b-5587-4794-99a9-375a3a83b9a9"},{"id":"76702912-1192-436d-ab3d-0f88d405201e","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"Retatrutide","indication":"Obesity","summary":"As of 20 July 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in obesity, in November 2026.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT06662383","source_url":"https://clinicaltrials.gov/study/NCT06662383","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-76702912-1192-436d-ab3d-0f88d405201e"},{"id":"9b94232f-6df8-404a-82ec-e9fd3b1fe000","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"Orforglipron","indication":"OSA","summary":"As of 29 September 2025, Eli Lilly and estimated primary completion of a Phase 3 trial in oSA, in November 2026.","as_of":"2025-09-29","source":"clinicaltrials","source_ref":"NCT06649045","source_url":"https://clinicaltrials.gov/study/NCT06649045","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b94232f-6df8-404a-82ec-e9fd3b1fe000"},{"id":"030f5da8-e6a2-4f1d-91e1-5e13ee6f1e2d","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"LY3938577","indication":"Diabetes Mellitus, Type 2","summary":"As of 13 July 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, in November 2026.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT07215312","source_url":"https://clinicaltrials.gov/study/NCT07215312","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-030f5da8-e6a2-4f1d-91e1-5e13ee6f1e2d"},{"id":"00110ffb-52ac-449f-a883-98b0fe7e49da","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"day","confidence":"estimated","company":"Epygenix","ticker":null,"asset":"Clemizole HCl","indication":"Lennox Gastaut Syndrome","summary":"As of 2 July 2026, Epygenix estimated primary completion of a Phase 3 trial in Lennox Gastaut Syndrome, on 1 November 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT05066217","source_url":"https://clinicaltrials.gov/study/NCT05066217","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-00110ffb-52ac-449f-a883-98b0fe7e49da"},{"id":"eafbd810-d485-4c2a-beaa-cbd6c17c80f9","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"day","confidence":"estimated","company":"Erasca, Inc.","ticker":null,"asset":"ERAS-007","indication":"Advanced or Metastatic Solid Tumors","summary":"As of 22 June 2026, Erasca estimated primary completion of a Phase 2 trial in Advanced or Metastatic Solid Tumors, on 1 November 2026.","as_of":"2026-06-22","source":"clinicaltrials","source_ref":"NCT04866134","source_url":"https://clinicaltrials.gov/study/NCT04866134","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-eafbd810-d485-4c2a-beaa-cbd6c17c80f9"},{"id":"6eb78fb2-23e7-4a04-8898-60f685650aa5","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Ferrer Internacional S.A.","ticker":null,"asset":"FNP-223","indication":"Progressive Supranuclear Palsy","summary":"As of 15 October 2025, Ferrer Internacional estimated primary completion of a Phase 2 trial in Progressive Supranuclear Palsy, in November 2026.","as_of":"2025-10-15","source":"clinicaltrials","source_ref":"NCT06355531","source_url":"https://clinicaltrials.gov/study/NCT06355531","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6eb78fb2-23e7-4a04-8898-60f685650aa5"},{"id":"f53ace6f-3a89-4619-92e5-ce9684364e1d","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Forge Biologics, Inc","ticker":null,"asset":"FBX-101","indication":"Krabbe Disease","summary":"As of 20 November 2025, Forge Biologics estimated primary completion of a Phase 2 trial in Krabbe Disease, in November 2026.","as_of":"2025-11-20","source":"clinicaltrials","source_ref":"NCT05739643","source_url":"https://clinicaltrials.gov/study/NCT05739643","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f53ace6f-3a89-4619-92e5-ce9684364e1d"},{"id":"b1c808e0-3ec4-4fb4-bb8f-29bc1b7785e8","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Forge Biologics, Inc","ticker":null,"asset":"FBX-101","indication":"Krabbe Disease","summary":"As of 2 June 2026, Forge Biologics estimated primary completion of a Phase 2 trial in Krabbe Disease, in November 2026.","as_of":"2026-06-02","source":"clinicaltrials","source_ref":"NCT04693598","source_url":"https://clinicaltrials.gov/study/NCT04693598","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b1c808e0-3ec4-4fb4-bb8f-29bc1b7785e8"},{"id":"8de46229-cfca-4c7a-adc7-f4868da0d935","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Immunic AG","ticker":null,"asset":"IMU-838 tablets","indication":"Multiple Sclerosis","summary":"As of 23 February 2026, Immunic estimated primary completion of a Phase 3 trial in Multiple Sclerosis, in November 2026.","as_of":"2026-02-23","source":"clinicaltrials","source_ref":"NCT05134441","source_url":"https://clinicaltrials.gov/study/NCT05134441","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8de46229-cfca-4c7a-adc7-f4868da0d935"},{"id":"8b2ee574-e7bb-4690-a78d-491448dd3244","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Immunic AG","ticker":null,"asset":"IMU-838 tablets","indication":"Multiple Sclerosis, Relapsing-Remitting","summary":"As of 23 February 2026, Immunic estimated primary completion of a Phase 3 trial in Multiple Sclerosis, Relapsing-Remitting, in November 2026.","as_of":"2026-02-23","source":"clinicaltrials","source_ref":"NCT05201638","source_url":"https://clinicaltrials.gov/study/NCT05201638","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8b2ee574-e7bb-4690-a78d-491448dd3244"},{"id":"630823e6-4368-4c34-a0b3-30a980efb1ed","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"SHR-A1811 combined with Pyrotinib.","indication":"HER2-expressing Advanced Solid Tumors","summary":"As of 5 August 2024, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in HER2-expressing Advanced Solid Tumors, in November 2026.","as_of":"2024-08-05","source":"clinicaltrials","source_ref":"NCT06015048","source_url":"https://clinicaltrials.gov/study/NCT06015048","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-630823e6-4368-4c34-a0b3-30a980efb1ed"},{"id":"3cee7160-ce80-4e1a-baff-3e94a008990d","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"Bupivacaine Liposome Injection","indication":"Local Analgesia Via Nerve Block","summary":"As of 12 March 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Local Analgesia Via Nerve Block, in November 2026.","as_of":"2026-03-12","source":"clinicaltrials","source_ref":"NCT06529432","source_url":"https://clinicaltrials.gov/study/NCT06529432","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3cee7160-ce80-4e1a-baff-3e94a008990d"},{"id":"3e700ba2-7e91-4488-97c0-0a6155fb710b","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"KeyBioscience AG","ticker":null,"asset":"KBP-336","indication":"Osteoarthritis in the Knee","summary":"As of 19 February 2025, KeyBioscience estimated primary completion of a Phase 2 trial in Osteoarthritis in the Knee, in November 2026.","as_of":"2025-02-19","source":"clinicaltrials","source_ref":"NCT06833749","source_url":"https://clinicaltrials.gov/study/NCT06833749","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3e700ba2-7e91-4488-97c0-0a6155fb710b"},{"id":"e10d77fb-8a85-472b-8d94-73ec2932f3d2","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Kiora Pharmaceuticals, Inc.","ticker":null,"asset":"KIO-104","indication":"Macular Edema","summary":"As of 16 June 2026, Kiora Pharmaceuticals estimated primary completion of a Phase 2 trial in Macular Edema, in November 2026.","as_of":"2026-06-16","source":"clinicaltrials","source_ref":"NCT06825702","source_url":"https://clinicaltrials.gov/study/NCT06825702","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e10d77fb-8a85-472b-8d94-73ec2932f3d2"},{"id":"025f4948-0f33-4f77-91f0-ab438c77303f","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"LG Chem","ticker":null,"asset":"LBVD","indication":"Diphtheria","summary":"As of 3 July 2025, LG Chem estimated primary completion of a Phase 3 trial in diphtheria, in November 2026.","as_of":"2025-07-03","source":"clinicaltrials","source_ref":"NCT06947499","source_url":"https://clinicaltrials.gov/study/NCT06947499","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-025f4948-0f33-4f77-91f0-ab438c77303f"},{"id":"8e694a7e-0952-41e7-a1a8-365440de3fd0","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Lynk Pharmaceuticals Co., Ltd","ticker":null,"asset":"LNK01001","indication":"Ankylosing Spondylitis","summary":"As of 20 November 2025, Lynk Pharmaceuticals Co. estimated primary completion of a Phase 3 trial in Ankylosing Spondylitis, in November 2026.","as_of":"2025-11-20","source":"clinicaltrials","source_ref":"NCT07237568","source_url":"https://clinicaltrials.gov/study/NCT07237568","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8e694a7e-0952-41e7-a1a8-365440de3fd0"},{"id":"a8a18174-e723-4037-9184-4620f6160a53","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"day","confidence":"estimated","company":"ML Bio Solutions, Inc.","ticker":null,"asset":"BBP-418","indication":"LGMD2I","summary":"As of 21 July 2026, ML Bio Solutions estimated primary completion of a Phase 2 trial in lGMD2I, on 1 November 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT04800874","source_url":"https://clinicaltrials.gov/study/NCT04800874","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a8a18174-e723-4037-9184-4620f6160a53"},{"id":"a91dea23-acd1-4546-bc7f-4922312c4c6f","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"MediLink Therapeutics (Suzhou) Co., Ltd.","ticker":null,"asset":"YL202 should be intravenously infused","indication":"NSCLC","summary":"As of 26 November 2025, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in nSCLC, in November 2026.","as_of":"2025-11-26","source":"clinicaltrials","source_ref":"NCT06107686","source_url":"https://clinicaltrials.gov/study/NCT06107686","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a91dea23-acd1-4546-bc7f-4922312c4c6f"},{"id":"f3bc0786-7076-46cc-9a0b-6ab0e4214686","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Medicure","ticker":null,"asset":"Pyridoxal Phosphate","indication":"Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency","summary":"As of 16 October 2025, Medicure estimated primary completion of a Phase 3 trial in Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency, in November 2026.","as_of":"2025-10-16","source":"clinicaltrials","source_ref":"NCT04706013","source_url":"https://clinicaltrials.gov/study/NCT04706013","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f3bc0786-7076-46cc-9a0b-6ab0e4214686"},{"id":"94602679-bc0e-4102-8a29-3ec51a2a52f1","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"NeuShen Therapeutics","ticker":null,"asset":"NS-136","indication":"Schizophrenia(Acute)","summary":"As of 13 April 2026, NeuShen Therapeutics estimated primary completion of a Phase 2 trial in schizophrenia(Acute), in November 2026.","as_of":"2026-04-13","source":"clinicaltrials","source_ref":"NCT07521683","source_url":"https://clinicaltrials.gov/study/NCT07521683","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-94602679-bc0e-4102-8a29-3ec51a2a52f1"},{"id":"9dd0a376-2272-49e9-8fd2-c1d4d92a1d6b","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"NewAmsterdam Pharma","ticker":null,"asset":"Obicetrapib","indication":"Atherosclerotic Cardiovascular Disease","summary":"As of 4 June 2024, NewAmsterdam Pharma estimated primary completion of a Phase 3 trial in Atherosclerotic Cardiovascular Disease, in November 2026.","as_of":"2024-06-04","source":"clinicaltrials","source_ref":"NCT05202509","source_url":"https://clinicaltrials.gov/study/NCT05202509","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9dd0a376-2272-49e9-8fd2-c1d4d92a1d6b"},{"id":"85961f5d-df09-4fda-afd6-ba3c7ec339e0","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"NewAmsterdam Pharma","ticker":null,"asset":"obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks","indication":"Dyslipidemias","summary":"As of 9 April 2026, NewAmsterdam Pharma estimated primary completion of a Phase 2 trial in dyslipidemias, in November 2026.","as_of":"2026-04-09","source":"clinicaltrials","source_ref":"NCT06496243","source_url":"https://clinicaltrials.gov/study/NCT06496243","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-85961f5d-df09-4fda-afd6-ba3c7ec339e0"},{"id":"6220624d-2fa8-4214-8b84-b9c8e4280b3a","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Nuance Hearing","ticker":null,"asset":"Spectacle Hearing Aid","indication":"Hearing Loss Mixed","summary":"As of 15 December 2025, Nuance Hearing estimated primary completion of a Phase 3 trial in Hearing Loss Mixed, in November 2026.","as_of":"2025-12-15","source":"clinicaltrials","source_ref":"NCT07282028","source_url":"https://clinicaltrials.gov/study/NCT07282028","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6220624d-2fa8-4214-8b84-b9c8e4280b3a"},{"id":"e38332fe-d60e-4720-a645-af1ca1ac6005","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Pacira Pharmaceuticals, Inc","ticker":null,"asset":"Enekinragene Inzadenovec (PCRX-201)","indication":"Osteoarthritis (OA) of the Knee","summary":"As of 7 August 2026, Pacira Pharmaceuticals estimated primary completion of a Phase 2 trial in Osteoarthritis (OA) of the Knee, in November 2026.","as_of":"2026-08-07","source":"clinicaltrials","source_ref":"NCT06884865","source_url":"https://clinicaltrials.gov/study/NCT06884865","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e38332fe-d60e-4720-a645-af1ca1ac6005"},{"id":"f1122ce9-e373-4f86-896d-8857c639e504","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Pharmazz, Inc.","ticker":null,"asset":"Normal Saline along with standard treatment","indication":"Hypoxic-Ischemic Encephalopathy","summary":"As of 31 December 2025, Pharmazz estimated primary completion of a Phase 2 trial in Hypoxic-Ischemic Encephalopathy, in November 2026.","as_of":"2025-12-31","source":"clinicaltrials","source_ref":"NCT05514340","source_url":"https://clinicaltrials.gov/study/NCT05514340","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f1122ce9-e373-4f86-896d-8857c639e504"},{"id":"34748fbd-d6d4-41d2-a7a3-b747d5364832","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Pharming Technologies B.V.","ticker":null,"asset":"Leniolisib","indication":"Primary Immunodeficiency Disorders (PIDs)","summary":"As of 13 February 2026, Pharming Technologies B.V. estimated primary completion of a Phase 2 trial in Primary Immunodeficiency Disorders (PIDs), in November 2026.","as_of":"2026-02-13","source":"clinicaltrials","source_ref":"NCT06549114","source_url":"https://clinicaltrials.gov/study/NCT06549114","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-34748fbd-d6d4-41d2-a7a3-b747d5364832"},{"id":"073668d4-e37b-46c6-b49b-113dd488e52e","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Reunion Neuroscience Inc","ticker":null,"asset":"RE104 for Injection","indication":"Adjustment Disorder","summary":"As of 6 August 2026, Reunion Neuroscience estimated primary completion of a Phase 2 trial in Adjustment Disorder, in November 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT07002034","source_url":"https://clinicaltrials.gov/study/NCT07002034","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-073668d4-e37b-46c6-b49b-113dd488e52e"},{"id":"14576b1f-280e-44f4-89e9-baab58334772","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"SK Life Science, Inc.","ticker":null,"asset":"Xcopri","indication":"Partial Epilepsy","summary":"As of 3 April 2026, SK Life Science estimated primary completion of a Phase 3 trial in Partial Epilepsy, in November 2026.","as_of":"2026-04-03","source":"clinicaltrials","source_ref":"NCT05067634","source_url":"https://clinicaltrials.gov/study/NCT05067634","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-14576b1f-280e-44f4-89e9-baab58334772"},{"id":"06f3ef94-c60f-4b3a-8dca-9cd793183d1f","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Sandoz","ticker":null,"asset":"CYB704","indication":"Relapsing Multiple Sclerosis","summary":"As of 29 May 2026, Sandoz estimated primary completion of a Phase 3 trial in Relapsing Multiple Sclerosis, in November 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT06847724","source_url":"https://clinicaltrials.gov/study/NCT06847724","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-06f3ef94-c60f-4b3a-8dca-9cd793183d1f"},{"id":"344be7af-398e-490b-aa7c-c80fedc50bd7","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"day","confidence":"estimated","company":"Scholar Rock, Inc.","ticker":null,"asset":"Apitegromab","indication":"Spinal Muscular Atrophy","summary":"As of 25 May 2025, Scholar Rock estimated primary completion of a Phase 3 trial in Spinal Muscular Atrophy, on 1 November 2026.","as_of":"2025-05-25","source":"clinicaltrials","source_ref":"NCT05626855","source_url":"https://clinicaltrials.gov/study/NCT05626855","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-344be7af-398e-490b-aa7c-c80fedc50bd7"},{"id":"d0e78d2b-cad9-4fe4-9595-051c5bc7e1fd","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"asset":"HRS-1780 Tablets","indication":"Primary Aldosteronism","summary":"As of 30 April 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Primary Aldosteronism, in November 2026.","as_of":"2026-04-30","source":"clinicaltrials","source_ref":"NCT07470983","source_url":"https://clinicaltrials.gov/study/NCT07470983","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d0e78d2b-cad9-4fe4-9595-051c5bc7e1fd"},{"id":"af8bafb8-05a6-40ae-acbd-b8480a769638","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","ticker":null,"asset":"TQH2722 injection","indication":"Seasonal Allergic Rhinitis","summary":"As of 27 March 2026, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co. estimated primary completion of a Phase 2 trial in Seasonal Allergic Rhinitis, in November 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT07398859","source_url":"https://clinicaltrials.gov/study/NCT07398859","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-af8bafb8-05a6-40ae-acbd-b8480a769638"},{"id":"5b8bc856-e77e-4969-8f78-33bd6a77ca3b","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"SI-B001","indication":"Head and Neck Squamous Cell Carcinoma","summary":"As of 21 January 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Head and Neck Squamous Cell Carcinoma, in November 2026.","as_of":"2026-01-21","source":"clinicaltrials","source_ref":"NCT06668961","source_url":"https://clinicaltrials.gov/study/NCT06668961","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5b8bc856-e77e-4969-8f78-33bd6a77ca3b"},{"id":"ab2f26d9-8f6f-427e-8e80-1287e30159d9","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Nasopharyngeal Carcinoma","summary":"As of 17 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Nasopharyngeal Carcinoma, in November 2026.","as_of":"2026-04-17","source":"clinicaltrials","source_ref":"NCT06118333","source_url":"https://clinicaltrials.gov/study/NCT06118333","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ab2f26d9-8f6f-427e-8e80-1287e30159d9"},{"id":"e2f4bd63-0ff8-461b-a495-fa2b8c7eab9d","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":null,"asset":"SKB264","indication":"Non-Small Cell Lung Cancer","summary":"As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, in November 2026.","as_of":"2026-05-08","source":"clinicaltrials","source_ref":"NCT06448312","source_url":"https://clinicaltrials.gov/study/NCT06448312","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e2f4bd63-0ff8-461b-a495-fa2b8c7eab9d"},{"id":"c6328b87-6064-40ed-a6fb-fade98eac439","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Sinovac Biotech Co., Ltd","ticker":null,"asset":"experimental vaccine","indication":"Epidemic Meningitis","summary":"As of 10 August 2026, Sinovac Biotech Co. estimated primary completion of a Phase 3 trial in Epidemic Meningitis, in November 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT07505888","source_url":"https://clinicaltrials.gov/study/NCT07505888","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c6328b87-6064-40ed-a6fb-fade98eac439"},{"id":"a1991adf-30fa-4e2e-a160-13bb5d88b4b6","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Stemline Therapeutics, Inc.","ticker":null,"asset":"Elacestrant","indication":"Metastatic Breast Cancer","summary":"As of 7 May 2026, Stemline Therapeutics estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in November 2026.","as_of":"2026-05-07","source":"clinicaltrials","source_ref":"NCT05596409","source_url":"https://clinicaltrials.gov/study/NCT05596409","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a1991adf-30fa-4e2e-a160-13bb5d88b4b6"},{"id":"9540dafa-0303-4e83-a813-9f315ca96e81","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"asset":"SHR-1681","indication":"Malignant Solid Tumors","summary":"As of 9 January 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Malignant Solid Tumors, in November 2026.","as_of":"2026-01-09","source":"clinicaltrials","source_ref":"NCT06737731","source_url":"https://clinicaltrials.gov/study/NCT06737731","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9540dafa-0303-4e83-a813-9f315ca96e81"},{"id":"b38b2f65-d32b-401b-b052-6184ddcf8172","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"day","confidence":"estimated","company":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","ticker":null,"asset":"ZGGS18 for Injection","indication":"Advanced Solid Tumor","summary":"As of 5 January 2026, Suzhou Zelgen Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 1 November 2026.","as_of":"2026-01-05","source":"clinicaltrials","source_ref":"NCT05584800","source_url":"https://clinicaltrials.gov/study/NCT05584800","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b38b2f65-d32b-401b-b052-6184ddcf8172"},{"id":"57daeb2e-5309-4245-a76f-ab545272c121","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Tyra Biosciences, Inc","ticker":null,"asset":"TYRA-300","indication":"Locally Advanced Urothelial Carcinoma","summary":"As of 12 January 2026, Tyra Biosciences estimated primary completion of a Phase 2 trial in Locally Advanced Urothelial Carcinoma, in November 2026.","as_of":"2026-01-12","source":"clinicaltrials","source_ref":"NCT05544552","source_url":"https://clinicaltrials.gov/study/NCT05544552","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-57daeb2e-5309-4245-a76f-ab545272c121"},{"id":"158817da-fc05-49c3-8039-fa84e91ef0e5","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Vir Biotechnology, Inc.","ticker":null,"asset":"Tobevibart","indication":"Viral Hepatitis","summary":"As of 16 January 2026, Vir Biotechnology estimated primary completion of a Phase 2 trial in Viral Hepatitis, in November 2026.","as_of":"2026-01-16","source":"clinicaltrials","source_ref":"NCT07142811","source_url":"https://clinicaltrials.gov/study/NCT07142811","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-158817da-fc05-49c3-8039-fa84e91ef0e5"},{"id":"4e0e9d5b-0aba-44c1-aa44-6e66504166c6","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Waterstone Pharmaceutical (Wuhan) Co., LTD.","ticker":null,"asset":"WS016","indication":"Hyperkalemia","summary":"As of 26 November 2025, Waterstone Pharmaceutical (Wuhan) Co. estimated primary completion of a Phase 3 trial in hyperkalemia, in November 2026.","as_of":"2025-11-26","source":"clinicaltrials","source_ref":"NCT07251309","source_url":"https://clinicaltrials.gov/study/NCT07251309","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4e0e9d5b-0aba-44c1-aa44-6e66504166c6"},{"id":"bb8663dc-c2f3-47c4-90bf-1f55a2e23108","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Wooshin Labottach Co., Ltd.","ticker":null,"asset":"Cosmetic patch containing urea applicated daily for 3 months","indication":"Nail Psoriasis","summary":"As of 26 January 2026, Wooshin Labottach Co. estimated primary completion of a Phase 3 trial in Nail Psoriasis, in November 2026.","as_of":"2026-01-26","source":"clinicaltrials","source_ref":"NCT07029516","source_url":"https://clinicaltrials.gov/study/NCT07029516","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bb8663dc-c2f3-47c4-90bf-1f55a2e23108"},{"id":"53ff4c6f-92cf-4531-8cbb-510801358f39","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Xentria, Inc.","ticker":null,"asset":"XTMAB-16","indication":"Pulmonary Sarcoidosis","summary":"As of 30 July 2026, Xentria estimated primary completion of a Phase 2 trial in Pulmonary Sarcoidosis, in November 2026.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT06169397","source_url":"https://clinicaltrials.gov/study/NCT06169397","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-53ff4c6f-92cf-4531-8cbb-510801358f39"},{"id":"33bc7f2c-e366-4c39-a359-81b434666617","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"Zura Bio Inc","ticker":null,"asset":"Tibulizumab Dose A","indication":"Hidradenitis Suppurativa (HS)","summary":"As of 30 June 2026, Zura Bio estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa (HS), in November 2026.","as_of":"2026-06-30","source":"clinicaltrials","source_ref":"NCT06993610","source_url":"https://clinicaltrials.gov/study/NCT06993610","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-33bc7f2c-e366-4c39-a359-81b434666617"},{"id":"fad39a2b-1253-4286-896b-945e1a9cd2bb","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"argenx","ticker":null,"asset":"Empasiprubart IV","indication":"Dermatomyositis","summary":"As of 25 September 2025, argenx estimated primary completion of a Phase 2 trial in dermatomyositis, in November 2026.","as_of":"2025-09-25","source":"clinicaltrials","source_ref":"NCT06284954","source_url":"https://clinicaltrials.gov/study/NCT06284954","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fad39a2b-1253-4286-896b-945e1a9cd2bb"},{"id":"c84648a9-0069-40aa-9281-0ce26dc83776","lane":"clinical","event_type":"primary-completion","date":"2026-11-01","date_precision":"month","confidence":"estimated","company":"medac GmbH","ticker":null,"asset":"Methotrexate","indication":"Moderate to Severe Atopic Dermatitis","summary":"As of 27 August 2025, medac estimated primary completion of a Phase 3 trial in Moderate to Severe Atopic Dermatitis, in November 2026.","as_of":"2025-08-27","source":"clinicaltrials","source_ref":"NCT06239311","source_url":"https://clinicaltrials.gov/study/NCT06239311","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c84648a9-0069-40aa-9281-0ce26dc83776"},{"id":"49218fcd-94bd-49c6-9151-09d4735fe2bb","lane":"clinical","event_type":"primary-completion","date":"2026-11-02","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Anifrolumab","indication":"Cutaneous Lupus Erythematosus","summary":"As of 29 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Cutaneous Lupus Erythematosus, on 2 November 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT06015737","source_url":"https://clinicaltrials.gov/study/NCT06015737","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-49218fcd-94bd-49c6-9151-09d4735fe2bb"},{"id":"e4201c20-3757-4af6-8b9f-64047e73e217","lane":"clinical","event_type":"primary-completion","date":"2026-11-02","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"KarXT","indication":"Bipolar Disorder Type I With Mania or Mania With Mixed Features","summary":"As of 20 July 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial on 2 November 2026.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT06951711","source_url":"https://clinicaltrials.gov/study/NCT06951711","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e4201c20-3757-4af6-8b9f-64047e73e217"},{"id":"14318c10-4c66-41be-917e-5389ade0ced8","lane":"clinical","event_type":"primary-completion","date":"2026-11-02","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Dostarlimab","indication":"Neoplasms, Rectal","summary":"As of 26 May 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Neoplasms, Rectal, on 2 November 2026.","as_of":"2026-05-26","source":"clinicaltrials","source_ref":"NCT05723562","source_url":"https://clinicaltrials.gov/study/NCT05723562","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-14318c10-4c66-41be-917e-5389ade0ced8"},{"id":"d96e923b-203e-4c89-8b42-0baa50cdb5a8","lane":"clinical","event_type":"primary-completion","date":"2026-11-02","date_precision":"day","confidence":"estimated","company":"Keymed Biosciences Co.Ltd","ticker":null,"asset":"CM512 injection","indication":"Chronic Spontaneous Urticaria (CSU)","summary":"As of 9 April 2026, Keymed Biosciences Co. estimated primary completion of a Phase 2 trial in Chronic Spontaneous Urticaria (CSU), on 2 November 2026.","as_of":"2026-04-09","source":"clinicaltrials","source_ref":"NCT07166211","source_url":"https://clinicaltrials.gov/study/NCT07166211","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d96e923b-203e-4c89-8b42-0baa50cdb5a8"},{"id":"f74ead14-9d87-475f-9033-64a79392ec3d","lane":"clinical","event_type":"primary-completion","date":"2026-11-02","date_precision":"day","confidence":"estimated","company":"Regeneron Pharmaceuticals","ticker":null,"asset":"cemiplimab","indication":"Melanoma","summary":"As of 10 February 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in melanoma, on 2 November 2026.","as_of":"2026-02-10","source":"clinicaltrials","source_ref":"NCT06190951","source_url":"https://clinicaltrials.gov/study/NCT06190951","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f74ead14-9d87-475f-9033-64a79392ec3d"},{"id":"42d8ef7d-25a3-4f2a-bcac-333ee5deca94","lane":"clinical","event_type":"primary-completion","date":"2026-11-03","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"LOU064 (blinded)","indication":"Chronic Spontaneous Urticaria","summary":"As of 20 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria, on 3 November 2026.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT05677451","source_url":"https://clinicaltrials.gov/study/NCT05677451","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-42d8ef7d-25a3-4f2a-bcac-333ee5deca94"},{"id":"09dc482a-fdf9-41b9-9d07-d9415b6492c3","lane":"clinical","event_type":"primary-completion","date":"2026-11-04","date_precision":"day","confidence":"estimated","company":"CMG Pharmaceutical Co. Ltd","ticker":null,"asset":"CMG190303(Dapagliflozin/Rosuvastatin)","indication":"Dyslipidemia","summary":"As of 15 January 2026, CMG Pharmaceutical Co. estimated primary completion of a Phase 3 trial in dyslipidemia, on 4 November 2026.","as_of":"2026-01-15","source":"clinicaltrials","source_ref":"NCT06772168","source_url":"https://clinicaltrials.gov/study/NCT06772168","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-09dc482a-fdf9-41b9-9d07-d9415b6492c3"},{"id":"4138cee3-f37b-4f24-b850-be707e2fa63c","lane":"clinical","event_type":"primary-completion","date":"2026-11-05","date_precision":"day","confidence":"estimated","company":"Genzyme, a Sanofi Company","ticker":null,"asset":"Fitusiran","indication":"Hemophilia","summary":"As of 17 December 2025, Genzyme, a Sanofi estimated primary completion of a Phase 3 trial in hemophilia, on 5 November 2026.","as_of":"2025-12-17","source":"clinicaltrials","source_ref":"NCT03754790","source_url":"https://clinicaltrials.gov/study/NCT03754790","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4138cee3-f37b-4f24-b850-be707e2fa63c"},{"id":"8d6f2124-9413-426f-a77e-24db7433e1e9","lane":"clinical","event_type":"primary-completion","date":"2026-11-05","date_precision":"day","confidence":"estimated","company":"Incyte Corporation","ticker":null,"asset":"Parsaclisib","indication":"B-Cell Malignancies","summary":"As of 25 June 2026, Incyte estimated primary completion of a Phase 2 trial in B-Cell Malignancies, on 5 November 2026.","as_of":"2026-06-25","source":"clinicaltrials","source_ref":"NCT04509700","source_url":"https://clinicaltrials.gov/study/NCT04509700","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8d6f2124-9413-426f-a77e-24db7433e1e9"},{"id":"63491608-1a64-496c-a048-bb38288dd4b4","lane":"clinical","event_type":"primary-completion","date":"2026-11-06","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"pembrolizumab","indication":"Hodgkin Lymphoma","summary":"As of 19 February 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Hodgkin Lymphoma, on 6 November 2026.","as_of":"2026-02-19","source":"clinicaltrials","source_ref":"NCT03407144","source_url":"https://clinicaltrials.gov/study/NCT03407144","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-63491608-1a64-496c-a048-bb38288dd4b4"},{"id":"cb637451-036e-458c-bb7b-d991d4a35170","lane":"clinical","event_type":"primary-completion","date":"2026-11-06","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"Itepekimab (SAR440340)","indication":"Chronic Rhinosinusitis With Nasal Polyps","summary":"As of 2 June 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Rhinosinusitis With Nasal Polyps, on 6 November 2026.","as_of":"2026-06-02","source":"clinicaltrials","source_ref":"NCT06834360","source_url":"https://clinicaltrials.gov/study/NCT06834360","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cb637451-036e-458c-bb7b-d991d4a35170"},{"id":"c6849c50-47cd-4afd-86e5-29482d3b168f","lane":"clinical","event_type":"primary-completion","date":"2026-11-09","date_precision":"day","confidence":"estimated","company":"Bio-Thera Solutions","ticker":null,"asset":"BAT8010 for Injection","indication":"Advanced Solid Tumors","summary":"As of 13 August 2025, Bio-Thera Solutions estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 9 November 2026.","as_of":"2025-08-13","source":"clinicaltrials","source_ref":"NCT06376136","source_url":"https://clinicaltrials.gov/study/NCT06376136","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c6849c50-47cd-4afd-86e5-29482d3b168f"},{"id":"621da785-181e-44ed-ba4f-1115fdd250ce","lane":"clinical","event_type":"primary-completion","date":"2026-11-09","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Pembrolizumab","indication":"Lung Cancer, Non-Small Cell","summary":"As of 15 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Lung Cancer, Non-Small Cell, on 9 November 2026.","as_of":"2026-06-15","source":"clinicaltrials","source_ref":"NCT05565378","source_url":"https://clinicaltrials.gov/study/NCT05565378","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-621da785-181e-44ed-ba4f-1115fdd250ce"},{"id":"28c858a4-4d04-43be-9a87-d2c2e251c360","lane":"clinical","event_type":"primary-completion","date":"2026-11-10","date_precision":"day","confidence":"estimated","company":"Gan & Lee Pharmaceuticals.","ticker":null,"asset":"GZR4","indication":"Diabetes","summary":"As of 25 November 2025, Gan & Lee Pharmaceuticals. estimated primary completion of a Phase 3 trial in diabetes, on 10 November 2026.","as_of":"2025-11-25","source":"clinicaltrials","source_ref":"NCT07165223","source_url":"https://clinicaltrials.gov/study/NCT07165223","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-28c858a4-4d04-43be-9a87-d2c2e251c360"},{"id":"cf4af585-d863-4640-8773-1b89de438a5a","lane":"clinical","event_type":"primary-completion","date":"2026-11-10","date_precision":"day","confidence":"estimated","company":"HELP Therapeutics Co., Ltd.","ticker":null,"asset":"HiCM-188 therapy","indication":"Heart Failure","summary":"As of 10 February 2026, HELP Therapeutics Co. estimated primary completion of a Phase 2 trial in Heart Failure, on 10 November 2026.","as_of":"2026-02-10","source":"clinicaltrials","source_ref":"NCT06340048","source_url":"https://clinicaltrials.gov/study/NCT06340048","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cf4af585-d863-4640-8773-1b89de438a5a"},{"id":"5bbc8a13-55f0-4a73-bc7b-8c78b92c260c","lane":"clinical","event_type":"primary-completion","date":"2026-11-11","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Trastuzumab deruxtecan","indication":"Breast Cancer; HER2-positive; Metastatic","summary":"As of 30 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Breast Cancer; HER2-positive; Metastatic, on 11 November 2026.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT04784715","source_url":"https://clinicaltrials.gov/study/NCT04784715","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5bbc8a13-55f0-4a73-bc7b-8c78b92c260c"},{"id":"eaf19ceb-a3c0-4494-ae07-e3d46e7dc9b7","lane":"clinical","event_type":"primary-completion","date":"2026-11-11","date_precision":"day","confidence":"estimated","company":"Janssen Research & Development, LLC","ticker":null,"asset":"Milvexian","indication":"Ischemic Stroke; Ischemic Attack, Transient","summary":"As of 31 July 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Ischemic Stroke; Ischemic Attack, Transient, on 11 November 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT05702034","source_url":"https://clinicaltrials.gov/study/NCT05702034","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-eaf19ceb-a3c0-4494-ae07-e3d46e7dc9b7"},{"id":"0106dc7a-c205-4505-8e1a-3f2b66e99bbb","lane":"clinical","event_type":"primary-completion","date":"2026-11-11","date_precision":"day","confidence":"estimated","company":"Precigen, Inc","ticker":null,"asset":"PRGN-2009 plus Pembrolizumab","indication":"Cervical Cancer","summary":"As of 23 April 2026, Precigen estimated primary completion of a Phase 2 trial in Cervical Cancer, on 11 November 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT06157151","source_url":"https://clinicaltrials.gov/study/NCT06157151","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0106dc7a-c205-4505-8e1a-3f2b66e99bbb"},{"id":"d3aa281f-ea9d-46db-9afd-9a221254adb6","lane":"clinical","event_type":"primary-completion","date":"2026-11-12","date_precision":"day","confidence":"estimated","company":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"asset":"Relugolix","indication":"Heavy Menstrual Bleeding","summary":"As of 2 February 2026, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Heavy Menstrual Bleeding, on 12 November 2026.","as_of":"2026-02-02","source":"clinicaltrials","source_ref":"NCT06671548","source_url":"https://clinicaltrials.gov/study/NCT06671548","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d3aa281f-ea9d-46db-9afd-9a221254adb6"},{"id":"7c123273-c418-46af-ba22-88f70a9cf1a3","lane":"clinical","event_type":"primary-completion","date":"2026-11-13","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD0486","indication":"B-cell Acute Lymphoblastic Leukemia (B-ALL)","summary":"As of 27 May 2026, AstraZeneca estimated primary completion of a Phase 2 trial in B-cell Acute Lymphoblastic Leukemia (B-ALL), on 13 November 2026.","as_of":"2026-05-27","source":"clinicaltrials","source_ref":"NCT06137118","source_url":"https://clinicaltrials.gov/study/NCT06137118","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7c123273-c418-46af-ba22-88f70a9cf1a3"},{"id":"3d9d5306-8393-42f9-b0eb-e013bd83399e","lane":"clinical","event_type":"primary-completion","date":"2026-11-13","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Inavolisib","indication":"Breast Cancer","summary":"As of 24 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Breast Cancer, on 13 November 2026.","as_of":"2026-06-24","source":"clinicaltrials","source_ref":"NCT05646862","source_url":"https://clinicaltrials.gov/study/NCT05646862","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3d9d5306-8393-42f9-b0eb-e013bd83399e"},{"id":"cb9fb371-eb09-480e-abe3-079d185722a3","lane":"clinical","event_type":"primary-completion","date":"2026-11-13","date_precision":"day","confidence":"estimated","company":"Regeneron Pharmaceuticals","ticker":null,"asset":"Olatorepatide","indication":"Overweight or Obesity","summary":"As of 17 June 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Overweight or Obesity, on 13 November 2026.","as_of":"2026-06-17","source":"clinicaltrials","source_ref":"NCT07431086","source_url":"https://clinicaltrials.gov/study/NCT07431086","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cb9fb371-eb09-480e-abe3-079d185722a3"},{"id":"bbb93cff-6742-4d06-99df-a13eb770604e","lane":"clinical","event_type":"primary-completion","date":"2026-11-13","date_precision":"day","confidence":"estimated","company":"Regeneron Pharmaceuticals","ticker":null,"asset":"REGN7075","indication":"Advanced Solid Tumors","summary":"As of 2 July 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 13 November 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT04626635","source_url":"https://clinicaltrials.gov/study/NCT04626635","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bbb93cff-6742-4d06-99df-a13eb770604e"},{"id":"f1a0825b-eafc-435a-a7c4-eaae7b72a024","lane":"clinical","event_type":"primary-completion","date":"2026-11-15","date_precision":"day","confidence":"estimated","company":"PolyActiva Pty Ltd","ticker":null,"asset":"PA5108 Ocular Implant low dose","indication":"Glaucoma, Open-Angle","summary":"As of 8 July 2026, PolyActiva Pty estimated primary completion of a Phase 2 trial in Glaucoma, Open-Angle, on 15 November 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT06964191","source_url":"https://clinicaltrials.gov/study/NCT06964191","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f1a0825b-eafc-435a-a7c4-eaae7b72a024"},{"id":"e729d350-75b1-4432-8f43-0df483d7c32c","lane":"clinical","event_type":"primary-completion","date":"2026-11-16","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Tulisokibart","indication":"Hidradenitis Suppurativa","summary":"As of 20 January 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa, on 16 November 2026.","as_of":"2026-01-20","source":"clinicaltrials","source_ref":"NCT06956235","source_url":"https://clinicaltrials.gov/study/NCT06956235","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e729d350-75b1-4432-8f43-0df483d7c32c"},{"id":"8163c546-13e7-4f1f-85b3-ce552340d7fe","lane":"clinical","event_type":"primary-completion","date":"2026-11-16","date_precision":"day","confidence":"estimated","company":"UCB Biopharma SRL","ticker":null,"asset":"Zilucoplan","indication":"Generalized Myasthenia Gravis","summary":"As of 31 July 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 16 November 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT06055959","source_url":"https://clinicaltrials.gov/study/NCT06055959","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8163c546-13e7-4f1f-85b3-ce552340d7fe"},{"id":"20854563-a7fc-45ff-9b80-467208f0cfad","lane":"clinical","event_type":"primary-completion","date":"2026-11-17","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD0901","indication":"Gastric Cancer","summary":"As of 29 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Gastric Cancer, on 17 November 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT06219941","source_url":"https://clinicaltrials.gov/study/NCT06219941","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-20854563-a7fc-45ff-9b80-467208f0cfad"},{"id":"b21210a1-45ad-4506-bfe6-0c8993047d28","lane":"clinical","event_type":"primary-completion","date":"2026-11-18","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"Deucravacitinib","indication":"Sjögren's Syndrome","summary":"As of 1 April 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Sjögren's Syndrome, on 18 November 2026.","as_of":"2026-04-01","source":"clinicaltrials","source_ref":"NCT05946941","source_url":"https://clinicaltrials.gov/study/NCT05946941","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b21210a1-45ad-4506-bfe6-0c8993047d28"},{"id":"6ab012d8-8f9a-4d29-921d-68a92d0cc344","lane":"clinical","event_type":"primary-completion","date":"2026-11-18","date_precision":"day","confidence":"estimated","company":"CSL Behring","ticker":null,"asset":"BE1116","indication":"Complex Cardiovascular Surgery With Cardiopulmonary Bypass","summary":"As of 11 May 2026, CSL Behring estimated primary completion of a Phase 3 trial in Complex Cardiovascular Surgery With Cardiopulmonary Bypass, on 18 November 2026.","as_of":"2026-05-11","source":"clinicaltrials","source_ref":"NCT07094087","source_url":"https://clinicaltrials.gov/study/NCT07094087","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6ab012d8-8f9a-4d29-921d-68a92d0cc344"},{"id":"a7d97d54-3e99-4832-adf1-e06a351d7dd0","lane":"clinical","event_type":"primary-completion","date":"2026-11-18","date_precision":"day","confidence":"estimated","company":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","ticker":null,"asset":"Abiraterone - Usual","indication":"Prostate Cancer","summary":"As of 10 June 2026, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair estimated primary completion of a Phase 3 trial in Prostate Cancer, on 18 November 2026.","as_of":"2026-06-10","source":"clinicaltrials","source_ref":"NCT03348670","source_url":"https://clinicaltrials.gov/study/NCT03348670","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a7d97d54-3e99-4832-adf1-e06a351d7dd0"},{"id":"f608047b-43cb-4196-89c4-3fc0bb34a3e2","lane":"clinical","event_type":"primary-completion","date":"2026-11-18","date_precision":"day","confidence":"estimated","company":"ToLymph Inc.","ticker":null,"asset":"SMS001","indication":"Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)","summary":"As of 6 March 2026, ToLymph estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung Cancer (NSCLC), on 18 November 2026.","as_of":"2026-03-06","source":"clinicaltrials","source_ref":"NCT06693336","source_url":"https://clinicaltrials.gov/study/NCT06693336","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f608047b-43cb-4196-89c4-3fc0bb34a3e2"},{"id":"f85b7701-0fc6-4d82-abd0-6130d4367a36","lane":"clinical","event_type":"primary-completion","date":"2026-11-19","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"RO7269162","indication":"Alzheimer's Disease","summary":"As of 18 May 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Alzheimer's Disease, on 19 November 2026.","as_of":"2026-05-18","source":"clinicaltrials","source_ref":"NCT06402838","source_url":"https://clinicaltrials.gov/study/NCT06402838","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f85b7701-0fc6-4d82-abd0-6130d4367a36"},{"id":"2d792856-277f-4a05-93c3-030d8509aede","lane":"clinical","event_type":"primary-completion","date":"2026-11-19","date_precision":"day","confidence":"estimated","company":"Janssen Research & Development, LLC","ticker":null,"asset":"JNJ-95597528","indication":"Dermatitis, Atopic","summary":"As of 31 July 2026, Janssen Research & Development estimated primary completion of a Phase 2 trial in Dermatitis, Atopic, on 19 November 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT07230860","source_url":"https://clinicaltrials.gov/study/NCT07230860","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2d792856-277f-4a05-93c3-030d8509aede"},{"id":"6b70bb2e-a18f-408f-8973-e8538a2d872f","lane":"clinical","event_type":"primary-completion","date":"2026-11-20","date_precision":"day","confidence":"estimated","company":"Incyte Corporation","ticker":null,"asset":"povorcitinib","indication":"Moderate to Severe Asthma","summary":"As of 7 July 2026, Incyte estimated primary completion of a Phase 2 trial in Moderate to Severe Asthma, on 20 November 2026.","as_of":"2026-07-07","source":"clinicaltrials","source_ref":"NCT05851443","source_url":"https://clinicaltrials.gov/study/NCT05851443","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6b70bb2e-a18f-408f-8973-e8538a2d872f"},{"id":"7985ed6d-a800-4f4f-91aa-066df7c35eae","lane":"clinical","event_type":"primary-completion","date":"2026-11-20","date_precision":"day","confidence":"estimated","company":"Skye Bioscience, Inc.","ticker":null,"asset":"Nimacimab injection","indication":"Obesity","summary":"As of 14 January 2026, Skye Bioscience estimated primary completion of a Phase 2 trial in obesity, on 20 November 2026.","as_of":"2026-01-14","source":"clinicaltrials","source_ref":"NCT06577090","source_url":"https://clinicaltrials.gov/study/NCT06577090","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7985ed6d-a800-4f4f-91aa-066df7c35eae"},{"id":"fe365ad1-15a1-484e-af00-e4c7afbdeb64","lane":"clinical","event_type":"primary-completion","date":"2026-11-21","date_precision":"day","confidence":"estimated","company":"Changchun GeneScience Pharmaceutical Co., Ltd.","ticker":null,"asset":"Cabergoline tablets","indication":"Hyperprolactinemia","summary":"As of 2 October 2025, Changchun GeneScience Pharmaceutical Co. estimated primary completion of a Phase 3 trial in hyperprolactinemia, on 21 November 2026.","as_of":"2025-10-02","source":"clinicaltrials","source_ref":"NCT07124221","source_url":"https://clinicaltrials.gov/study/NCT07124221","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fe365ad1-15a1-484e-af00-e4c7afbdeb64"},{"id":"03add45c-d2d2-4c02-86ce-d99facdceab9","lane":"clinical","event_type":"primary-completion","date":"2026-11-22","date_precision":"day","confidence":"estimated","company":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"HSK55718 dose level1","indication":"Pain After Surgery","summary":"As of 28 May 2026, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Pain After Surgery, on 22 November 2026.","as_of":"2026-05-28","source":"clinicaltrials","source_ref":"NCT07533786","source_url":"https://clinicaltrials.gov/study/NCT07533786","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-03add45c-d2d2-4c02-86ce-d99facdceab9"},{"id":"b5b883e4-a08a-4f43-9d27-5d9c21c5c379","lane":"clinical","event_type":"primary-completion","date":"2026-11-22","date_precision":"day","confidence":"estimated","company":"Shanghai Henlius Biotech","ticker":null,"asset":"HLX43 DOSE 1","indication":"Nasopharyngeal Carcinoma (NPC)","summary":"As of 24 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Nasopharyngeal Carcinoma (NPC), on 22 November 2026.","as_of":"2025-11-24","source":"clinicaltrials","source_ref":"NCT06839066","source_url":"https://clinicaltrials.gov/study/NCT06839066","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b5b883e4-a08a-4f43-9d27-5d9c21c5c379"},{"id":"8380a5b5-8183-44c1-b5ac-9d74c5e1a242","lane":"clinical","event_type":"primary-completion","date":"2026-11-23","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Investigational varicella vaccine","indication":"Chickenpox","summary":"As of 29 May 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in chickenpox, on 23 November 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT06693895","source_url":"https://clinicaltrials.gov/study/NCT06693895","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8380a5b5-8183-44c1-b5ac-9d74c5e1a242"},{"id":"66b09fee-5b4e-46fc-9e05-fd569602a77f","lane":"clinical","event_type":"primary-completion","date":"2026-11-23","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Dostarlimab","indication":"Neoplasms, Colon","summary":"As of 22 May 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Neoplasms, Colon, on 23 November 2026.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT06567782","source_url":"https://clinicaltrials.gov/study/NCT06567782","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-66b09fee-5b4e-46fc-9e05-fd569602a77f"},{"id":"65f78f96-4c70-4d45-bb24-6bf04f9f9c28","lane":"clinical","event_type":"primary-completion","date":"2026-11-24","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD0754","indication":"Metastatic Prostate Cancer","summary":"As of 23 February 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Metastatic Prostate Cancer, on 24 November 2026.","as_of":"2026-02-23","source":"clinicaltrials","source_ref":"NCT06267729","source_url":"https://clinicaltrials.gov/study/NCT06267729","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-65f78f96-4c70-4d45-bb24-6bf04f9f9c28"},{"id":"2d58b7ed-cc4c-4e96-a2af-4b2a628cab08","lane":"clinical","event_type":"primary-completion","date":"2026-11-24","date_precision":"day","confidence":"estimated","company":"CanSino Biologics Inc.","ticker":null,"asset":"24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M)","indication":"Streptococcus Pneumoniae Infection","summary":"As of 5 August 2026, CanSino Biologics estimated primary completion of a Phase 2 trial in Streptococcus Pneumoniae Infection, on 24 November 2026.","as_of":"2026-08-05","source":"clinicaltrials","source_ref":"NCT07600983","source_url":"https://clinicaltrials.gov/study/NCT07600983","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2d58b7ed-cc4c-4e96-a2af-4b2a628cab08"},{"id":"333b8d80-5fed-462d-a8e9-ee1057a221be","lane":"clinical","event_type":"primary-completion","date":"2026-11-24","date_precision":"day","confidence":"estimated","company":"HTA Co., Ltd.","ticker":null,"asset":"177Lu-DOTATATE injection","indication":"NETS Ga68 Lu177","summary":"As of 10 July 2025, HTA Co. estimated primary completion of a Phase 3 trial in NETS Ga68 Lu177, on 24 November 2026.","as_of":"2025-07-10","source":"clinicaltrials","source_ref":"NCT07057622","source_url":"https://clinicaltrials.gov/study/NCT07057622","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-333b8d80-5fed-462d-a8e9-ee1057a221be"},{"id":"88266ca3-1467-44f6-97c0-1c9a68017cf7","lane":"clinical","event_type":"primary-completion","date":"2026-11-24","date_precision":"day","confidence":"estimated","company":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","ticker":null,"asset":"KarXT","indication":"Alzheimer Disease","summary":"As of 30 July 2026, Karuna Therapeutics, Inc., a Bristol Myers Squibb estimated primary completion of a Phase 3 trial in Alzheimer Disease, on 24 November 2026.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT06585787","source_url":"https://clinicaltrials.gov/study/NCT06585787","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-88266ca3-1467-44f6-97c0-1c9a68017cf7"},{"id":"d2266495-0c33-4502-acd5-44a0b42f739b","lane":"clinical","event_type":"primary-completion","date":"2026-11-24","date_precision":"day","confidence":"estimated","company":"Tectonic Therapeutic","ticker":null,"asset":"TX000045- Dose A","indication":"Pulmonary Hypertension","summary":"As of 7 July 2026, Tectonic Therapeutic estimated primary completion of a Phase 2 trial in Pulmonary Hypertension, on 24 November 2026.","as_of":"2026-07-07","source":"clinicaltrials","source_ref":"NCT06616974","source_url":"https://clinicaltrials.gov/study/NCT06616974","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d2266495-0c33-4502-acd5-44a0b42f739b"},{"id":"ffc5b4f0-1ad4-4bbb-b68d-3fd93bba3765","lane":"clinical","event_type":"primary-completion","date":"2026-11-25","date_precision":"day","confidence":"estimated","company":"Beijing InnoCare Pharma Tech Co., Ltd.","ticker":null,"asset":"ICP-332 Tablets","indication":"Atopic Dermatitis","summary":"As of 8 September 2025, Beijing InnoCare Pharma Tech Co. estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 25 November 2026.","as_of":"2025-09-08","source":"clinicaltrials","source_ref":"NCT06775860","source_url":"https://clinicaltrials.gov/study/NCT06775860","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ffc5b4f0-1ad4-4bbb-b68d-3fd93bba3765"},{"id":"d2933aa0-4e32-4ac2-9c2b-a5ee625ca8a4","lane":"clinical","event_type":"primary-completion","date":"2026-11-26","date_precision":"day","confidence":"estimated","company":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","ticker":null,"asset":"MT1013","indication":"Secondary Hyperparathyroidism, Chronic Kidney Disease","summary":"As of 1 October 2025, Shaanxi Micot Pharmaceutical Technology Co. estimated primary completion of a Phase 3 trial in Secondary Hyperparathyroidism, Chronic Kidney Disease, on 26 November 2026.","as_of":"2025-10-01","source":"clinicaltrials","source_ref":"NCT07122401","source_url":"https://clinicaltrials.gov/study/NCT07122401","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d2933aa0-4e32-4ac2-9c2b-a5ee625ca8a4"},{"id":"1ffb5c23-d7b4-4cd2-a708-ddb8704e5663","lane":"clinical","event_type":"primary-completion","date":"2026-11-26","date_precision":"day","confidence":"estimated","company":"Tesaro, Inc.","ticker":null,"asset":"Dostarlimab","indication":"Neoplasms","summary":"As of 3 September 2025, Tesaro estimated primary completion of a Phase 3 trial in neoplasms, on 26 November 2026.","as_of":"2025-09-03","source":"clinicaltrials","source_ref":"NCT03981796","source_url":"https://clinicaltrials.gov/study/NCT03981796","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1ffb5c23-d7b4-4cd2-a708-ddb8704e5663"},{"id":"8b07b0a0-856f-4ae8-8145-53e0b73ae23d","lane":"clinical","event_type":"primary-completion","date":"2026-11-27","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"RO7795081","indication":"Type 2 Diabetes Mellitus","summary":"As of 7 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Type 2 Diabetes Mellitus, on 27 November 2026.","as_of":"2026-07-07","source":"clinicaltrials","source_ref":"NCT07112872","source_url":"https://clinicaltrials.gov/study/NCT07112872","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8b07b0a0-856f-4ae8-8145-53e0b73ae23d"},{"id":"33163082-51e9-4e0d-9ce7-a058d753b7c6","lane":"clinical","event_type":"primary-completion","date":"2026-11-28","date_precision":"day","confidence":"estimated","company":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"HSK31858, tablet","indication":"Non-cystic Fibrosis Bronchiectasis","summary":"As of 28 October 2024, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Non-cystic Fibrosis Bronchiectasis, on 28 November 2026.","as_of":"2024-10-28","source":"clinicaltrials","source_ref":"NCT06660992","source_url":"https://clinicaltrials.gov/study/NCT06660992","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-33163082-51e9-4e0d-9ce7-a058d753b7c6"},{"id":"2f061d56-f6fb-4332-916c-7364ab0a562f","lane":"clinical","event_type":"primary-completion","date":"2026-11-28","date_precision":"day","confidence":"estimated","company":"TrueBinding, Inc.","ticker":null,"asset":"TB006","indication":"Parkinson's Disease (PD)","summary":"As of 23 April 2026, TrueBinding estimated primary completion of a Phase 2 trial in Parkinson's Disease (PD), on 28 November 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT06773962","source_url":"https://clinicaltrials.gov/study/NCT06773962","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2f061d56-f6fb-4332-916c-7364ab0a562f"},{"id":"efdf291c-9652-4ca9-a343-0f65772c575f","lane":"clinical","event_type":"primary-completion","date":"2026-11-29","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"Rimegepant","indication":"Menstrual Migraine","summary":"As of 9 July 2026, Pfizer estimated primary completion of a Phase 3 trial in Menstrual Migraine, on 29 November 2026.","as_of":"2026-07-09","source":"clinicaltrials","source_ref":"NCT06641466","source_url":"https://clinicaltrials.gov/study/NCT06641466","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-efdf291c-9652-4ca9-a343-0f65772c575f"},{"id":"7b7b1fbc-b424-429b-b823-710754fb31d9","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"AUG Therapeutics","ticker":null,"asset":"AVTX-803 (L-Fucose)","indication":"Leukocyte Adhesion Deficiency","summary":"As of 1 May 2026, AUG Therapeutics estimated primary completion of a Phase 3 trial in Leukocyte Adhesion Deficiency, on 30 November 2026.","as_of":"2026-05-01","source":"clinicaltrials","source_ref":"NCT05462587","source_url":"https://clinicaltrials.gov/study/NCT05462587","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7b7b1fbc-b424-429b-b823-710754fb31d9"},{"id":"87e67402-62e8-4fff-9a74-68d4b981f846","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Amgen","ticker":null,"asset":"Anvumetostat","indication":"Advanced MTAP-null Solid Tumors","summary":"As of 28 May 2026, Amgen estimated primary completion of a Phase 2 trial in Advanced MTAP-null Solid Tumors, on 30 November 2026.","as_of":"2026-05-28","source":"clinicaltrials","source_ref":"NCT05094336","source_url":"https://clinicaltrials.gov/study/NCT05094336","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-87e67402-62e8-4fff-9a74-68d4b981f846"},{"id":"e545da37-2dff-41ff-b444-482cfb50622d","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Durvalumab","indication":"Hepatocellular Carcinoma","summary":"As of 12 May 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 30 November 2026.","as_of":"2026-05-12","source":"clinicaltrials","source_ref":"NCT07081633","source_url":"https://clinicaltrials.gov/study/NCT07081633","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e545da37-2dff-41ff-b444-482cfb50622d"},{"id":"88888793-194a-4a19-910a-760c8de92b03","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Aura Biosciences","ticker":null,"asset":"AU-011","indication":"Eye Cancer","summary":"As of 13 March 2026, Aura Biosciences estimated primary completion of a Phase 2 trial in Eye Cancer, on 30 November 2026.","as_of":"2026-03-13","source":"clinicaltrials","source_ref":"NCT06643884","source_url":"https://clinicaltrials.gov/study/NCT06643884","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-88888793-194a-4a19-910a-760c8de92b03"},{"id":"1fd02064-efbb-47a2-a919-6579bde4ae78","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Bavarian Nordic","ticker":null,"asset":"Jynneos","indication":"Monkeypox (Mpox)","summary":"As of 8 April 2026, Bavarian Nordic estimated primary completion of a Phase 2 trial in monkeypox (Mpox), on 30 November 2026.","as_of":"2026-04-08","source":"clinicaltrials","source_ref":"NCT07199569","source_url":"https://clinicaltrials.gov/study/NCT07199569","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1fd02064-efbb-47a2-a919-6579bde4ae78"},{"id":"468de375-5b25-4e26-8ee7-5bab2b7ae969","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"BeyondBio Inc.","ticker":null,"asset":"BEY1107","indication":"Locally Advanced or Metastatic Pancreatic Cancer","summary":"As of 10 March 2025, BeyondBio estimated primary completion of a Phase 2 trial in Locally Advanced or Metastatic Pancreatic Cancer, on 30 November 2026.","as_of":"2025-03-10","source":"clinicaltrials","source_ref":"NCT03579836","source_url":"https://clinicaltrials.gov/study/NCT03579836","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-468de375-5b25-4e26-8ee7-5bab2b7ae969"},{"id":"0f164896-bcc5-4645-a16d-5d27f8975408","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"BeyondBio Inc.","ticker":null,"asset":"BEY1107","indication":"Metastatic Colorectal Cancer","summary":"As of 10 March 2025, BeyondBio estimated primary completion of a Phase 2 trial in Metastatic Colorectal Cancer, on 30 November 2026.","as_of":"2025-03-10","source":"clinicaltrials","source_ref":"NCT05093907","source_url":"https://clinicaltrials.gov/study/NCT05093907","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0f164896-bcc5-4645-a16d-5d27f8975408"},{"id":"148f1509-03e9-4627-a458-97881e6d3b03","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"BioAge Labs, Inc.","ticker":null,"asset":"Oral BGE-102","indication":"Obesity and Cardiovascular Risk","summary":"As of 18 June 2026, BioAge Labs estimated primary completion of a Phase 2 trial in Obesity and Cardiovascular Risk, on 30 November 2026.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT07656727","source_url":"https://clinicaltrials.gov/study/NCT07656727","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-148f1509-03e9-4627-a458-97881e6d3b03"},{"id":"b2090292-9d69-4da5-9cf0-cb254a9710b2","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Cartesian Therapeutics","ticker":null,"asset":"Decartes-08","indication":"Myasthaenia Gravis","summary":"As of 24 March 2026, Cartesian Therapeutics estimated primary completion of a Phase 3 trial in Myasthaenia Gravis, on 30 November 2026.","as_of":"2026-03-24","source":"clinicaltrials","source_ref":"NCT06799247","source_url":"https://clinicaltrials.gov/study/NCT06799247","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b2090292-9d69-4da5-9cf0-cb254a9710b2"},{"id":"1a1292f9-f1a8-4fd9-bb2a-d955755ab9ee","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Celgene","ticker":null,"asset":"CC-92480","indication":"Multiple Myeloma","summary":"As of 29 November 2024, Celgene estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 30 November 2026.","as_of":"2024-11-29","source":"clinicaltrials","source_ref":"NCT03989414","source_url":"https://clinicaltrials.gov/study/NCT03989414","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1a1292f9-f1a8-4fd9-bb2a-d955755ab9ee"},{"id":"595f8df0-b7c9-49f5-b16e-58db4e5b0429","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Cytopeutics Sdn. Bhd.","ticker":null,"asset":"Neuroncell-EX","indication":"Acute Ischemic Stroke","summary":"As of 2 January 2026, Cytopeutics Sdn. Bhd. estimated primary completion of a Phase 3 trial in Acute Ischemic Stroke, on 30 November 2026.","as_of":"2026-01-02","source":"clinicaltrials","source_ref":"NCT06129175","source_url":"https://clinicaltrials.gov/study/NCT06129175","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-595f8df0-b7c9-49f5-b16e-58db4e5b0429"},{"id":"0775ac25-5ada-4c7d-9376-6673e8dee6a7","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Genentech, Inc.","ticker":null,"asset":"Alectinib","indication":"Non-small Cell Lung Cancer","summary":"As of 11 August 2026, Genentech estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, on 30 November 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT04302025","source_url":"https://clinicaltrials.gov/study/NCT04302025","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0775ac25-5ada-4c7d-9376-6673e8dee6a7"},{"id":"c2334fdd-1073-40f6-aa1c-0d40bc9cb54c","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Gritgen Therapeutics Co., Ltd.","ticker":null,"asset":"GS1191-0445 injection","indication":"Hemophilia A","summary":"As of 9 December 2025, Gritgen Therapeutics Co. estimated primary completion of a Phase 3 trial in Hemophilia A, on 30 November 2026.","as_of":"2025-12-09","source":"clinicaltrials","source_ref":"NCT06833983","source_url":"https://clinicaltrials.gov/study/NCT06833983","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c2334fdd-1073-40f6-aa1c-0d40bc9cb54c"},{"id":"f875613f-b7eb-4123-be69-5dd7d9ec77cf","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Immunocore Ltd","ticker":null,"asset":"IMC-R117C","indication":"Cancer","summary":"As of 28 January 2026, Immunocore estimated primary completion of a Phase 2 trial in cancer, on 30 November 2026.","as_of":"2026-01-28","source":"clinicaltrials","source_ref":"NCT06840119","source_url":"https://clinicaltrials.gov/study/NCT06840119","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f875613f-b7eb-4123-be69-5dd7d9ec77cf"},{"id":"ae94f483-4bc6-40d7-8258-b6cd1bc7e385","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"InventisBio Co., Ltd","ticker":null,"asset":"D-0502","indication":"Breast Cancer","summary":"As of 31 March 2026, InventisBio Co. estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 November 2026.","as_of":"2026-03-31","source":"clinicaltrials","source_ref":"NCT06954961","source_url":"https://clinicaltrials.gov/study/NCT06954961","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ae94f483-4bc6-40d7-8258-b6cd1bc7e385"},{"id":"9e2b8165-69bd-49cb-b661-8b23453180fe","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Mirati Therapeutics Inc.","ticker":null,"asset":"Adagrasib","indication":"Advanced Cancer","summary":"As of 4 August 2026, Mirati Therapeutics estimated primary completion of a Phase 2 trial in Advanced Cancer, on 30 November 2026.","as_of":"2026-08-04","source":"clinicaltrials","source_ref":"NCT05853575","source_url":"https://clinicaltrials.gov/study/NCT05853575","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9e2b8165-69bd-49cb-b661-8b23453180fe"},{"id":"9297d33d-8213-444e-aa1a-47322bcaab8f","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"ModernaTX, Inc.","ticker":null,"asset":"mRNA-3745","indication":"Glycogen Storage Disease","summary":"As of 15 December 2025, ModernaTX estimated primary completion of a Phase 2 trial in Glycogen Storage Disease, on 30 November 2026.","as_of":"2025-12-15","source":"clinicaltrials","source_ref":"NCT05095727","source_url":"https://clinicaltrials.gov/study/NCT05095727","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9297d33d-8213-444e-aa1a-47322bcaab8f"},{"id":"b05b350d-a56b-4d2f-9320-addac237a979","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Mundipharma Research Limited","ticker":null,"asset":"Rezafungin Acetate","indication":"Chronic Pulmonary Aspergillosis","summary":"As of 14 May 2026, Mundipharma Research estimated primary completion of a Phase 2 trial in Chronic Pulmonary Aspergillosis, on 30 November 2026.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT06794554","source_url":"https://clinicaltrials.gov/study/NCT06794554","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b05b350d-a56b-4d2f-9320-addac237a979"},{"id":"152e99f6-65c0-49eb-ac82-73d136ec09a3","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Mylan Pharmaceuticals Inc","ticker":null,"asset":"MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)","indication":"Contraception","summary":"As of 26 January 2026, Mylan Pharmaceuticals estimated primary completion of a Phase 2 trial in contraception, on 30 November 2026.","as_of":"2026-01-26","source":"clinicaltrials","source_ref":"NCT07365904","source_url":"https://clinicaltrials.gov/study/NCT07365904","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-152e99f6-65c0-49eb-ac82-73d136ec09a3"},{"id":"6e151d44-2e90-4fd3-bcd1-c4c2050fe1da","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"OncoC4, Inc.","ticker":null,"asset":"ONC-392 low","indication":"Metastatic Castration-resistant Prostate Cancer","summary":"As of 22 May 2026, OncoC4 estimated primary completion of a Phase 2 trial in Metastatic Castration-resistant Prostate Cancer, on 30 November 2026.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT05682443","source_url":"https://clinicaltrials.gov/study/NCT05682443","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6e151d44-2e90-4fd3-bcd1-c4c2050fe1da"},{"id":"e5f85d38-b153-4fb2-96d4-ba0e2a2c0a57","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"OriCell Therapeutics Co., Ltd.","ticker":null,"asset":"OriCAR-017","indication":"Relapsed and/or Refractory Multiple Myeloma","summary":"As of 31 May 2024, OriCell Therapeutics Co. estimated primary completion of a Phase 2 trial in Relapsed and/or Refractory Multiple Myeloma, on 30 November 2026.","as_of":"2024-05-31","source":"clinicaltrials","source_ref":"NCT06182696","source_url":"https://clinicaltrials.gov/study/NCT06182696","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e5f85d38-b153-4fb2-96d4-ba0e2a2c0a57"},{"id":"c2b47552-6978-4059-9626-cf8d6b2b5a6e","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Pharming Technologies B.V.","ticker":null,"asset":"Leniolisib","indication":"APDS","summary":"As of 6 May 2026, Pharming Technologies B.V. estimated primary completion of a Phase 3 trial in aPDS, on 30 November 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT05438407","source_url":"https://clinicaltrials.gov/study/NCT05438407","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c2b47552-6978-4059-9626-cf8d6b2b5a6e"},{"id":"6624b452-bcf2-4a7b-ae36-6f3a10deb542","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Ranok Therapeutics (Hangzhou) Co., Ltd.","ticker":null,"asset":"RNK08954","indication":"KRAS G12D Mutations","summary":"As of 24 December 2025, Ranok Therapeutics (Hangzhou) Co. estimated primary completion of a Phase 2 trial in KRAS G12D Mutations, on 30 November 2026.","as_of":"2025-12-24","source":"clinicaltrials","source_ref":"NCT07303465","source_url":"https://clinicaltrials.gov/study/NCT07303465","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6624b452-bcf2-4a7b-ae36-6f3a10deb542"},{"id":"db0ffbbd-747e-43b4-8e02-273aef391567","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"rilzabrutinib","indication":"Immune Thrombocytopenia","summary":"As of 6 November 2025, Sanofi estimated primary completion of a Phase 3 trial in Immune Thrombocytopenia, on 30 November 2026.","as_of":"2025-11-06","source":"clinicaltrials","source_ref":"NCT07216079","source_url":"https://clinicaltrials.gov/study/NCT07216079","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-db0ffbbd-747e-43b4-8e02-273aef391567"},{"id":"db4e59eb-8575-468e-bc31-8cc263ad60a0","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Saol Therapeutics Inc","ticker":null,"asset":"SL1002","indication":"Osteoarthritis Knee Pain","summary":"As of 21 July 2026, Saol Therapeutics estimated primary completion of a Phase 3 trial in Osteoarthritis Knee Pain, on 30 November 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT07226258","source_url":"https://clinicaltrials.gov/study/NCT07226258","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-db4e59eb-8575-468e-bc31-8cc263ad60a0"},{"id":"0731059e-7dc2-4ccc-b9d6-d0cdf82833c1","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Shanghai JMT-Bio Inc.","ticker":null,"asset":"JMT108","indication":"Unresectable Locally Advanced or Metastatic Melanoma","summary":"As of 7 January 2026, Shanghai JMT-Bio estimated primary completion of a Phase 2 trial in Unresectable Locally Advanced or Metastatic Melanoma, on 30 November 2026.","as_of":"2026-01-07","source":"clinicaltrials","source_ref":"NCT07280832","source_url":"https://clinicaltrials.gov/study/NCT07280832","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0731059e-7dc2-4ccc-b9d6-d0cdf82833c1"},{"id":"067346cd-a202-4e5a-ab06-81eedc65b7c7","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":null,"asset":"A166","indication":"HER2-positive Breast Cancer","summary":"As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in HER2-positive Breast Cancer, on 30 November 2026.","as_of":"2026-05-08","source":"clinicaltrials","source_ref":"NCT06968585","source_url":"https://clinicaltrials.gov/study/NCT06968585","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-067346cd-a202-4e5a-ab06-81eedc65b7c7"},{"id":"cdb55452-9f36-429c-b3ef-dc42cc09e326","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Taisho Pharmaceutical Co., Ltd.","ticker":null,"asset":"TS-172 20~60 mg/day","indication":"Hyperphosphatemia Patients on Hemodialysis","summary":"As of 15 May 2026, Taisho Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Hyperphosphatemia Patients on Hemodialysis, on 30 November 2026.","as_of":"2026-05-15","source":"clinicaltrials","source_ref":"NCT07548840","source_url":"https://clinicaltrials.gov/study/NCT07548840","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cdb55452-9f36-429c-b3ef-dc42cc09e326"},{"id":"5babbbd8-9ce9-49cc-a319-4f50e03a1e54","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Takeda","ticker":null,"asset":"TAK-360","indication":"Narcolepsy Type 2","summary":"As of 16 July 2026, Takeda estimated primary completion of a Phase 2 trial in Narcolepsy Type 2, on 30 November 2026.","as_of":"2026-07-16","source":"clinicaltrials","source_ref":"NCT06952699","source_url":"https://clinicaltrials.gov/study/NCT06952699","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5babbbd8-9ce9-49cc-a319-4f50e03a1e54"},{"id":"745d1349-00a8-416f-a02f-bae817e528fa","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Takeda","ticker":null,"asset":"TAK-360","indication":"Idiopathic Hypersomnia","summary":"As of 15 July 2026, Takeda estimated primary completion of a Phase 2 trial in Idiopathic Hypersomnia, on 30 November 2026.","as_of":"2026-07-15","source":"clinicaltrials","source_ref":"NCT06812078","source_url":"https://clinicaltrials.gov/study/NCT06812078","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-745d1349-00a8-416f-a02f-bae817e528fa"},{"id":"9b224f7c-011d-4e73-88db-e1af80e981f8","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"UniQure Biopharma B.V.","ticker":null,"asset":"AAV9-hSyn1-miGRIK2","indication":"Mesial Temporal Lobe Epilepsy","summary":"As of 29 July 2026, UniQure Biopharma B.V. estimated primary completion of a Phase 2 trial in Mesial Temporal Lobe Epilepsy, on 30 November 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT06063850","source_url":"https://clinicaltrials.gov/study/NCT06063850","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b224f7c-011d-4e73-88db-e1af80e981f8"},{"id":"1f38fdf0-4532-4b01-b2ce-1a86fb76a828","lane":"clinical","event_type":"primary-completion","date":"2026-11-30","date_precision":"day","confidence":"estimated","company":"Verdiva Bio Dev Limited","ticker":null,"asset":"VRB-101","indication":"Obesity","summary":"As of 4 August 2026, Verdiva Bio Dev estimated primary completion of a Phase 2 trial in obesity, on 30 November 2026.","as_of":"2026-08-04","source":"clinicaltrials","source_ref":"NCT07553299","source_url":"https://clinicaltrials.gov/study/NCT07553299","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1f38fdf0-4532-4b01-b2ce-1a86fb76a828"},{"id":"c7e1b606-c042-4338-8e61-142777c8a01b","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"3D Medicines (Sichuan) Co., Ltd.","ticker":null,"asset":"Lenvatinib + Envafolimab","indication":"Solid Tumors","summary":"As of 25 March 2026, 3D Medicines (Sichuan) Co. estimated primary completion of a Phase 2 trial in Solid Tumors, in December 2026.","as_of":"2026-03-25","source":"clinicaltrials","source_ref":"NCT05024214","source_url":"https://clinicaltrials.gov/study/NCT05024214","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c7e1b606-c042-4338-8e61-142777c8a01b"},{"id":"211c3528-7319-4816-9935-7c1cda85f3ab","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"3D Medicines (Sichuan) Co., Ltd.","ticker":null,"asset":"Envafolimab+Lenvatinib","indication":"Advanced Endometrial Cancer","summary":"As of 25 March 2026, 3D Medicines (Sichuan) Co. estimated primary completion of a Phase 2 trial in Advanced Endometrial Cancer, in December 2026.","as_of":"2026-03-25","source":"clinicaltrials","source_ref":"NCT05112991","source_url":"https://clinicaltrials.gov/study/NCT05112991","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-211c3528-7319-4816-9935-7c1cda85f3ab"},{"id":"5b33edc9-e7a9-49d4-beb7-2b82f9fdfb0b","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"858 Therapeutics, Inc.","ticker":null,"asset":"ETX-19477","indication":"Advanced or Metastatic Solid Tumors","summary":"As of 27 March 2026, 858 Therapeutics estimated primary completion of a Phase 2 trial in Advanced or Metastatic Solid Tumors, in December 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT06395519","source_url":"https://clinicaltrials.gov/study/NCT06395519","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5b33edc9-e7a9-49d4-beb7-2b82f9fdfb0b"},{"id":"b56af958-0a08-4b71-9ffd-6ce6109ec15c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"A2 Biotherapeutics Inc.","ticker":null,"asset":"A2B530","indication":"Solid Tumor, Adult","summary":"As of 25 April 2025, A2 Biotherapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, in December 2026.","as_of":"2025-04-25","source":"clinicaltrials","source_ref":"NCT05736731","source_url":"https://clinicaltrials.gov/study/NCT05736731","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b56af958-0a08-4b71-9ffd-6ce6109ec15c"},{"id":"352a7e72-3dbe-4426-ba31-fa8968c8fff7","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"AP Biosciences Inc.","ticker":null,"asset":"AP203","indication":"Locally Advanced or Metastatic Solid Tumors","summary":"As of 26 March 2025, AP Biosciences estimated primary completion of a Phase 2 trial in Locally Advanced or Metastatic Solid Tumors, in December 2026.","as_of":"2025-03-26","source":"clinicaltrials","source_ref":"NCT05473156","source_url":"https://clinicaltrials.gov/study/NCT05473156","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-352a7e72-3dbe-4426-ba31-fa8968c8fff7"},{"id":"1c73d318-ab2a-4328-a288-02fee16904de","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"AP Biosciences Inc.","ticker":null,"asset":"AP402 (Part 1 Dose esclation)","indication":"Advanced Solid Tumor","summary":"As of 25 April 2025, AP Biosciences estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 1 December 2026.","as_of":"2025-04-25","source":"clinicaltrials","source_ref":"NCT06669975","source_url":"https://clinicaltrials.gov/study/NCT06669975","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1c73d318-ab2a-4328-a288-02fee16904de"},{"id":"2e34a95b-5903-4331-b69b-e10d39f64499","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"ASTEROGENE Biomedical Co. Ltd.","ticker":null,"asset":"aNPC","indication":"Intervertebral Disc Degeneration","summary":"As of 3 April 2026, ASTEROGENE Biomedical Co. estimated primary completion of a Phase 2 trial in Intervertebral Disc Degeneration, on 1 December 2026.","as_of":"2026-04-03","source":"clinicaltrials","source_ref":"NCT07168603","source_url":"https://clinicaltrials.gov/study/NCT07168603","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2e34a95b-5903-4331-b69b-e10d39f64499"},{"id":"1fd698a3-fdd1-4c64-b3a4-7534765880f1","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Aadi Bioscience, Inc.","ticker":null,"asset":"nab-sirolimus","indication":"Endometrial Cancer","summary":"As of 13 November 2025, Aadi Bioscience estimated primary completion of a Phase 2 trial in Endometrial Cancer, in December 2026.","as_of":"2025-11-13","source":"clinicaltrials","source_ref":"NCT05997017","source_url":"https://clinicaltrials.gov/study/NCT05997017","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1fd698a3-fdd1-4c64-b3a4-7534765880f1"},{"id":"3ddf62c3-a8da-4ca7-98b1-e4ae0c14d656","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"Lutikizumab","indication":"Hidradenitis Suppurativa","summary":"As of 16 July 2026, AbbVie estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, in December 2026.","as_of":"2026-07-16","source":"clinicaltrials","source_ref":"NCT06468228","source_url":"https://clinicaltrials.gov/study/NCT06468228","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3ddf62c3-a8da-4ca7-98b1-e4ae0c14d656"},{"id":"c9c6a6ef-05fb-4514-ae49-44530d85f9b6","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"ABBV-RGX-314","indication":"AMD","summary":"As of 28 April 2026, AbbVie estimated primary completion of a Phase 3 trial in aMD, in December 2026.","as_of":"2026-04-28","source":"clinicaltrials","source_ref":"NCT04704921","source_url":"https://clinicaltrials.gov/study/NCT04704921","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c9c6a6ef-05fb-4514-ae49-44530d85f9b6"},{"id":"7bb10289-de25-47f4-9ddb-e766d23e6130","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"ABBV-400","indication":"Unresectable Metastatic Colorectal Cancer","summary":"As of 12 December 2025, AbbVie estimated primary completion of a Phase 2 trial in Unresectable Metastatic Colorectal Cancer, in December 2026.","as_of":"2025-12-12","source":"clinicaltrials","source_ref":"NCT06107413","source_url":"https://clinicaltrials.gov/study/NCT06107413","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7bb10289-de25-47f4-9ddb-e766d23e6130"},{"id":"aba5b3b3-ca5e-4276-8c35-67736278c69f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"Eluxadoline","indication":"Irritable Bowel Syndrome","summary":"As of 19 September 2025, AbbVie estimated primary completion of a Phase 2 trial in Irritable Bowel Syndrome, in December 2026.","as_of":"2025-09-19","source":"clinicaltrials","source_ref":"NCT03339128","source_url":"https://clinicaltrials.gov/study/NCT03339128","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-aba5b3b3-ca5e-4276-8c35-67736278c69f"},{"id":"b5db6875-2a3c-482a-8f3e-fd81eafafd6c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Abivax S.A.","ticker":null,"asset":"Obefazimod","indication":"Moderately to Severely Active Crohn Disease","summary":"As of 27 April 2026, Abivax estimated primary completion of a Phase 2 trial in Moderately to Severely Active Crohn Disease, in December 2026.","as_of":"2026-04-27","source":"clinicaltrials","source_ref":"NCT06456593","source_url":"https://clinicaltrials.gov/study/NCT06456593","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b5db6875-2a3c-482a-8f3e-fd81eafafd6c"},{"id":"040bcfbc-212f-4540-a35c-f209c3941843","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Akeso","ticker":null,"asset":"AK112","indication":"Triple-Negative Breast Cancer (TNBC)","summary":"As of 16 March 2026, Akeso estimated primary completion of a Phase 3 trial in Triple-Negative Breast Cancer (TNBC), in December 2026.","as_of":"2026-03-16","source":"clinicaltrials","source_ref":"NCT06767527","source_url":"https://clinicaltrials.gov/study/NCT06767527","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-040bcfbc-212f-4540-a35c-f209c3941843"},{"id":"354ee598-fc31-441e-8c03-e29244cd4f7b","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Akeso","ticker":null,"asset":"AK119","indication":"Solid Tumor, Adult","summary":"As of 18 March 2026, Akeso estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, in December 2026.","as_of":"2026-03-18","source":"clinicaltrials","source_ref":"NCT05689853","source_url":"https://clinicaltrials.gov/study/NCT05689853","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-354ee598-fc31-441e-8c03-e29244cd4f7b"},{"id":"c61f0733-43e5-45fc-827b-6371947d9b95","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Akeso","ticker":null,"asset":"AK129(dose 1)","indication":"Non-small Cell Lung Cancer Stage IIIB/IV","summary":"As of 3 June 2025, Akeso estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer Stage IIIB/IV, in December 2026.","as_of":"2025-06-03","source":"clinicaltrials","source_ref":"NCT06943820","source_url":"https://clinicaltrials.gov/study/NCT06943820","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c61f0733-43e5-45fc-827b-6371947d9b95"},{"id":"e047af00-1366-497c-8a99-7199065e455a","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Aldeyra Therapeutics, Inc.","ticker":null,"asset":"ICM ADX-2191 injection","indication":"Primary Vitreoretinal Lymphoma","summary":"As of 11 February 2026, Aldeyra Therapeutics estimated primary completion of a Phase 3 trial in Primary Vitreoretinal Lymphoma, in December 2026.","as_of":"2026-02-11","source":"clinicaltrials","source_ref":"NCT07402876","source_url":"https://clinicaltrials.gov/study/NCT07402876","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e047af00-1366-497c-8a99-7199065e455a"},{"id":"54d3f9ea-5d26-447d-aca5-65a2e265c03f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Alkeus Pharmaceuticals, Inc.","ticker":null,"asset":"ALK-001","indication":"Stargardt Disease","summary":"As of 27 April 2025, Alkeus Pharmaceuticals estimated primary completion of a Phase 2 trial in Stargardt Disease, in December 2026.","as_of":"2025-04-27","source":"clinicaltrials","source_ref":"NCT04239625","source_url":"https://clinicaltrials.gov/study/NCT04239625","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-54d3f9ea-5d26-447d-aca5-65a2e265c03f"},{"id":"e8d5dcfd-5d95-46d2-970a-22513efefef6","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Alto Neuroscience","ticker":null,"asset":"ALTO-300","indication":"Major Depressive Disorder","summary":"As of 24 July 2025, Alto Neuroscience estimated primary completion of a Phase 2 trial in Major Depressive Disorder, in December 2026.","as_of":"2025-07-24","source":"clinicaltrials","source_ref":"NCT05922878","source_url":"https://clinicaltrials.gov/study/NCT05922878","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e8d5dcfd-5d95-46d2-970a-22513efefef6"},{"id":"a5b911cd-1c02-4a37-9529-cfc17535e414","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Alyssum Therapeutics","ticker":null,"asset":"AT-1965 Liposome Injection","indication":"Solid Tumor","summary":"As of 23 July 2026, Alyssum Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT06234098","source_url":"https://clinicaltrials.gov/study/NCT06234098","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a5b911cd-1c02-4a37-9529-cfc17535e414"},{"id":"71bfa4c2-8fb5-41ed-8e23-c08ca669f14e","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Alzamend Neuro, Inc.","ticker":null,"asset":"AL001","indication":"Bipolar I Disorder","summary":"As of 28 July 2026, Alzamend Neuro estimated primary completion of a Phase 2 trial in Bipolar I Disorder, in December 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT07540338","source_url":"https://clinicaltrials.gov/study/NCT07540338","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-71bfa4c2-8fb5-41ed-8e23-c08ca669f14e"},{"id":"f99e2950-b359-439d-a654-d8b45c40064f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Ambrx, Inc.","ticker":null,"asset":"ARX788","indication":"HER2 Positive Metastatic Breast Cancer","summary":"As of 9 March 2026, Ambrx estimated primary completion of a Phase 2 trial in HER2 Positive Metastatic Breast Cancer, in December 2026.","as_of":"2026-03-09","source":"clinicaltrials","source_ref":"NCT04829604","source_url":"https://clinicaltrials.gov/study/NCT04829604","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f99e2950-b359-439d-a654-d8b45c40064f"},{"id":"973f474c-9d09-479e-be11-e38bc5dcf547","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Amydis Inc.","ticker":null,"asset":"AMDX-2011P","indication":"Cerebral Amyloid Angiopathy","summary":"As of 13 February 2026, Amydis estimated primary completion of a Phase 2 trial in Cerebral Amyloid Angiopathy, in December 2026.","as_of":"2026-02-13","source":"clinicaltrials","source_ref":"NCT05709314","source_url":"https://clinicaltrials.gov/study/NCT05709314","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-973f474c-9d09-479e-be11-e38bc5dcf547"},{"id":"a69e3e87-0b6c-42f6-9daa-795a1c978721","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Angitia Biopharmaceuticals","ticker":null,"asset":"AGA2118","indication":"Postmenopausal Osteoporosis","summary":"As of 10 February 2026, Angitia Biopharmaceuticals estimated primary completion of a Phase 2 trial in Postmenopausal Osteoporosis, in December 2026.","as_of":"2026-02-10","source":"clinicaltrials","source_ref":"NCT06577935","source_url":"https://clinicaltrials.gov/study/NCT06577935","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a69e3e87-0b6c-42f6-9daa-795a1c978721"},{"id":"ccc6a76c-04c7-4b57-87c2-3760ae503591","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Ascentage Pharma Group Inc.","ticker":null,"asset":"APG2575","indication":"Chronic Lymphocytic Leukemia","summary":"As of 27 March 2026, Ascentage Pharma Group estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, in December 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT05147467","source_url":"https://clinicaltrials.gov/study/NCT05147467","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ccc6a76c-04c7-4b57-87c2-3760ae503591"},{"id":"ff534f37-e355-4b6d-aa67-a30d340b6f16","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Aspeya, Inc.","ticker":null,"asset":"ASY202","indication":"Migraine","summary":"As of 21 July 2026, Aspeya estimated primary completion of a Phase 2 trial in migraine, in December 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT07646613","source_url":"https://clinicaltrials.gov/study/NCT07646613","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ff534f37-e355-4b6d-aa67-a30d340b6f16"},{"id":"baf6bbfd-2319-4edf-8066-1156fb265a7b","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Astria Therapeutics, Inc.","ticker":null,"asset":"navenibart","indication":"Hereditary Angioedema (HAE)","summary":"As of 30 June 2026, Astria Therapeutics estimated primary completion of a Phase 3 trial in Hereditary Angioedema (HAE), in December 2026.","as_of":"2026-06-30","source":"clinicaltrials","source_ref":"NCT06842823","source_url":"https://clinicaltrials.gov/study/NCT06842823","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-baf6bbfd-2319-4edf-8066-1156fb265a7b"},{"id":"693f7de3-4ba2-4be1-bb4d-dfb1a825ada0","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Atea Pharmaceuticals, Inc.","ticker":null,"asset":"Bemnifosbuvir-Ruzasvir","indication":"HEPATITIS C VIRUS CHRONIC INFECTION","summary":"As of 29 June 2026, Atea Pharmaceuticals estimated primary completion of a Phase 3 trial in HEPATITIS C VIRUS CHRONIC INFECTION, in December 2026.","as_of":"2026-06-29","source":"clinicaltrials","source_ref":"NCT07037277","source_url":"https://clinicaltrials.gov/study/NCT07037277","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-693f7de3-4ba2-4be1-bb4d-dfb1a825ada0"},{"id":"d96bb84d-6bc4-490f-ac78-152248e0a331","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Avalyn Pharma Inc.","ticker":null,"asset":"AP02","indication":"Idiopathic Pulmonary Fibrosis (IPF)","summary":"As of 10 August 2026, Avalyn Pharma estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis (IPF), in December 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT07194382","source_url":"https://clinicaltrials.gov/study/NCT07194382","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d96bb84d-6bc4-490f-ac78-152248e0a331"},{"id":"41b4233f-6d5e-4193-960c-575d17a29983","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Aveta Biomics, Inc.","ticker":null,"asset":"APG-157","indication":"Head and Neck Cancer","summary":"As of 16 January 2026, Aveta Biomics estimated primary completion of a Phase 2 trial in Head and Neck Cancer, in December 2026.","as_of":"2026-01-16","source":"clinicaltrials","source_ref":"NCT05312710","source_url":"https://clinicaltrials.gov/study/NCT05312710","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-41b4233f-6d5e-4193-960c-575d17a29983"},{"id":"660bf3a0-94e6-4c8b-8d26-95b7b08269dc","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Axsome Therapeutics, Inc.","ticker":null,"asset":"Solriamfetol 150 mg","indication":"Binge-Eating Disorder","summary":"As of 28 July 2026, Axsome Therapeutics estimated primary completion of a Phase 3 trial in Binge-Eating Disorder, in December 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT06413433","source_url":"https://clinicaltrials.gov/study/NCT06413433","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-660bf3a0-94e6-4c8b-8d26-95b7b08269dc"},{"id":"16f11e9b-289a-4176-85de-487893ed5108","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Axsome Therapeutics, Inc.","ticker":null,"asset":"Solriamfetol 150 mg","indication":"Excessive Sleepiness","summary":"As of 24 July 2026, Axsome Therapeutics estimated primary completion of a Phase 3 trial in Excessive Sleepiness, in December 2026.","as_of":"2026-07-24","source":"clinicaltrials","source_ref":"NCT06568367","source_url":"https://clinicaltrials.gov/study/NCT06568367","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-16f11e9b-289a-4176-85de-487893ed5108"},{"id":"6643f97c-97ae-4d89-9ae1-0a3d4e4202cc","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Beam Therapeutics Inc.","ticker":null,"asset":"BEAM-201","indication":"Lymphoblastic Lymphoma","summary":"As of 13 January 2025, Beam Therapeutics estimated primary completion of a Phase 2 trial in Lymphoblastic Lymphoma, in December 2026.","as_of":"2025-01-13","source":"clinicaltrials","source_ref":"NCT05885464","source_url":"https://clinicaltrials.gov/study/NCT05885464","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6643f97c-97ae-4d89-9ae1-0a3d4e4202cc"},{"id":"9843d9df-9f98-4588-9dde-a4fcbfab6741","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Beijing Scitech-Mq Pharmaceuticals Limited","ticker":null,"asset":"ST-1898 tablets","indication":"Unresectable or Metastatic Melanoma","summary":"As of 24 August 2025, Beijing Scitech-Mq Pharmaceuticals estimated primary completion of a Phase 2 trial in Unresectable or Metastatic Melanoma, in December 2026.","as_of":"2025-08-24","source":"clinicaltrials","source_ref":"NCT06359860","source_url":"https://clinicaltrials.gov/study/NCT06359860","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9843d9df-9f98-4588-9dde-a4fcbfab6741"},{"id":"a092b8b2-7414-4ae9-ae0b-1c49f130f638","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"BioCardia, Inc.","ticker":null,"asset":"CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)","indication":"Heart Failure, Systolic","summary":"As of 12 December 2025, BioCardia estimated primary completion of a Phase 2 trial in Heart Failure, Systolic, in December 2026.","as_of":"2025-12-12","source":"clinicaltrials","source_ref":"NCT05925608","source_url":"https://clinicaltrials.gov/study/NCT05925608","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a092b8b2-7414-4ae9-ae0b-1c49f130f638"},{"id":"5cd5f9e4-f5b2-4c90-953a-2a5ac8afb4bf","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"BioRestorative Therapies","ticker":null,"asset":"BRTX-100","indication":"Lumbar Disc Disease","summary":"As of 26 August 2025, BioRestorative Therapies estimated primary completion of a Phase 2 trial in Lumbar Disc Disease, in December 2026.","as_of":"2025-08-26","source":"clinicaltrials","source_ref":"NCT04042844","source_url":"https://clinicaltrials.gov/study/NCT04042844","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5cd5f9e4-f5b2-4c90-953a-2a5ac8afb4bf"},{"id":"0e36dee3-2bc5-4504-ab2a-21e93ec46e61","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Biocomposites Ltd","ticker":null,"asset":"STIMULAN VG","indication":"Pressure Ulcer, Stage IV","summary":"As of 6 May 2026, Biocomposites estimated primary completion of a Phase 2 trial in Pressure Ulcer, Stage IV, on 1 December 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT06283979","source_url":"https://clinicaltrials.gov/study/NCT06283979","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0e36dee3-2bc5-4504-ab2a-21e93ec46e61"},{"id":"6f758232-5b14-4d67-a53a-0ce24f1a2036","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Biogen","ticker":null,"asset":"Felzartamab","indication":"Antibody-mediated Rejection","summary":"As of 5 June 2026, Biogen estimated primary completion of a Phase 3 trial in Antibody-mediated Rejection, on 1 December 2026.","as_of":"2026-06-05","source":"clinicaltrials","source_ref":"NCT06685757","source_url":"https://clinicaltrials.gov/study/NCT06685757","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6f758232-5b14-4d67-a53a-0ce24f1a2036"},{"id":"e7e73b3f-ffe9-4e84-bdcc-a4f577f23e5c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Biohaven Therapeutics Ltd.","ticker":null,"asset":"BHV-7000","indication":"Focal Epilepsy","summary":"As of 1 May 2026, Biohaven Therapeutics estimated primary completion of a Phase 3 trial in Focal Epilepsy, in December 2026.","as_of":"2026-05-01","source":"clinicaltrials","source_ref":"NCT06132893","source_url":"https://clinicaltrials.gov/study/NCT06132893","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e7e73b3f-ffe9-4e84-bdcc-a4f577f23e5c"},{"id":"ed548f44-9ea5-47f0-814f-3b920fe05884","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Biohaven Therapeutics Ltd.","ticker":null,"asset":"BHV-7000","indication":"Focal Epilepsy","summary":"As of 1 May 2026, Biohaven Therapeutics estimated primary completion of a Phase 2 trial in Focal Epilepsy, in December 2026.","as_of":"2026-05-01","source":"clinicaltrials","source_ref":"NCT06443463","source_url":"https://clinicaltrials.gov/study/NCT06443463","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ed548f44-9ea5-47f0-814f-3b920fe05884"},{"id":"ce5245ca-f342-44d1-aeb1-4b5101add5ed","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Brii Biosciences Limited","ticker":null,"asset":"BRII-179","indication":"For Treatment of Chronic Hepatitis B Virus Infection","summary":"As of 30 December 2024, Brii Biosciences estimated primary completion of a Phase 2 trial in For Treatment of Chronic Hepatitis B Virus Infection, in December 2026.","as_of":"2024-12-30","source":"clinicaltrials","source_ref":"NCT06491563","source_url":"https://clinicaltrials.gov/study/NCT06491563","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ce5245ca-f342-44d1-aeb1-4b5101add5ed"},{"id":"ce9e11a7-68f8-4051-85e7-b49a0315af07","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"COUR Pharmaceutical Development Company, Inc.","ticker":null,"asset":"CNP-103","indication":"Type 1 Diabetes Mellitus","summary":"As of 6 August 2026, COUR Pharmaceutical Development Company estimated primary completion of a Phase 2 trial in Type 1 Diabetes Mellitus, in December 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT06783309","source_url":"https://clinicaltrials.gov/study/NCT06783309","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ce9e11a7-68f8-4051-85e7-b49a0315af07"},{"id":"745a6c2e-d334-49ac-aafd-2a7372c45d16","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Cancer Vaccines Limited","ticker":null,"asset":"ACIT-1","indication":"Cancer","summary":"As of 20 January 2026, Cancer Vaccines estimated primary completion of a Phase 2 trial in cancer, in December 2026.","as_of":"2026-01-20","source":"clinicaltrials","source_ref":"NCT03096093","source_url":"https://clinicaltrials.gov/study/NCT03096093","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-745a6c2e-d334-49ac-aafd-2a7372c45d16"},{"id":"516bfa7b-eb61-49dc-91b6-e9d86a90d510","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Cartesian Therapeutics","ticker":null,"asset":"Descartes-08","indication":"Systemic Lupus Erythematosus (SLE)","summary":"As of 27 March 2026, Cartesian Therapeutics estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus (SLE), on 1 December 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT06038474","source_url":"https://clinicaltrials.gov/study/NCT06038474","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-516bfa7b-eb61-49dc-91b6-e9d86a90d510"},{"id":"f3933623-4e6b-4843-a1d1-94e796071f3c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"CellARTs Inc.","ticker":null,"asset":"Stem cell","indication":"Infertility, Male","summary":"As of 24 February 2025, CellARTs estimated primary completion of a Phase 2 trial in Infertility, Male, on 1 December 2026.","as_of":"2025-02-24","source":"clinicaltrials","source_ref":"NCT06841861","source_url":"https://clinicaltrials.gov/study/NCT06841861","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f3933623-4e6b-4843-a1d1-94e796071f3c"},{"id":"5959e88e-20d8-495b-a695-d402974ff322","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Celltrion","ticker":null,"asset":"Metformin","indication":"T2DM","summary":"As of 11 August 2025, Celltrion estimated primary completion of a Phase 3 trial in t2DM, in December 2026.","as_of":"2025-08-11","source":"clinicaltrials","source_ref":"NCT07093476","source_url":"https://clinicaltrials.gov/study/NCT07093476","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5959e88e-20d8-495b-a695-d402974ff322"},{"id":"1e17b4a9-f7fa-4571-9005-6e0511ea0a51","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Centessa Pharmaceuticals (UK) Limited","ticker":null,"asset":"ORX750","indication":"Narcolepsy Type 1","summary":"As of 27 April 2026, Centessa Pharmaceuticals (UK) estimated primary completion of a Phase 2 trial in Narcolepsy Type 1, in December 2026.","as_of":"2026-04-27","source":"clinicaltrials","source_ref":"NCT06752668","source_url":"https://clinicaltrials.gov/study/NCT06752668","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1e17b4a9-f7fa-4571-9005-6e0511ea0a51"},{"id":"6817c394-c879-470f-b5f3-c94fa4e15ad5","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"TQB2930 for injection","indication":"Metastatic Breast Cancer","summary":"As of 12 March 2024, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in December 2026.","as_of":"2024-03-12","source":"clinicaltrials","source_ref":"NCT06202261","source_url":"https://clinicaltrials.gov/study/NCT06202261","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6817c394-c879-470f-b5f3-c94fa4e15ad5"},{"id":"3a2857d9-15e0-4c1b-a147-8b8b9f9c4c25","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"AK105 Injection","indication":"Advanced Hepatocellular Carcinoma (HCC)","summary":"As of 20 February 2025, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Advanced Hepatocellular Carcinoma (HCC), in December 2026.","as_of":"2025-02-20","source":"clinicaltrials","source_ref":"NCT04344158","source_url":"https://clinicaltrials.gov/study/NCT04344158","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3a2857d9-15e0-4c1b-a147-8b8b9f9c4c25"},{"id":"da120f74-79f4-48a7-8281-de0d9d2132e0","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"TQB3454 tablets","indication":"Biliary Carcinoma","summary":"As of 11 March 2026, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Biliary Carcinoma, in December 2026.","as_of":"2026-03-11","source":"clinicaltrials","source_ref":"NCT05987358","source_url":"https://clinicaltrials.gov/study/NCT05987358","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-da120f74-79f4-48a7-8281-de0d9d2132e0"},{"id":"74c6670f-1f97-4be8-aaa3-24201dfbceea","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"TQ05105 Tablets","indication":"Myelofibrosis","summary":"As of 8 December 2025, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in myelofibrosis, in December 2026.","as_of":"2025-12-08","source":"clinicaltrials","source_ref":"NCT06122831","source_url":"https://clinicaltrials.gov/study/NCT06122831","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-74c6670f-1f97-4be8-aaa3-24201dfbceea"},{"id":"292ddf99-1977-45d4-9b50-72952452e87d","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen","indication":"Breast Cancer","summary":"As of 17 April 2026, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Breast Cancer, in December 2026.","as_of":"2026-04-17","source":"clinicaltrials","source_ref":"NCT05780567","source_url":"https://clinicaltrials.gov/study/NCT05780567","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-292ddf99-1977-45d4-9b50-72952452e87d"},{"id":"35c5148a-3f28-41df-b5a9-2b2e03b61483","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","ticker":null,"asset":"TQA2225/AP025 or TQA2225/AP025 Placebo 25mg","indication":"Non-alcoholic Steatohepatitis","summary":"As of 26 August 2024, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-alcoholic Steatohepatitis, in December 2026.","as_of":"2024-08-26","source":"clinicaltrials","source_ref":"NCT06569524","source_url":"https://clinicaltrials.gov/study/NCT06569524","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-35c5148a-3f28-41df-b5a9-2b2e03b61483"},{"id":"17977b31-83df-4854-a834-6f267661ba77","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"CivaTech Oncology","ticker":null,"asset":"CivaSheet","indication":"Lung Cancer","summary":"As of 4 April 2025, CivaTech Oncology estimated primary completion of a Phase 2 trial in Lung Cancer, in December 2026.","as_of":"2025-04-04","source":"clinicaltrials","source_ref":"NCT03290534","source_url":"https://clinicaltrials.gov/study/NCT03290534","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-17977b31-83df-4854-a834-6f267661ba77"},{"id":"985b58a5-e26d-410c-80c7-2a81bfd78e51","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Compass Therapeutics","ticker":null,"asset":"CTX-009","indication":"Biliary Tract Cancer","summary":"As of 7 May 2026, Compass Therapeutics estimated primary completion of a Phase 3 trial in Biliary Tract Cancer, on 1 December 2026.","as_of":"2026-05-07","source":"clinicaltrials","source_ref":"NCT05506943","source_url":"https://clinicaltrials.gov/study/NCT05506943","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-985b58a5-e26d-410c-80c7-2a81bfd78e51"},{"id":"6a2ac680-55b0-40dc-97d2-0c0dd355689c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Cook MyoSite","ticker":null,"asset":"Iltamiocel","indication":"Fecal Incontinence","summary":"As of 21 July 2026, Cook MyoSite estimated primary completion of a Phase 3 trial in Fecal Incontinence, in December 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT05776277","source_url":"https://clinicaltrials.gov/study/NCT05776277","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6a2ac680-55b0-40dc-97d2-0c0dd355689c"},{"id":"91e0ac14-5656-4dd3-b16b-777eb7ff2661","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Corcept Therapeutics","ticker":null,"asset":"relacorilant","indication":"Cushing Syndrome","summary":"As of 21 April 2026, Corcept Therapeutics estimated primary completion of a Phase 2 trial in Cushing Syndrome, in December 2026.","as_of":"2026-04-21","source":"clinicaltrials","source_ref":"NCT03604198","source_url":"https://clinicaltrials.gov/study/NCT03604198","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-91e0ac14-5656-4dd3-b16b-777eb7ff2661"},{"id":"f3cff238-bd57-429b-b20e-511d85b27431","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Delcath Systems Inc.","ticker":null,"asset":"Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab","indication":"Refractory Metastatic Colorectal Cancer","summary":"As of 1 June 2026, Delcath Systems estimated primary completion of a Phase 2 trial in Refractory Metastatic Colorectal Cancer, in December 2026.","as_of":"2026-06-01","source":"clinicaltrials","source_ref":"NCT06607458","source_url":"https://clinicaltrials.gov/study/NCT06607458","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f3cff238-bd57-429b-b20e-511d85b27431"},{"id":"601ec669-cc9c-47a7-b00f-ffe0dfa7c4e6","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Denali Therapeutics Inc.","ticker":null,"asset":"DNL593","indication":"Frontotemporal Dementia","summary":"As of 15 January 2026, Denali Therapeutics estimated primary completion of a Phase 2 trial in Frontotemporal Dementia, in December 2026.","as_of":"2026-01-15","source":"clinicaltrials","source_ref":"NCT05262023","source_url":"https://clinicaltrials.gov/study/NCT05262023","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-601ec669-cc9c-47a7-b00f-ffe0dfa7c4e6"},{"id":"50edfc8f-6032-4222-84a5-68ccaba51b65","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Design Therapeutics, Inc.","ticker":null,"asset":"DT-216P2","indication":"Friedreich Ataxia","summary":"As of 18 May 2025, Design Therapeutics estimated primary completion of a Phase 2 trial in Friedreich Ataxia, in December 2026.","as_of":"2025-05-18","source":"clinicaltrials","source_ref":"NCT06874010","source_url":"https://clinicaltrials.gov/study/NCT06874010","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-50edfc8f-6032-4222-84a5-68ccaba51b65"},{"id":"0a39b3ec-da8c-480b-8eee-4a44fde67ebe","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"DiaMedica Therapeutics Inc","ticker":null,"asset":"Recombinant human tissue kallikrein","indication":"Acute Stroke","summary":"As of 28 April 2026, DiaMedica Therapeutics estimated primary completion of a Phase 3 trial in Acute Stroke, in December 2026.","as_of":"2026-04-28","source":"clinicaltrials","source_ref":"NCT05065216","source_url":"https://clinicaltrials.gov/study/NCT05065216","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0a39b3ec-da8c-480b-8eee-4a44fde67ebe"},{"id":"4ac00c9e-e1d5-47f5-adf3-b59e9fe0151c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Dianthus Therapeutics","ticker":null,"asset":"Claseprubart","indication":"Multifocal Motor Neuropathy","summary":"As of 10 August 2026, Dianthus Therapeutics estimated primary completion of a Phase 2 trial in Multifocal Motor Neuropathy, in December 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT06537999","source_url":"https://clinicaltrials.gov/study/NCT06537999","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4ac00c9e-e1d5-47f5-adf3-b59e9fe0151c"},{"id":"ebcf836e-907f-4bf8-9ba5-6dfd25ee8c69","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Dizal Pharmaceuticals","ticker":null,"asset":"DZD9008+AZD4205","indication":"Non-small Cell Lung Cancer","summary":"As of 31 December 2025, Dizal Pharmaceuticals estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026.","as_of":"2025-12-31","source":"clinicaltrials","source_ref":"NCT06295432","source_url":"https://clinicaltrials.gov/study/NCT06295432","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ebcf836e-907f-4bf8-9ba5-6dfd25ee8c69"},{"id":"e8e944a2-5bff-4555-bdc5-93b58c3fb5c4","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Dr. Falk Pharma GmbH","ticker":null,"asset":"Budesonide","indication":"Eosinophilic Esophagitis","summary":"As of 10 July 2026, Dr. Falk Pharma estimated primary completion of a Phase 3 trial in Eosinophilic Esophagitis, in December 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT06596252","source_url":"https://clinicaltrials.gov/study/NCT06596252","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e8e944a2-5bff-4555-bdc5-93b58c3fb5c4"},{"id":"05c46f9b-dd55-49e2-9e48-a21dc9889a1a","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Dren Bio","ticker":null,"asset":"DR-01","indication":"LGLL - Large Granular Lymphocytic Leukemia","summary":"As of 17 June 2026, Dren Bio estimated primary completion of a Phase 2 trial in LGLL - Large Granular Lymphocytic Leukemia, in December 2026.","as_of":"2026-06-17","source":"clinicaltrials","source_ref":"NCT05475925","source_url":"https://clinicaltrials.gov/study/NCT05475925","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-05c46f9b-dd55-49e2-9e48-a21dc9889a1a"},{"id":"7e959ca2-c92a-4f3e-998c-65a04df06cde","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"EicOsis Human Health Inc.","ticker":null,"asset":"EC5026 oral tablet","indication":"Parkinson's Disease (PD)","summary":"As of 10 July 2026, EicOsis Human Health estimated primary completion of a Phase 2 trial in Parkinson's Disease (PD), in December 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT07142044","source_url":"https://clinicaltrials.gov/study/NCT07142044","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7e959ca2-c92a-4f3e-998c-65a04df06cde"},{"id":"38b3ecb9-5334-4f40-816b-5c7e1d6ff94d","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Eikon Therapeutics","ticker":null,"asset":"EIK1001","indication":"NSCLC","summary":"As of 28 May 2026, Eikon Therapeutics estimated primary completion of a Phase 2 trial in nSCLC, in December 2026.","as_of":"2026-05-28","source":"clinicaltrials","source_ref":"NCT06246110","source_url":"https://clinicaltrials.gov/study/NCT06246110","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-38b3ecb9-5334-4f40-816b-5c7e1d6ff94d"},{"id":"f9e3e887-dce3-46e4-98e4-104019a57feb","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"LY3457263","indication":"Type 2 Diabetes","summary":"As of 6 August 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Type 2 Diabetes, in December 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT06897475","source_url":"https://clinicaltrials.gov/study/NCT06897475","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f9e3e887-dce3-46e4-98e4-104019a57feb"},{"id":"96e51698-4604-4e2c-9ea5-38c5db95cf08","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"LY3537021","indication":"Nausea","summary":"As of 6 August 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in nausea, in December 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT07169851","source_url":"https://clinicaltrials.gov/study/NCT07169851","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-96e51698-4604-4e2c-9ea5-38c5db95cf08"},{"id":"fbb9f48b-2c65-4e99-baab-5db77a1d4df7","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Elion Therapeutics, Inc.","ticker":null,"asset":"EL219","indication":"Invasive Mould Infection","summary":"As of 5 August 2026, Elion Therapeutics estimated primary completion of a Phase 2 trial in Invasive Mould Infection, in December 2026.","as_of":"2026-08-05","source":"clinicaltrials","source_ref":"NCT07215273","source_url":"https://clinicaltrials.gov/study/NCT07215273","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fbb9f48b-2c65-4e99-baab-5db77a1d4df7"},{"id":"27c8c735-fa18-47b4-a381-3513a71dce96","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Elixiron Immunotherapeutics Inc.","ticker":null,"asset":"EI-1071 tablet, oral","indication":"Mild, Moderate, or Severe Alzheimer's Disease","summary":"As of 9 June 2026, Elixiron Immunotherapeutics estimated primary completion of a Phase 2 trial in Mild, Moderate, or Severe Alzheimer's Disease, in December 2026.","as_of":"2026-06-09","source":"clinicaltrials","source_ref":"NCT06745583","source_url":"https://clinicaltrials.gov/study/NCT06745583","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-27c8c735-fa18-47b4-a381-3513a71dce96"},{"id":"94891087-7aa8-4f33-95af-0c45a5f164b8","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Enanta Pharmaceuticals, Inc","ticker":null,"asset":"zelicapavir","indication":"RSV Infection","summary":"As of 20 July 2026, Enanta Pharmaceuticals estimated primary completion of a Phase 2 trial in RSV Infection, in December 2026.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT07482657","source_url":"https://clinicaltrials.gov/study/NCT07482657","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-94891087-7aa8-4f33-95af-0c45a5f164b8"},{"id":"db319def-4b0d-4f5c-99a7-5fa810ce4257","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Enveda Therapeutics","ticker":null,"asset":"ENV-294","indication":"Asthma","summary":"As of 29 July 2026, Enveda Therapeutics estimated primary completion of a Phase 2 trial in asthma, in December 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT07301255","source_url":"https://clinicaltrials.gov/study/NCT07301255","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-db319def-4b0d-4f5c-99a7-5fa810ce4257"},{"id":"a018f4b0-aa6b-4afa-8bad-e0d786ac6446","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Enveda Therapeutics","ticker":null,"asset":"ENV-294","indication":"Atopic Dermatitis (AD)","summary":"As of 29 July 2026, Enveda Therapeutics estimated primary completion of a Phase 2 trial in Atopic Dermatitis (AD), in December 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT07298395","source_url":"https://clinicaltrials.gov/study/NCT07298395","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a018f4b0-aa6b-4afa-8bad-e0d786ac6446"},{"id":"f4db22a6-1113-4a11-b739-03429dbfcd51","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"EpicentRx, Inc.","ticker":null,"asset":"AdAPT-001","indication":"Solid Tumor, Adult","summary":"As of 26 June 2026, EpicentRx estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 1 December 2026.","as_of":"2026-06-26","source":"clinicaltrials","source_ref":"NCT04673942","source_url":"https://clinicaltrials.gov/study/NCT04673942","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f4db22a6-1113-4a11-b739-03429dbfcd51"},{"id":"5c7e60cf-5fba-430f-b437-d51a2573e2b6","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Eupraxia Pharmaceuticals Inc.","ticker":null,"asset":"EP-104GI","indication":"Eosinophilic Esophagitis","summary":"As of 19 March 2026, Eupraxia Pharmaceuticals estimated primary completion of a Phase 2 trial in Eosinophilic Esophagitis, in December 2026.","as_of":"2026-03-19","source":"clinicaltrials","source_ref":"NCT05608681","source_url":"https://clinicaltrials.gov/study/NCT05608681","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5c7e60cf-5fba-430f-b437-d51a2573e2b6"},{"id":"a7b45be6-1c0a-407f-8220-6a146461208f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Frantz Viral Therapeutics, LLC","ticker":null,"asset":"Artesunate ointment","indication":"Vulvar Diseases","summary":"As of 14 August 2025, Frantz Viral Therapeutics estimated primary completion of a Phase 2 trial in Vulvar Diseases, in December 2026.","as_of":"2025-08-14","source":"clinicaltrials","source_ref":"NCT06075264","source_url":"https://clinicaltrials.gov/study/NCT06075264","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a7b45be6-1c0a-407f-8220-6a146461208f"},{"id":"74913fa2-8ffa-4a6b-8ded-fefa276a406f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Fujian Akeylink Biotechnology Co., Ltd.","ticker":null,"asset":"GST-HG141","indication":"Chronic Hepatitis b","summary":"As of 23 January 2026, Fujian Akeylink Biotechnology Co. estimated primary completion of a Phase 3 trial in Chronic Hepatitis b, on 1 December 2026.","as_of":"2026-01-23","source":"clinicaltrials","source_ref":"NCT07090759","source_url":"https://clinicaltrials.gov/study/NCT07090759","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-74913fa2-8ffa-4a6b-8ded-fefa276a406f"},{"id":"0b221cbe-4d22-41d5-a3dd-11be1b62b1f8","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"asset":"HRS9531","indication":"Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy","summary":"As of 26 January 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in December 2026.","as_of":"2026-01-26","source":"clinicaltrials","source_ref":"NCT06994650","source_url":"https://clinicaltrials.gov/study/NCT06994650","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0b221cbe-4d22-41d5-a3dd-11be1b62b1f8"},{"id":"f4569427-ac09-40a0-94b7-bc50333d4812","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"asset":"HRS9531","indication":"Bstructive Sleep Apnea (OSA) and Obesity","summary":"As of 17 November 2025, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Bstructive Sleep Apnea (OSA) and Obesity, in December 2026.","as_of":"2025-11-17","source":"clinicaltrials","source_ref":"NCT06974851","source_url":"https://clinicaltrials.gov/study/NCT06974851","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f4569427-ac09-40a0-94b7-bc50333d4812"},{"id":"0b26f6ae-dde5-406a-9f2a-00b46bcbff05","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"asset":"HRS-9563 Injection","indication":"Mild to Moderate Hypertension","summary":"As of 31 July 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Mild to Moderate Hypertension, in December 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT07297797","source_url":"https://clinicaltrials.gov/study/NCT07297797","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0b26f6ae-dde5-406a-9f2a-00b46bcbff05"},{"id":"bb94f429-c35b-4fca-a983-40463781ca7e","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"GC Cell Corporation","ticker":null,"asset":"Immuncell-LC","indication":"Pancreatic Ductal Adenocarcinoma","summary":"As of 22 November 2021, GC Cell estimated primary completion of a Phase 3 trial in Pancreatic Ductal Adenocarcinoma, in December 2026.","as_of":"2021-11-22","source":"clinicaltrials","source_ref":"NCT04969731","source_url":"https://clinicaltrials.gov/study/NCT04969731","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bb94f429-c35b-4fca-a983-40463781ca7e"},{"id":"0c68e635-8259-4352-9587-6827e1bed185","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"GE Healthcare","ticker":null,"asset":"Regadenoson","indication":"Myocardial Ischemia","summary":"As of 6 May 2026, GE Healthcare estimated primary completion of a Phase 2 trial in Myocardial Ischemia, in December 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT04604782","source_url":"https://clinicaltrials.gov/study/NCT04604782","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0c68e635-8259-4352-9587-6827e1bed185"},{"id":"c272c778-1d50-4dd6-a3fc-2a20d5521246","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Galderma R&D","ticker":null,"asset":"nemolizumab","indication":"Chronic Pruritus of Unknown Origin","summary":"As of 27 July 2026, Galderma R&D estimated primary completion of a Phase 2 trial in Chronic Pruritus of Unknown Origin, in December 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT07074977","source_url":"https://clinicaltrials.gov/study/NCT07074977","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c272c778-1d50-4dd6-a3fc-2a20d5521246"},{"id":"4d6ef217-78a2-4609-bbe2-4ad587a2c037","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"GeneCradle Inc","ticker":null,"asset":"GC101","indication":"Spinal Muscular Atrophy","summary":"As of 3 July 2025, GeneCradle estimated primary completion of a Phase 2 trial in Spinal Muscular Atrophy, in December 2026.","as_of":"2025-07-03","source":"clinicaltrials","source_ref":"NCT05824169","source_url":"https://clinicaltrials.gov/study/NCT05824169","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4d6ef217-78a2-4609-bbe2-4ad587a2c037"},{"id":"11da08f2-89dd-4494-909b-418f65b620c2","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"GeneCradle Inc","ticker":null,"asset":"GC301","indication":"Pompe Disease (Late-onset)","summary":"As of 3 July 2025, GeneCradle estimated primary completion of a Phase 2 trial in Pompe Disease (Late-onset), in December 2026.","as_of":"2025-07-03","source":"clinicaltrials","source_ref":"NCT06391736","source_url":"https://clinicaltrials.gov/study/NCT06391736","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-11da08f2-89dd-4494-909b-418f65b620c2"},{"id":"a57e9900-6849-447b-839c-14f07b77479f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"GeneCradle Inc","ticker":null,"asset":"GC101","indication":"Spinal Muscular Atrophy Type 3","summary":"As of 3 July 2025, GeneCradle estimated primary completion of a Phase 2 trial in Spinal Muscular Atrophy Type 3, in December 2026.","as_of":"2025-07-03","source":"clinicaltrials","source_ref":"NCT06421831","source_url":"https://clinicaltrials.gov/study/NCT06421831","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a57e9900-6849-447b-839c-14f07b77479f"},{"id":"34575a0f-6fd7-4831-a910-19720ea253cc","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Genelux Corporation","ticker":null,"asset":"olvimulogene nanivacirepvec","indication":"Platinum-resistant Ovarian Cancer","summary":"As of 10 July 2026, Genelux estimated primary completion of a Phase 3 trial in Platinum-resistant Ovarian Cancer, in December 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT05281471","source_url":"https://clinicaltrials.gov/study/NCT05281471","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-34575a0f-6fd7-4831-a910-19720ea253cc"},{"id":"7fa803ed-35a1-4c8c-a251-319354b09e61","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Georgiamune Inc","ticker":null,"asset":"GIM-531","indication":"Melanoma Stage IV","summary":"As of 27 March 2026, Georgiamune estimated primary completion of a Phase 2 trial in Melanoma Stage IV, in December 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT06425926","source_url":"https://clinicaltrials.gov/study/NCT06425926","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7fa803ed-35a1-4c8c-a251-319354b09e61"},{"id":"e5d060a0-3820-4d44-8f6b-9d12b00b45d0","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Gilead Sciences","ticker":null,"asset":"Sacituzumab Govitecan-hziy","indication":"Metastatic Breast Cancer","summary":"As of 9 February 2026, Gilead Sciences estimated primary completion of a Phase 3 trial in Metastatic Breast Cancer, in December 2026.","as_of":"2026-02-09","source":"clinicaltrials","source_ref":"NCT04639986","source_url":"https://clinicaltrials.gov/study/NCT04639986","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e5d060a0-3820-4d44-8f6b-9d12b00b45d0"},{"id":"4983b8bd-c99a-4f72-9c3a-ac4b271a7a9a","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Gossamer Bio USA, Inc.","ticker":null,"asset":"Seralutinib","indication":"Pulmonary Arterial Hypertension","summary":"As of 29 July 2026, Gossamer Bio USA estimated primary completion of a Phase 3 trial in Pulmonary Arterial Hypertension, in December 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT06274801","source_url":"https://clinicaltrials.gov/study/NCT06274801","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4983b8bd-c99a-4f72-9c3a-ac4b271a7a9a"},{"id":"256612f8-27dd-4a7f-9dc1-a3e9b40dd878","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Grand Shuyang Life Sciences (Chengdu) Co., Ltd.","ticker":null,"asset":"Human immunoglobulin (pH4) for intravenous injection","indication":"Primary Immune Thrombocytopenia (ITP)","summary":"As of 8 April 2026, Grand Shuyang Life Sciences (Chengdu) Co. estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia (ITP), in December 2026.","as_of":"2026-04-08","source":"clinicaltrials","source_ref":"NCT07233213","source_url":"https://clinicaltrials.gov/study/NCT07233213","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-256612f8-27dd-4a7f-9dc1-a3e9b40dd878"},{"id":"d09233d7-1712-46df-8383-0260d6315728","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Guangzhou Gloria Biosciences Co., Ltd.","ticker":null,"asset":"GLS-012","indication":"Solid Tumor","summary":"As of 18 June 2023, Guangzhou Gloria Biosciences Co. estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026.","as_of":"2023-06-18","source":"clinicaltrials","source_ref":"NCT05909436","source_url":"https://clinicaltrials.gov/study/NCT05909436","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d09233d7-1712-46df-8383-0260d6315728"},{"id":"2504b73e-1141-4661-bea0-0bd8dd88625f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Henan Genuine Biotech Co., Ltd.","ticker":null,"asset":"CL-197 capsules","indication":"HIV-1 Infection","summary":"As of 6 January 2026, Henan Genuine Biotech Co. estimated primary completion of a Phase 2 trial in HIV-1 Infection, in December 2026.","as_of":"2026-01-06","source":"clinicaltrials","source_ref":"NCT07308782","source_url":"https://clinicaltrials.gov/study/NCT07308782","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2504b73e-1141-4661-bea0-0bd8dd88625f"},{"id":"8029557e-f8e4-44a6-8cd4-ac1e8c43ba43","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Heron Neutron Medical Corp.","ticker":null,"asset":"F18 FBPA Injection","indication":"Solid Tumor","summary":"As of 9 July 2026, Heron Neutron Medical estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026.","as_of":"2026-07-09","source":"clinicaltrials","source_ref":"NCT07691775","source_url":"https://clinicaltrials.gov/study/NCT07691775","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8029557e-f8e4-44a6-8cd4-ac1e8c43ba43"},{"id":"2a511603-3ad9-4fc6-b1dd-3bc8936d7913","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Imbria Pharmaceuticals, Inc.","ticker":null,"asset":"Ninerafaxstat 200mg MR","indication":"Non-obstructive Hypertrophic Cardiomyopathy","summary":"As of 18 May 2026, Imbria Pharmaceuticals estimated primary completion of a Phase 2 trial in Non-obstructive Hypertrophic Cardiomyopathy, in December 2026.","as_of":"2026-05-18","source":"clinicaltrials","source_ref":"NCT07023614","source_url":"https://clinicaltrials.gov/study/NCT07023614","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2a511603-3ad9-4fc6-b1dd-3bc8936d7913"},{"id":"c82a384a-ed87-44be-b6cc-acb41f63db08","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Inmunotek S.L.","ticker":null,"asset":"10,000 MM09","indication":"Rhinitis, Allergic","summary":"As of 13 May 2025, Inmunotek S.L. estimated primary completion of a Phase 3 trial in Rhinitis, Allergic, in December 2026.","as_of":"2025-05-13","source":"clinicaltrials","source_ref":"NCT04435990","source_url":"https://clinicaltrials.gov/study/NCT04435990","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c82a384a-ed87-44be-b6cc-acb41f63db08"},{"id":"eca190d5-6e2d-4f28-ae27-a4a3efa02dfd","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Institut de Recherches Internationales Servier (I.R.I.S.)","ticker":null,"asset":"BN104 monotherapy","indication":"ALL, Adult","summary":"As of 25 February 2026, Institut de Recherches Internationales Servier estimated primary completion of a Phase 2 trial in ALL, Adult, in December 2026.","as_of":"2026-02-25","source":"clinicaltrials","source_ref":"NCT06052813","source_url":"https://clinicaltrials.gov/study/NCT06052813","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-eca190d5-6e2d-4f28-ae27-a4a3efa02dfd"},{"id":"a2c2c87a-4b10-496c-ba2e-2430974a2a56","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Intra-IMMUSG Pte Ltd","ticker":null,"asset":"PRL3-zumab","indication":"Solid Tumor","summary":"As of 22 April 2026, Intra-IMMUSG Pte estimated primary completion of a Phase 2 trial in Solid Tumor, on 1 December 2026.","as_of":"2026-04-22","source":"clinicaltrials","source_ref":"NCT04452955","source_url":"https://clinicaltrials.gov/study/NCT04452955","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a2c2c87a-4b10-496c-ba2e-2430974a2a56"},{"id":"fa18a0d2-f609-4bc7-a47d-05d5f8e58555","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Intra-IMMUSG Pte Ltd","ticker":null,"asset":"PRL3-ZUMAB","indication":"Advanced Solid Cancers","summary":"As of 16 April 2026, Intra-IMMUSG Pte estimated primary completion of a Phase 3 trial in Advanced Solid Cancers, in December 2026.","as_of":"2026-04-16","source":"clinicaltrials","source_ref":"NCT07290088","source_url":"https://clinicaltrials.gov/study/NCT07290088","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fa18a0d2-f609-4bc7-a47d-05d5f8e58555"},{"id":"aee4ca71-06b6-4019-82b8-d097cf5ad36c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Ionis Pharmaceuticals, Inc.","ticker":null,"asset":"Donidalorsen","indication":"Hereditary Angioedema","summary":"As of 12 December 2025, Ionis Pharmaceuticals estimated primary completion of a Phase 3 trial in Hereditary Angioedema, in December 2026.","as_of":"2025-12-12","source":"clinicaltrials","source_ref":"NCT05392114","source_url":"https://clinicaltrials.gov/study/NCT05392114","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-aee4ca71-06b6-4019-82b8-d097cf5ad36c"},{"id":"55e5353f-46c2-4c2e-a3ee-2df359470ec0","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Iperboreal Pharma Srl","ticker":null,"asset":"PolyCore (Polydextrin, L-Carnitine, D-xylitol)","indication":"Congestive Heart Failure","summary":"As of 16 May 2025, Iperboreal Pharma Srl estimated primary completion of a Phase 2 trial in Congestive Heart Failure, in December 2026.","as_of":"2025-05-16","source":"clinicaltrials","source_ref":"NCT03994874","source_url":"https://clinicaltrials.gov/study/NCT03994874","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-55e5353f-46c2-4c2e-a3ee-2df359470ec0"},{"id":"292138f6-6184-40c1-affa-ff71029bd891","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Italfarmaco","ticker":null,"asset":"givinostat","indication":"Chronic Myeloproliferative Neoplasms","summary":"As of 30 April 2025, Italfarma estimated primary completion of a Phase 2 trial in Chronic Myeloproliferative Neoplasms, in December 2026.","as_of":"2025-04-30","source":"clinicaltrials","source_ref":"NCT01761968","source_url":"https://clinicaltrials.gov/study/NCT01761968","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-292138f6-6184-40c1-affa-ff71029bd891"},{"id":"c9b1d157-f967-48ad-9254-f639e3c59ee0","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"JYAMS PET Research & Development Limited","ticker":null,"asset":"[18F]-APN-1607","indication":"Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia","summary":"As of 20 February 2026, JYAMS PET Research & Development estimated primary completion of a Phase 3 trial on 1 December 2026.","as_of":"2026-02-20","source":"clinicaltrials","source_ref":"NCT07422857","source_url":"https://clinicaltrials.gov/study/NCT07422857","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c9b1d157-f967-48ad-9254-f639e3c59ee0"},{"id":"6356f1e5-211e-4aca-8edf-d89872950490","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Janssen Research & Development, LLC","ticker":null,"asset":"Apalutamide","indication":"Prostatic Neoplasms","summary":"As of 31 July 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Prostatic Neoplasms, on 1 December 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT03767244","source_url":"https://clinicaltrials.gov/study/NCT03767244","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6356f1e5-211e-4aca-8edf-d89872950490"},{"id":"2425a7b8-316f-4305-9eda-3ddbfd6686bb","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"HRS-6209 Capsules","indication":"Breast Cancer","summary":"As of 12 June 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Breast Cancer, in December 2026.","as_of":"2026-06-12","source":"clinicaltrials","source_ref":"NCT06974929","source_url":"https://clinicaltrials.gov/study/NCT06974929","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2425a7b8-316f-4305-9eda-3ddbfd6686bb"},{"id":"e57ef7b0-cae9-4ac4-b64f-57540d85b64d","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"SHR-3167 Injection","indication":"Diabetes Mellitus, Type 2","summary":"As of 4 June 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, in December 2026.","as_of":"2026-06-04","source":"clinicaltrials","source_ref":"NCT07472725","source_url":"https://clinicaltrials.gov/study/NCT07472725","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e57ef7b0-cae9-4ac4-b64f-57540d85b64d"},{"id":"39f55bed-7db8-4636-bd8c-377ae131bf0d","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316","indication":"Advanced Non-small Cell Lung Cancer","summary":"As of 20 April 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Advanced Non-small Cell Lung Cancer, in December 2026.","as_of":"2026-04-20","source":"clinicaltrials","source_ref":"NCT05482568","source_url":"https://clinicaltrials.gov/study/NCT05482568","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-39f55bed-7db8-4636-bd8c-377ae131bf0d"},{"id":"7de6fefa-07d3-464c-b135-ebf9cba7e221","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"Herombopag tablets","indication":"Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery","summary":"As of 17 July 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in December 2026.","as_of":"2026-07-17","source":"clinicaltrials","source_ref":"NCT06507436","source_url":"https://clinicaltrials.gov/study/NCT06507436","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7de6fefa-07d3-464c-b135-ebf9cba7e221"},{"id":"278d9e9f-8fc9-47a5-b3d5-70666c57c917","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide","indication":"Advanced Gastroenteropancreatic Neuroendocrine Tumor","summary":"As of 19 May 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in Advanced Gastroenteropancreatic Neuroendocrine Tumor, in December 2026.","as_of":"2026-05-19","source":"clinicaltrials","source_ref":"NCT05884255","source_url":"https://clinicaltrials.gov/study/NCT05884255","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-278d9e9f-8fc9-47a5-b3d5-70666c57c917"},{"id":"15a7dcd6-b1a7-49a1-8668-35e1a8cfbbd9","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","ticker":null,"asset":"azenosertib","indication":"High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","summary":"As of 1 July 2026, K-Group, Beta estimated primary completion of a Phase 2 trial on 1 December 2026.","as_of":"2026-07-01","source":"clinicaltrials","source_ref":"NCT05128825","source_url":"https://clinicaltrials.gov/study/NCT05128825","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-15a7dcd6-b1a7-49a1-8668-35e1a8cfbbd9"},{"id":"f4e53932-da23-4060-a6fd-67808b14411a","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Kardigan, Inc.","ticker":null,"asset":"Tonlamarsen","indication":"Hypertension","summary":"As of 1 July 2026, Kardigan estimated primary completion of a Phase 2 trial in hypertension, in December 2026.","as_of":"2026-07-01","source":"clinicaltrials","source_ref":"NCT07511361","source_url":"https://clinicaltrials.gov/study/NCT07511361","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f4e53932-da23-4060-a6fd-67808b14411a"},{"id":"f2f9ffdc-fbf5-42db-8cee-f587372652a8","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Karyopharm Therapeutics Inc","ticker":null,"asset":"Selinexor (combination therapy)","indication":"Relapsed/Refractory Diffuse Large B-cell Lymphoma","summary":"As of 2 July 2026, Karyopharm Therapeutics estimated primary completion of a Phase 3 trial in Relapsed/Refractory Diffuse Large B-cell Lymphoma, in December 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT04442022","source_url":"https://clinicaltrials.gov/study/NCT04442022","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f2f9ffdc-fbf5-42db-8cee-f587372652a8"},{"id":"d4c2ee90-2f7e-4aec-b9ec-56ae08970ae1","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Karyopharm Therapeutics Inc","ticker":null,"asset":"Selinexor","indication":"Diffuse Large B-cell Lymphoma","summary":"As of 2 July 2026, Karyopharm Therapeutics estimated primary completion of a Phase 2 trial in Diffuse Large B-cell Lymphoma, in December 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT02227251","source_url":"https://clinicaltrials.gov/study/NCT02227251","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d4c2ee90-2f7e-4aec-b9ec-56ae08970ae1"},{"id":"8ed26047-e0ad-4a6d-a39a-e026599228be","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Kedrion S.p.A.","ticker":null,"asset":"Kedrion IVIG 10%","indication":"Primary Immunodeficiency Disease","summary":"As of 29 May 2026, Kedrion S.p.A. estimated primary completion of a Phase 3 trial in Primary Immunodeficiency Disease, in December 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT04944979","source_url":"https://clinicaltrials.gov/study/NCT04944979","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8ed26047-e0ad-4a6d-a39a-e026599228be"},{"id":"73ae2cd4-8c3d-45fe-9878-2804519bac67","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Kedrion S.p.A.","ticker":null,"asset":"Kedrion IVIG 10%","indication":"Chronic Primary Immune Thrombocytopenia (ITP)","summary":"As of 6 August 2026, Kedrion S.p.A. estimated primary completion of a Phase 3 trial in Chronic Primary Immune Thrombocytopenia (ITP), in December 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT07059000","source_url":"https://clinicaltrials.gov/study/NCT07059000","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-73ae2cd4-8c3d-45fe-9878-2804519bac67"},{"id":"3da6dbc1-7907-4c5f-9def-3fe32b611b3a","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Keymed Biosciences Co.Ltd","ticker":null,"asset":"CM336_group 1","indication":"Multiple Myeloma","summary":"As of 15 October 2024, Keymed Biosciences Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, in December 2026.","as_of":"2024-10-15","source":"clinicaltrials","source_ref":"NCT05299424","source_url":"https://clinicaltrials.gov/study/NCT05299424","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3da6dbc1-7907-4c5f-9def-3fe32b611b3a"},{"id":"d90fb1fd-e2ef-4cc4-97d4-7a2112d91064","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Kind Pharmaceuticals LLC","ticker":null,"asset":"AND017 capsules","indication":"β -Thalassemia","summary":"As of 27 February 2026, Kind Pharmaceuticals estimated primary completion of a Phase 2 trial in β -Thalassemia, in December 2026.","as_of":"2026-02-27","source":"clinicaltrials","source_ref":"NCT06302491","source_url":"https://clinicaltrials.gov/study/NCT06302491","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d90fb1fd-e2ef-4cc4-97d4-7a2112d91064"},{"id":"edef4c56-ca3f-46b5-b964-bd05d5573908","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Kind Pharmaceuticals LLC","ticker":null,"asset":"AND017","indication":"Myelodysplastic Syndromes","summary":"As of 27 February 2026, Kind Pharmaceuticals estimated primary completion of a Phase 2 trial in Myelodysplastic Syndromes, in December 2026.","as_of":"2026-02-27","source":"clinicaltrials","source_ref":"NCT06304103","source_url":"https://clinicaltrials.gov/study/NCT06304103","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-edef4c56-ca3f-46b5-b964-bd05d5573908"},{"id":"bf40d59b-41ab-43b4-9e5b-a133d644060b","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Kind Pharmaceuticals LLC","ticker":null,"asset":"AND017","indication":"Anemia Due to Chronic Kidney Disease","summary":"As of 27 March 2026, Kind Pharmaceuticals estimated primary completion of a Phase 3 trial in Anemia Due to Chronic Kidney Disease, on 1 December 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT07487727","source_url":"https://clinicaltrials.gov/study/NCT07487727","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bf40d59b-41ab-43b4-9e5b-a133d644060b"},{"id":"dd67a9b6-ced2-45d7-832e-1e1891a13022","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Kite, A Gilead Company","ticker":null,"asset":"anitocabtagene-autoleucel","indication":"Multiple Myeloma","summary":"As of 11 February 2026, Kite, A Gilead estimated primary completion of a Phase 2 trial in Multiple Myeloma, in December 2026.","as_of":"2026-02-11","source":"clinicaltrials","source_ref":"NCT05396885","source_url":"https://clinicaltrials.gov/study/NCT05396885","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dd67a9b6-ced2-45d7-832e-1e1891a13022"},{"id":"bb9dce72-6407-497d-91c7-37e0a5dd0352","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Krystal Biotech, Inc.","ticker":null,"asset":"KB803","indication":"Dystrophic Epidermolysis Bullosa","summary":"As of 12 March 2026, Krystal Biotech estimated primary completion of a Phase 3 trial in Dystrophic Epidermolysis Bullosa, in December 2026.","as_of":"2026-03-12","source":"clinicaltrials","source_ref":"NCT07016750","source_url":"https://clinicaltrials.gov/study/NCT07016750","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bb9dce72-6407-497d-91c7-37e0a5dd0352"},{"id":"ebf90380-c494-42e4-b79d-d0c86b8ff8e4","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Krystal Biotech, Inc.","ticker":null,"asset":"KB801","indication":"Neurotrophic Keratitis","summary":"As of 27 February 2026, Krystal Biotech estimated primary completion of a Phase 2 trial in Neurotrophic Keratitis, in December 2026.","as_of":"2026-02-27","source":"clinicaltrials","source_ref":"NCT06999733","source_url":"https://clinicaltrials.gov/study/NCT06999733","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ebf90380-c494-42e4-b79d-d0c86b8ff8e4"},{"id":"b3dab1bb-1eca-4f34-acf8-3f3ab237aee6","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"LaNova Medicines Limited","ticker":null,"asset":"LM-299","indication":"Malignant Tumors","summary":"As of 2 May 2025, LaNova Medicines estimated primary completion of a Phase 2 trial in Malignant Tumors, in December 2026.","as_of":"2025-05-02","source":"clinicaltrials","source_ref":"NCT06650566","source_url":"https://clinicaltrials.gov/study/NCT06650566","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b3dab1bb-1eca-4f34-acf8-3f3ab237aee6"},{"id":"46f59450-e5b0-4dab-8b61-6709bcb9765d","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Lantern Pharma Inc.","ticker":null,"asset":"LP-300","indication":"Adenocarcinoma of Lung","summary":"As of 4 May 2026, Lantern Pharma estimated primary completion of a Phase 2 trial in Adenocarcinoma of Lung, in December 2026.","as_of":"2026-05-04","source":"clinicaltrials","source_ref":"NCT05456256","source_url":"https://clinicaltrials.gov/study/NCT05456256","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-46f59450-e5b0-4dab-8b61-6709bcb9765d"},{"id":"847009bb-bb9f-49ce-b698-b18b35d790ba","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Latticon Antibody Therapeutics, Inc","ticker":null,"asset":"LAT010","indication":"Advanced Solid Tumor","summary":"As of 8 July 2025, Latticon Antibody Therapeutics estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in December 2026.","as_of":"2025-07-08","source":"clinicaltrials","source_ref":"NCT06277219","source_url":"https://clinicaltrials.gov/study/NCT06277219","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-847009bb-bb9f-49ce-b698-b18b35d790ba"},{"id":"69b84a78-23b0-446f-bd0b-c6f8b24f217c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Lexeo Therapeutics","ticker":null,"asset":"LX2020","indication":"Arrhythmogenic Cardiomyopathy","summary":"As of 12 November 2025, Lexeo Therapeutics estimated primary completion of a Phase 2 trial in Arrhythmogenic Cardiomyopathy, in December 2026.","as_of":"2025-11-12","source":"clinicaltrials","source_ref":"NCT06109181","source_url":"https://clinicaltrials.gov/study/NCT06109181","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-69b84a78-23b0-446f-bd0b-c6f8b24f217c"},{"id":"52ed28d4-8654-4863-88f8-9e40129494f2","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Lumicell, Inc.","ticker":null,"asset":"LUM015","indication":"Colorectal Cancer","summary":"As of 16 January 2026, Lumicell estimated primary completion of a Phase 2 trial in Colorectal Cancer, in December 2026.","as_of":"2026-01-16","source":"clinicaltrials","source_ref":"NCT02584244","source_url":"https://clinicaltrials.gov/study/NCT02584244","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-52ed28d4-8654-4863-88f8-9e40129494f2"},{"id":"f170b539-9d3a-4ea5-b835-19c59fa28e3a","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Luxa Biotechnology, LLC","ticker":null,"asset":"RPESC-RPE-4W","indication":"Dry Age-related Macular Degeneration","summary":"As of 15 October 2025, Luxa Biotechnology estimated primary completion of a Phase 2 trial in Dry Age-related Macular Degeneration, on 1 December 2026.","as_of":"2025-10-15","source":"clinicaltrials","source_ref":"NCT04627428","source_url":"https://clinicaltrials.gov/study/NCT04627428","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f170b539-9d3a-4ea5-b835-19c59fa28e3a"},{"id":"581b9a15-cc4a-46aa-a705-9eff72ff1240","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Mabscale, LLC","ticker":null,"asset":"Bevacizumab","indication":"Non-Small Cell Lung Cancer","summary":"As of 16 August 2024, Mabscale estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, in December 2026.","as_of":"2024-08-16","source":"clinicaltrials","source_ref":"NCT05654454","source_url":"https://clinicaltrials.gov/study/NCT05654454","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-581b9a15-cc4a-46aa-a705-9eff72ff1240"},{"id":"8f3f342d-1b56-40be-887d-76cd377ed1cb","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Mabwell (Shanghai) Bioscience Co., Ltd.","ticker":null,"asset":"9MW3811 Injection","indication":"Scar","summary":"As of 8 May 2026, Mabwell (Shanghai) Bioscience Co. estimated primary completion of a Phase 2 trial in scar, in December 2026.","as_of":"2026-05-08","source":"clinicaltrials","source_ref":"NCT07576608","source_url":"https://clinicaltrials.gov/study/NCT07576608","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8f3f342d-1b56-40be-887d-76cd377ed1cb"},{"id":"da316791-392c-4327-bc8c-05f285df9008","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Madrigal Pharmaceuticals, Inc.","ticker":null,"asset":"Resmetirom","indication":"NASH","summary":"As of 8 July 2026, Madrigal Pharmaceuticals estimated primary completion of a Phase 3 trial in nASH, in December 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT05500222","source_url":"https://clinicaltrials.gov/study/NCT05500222","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-da316791-392c-4327-bc8c-05f285df9008"},{"id":"cc1df79e-ab7b-432f-b118-5e421de1c642","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"MediWound Ltd","ticker":null,"asset":"EscharEx (EX-03)","indication":"Venous Leg Ulcer (VLU)","summary":"As of 2 April 2026, MediWound estimated primary completion of a Phase 3 trial in Venous Leg Ulcer (VLU), in December 2026.","as_of":"2026-04-02","source":"clinicaltrials","source_ref":"NCT06568627","source_url":"https://clinicaltrials.gov/study/NCT06568627","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cc1df79e-ab7b-432f-b118-5e421de1c642"},{"id":"6ff9a73f-c5ca-4245-8949-771af5879bae","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Meribank Biotech Co., Ltd.","ticker":null,"asset":"umbilical cord mesenchymal stem cells","indication":"Pathologic Processes","summary":"As of 15 July 2024, Meribank Biotech Co. estimated primary completion of a Phase 2 trial in Pathologic Processes, in December 2026.","as_of":"2024-07-15","source":"clinicaltrials","source_ref":"NCT06501066","source_url":"https://clinicaltrials.gov/study/NCT06501066","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6ff9a73f-c5ca-4245-8949-771af5879bae"},{"id":"45f11ef0-14cc-4e6a-9db8-65e78fad0370","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Minovia Therapeutics Ltd.","ticker":null,"asset":"MNV-201","indication":"Mitochondrial Diseases","summary":"As of 22 June 2025, Minovia Therapeutics estimated primary completion of a Phase 2 trial in Mitochondrial Diseases, in December 2026.","as_of":"2025-06-22","source":"clinicaltrials","source_ref":"NCT06017869","source_url":"https://clinicaltrials.gov/study/NCT06017869","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-45f11ef0-14cc-4e6a-9db8-65e78fad0370"},{"id":"11b2c1b9-50df-4607-957f-a80a8d5d9762","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"NKGen Biotech, Inc.","ticker":null,"asset":"SNK01","indication":"Moderate Alzheimer Disease","summary":"As of 2 July 2026, NKGen Biotech estimated primary completion of a Phase 2 trial in Moderate Alzheimer Disease, in December 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT06189963","source_url":"https://clinicaltrials.gov/study/NCT06189963","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-11b2c1b9-50df-4607-957f-a80a8d5d9762"},{"id":"6909f41a-e29e-44ac-89c6-9dc49ad92f95","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"NMD Pharma A/S","ticker":null,"asset":"NMD670","indication":"Myasthenia Gravis","summary":"As of 1 July 2026, NMD Pharma estimated primary completion of a Phase 2 trial in Myasthenia Gravis, in December 2026.","as_of":"2026-07-01","source":"clinicaltrials","source_ref":"NCT06414954","source_url":"https://clinicaltrials.gov/study/NCT06414954","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6909f41a-e29e-44ac-89c6-9dc49ad92f95"},{"id":"53835fa3-c7a5-47fa-9807-ee97a216c1a0","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"NS Pharma, Inc.","ticker":null,"asset":"NS-229","indication":"Eosinophilic Granulomatosis With Polyangiitis","summary":"As of 26 May 2026, NS Pharma estimated primary completion of a Phase 2 trial in Eosinophilic Granulomatosis With Polyangiitis, in December 2026.","as_of":"2026-05-26","source":"clinicaltrials","source_ref":"NCT06046222","source_url":"https://clinicaltrials.gov/study/NCT06046222","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-53835fa3-c7a5-47fa-9807-ee97a216c1a0"},{"id":"028a7dcc-69c0-4972-873a-9e9a6f0b4e49","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Nanjing Leads Biolabs Co.,Ltd","ticker":null,"asset":"LBL-024 for Injection","indication":"Advanced Solid Tumor","summary":"As of 30 June 2026, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in December 2026.","as_of":"2026-06-30","source":"clinicaltrials","source_ref":"NCT05170958","source_url":"https://clinicaltrials.gov/study/NCT05170958","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-028a7dcc-69c0-4972-873a-9e9a6f0b4e49"},{"id":"8a2b0004-0aeb-4387-930a-27566833a3d8","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Napo Pharmaceuticals, Inc.","ticker":null,"asset":"Crofelemer Powder for Oral Solution","indication":"Microvillus Inclusion Disease","summary":"As of 9 June 2026, Napo Pharmaceuticals estimated primary completion of a Phase 3 trial in Microvillus Inclusion Disease, in December 2026.","as_of":"2026-06-09","source":"clinicaltrials","source_ref":"NCT06721871","source_url":"https://clinicaltrials.gov/study/NCT06721871","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8a2b0004-0aeb-4387-930a-27566833a3d8"},{"id":"3003e0b5-6f1b-40a3-99ef-f9620be82ef0","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.","ticker":null,"asset":"Olvi-Vec","indication":"SCLC, Extensive Stage","summary":"As of 3 December 2025, Newsoara HYK Biopharmaceutical (Shanghai) Co. estimated primary completion of a Phase 2 trial in SCLC, Extensive Stage, in December 2026.","as_of":"2025-12-03","source":"clinicaltrials","source_ref":"NCT07136285","source_url":"https://clinicaltrials.gov/study/NCT07136285","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3003e0b5-6f1b-40a3-99ef-f9620be82ef0"},{"id":"721f37c7-2ddf-4255-9d9c-9ad86a889683","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Nexcella Inc.","ticker":null,"asset":"NXC-201 CAR-T","indication":"Light Chain (AL) Amyloidosis","summary":"As of 14 July 2026, Nexcella estimated primary completion of a Phase 2 trial in Light Chain (AL) Amyloidosis, in December 2026.","as_of":"2026-07-14","source":"clinicaltrials","source_ref":"NCT06097832","source_url":"https://clinicaltrials.gov/study/NCT06097832","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-721f37c7-2ddf-4255-9d9c-9ad86a889683"},{"id":"9b223018-da7b-427d-86ee-549625b0886c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"NoNO Inc.","ticker":null,"asset":"NoNO-42","indication":"Acute Ischemic Stroke","summary":"As of 15 July 2025, NoNO estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, in December 2026.","as_of":"2025-07-15","source":"clinicaltrials","source_ref":"NCT06403267","source_url":"https://clinicaltrials.gov/study/NCT06403267","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b223018-da7b-427d-86ee-549625b0886c"},{"id":"6972f29a-c0c3-4804-a8b5-91701f0ef00b","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Octapharma","ticker":null,"asset":"Atenativ","indication":"Congenital Antithrombin Deficiency","summary":"As of 3 June 2026, Octapharma estimated primary completion of a Phase 3 trial in Congenital Antithrombin Deficiency, on 1 December 2026.","as_of":"2026-06-03","source":"clinicaltrials","source_ref":"NCT04918173","source_url":"https://clinicaltrials.gov/study/NCT04918173","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6972f29a-c0c3-4804-a8b5-91701f0ef00b"},{"id":"b80bdb85-8789-4b36-abdb-bbd1942cc6ac","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Octapharma","ticker":null,"asset":"OCTA-C1-INH","indication":"Acute Hereditary Angio Edema","summary":"As of 6 August 2026, Octapharma estimated primary completion of a Phase 3 trial in Acute Hereditary Angio Edema, in December 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT06361537","source_url":"https://clinicaltrials.gov/study/NCT06361537","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b80bdb85-8789-4b36-abdb-bbd1942cc6ac"},{"id":"5fc920ba-9fe9-4b1b-84b8-bddd9e1c45c5","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Oculis","ticker":null,"asset":"Artificial Tear Run-in","indication":"Dry Eye Disease (DED)","summary":"As of 6 July 2026, Oculis estimated primary completion of a Phase 3 trial in Dry Eye Disease (DED), in December 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT07548632","source_url":"https://clinicaltrials.gov/study/NCT07548632","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5fc920ba-9fe9-4b1b-84b8-bddd9e1c45c5"},{"id":"7af87ef7-1da7-4443-83d2-023ccb152d66","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Omeros Corporation","ticker":null,"asset":"OMS906 study drug","indication":"Paroxysmal Nocturnal Hemoglobinuria","summary":"As of 16 July 2026, Omeros estimated primary completion of a Phase 2 trial in Paroxysmal Nocturnal Hemoglobinuria, in December 2026.","as_of":"2026-07-16","source":"clinicaltrials","source_ref":"NCT06298955","source_url":"https://clinicaltrials.gov/study/NCT06298955","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7af87ef7-1da7-4443-83d2-023ccb152d66"},{"id":"dac2a2f7-fb94-4d30-8542-e09b4fed59fa","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"One-carbon Therapeutics AB","ticker":null,"asset":"TH9619","indication":"Solid Tumor","summary":"As of 28 January 2026, One-carbon Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026.","as_of":"2026-01-28","source":"clinicaltrials","source_ref":"NCT07151040","source_url":"https://clinicaltrials.gov/study/NCT07151040","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dac2a2f7-fb94-4d30-8542-e09b4fed59fa"},{"id":"583fe4a8-d138-4355-b240-2213305ebcf1","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"OriCell Therapeutics Co., Ltd.","ticker":null,"asset":"Ori-C101","indication":"Hepatocellular Carcinoma","summary":"As of 3 April 2024, OriCell Therapeutics Co. estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, in December 2026.","as_of":"2024-04-03","source":"clinicaltrials","source_ref":"NCT05652920","source_url":"https://clinicaltrials.gov/study/NCT05652920","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-583fe4a8-d138-4355-b240-2213305ebcf1"},{"id":"97b35224-e645-4e70-aa80-8ab5c0064abf","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"PT. Prodia Stem Cell Indonesia","ticker":null,"asset":"Control (NaCl 0.9%)","indication":"Acute Respiratory Distress Syndrome","summary":"As of 27 February 2026, PT. Prodia Stem Cell Indonesia estimated primary completion of a Phase 2 trial in Acute Respiratory Distress Syndrome, in December 2026.","as_of":"2026-02-27","source":"clinicaltrials","source_ref":"NCT07439848","source_url":"https://clinicaltrials.gov/study/NCT07439848","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-97b35224-e645-4e70-aa80-8ab5c0064abf"},{"id":"1eb5421c-ff6d-4561-b1cc-4b9df1767e9d","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Pacira Pharmaceuticals, Inc","ticker":null,"asset":"ZILRETTA","indication":"Glenohumeral Osteoarthritis","summary":"As of 29 May 2026, Pacira Pharmaceuticals estimated primary completion of a Phase 3 trial in Glenohumeral Osteoarthritis, in December 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT06269705","source_url":"https://clinicaltrials.gov/study/NCT06269705","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1eb5421c-ff6d-4561-b1cc-4b9df1767e9d"},{"id":"1544fc7e-efda-4ae1-b5c5-d03e520ce735","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Panafina, Inc.","ticker":null,"asset":"RABI-767","indication":"Acute Pancreatitis","summary":"As of 5 August 2026, Panafina estimated primary completion of a Phase 2 trial in Acute Pancreatitis, in December 2026.","as_of":"2026-08-05","source":"clinicaltrials","source_ref":"NCT06080789","source_url":"https://clinicaltrials.gov/study/NCT06080789","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1544fc7e-efda-4ae1-b5c5-d03e520ce735"},{"id":"c48a7dd1-30b6-4d47-90bc-f9a4dcf05aaf","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Phoenix Molecular Designs","ticker":null,"asset":"PMD-026","indication":"Metastatic Breast Cancer","summary":"As of 16 July 2026, Phoenix Molecular Designs estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in December 2026.","as_of":"2026-07-16","source":"clinicaltrials","source_ref":"NCT04115306","source_url":"https://clinicaltrials.gov/study/NCT04115306","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c48a7dd1-30b6-4d47-90bc-f9a4dcf05aaf"},{"id":"8e21398c-7402-456e-89fb-6ec332597e8f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Praxis Precision Medicines","ticker":null,"asset":"1.0mg/kg/day PRAX-562","indication":"Developmental and Epileptic Encephalopathy 1","summary":"As of 4 August 2026, Praxis Precision Medicines estimated primary completion of a Phase 3 trial in Developmental and Epileptic Encephalopathy 1, in December 2026.","as_of":"2026-08-04","source":"clinicaltrials","source_ref":"NCT07010471","source_url":"https://clinicaltrials.gov/study/NCT07010471","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8e21398c-7402-456e-89fb-6ec332597e8f"},{"id":"2712b3b5-3c3b-4cd3-b483-69cf0969e3fd","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Praxis Precision Medicines","ticker":null,"asset":"1mg elsunersen","indication":"Epileptic Encephalopathy","summary":"As of 3 August 2026, Praxis Precision Medicines estimated primary completion of a Phase 3 trial in Epileptic Encephalopathy, in December 2026.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT07019922","source_url":"https://clinicaltrials.gov/study/NCT07019922","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2712b3b5-3c3b-4cd3-b483-69cf0969e3fd"},{"id":"eceecf99-c057-4a83-93b4-663770e5d19d","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Priovant Therapeutics, Inc.","ticker":null,"asset":"Oral Brepocitinib","indication":"Cutaneous Sarcoidosis","summary":"As of 18 May 2025, Priovant Therapeutics estimated primary completion of a Phase 2 trial in Cutaneous Sarcoidosis, in December 2026.","as_of":"2025-05-18","source":"clinicaltrials","source_ref":"NCT06978725","source_url":"https://clinicaltrials.gov/study/NCT06978725","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-eceecf99-c057-4a83-93b4-663770e5d19d"},{"id":"e0c60b72-f23f-4b16-863a-951ab50cef80","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Protara Therapeutics","ticker":null,"asset":"TARA-002","indication":"Lymphatic Malformation","summary":"As of 18 May 2026, Protara Therapeutics estimated primary completion of a Phase 2 trial in Lymphatic Malformation, in December 2026.","as_of":"2026-05-18","source":"clinicaltrials","source_ref":"NCT05871970","source_url":"https://clinicaltrials.gov/study/NCT05871970","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e0c60b72-f23f-4b16-863a-951ab50cef80"},{"id":"b5fb4f84-6905-40c3-bd72-f76032eeab04","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Pulmovant, Inc.","ticker":null,"asset":"Mosliciguat","indication":"Pulmonary Hypertension","summary":"As of 20 February 2026, Pulmovant estimated primary completion of a Phase 2 trial in Pulmonary Hypertension, in December 2026.","as_of":"2026-02-20","source":"clinicaltrials","source_ref":"NCT06635850","source_url":"https://clinicaltrials.gov/study/NCT06635850","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b5fb4f84-6905-40c3-bd72-f76032eeab04"},{"id":"acac3771-f742-457a-9268-9c3e97a14683","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Pulmovant, Inc.","ticker":null,"asset":"inhaled mosliciguat","indication":"Pulmonary Hypertension","summary":"As of 22 April 2026, Pulmovant estimated primary completion of a Phase 2 trial in Pulmonary Hypertension, in December 2026.","as_of":"2026-04-22","source":"clinicaltrials","source_ref":"NCT07333183","source_url":"https://clinicaltrials.gov/study/NCT07333183","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-acac3771-f742-457a-9268-9c3e97a14683"},{"id":"df90586e-2022-493f-aabb-a64abc75bd92","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"asset":"QL2107","indication":"NSCLC","summary":"As of 10 June 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in nSCLC, in December 2026.","as_of":"2025-06-10","source":"clinicaltrials","source_ref":"NCT06754644","source_url":"https://clinicaltrials.gov/study/NCT06754644","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-df90586e-2022-493f-aabb-a64abc75bd92"},{"id":"60379447-bd5e-4c3b-b7db-f3738ce8f3bd","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"asset":"QLC5508","indication":"Advanced Prostate Cancer","summary":"As of 2 June 2026, Qilu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced Prostate Cancer, in December 2026.","as_of":"2026-06-02","source":"clinicaltrials","source_ref":"NCT07198633","source_url":"https://clinicaltrials.gov/study/NCT07198633","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-60379447-bd5e-4c3b-b7db-f3738ce8f3bd"},{"id":"fdf9a2af-491d-4acb-aee5-d3e8dfe0431c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"asset":"Dose 1 of QLS1410","indication":"Hypertension (HTN)","summary":"As of 22 May 2026, Qilu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in hypertension (HTN), in December 2026.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT07489612","source_url":"https://clinicaltrials.gov/study/NCT07489612","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fdf9a2af-491d-4acb-aee5-d3e8dfe0431c"},{"id":"7aa4c620-caa8-4204-992b-c9a97c0532f4","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"asset":"Meropenem and Pralurbactam","indication":"Hospital-acquired Bacterial Pneumonia (HABP)","summary":"As of 30 July 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Hospital-acquired Bacterial Pneumonia (HABP), in December 2026.","as_of":"2025-07-30","source":"clinicaltrials","source_ref":"NCT07089186","source_url":"https://clinicaltrials.gov/study/NCT07089186","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7aa4c620-caa8-4204-992b-c9a97c0532f4"},{"id":"ce695ed0-ddfb-42ff-9531-16ca1d1e5fc1","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"RDC Clinical Pty Ltd","ticker":null,"asset":"life'sTM omega O1035DS nTG","indication":"Absorption of Omega-3","summary":"As of 2 July 2026, RDC Clinical Pty estimated primary completion of a Phase 3 trial in Absorption of Omega-3, in December 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT07241377","source_url":"https://clinicaltrials.gov/study/NCT07241377","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ce695ed0-ddfb-42ff-9531-16ca1d1e5fc1"},{"id":"d4c3e029-8d56-448c-a735-e5fbbfa6f031","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Ranok Therapeutics (Hangzhou) Co., Ltd.","ticker":null,"asset":"RNK08954-01","indication":"KRAS G12D Mutation","summary":"As of 30 October 2025, Ranok Therapeutics (Hangzhou) Co. estimated primary completion of a Phase 2 trial in KRAS G12D Mutation, in December 2026.","as_of":"2025-10-30","source":"clinicaltrials","source_ref":"NCT06667544","source_url":"https://clinicaltrials.gov/study/NCT06667544","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d4c3e029-8d56-448c-a735-e5fbbfa6f031"},{"id":"5d902738-38a8-4b12-ba92-f0eaeee65b37","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"RayzeBio, Inc.","ticker":null,"asset":"RYZ101","indication":"GEP-NET","summary":"As of 30 March 2026, RayzeBio estimated primary completion of a Phase 3 trial in gEP-NET, in December 2026.","as_of":"2026-03-30","source":"clinicaltrials","source_ref":"NCT05477576","source_url":"https://clinicaltrials.gov/study/NCT05477576","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5d902738-38a8-4b12-ba92-f0eaeee65b37"},{"id":"fc1a103a-5a90-4122-96ca-aad119857ede","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"ReAlta Life Sciences, Inc.","ticker":null,"asset":"RLS-0071","indication":"Steroid Refractory GVHD","summary":"As of 24 November 2025, ReAlta Life Sciences estimated primary completion of a Phase 2 trial in Steroid Refractory GVHD, in December 2026.","as_of":"2025-11-24","source":"clinicaltrials","source_ref":"NCT06343792","source_url":"https://clinicaltrials.gov/study/NCT06343792","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fc1a103a-5a90-4122-96ca-aad119857ede"},{"id":"77ed5667-6526-42d1-b050-58c647609919","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"ReAlta Life Sciences, Inc.","ticker":null,"asset":"RLS-0071","indication":"Hypoxic-Ischemic Encephalopathy","summary":"As of 13 April 2026, ReAlta Life Sciences estimated primary completion of a Phase 2 trial in Hypoxic-Ischemic Encephalopathy, in December 2026.","as_of":"2026-04-13","source":"clinicaltrials","source_ref":"NCT05778188","source_url":"https://clinicaltrials.gov/study/NCT05778188","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-77ed5667-6526-42d1-b050-58c647609919"},{"id":"0c48e8fe-786e-46bb-bd7b-310b6e8d8742","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Red de Terapia Celular","ticker":null,"asset":"Mesenchymal stem cells (MSC)","indication":"Lupus Nephritis","summary":"As of 24 July 2025, Red de Terapia Celular estimated primary completion of a Phase 2 trial in Lupus Nephritis, in December 2026.","as_of":"2025-07-24","source":"clinicaltrials","source_ref":"NCT03673748","source_url":"https://clinicaltrials.gov/study/NCT03673748","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0c48e8fe-786e-46bb-bd7b-310b6e8d8742"},{"id":"e0ff6b3c-086b-40fd-af9d-420e39fd33d8","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Regenerative Ocular Immunobiologics LLC","ticker":null,"asset":"d-MAPPS","indication":"oGHVD","summary":"As of 8 July 2026, Regenerative Ocular Immunobiologics estimated primary completion of a Phase 2 trial in oGHVD, in December 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT06852768","source_url":"https://clinicaltrials.gov/study/NCT06852768","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e0ff6b3c-086b-40fd-af9d-420e39fd33d8"},{"id":"28156148-f736-4377-b99d-83cf4daba384","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"RemeGen Co., Ltd.","ticker":null,"asset":"Disitamab Vedotin Injection","indication":"Gastric Cancer","summary":"As of 3 April 2024, RemeGen Co. estimated primary completion of a Phase 3 trial in Gastric Cancer, in December 2026.","as_of":"2024-04-03","source":"clinicaltrials","source_ref":"NCT06221748","source_url":"https://clinicaltrials.gov/study/NCT06221748","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-28156148-f736-4377-b99d-83cf4daba384"},{"id":"b65d27af-8b05-4c16-8ffe-d1a6ab9c351a","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Resolve Therapeutics","ticker":null,"asset":"RSLV-132","indication":"Primary Sjögren Syndrome","summary":"As of 18 July 2025, Resolve Therapeutics estimated primary completion of a Phase 2 trial in Primary Sjögren Syndrome, on 1 December 2026.","as_of":"2025-07-18","source":"clinicaltrials","source_ref":"NCT06440525","source_url":"https://clinicaltrials.gov/study/NCT06440525","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b65d27af-8b05-4c16-8ffe-d1a6ab9c351a"},{"id":"3295f158-0f76-4b70-8bca-73ac2836a45d","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Rottapharm Biotech","ticker":null,"asset":"CR6086","indication":"Refractory Metastatic Colorectal Cancer","summary":"As of 29 October 2025, Rottapharm Biotech estimated primary completion of a Phase 2 trial in Refractory Metastatic Colorectal Cancer, in December 2026.","as_of":"2025-10-29","source":"clinicaltrials","source_ref":"NCT05205330","source_url":"https://clinicaltrials.gov/study/NCT05205330","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3295f158-0f76-4b70-8bca-73ac2836a45d"},{"id":"bf8eba2a-163c-4021-848b-e797c7275a31","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Ryvu Therapeutics SA","ticker":null,"asset":"MEN1703","indication":"Non-Hodgkin Lymphoma, B-cell","summary":"As of 29 September 2025, Ryvu Therapeutics SA estimated primary completion of a Phase 2 trial in Non-Hodgkin Lymphoma, B-cell, in December 2026.","as_of":"2025-09-29","source":"clinicaltrials","source_ref":"NCT06534437","source_url":"https://clinicaltrials.gov/study/NCT06534437","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bf8eba2a-163c-4021-848b-e797c7275a31"},{"id":"b9ba0c88-8916-4ea3-9334-87ebb555905f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"SERDA bv","ticker":null,"asset":"SN514-066b","indication":"Burn Injury","summary":"As of 7 August 2026, SERDA bv estimated primary completion of a Phase 2 trial in Burn Injury, in December 2026.","as_of":"2026-08-07","source":"clinicaltrials","source_ref":"NCT06628037","source_url":"https://clinicaltrials.gov/study/NCT06628037","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b9ba0c88-8916-4ea3-9334-87ebb555905f"},{"id":"40f845a6-047b-4680-b8bd-184434869848","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"Pandemic flu H5 HA mRNA SD2 vaccine","indication":"Pandemic Influenza Immunization","summary":"As of 16 January 2026, Sanofi estimated primary completion of a Phase 2 trial in Pandemic Influenza Immunization, on 1 December 2026.","as_of":"2026-01-16","source":"clinicaltrials","source_ref":"NCT06907511","source_url":"https://clinicaltrials.gov/study/NCT06907511","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-40f845a6-047b-4680-b8bd-184434869848"},{"id":"58122035-ccf0-4091-ad25-81227301538f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"Itepekimab (SAR440340)","indication":"Chronic Obstructive Pulmonary Disease","summary":"As of 18 May 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Obstructive Pulmonary Disease, on 1 December 2026.","as_of":"2026-05-18","source":"clinicaltrials","source_ref":"NCT06208306","source_url":"https://clinicaltrials.gov/study/NCT06208306","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-58122035-ccf0-4091-ad25-81227301538f"},{"id":"732b5197-eadb-47a2-9e1a-c828db470c69","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Sanofi Pasteur, a Sanofi Company","ticker":null,"asset":"PCV21","indication":"Pneumococcal Infections","summary":"As of 6 October 2025, Sanofi Pasteur, a Sanofi estimated primary completion of a Phase 3 trial in Pneumococcal Infections, on 1 December 2026.","as_of":"2025-10-06","source":"clinicaltrials","source_ref":"NCT06838000","source_url":"https://clinicaltrials.gov/study/NCT06838000","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-732b5197-eadb-47a2-9e1a-c828db470c69"},{"id":"3e79bb92-2203-4c7d-950d-6a74318d12e2","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sapience Therapeutics","ticker":null,"asset":"ST101","indication":"Glioblastoma","summary":"As of 9 February 2026, Sapience Therapeutics estimated primary completion of a Phase 2 trial in glioblastoma, in December 2026.","as_of":"2026-02-09","source":"clinicaltrials","source_ref":"NCT04478279","source_url":"https://clinicaltrials.gov/study/NCT04478279","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3e79bb92-2203-4c7d-950d-6a74318d12e2"},{"id":"46123a3b-3ef0-4330-988f-dee0eac3d44c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"asset":"HRS-7085","indication":"Adult Patients With Moderately to Severely Active Ulcerative Colitis","summary":"As of 2 June 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in December 2026.","as_of":"2026-06-02","source":"clinicaltrials","source_ref":"NCT07229950","source_url":"https://clinicaltrials.gov/study/NCT07229950","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-46123a3b-3ef0-4330-988f-dee0eac3d44c"},{"id":"089acecf-28d3-48cf-9b58-e2b906f77c51","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"asset":"HRS-7058 + SHR-1316","indication":"Advanced Malignant Tumour","summary":"As of 26 January 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Advanced Malignant Tumour, in December 2026.","as_of":"2026-01-26","source":"clinicaltrials","source_ref":"NCT06915142","source_url":"https://clinicaltrials.gov/study/NCT06915142","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-089acecf-28d3-48cf-9b58-e2b906f77c51"},{"id":"8313d0e5-f3d6-47b2-ad9f-0270adb6411d","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"asset":"HRS-8080 Tablet","indication":"Locally Advanced Breast Cancer","summary":"As of 26 January 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 3 trial in Locally Advanced Breast Cancer, in December 2026.","as_of":"2026-01-26","source":"clinicaltrials","source_ref":"NCT07024173","source_url":"https://clinicaltrials.gov/study/NCT07024173","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8313d0e5-f3d6-47b2-ad9f-0270adb6411d"},{"id":"fbc6dd34-f920-4eba-98b1-ec8ac750d3a6","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Shandong Suncadia Medicine Co., Ltd.","ticker":null,"asset":"HRS-7535 tablet","indication":"Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fracti...","summary":"As of 29 December 2025, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in December 2026.","as_of":"2025-12-29","source":"clinicaltrials","source_ref":"NCT06820099","source_url":"https://clinicaltrials.gov/study/NCT06820099","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fbc6dd34-f920-4eba-98b1-ec8ac750d3a6"},{"id":"4cc058b3-93e9-4fb5-90d4-8c2ee9241dce","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Shanghai BDgene Co., Ltd.","ticker":null,"asset":"BD111 Injection (investigational new drug)","indication":"Herpes Simplex Virus Type I Stromal Keratitis","summary":"As of 18 May 2025, Shanghai BDgene Co. estimated primary completion of a Phase 2 trial in Herpes Simplex Virus Type I Stromal Keratitis, in December 2026.","as_of":"2025-05-18","source":"clinicaltrials","source_ref":"NCT06474442","source_url":"https://clinicaltrials.gov/study/NCT06474442","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4cc058b3-93e9-4fb5-90d4-8c2ee9241dce"},{"id":"827b6088-db59-40c5-9b9f-010d16ef3083","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","ticker":null,"asset":"FCN-338 + Azacitidine","indication":"Safety","summary":"As of 5 March 2025, Shanghai Fosun Pharmaceutical Industrial Development Co. estimated primary completion of a Phase 2 trial in safety, on 1 December 2026.","as_of":"2025-03-05","source":"clinicaltrials","source_ref":"NCT06858618","source_url":"https://clinicaltrials.gov/study/NCT06858618","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-827b6088-db59-40c5-9b9f-010d16ef3083"},{"id":"a7a9834a-fdb8-4cb5-b5d9-485cdf8f5573","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"asset":"SPH4336 Tablets","indication":"Locally Advanced or Metastatic Breast Cancer","summary":"As of 14 January 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 3 trial in Locally Advanced or Metastatic Breast Cancer, on 1 December 2026.","as_of":"2026-01-14","source":"clinicaltrials","source_ref":"NCT05860465","source_url":"https://clinicaltrials.gov/study/NCT05860465","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a7a9834a-fdb8-4cb5-b5d9-485cdf8f5573"},{"id":"075cd82a-5835-46a1-b178-c49e1f7c3534","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Shanghai Vitalgen BioPharma Co., Ltd.","ticker":null,"asset":"VGR-R01","indication":"Bietti Crystalline Dystrophy","summary":"As of 24 December 2025, Shanghai Vitalgen BioPharma Co. estimated primary completion of a Phase 3 trial in Bietti Crystalline Dystrophy, on 1 December 2026.","as_of":"2025-12-24","source":"clinicaltrials","source_ref":"NCT06699108","source_url":"https://clinicaltrials.gov/study/NCT06699108","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-075cd82a-5835-46a1-b178-c49e1f7c3534"},{"id":"91a76d5b-7942-4602-a9c0-951c124c4a0b","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.","ticker":null,"asset":"YD0743","indication":"Sepsis","summary":"As of 17 February 2026, Shanghai Yidian Pharmaceutical Technology Development Co. estimated primary completion of a Phase 2 trial in sepsis, in December 2026.","as_of":"2026-02-17","source":"clinicaltrials","source_ref":"NCT07413094","source_url":"https://clinicaltrials.gov/study/NCT07413094","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-91a76d5b-7942-4602-a9c0-951c124c4a0b"},{"id":"d12b427f-09c2-4945-9376-a2849f17f3ca","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Cervical Cancer","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Cervical Cancer, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT05990803","source_url":"https://clinicaltrials.gov/study/NCT05990803","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d12b427f-09c2-4945-9376-a2849f17f3ca"},{"id":"a2cf32b5-b0ae-4ef0-9b4f-0dfe410216cf","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"SI-B003","indication":"Esophageal Cancer","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Esophageal Cancer, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT06008054","source_url":"https://clinicaltrials.gov/study/NCT06008054","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a2cf32b5-b0ae-4ef0-9b4f-0dfe410216cf"},{"id":"ce468367-d8d7-4335-8f53-5a17bf1ac7f7","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"GNC-035","indication":"Non-hodgkin's Lymphoma","summary":"As of 1 October 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-hodgkin's Lymphoma, in December 2026.","as_of":"2025-10-01","source":"clinicaltrials","source_ref":"NCT06066203","source_url":"https://clinicaltrials.gov/study/NCT06066203","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ce468367-d8d7-4335-8f53-5a17bf1ac7f7"},{"id":"f796d7ab-d48e-457d-b8aa-6cfe6973a2ef","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Head and Neck Squamous Cell Carcinoma","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Head and Neck Squamous Cell Carcinoma, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT06006169","source_url":"https://clinicaltrials.gov/study/NCT06006169","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f796d7ab-d48e-457d-b8aa-6cfe6973a2ef"},{"id":"9c3cc713-6f92-4f6c-8d79-becbf7a1d3ba","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Small Cell Lung Cancer","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Small Cell Lung Cancer, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT05924841","source_url":"https://clinicaltrials.gov/study/NCT05924841","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9c3cc713-6f92-4f6c-8d79-becbf7a1d3ba"},{"id":"906c4d8f-03d6-4b25-9e88-027a681a61fc","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Extensive-stage Small-cell Lung Cancer","summary":"As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Extensive-stage Small-cell Lung Cancer, in December 2026.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT06437509","source_url":"https://clinicaltrials.gov/study/NCT06437509","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-906c4d8f-03d6-4b25-9e88-027a681a61fc"},{"id":"203bd779-b149-41be-88bb-8189a5ba7b9b","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-M07D1","indication":"Gynecological Malignancies","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Gynecological Malignancies, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT06131450","source_url":"https://clinicaltrials.gov/study/NCT06131450","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-203bd779-b149-41be-88bb-8189a5ba7b9b"},{"id":"87459ee8-43d8-484d-a163-c2541451a2b4","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Gynecological Malignant Tumor","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Gynecological Malignant Tumor, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT05803018","source_url":"https://clinicaltrials.gov/study/NCT05803018","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-87459ee8-43d8-484d-a163-c2541451a2b4"},{"id":"6cd44428-a8d3-440a-9b45-2a8afce9a7ab","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"SI-B001","indication":"Non-small Cell Lung Cancer","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT05949606","source_url":"https://clinicaltrials.gov/study/NCT05949606","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6cd44428-a8d3-440a-9b45-2a8afce9a7ab"},{"id":"246d23f3-1ba0-454f-b926-d493208570d9","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Breast Cancer","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Breast Cancer, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT06042894","source_url":"https://clinicaltrials.gov/study/NCT06042894","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-246d23f3-1ba0-454f-b926-d493208570d9"},{"id":"0ac913e5-0634-4a22-82aa-ba0bbd38ff38","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-M07D1","indication":"Her2-positive/Low-expression Urinary and Digestive Tract Tumors","summary":"As of 8 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Her2-positive/Low-expression Urinary and Digestive Tract Tumors, in December 2026.","as_of":"2026-04-08","source":"clinicaltrials","source_ref":"NCT06031584","source_url":"https://clinicaltrials.gov/study/NCT06031584","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0ac913e5-0634-4a22-82aa-ba0bbd38ff38"},{"id":"2da8486c-cead-4643-8875-bd50bb42b2ac","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Non-small Cell Lung Cancer","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT05956587","source_url":"https://clinicaltrials.gov/study/NCT05956587","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2da8486c-cead-4643-8875-bd50bb42b2ac"},{"id":"6e3ec064-cd59-49c9-96ab-dc8766c9107f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Urothelial Carcinoma","summary":"As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Urothelial Carcinoma, in December 2026.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT06405425","source_url":"https://clinicaltrials.gov/study/NCT06405425","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6e3ec064-cd59-49c9-96ab-dc8766c9107f"},{"id":"3071ebdb-3ad1-4c20-a3de-a009e143528b","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Small Cell Lung Cancer","summary":"As of 17 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Small Cell Lung Cancer, in December 2026.","as_of":"2026-04-17","source":"clinicaltrials","source_ref":"NCT06500026","source_url":"https://clinicaltrials.gov/study/NCT06500026","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3071ebdb-3ad1-4c20-a3de-a009e143528b"},{"id":"a257343b-b53a-402d-865c-4a6c19cceefe","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"GNC-038","indication":"Non-hodgkin's Lymphoma","summary":"As of 29 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-hodgkin's Lymphoma, in December 2026.","as_of":"2025-09-29","source":"clinicaltrials","source_ref":"NCT05623982","source_url":"https://clinicaltrials.gov/study/NCT05623982","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a257343b-b53a-402d-865c-4a6c19cceefe"},{"id":"63678e71-efdb-449f-b91c-5a9f48b930b1","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Triple-negative Breast Cancer","summary":"As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Triple-negative Breast Cancer, in December 2026.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT06471205","source_url":"https://clinicaltrials.gov/study/NCT06471205","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-63678e71-efdb-449f-b91c-5a9f48b930b1"},{"id":"366f27ee-d10a-4c38-b405-d69e41d8be97","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-M07D1","indication":"Non-small Cell Lung Cancer","summary":"As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT06114511","source_url":"https://clinicaltrials.gov/study/NCT06114511","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-366f27ee-d10a-4c38-b405-d69e41d8be97"},{"id":"145c70ef-f9c7-4c67-af8d-ae2ff3822ac9","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Urothelial Carcinoma","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Urothelial Carcinoma, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT05965856","source_url":"https://clinicaltrials.gov/study/NCT05965856","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-145c70ef-f9c7-4c67-af8d-ae2ff3822ac9"},{"id":"6168e15a-7fe0-4cea-aa15-0c5d482bd7b5","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"SI-B001","indication":"Squamous Cell Carcinoma of Head and Neck","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Squamous Cell Carcinoma of Head and Neck, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT05668858","source_url":"https://clinicaltrials.gov/study/NCT05668858","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6168e15a-7fe0-4cea-aa15-0c5d482bd7b5"},{"id":"aa402d1d-2a38-44f1-beea-cad471461928","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Urinary System Tumor","summary":"As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Urinary System Tumor, in December 2026.","as_of":"2025-09-26","source":"clinicaltrials","source_ref":"NCT05785039","source_url":"https://clinicaltrials.gov/study/NCT05785039","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-aa402d1d-2a38-44f1-beea-cad471461928"},{"id":"7af7884c-c440-4008-838b-4108e1b7313f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Baili Pharmaceutical Co., Ltd.","ticker":null,"asset":"BL-B01D1","indication":"Non-small Cell Lung Cancer","summary":"As of 17 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-small Cell Lung Cancer, in December 2026.","as_of":"2026-04-17","source":"clinicaltrials","source_ref":"NCT06382129","source_url":"https://clinicaltrials.gov/study/NCT06382129","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7af7884c-c440-4008-838b-4108e1b7313f"},{"id":"a52e621c-70ac-4508-96af-765acff83bbe","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Huiyu Pharmaceutical Co., Ltd","ticker":null,"asset":"Test product: HYP-2090PTSA","indication":"Safety","summary":"As of 29 January 2026, Sichuan Huiyu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in safety, in December 2026.","as_of":"2026-01-29","source":"clinicaltrials","source_ref":"NCT06243354","source_url":"https://clinicaltrials.gov/study/NCT06243354","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a52e621c-70ac-4508-96af-765acff83bbe"},{"id":"44c371ca-3536-44e5-b358-ddf8394df6dd","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":null,"asset":"SKB264","indication":"Non-Small Cell Lung Cancer","summary":"As of 8 July 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, in December 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT06711900","source_url":"https://clinicaltrials.gov/study/NCT06711900","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-44c371ca-3536-44e5-b358-ddf8394df6dd"},{"id":"c8a29cc8-0e31-4d7a-ab95-3d7521e6e1be","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sinew Pharma Inc.","ticker":null,"asset":"TYNADOTE","indication":"Hepatitis","summary":"As of 10 January 2024, Sinew Pharma estimated primary completion of a Phase 2 trial in hepatitis, in December 2026.","as_of":"2024-01-10","source":"clinicaltrials","source_ref":"NCT05557448","source_url":"https://clinicaltrials.gov/study/NCT05557448","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c8a29cc8-0e31-4d7a-ab95-3d7521e6e1be"},{"id":"acffb208-8875-40ff-851a-5a26eb0976ac","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Songqi Gao","ticker":null,"asset":"MT218 injection","indication":"MRI Scan","summary":"As of 19 December 2025, Songqi Gao estimated primary completion of a Phase 2 trial in MRI Scan, in December 2026.","as_of":"2025-12-19","source":"clinicaltrials","source_ref":"NCT06262139","source_url":"https://clinicaltrials.gov/study/NCT06262139","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-acffb208-8875-40ff-851a-5a26eb0976ac"},{"id":"9497f0e4-8b67-4684-9d00-b5cb8631051a","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sound Pharmaceuticals, Incorporated","ticker":null,"asset":"Ebselen","indication":"Hearing Loss","summary":"As of 26 June 2026, Sound Pharmaceuticals, Incorporated estimated primary completion of a Phase 2 trial in Hearing Loss, in December 2026.","as_of":"2026-06-26","source":"clinicaltrials","source_ref":"NCT06340633","source_url":"https://clinicaltrials.gov/study/NCT06340633","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9497f0e4-8b67-4684-9d00-b5cb8631051a"},{"id":"20ceb622-dad2-4158-8925-813569ab8271","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sound Pharmaceuticals, Incorporated","ticker":null,"asset":"Ebselen","indication":"Meniere's Disease","summary":"As of 13 July 2026, Sound Pharmaceuticals, Incorporated estimated primary completion of a Phase 3 trial in Meniere's Disease, in December 2026.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT06859788","source_url":"https://clinicaltrials.gov/study/NCT06859788","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-20ceb622-dad2-4158-8925-813569ab8271"},{"id":"e605628e-76e2-4be7-8be1-ecd8b9591104","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Stemline Therapeutics, Inc.","ticker":null,"asset":"Elacestrant","indication":"Breast Neoplasms","summary":"As of 6 August 2026, Stemline Therapeutics estimated primary completion of a Phase 2 trial in Breast Neoplasms, in December 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT05386108","source_url":"https://clinicaltrials.gov/study/NCT05386108","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e605628e-76e2-4be7-8be1-ecd8b9591104"},{"id":"3c2aad7a-d5b3-4846-baac-19327048b4bf","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Step Pharma, SAS","ticker":null,"asset":"STP938","indication":"Lymphoma, B-Cell","summary":"As of 16 June 2026, Step Pharma estimated primary completion of a Phase 2 trial in Lymphoma, B-Cell, in December 2026.","as_of":"2026-06-16","source":"clinicaltrials","source_ref":"NCT05463263","source_url":"https://clinicaltrials.gov/study/NCT05463263","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3c2aad7a-d5b3-4846-baac-19327048b4bf"},{"id":"667a527d-3fe9-4111-bc1b-6de813e5b4af","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sunhawk Vision Biotech, Inc.","ticker":null,"asset":"SHJ002","indication":"Myopia, Progressive","summary":"As of 23 January 2026, Sunhawk Vision Biotech estimated primary completion of a Phase 2 trial in Myopia, Progressive, in December 2026.","as_of":"2026-01-23","source":"clinicaltrials","source_ref":"NCT06579287","source_url":"https://clinicaltrials.gov/study/NCT06579287","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-667a527d-3fe9-4111-bc1b-6de813e5b4af"},{"id":"b22fefc3-444d-4061-910a-f0bdd8eedf4b","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Sunshine Lake Pharma Co., Ltd.","ticker":null,"asset":"HEC585 dose A","indication":"Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibros...","summary":"As of 24 April 2026, Sunshine Lake Pharma Co. estimated primary completion of a Phase 2 trial in December 2026.","as_of":"2026-04-24","source":"clinicaltrials","source_ref":"NCT05139719","source_url":"https://clinicaltrials.gov/study/NCT05139719","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b22fefc3-444d-4061-910a-f0bdd8eedf4b"},{"id":"36f934a5-1408-4da6-ac59-fd8e3dbae350","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Suven Life Sciences Limited","ticker":null,"asset":"Masupirdine 50 mg","indication":"Agitation","summary":"As of 12 January 2026, Suven Life Sciences estimated primary completion of a Phase 3 trial in agitation, in December 2026.","as_of":"2026-01-12","source":"clinicaltrials","source_ref":"NCT05397639","source_url":"https://clinicaltrials.gov/study/NCT05397639","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-36f934a5-1408-4da6-ac59-fd8e3dbae350"},{"id":"b4397911-cef1-4cd7-90dd-c93ffd39373f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"asset":"SHR-A2009 monotherapy","indication":"Non-small Cell Lung Cancer","summary":"As of 19 March 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 3 trial in Non-small Cell Lung Cancer, in December 2026.","as_of":"2026-03-19","source":"clinicaltrials","source_ref":"NCT06671379","source_url":"https://clinicaltrials.gov/study/NCT06671379","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b4397911-cef1-4cd7-90dd-c93ffd39373f"},{"id":"a6801888-edd2-4bdd-815a-1b99af7260b3","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"SynDevRx, Inc.","ticker":null,"asset":"Evexomostat","indication":"HR+/HER2-negative Breast Cancer","summary":"As of 22 April 2026, SynDevRx estimated primary completion of a Phase 2 trial in HR+/HER2-negative Breast Cancer, in December 2026.","as_of":"2026-04-22","source":"clinicaltrials","source_ref":"NCT05455619","source_url":"https://clinicaltrials.gov/study/NCT05455619","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a6801888-edd2-4bdd-815a-1b99af7260b3"},{"id":"1d76e235-fdc5-4ec1-b3e0-7bdf79dc5b4e","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"SynerGene Therapeutics, Inc.","ticker":null,"asset":"SGT-53","indication":"Metastatic Pancreatic Cancer","summary":"As of 30 May 2025, SynerGene Therapeutics estimated primary completion of a Phase 2 trial in Metastatic Pancreatic Cancer, in December 2026.","as_of":"2025-05-30","source":"clinicaltrials","source_ref":"NCT02340117","source_url":"https://clinicaltrials.gov/study/NCT02340117","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1d76e235-fdc5-4ec1-b3e0-7bdf79dc5b4e"},{"id":"0d5b59d9-a036-4a5b-a780-11dc149b3f78","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"TBF Genie Tissulaire","ticker":null,"asset":"SclerFIX-IP","indication":"Osteoarthritis Hand","summary":"As of 30 September 2025, TBF Genie Tissulaire estimated primary completion of a Phase 2 trial in Osteoarthritis Hand, in December 2026.","as_of":"2025-09-30","source":"clinicaltrials","source_ref":"NCT06038331","source_url":"https://clinicaltrials.gov/study/NCT06038331","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0d5b59d9-a036-4a5b-a780-11dc149b3f78"},{"id":"983c7e56-e185-45d0-b02f-65030462840a","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"TR Therapeutics","ticker":null,"asset":"TR987 0.1% gel + Standard of Care","indication":"Venous Leg Ulcer","summary":"As of 2 April 2025, TR Therapeutics estimated primary completion of a Phase 3 trial in Venous Leg Ulcer, in December 2026.","as_of":"2025-04-02","source":"clinicaltrials","source_ref":"NCT06707103","source_url":"https://clinicaltrials.gov/study/NCT06707103","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-983c7e56-e185-45d0-b02f-65030462840a"},{"id":"7a809f3b-0ae8-4ad6-adcb-1b874b2e5df1","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"TVAX Biomedical","ticker":null,"asset":"TVI-Brain-1","indication":"Glioblastoma Multiforme of Brain","summary":"As of 1 July 2025, TVAX Biomedical estimated primary completion of a Phase 3 trial in Glioblastoma Multiforme of Brain, in December 2026.","as_of":"2025-07-01","source":"clinicaltrials","source_ref":"NCT05685004","source_url":"https://clinicaltrials.gov/study/NCT05685004","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7a809f3b-0ae8-4ad6-adcb-1b874b2e5df1"},{"id":"c0bfc9f8-1b31-44e0-8b3e-4e53d2f5964c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Taiho Oncology, Inc.","ticker":null,"asset":"TAS-120","indication":"Advanced Cholangiocarcinoma","summary":"As of 28 July 2026, Taiho Oncology estimated primary completion of a Phase 2 trial in Advanced Cholangiocarcinoma, in December 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT05727176","source_url":"https://clinicaltrials.gov/study/NCT05727176","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c0bfc9f8-1b31-44e0-8b3e-4e53d2f5964c"},{"id":"82d4995c-94d2-49c5-882b-ac7466e2c713","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Tasly Pharmaceutical Group Co., Ltd","ticker":null,"asset":"Jitongning tablets","indication":"Ankylosing Spondylitis","summary":"As of 21 November 2024, Tasly Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Ankylosing Spondylitis, on 1 December 2026.","as_of":"2024-11-21","source":"clinicaltrials","source_ref":"NCT06000956","source_url":"https://clinicaltrials.gov/study/NCT06000956","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-82d4995c-94d2-49c5-882b-ac7466e2c713"},{"id":"2b31f0af-37d5-480e-b912-062e2d0f81c6","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Tasly Pharmaceuticals, Inc.","ticker":null,"asset":"T89 capsule","indication":"Chronic Stable Angina Pectoris","summary":"As of 9 April 2025, Tasly Pharmaceuticals estimated primary completion of a Phase 3 trial in Chronic Stable Angina Pectoris, in December 2026.","as_of":"2025-04-09","source":"clinicaltrials","source_ref":"NCT03789552","source_url":"https://clinicaltrials.gov/study/NCT03789552","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2b31f0af-37d5-480e-b912-062e2d0f81c6"},{"id":"2ed0f8a8-6aad-4a79-aec6-20aa5fa7de4e","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Technophage, SA","ticker":null,"asset":"Eletriptan HBr 40 mg","indication":"Acute Spinal Cord Injury (SCI)","summary":"As of 9 September 2025, Technophage, SA estimated primary completion of a Phase 2 trial in Acute Spinal Cord Injury (SCI), in December 2026.","as_of":"2025-09-09","source":"clinicaltrials","source_ref":"NCT06677229","source_url":"https://clinicaltrials.gov/study/NCT06677229","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2ed0f8a8-6aad-4a79-aec6-20aa5fa7de4e"},{"id":"7d00f5d7-c40b-4b96-9909-106940ce81e2","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Theralase® Technologies Inc.","ticker":null,"asset":"Ruvidar® (TLD-1433) bladder infusion and PDT","indication":"Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG","summary":"As of 24 November 2025, Theralase® Technologies estimated primary completion of a Phase 2 trial in Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG, in December 2026.","as_of":"2025-11-24","source":"clinicaltrials","source_ref":"NCT03945162","source_url":"https://clinicaltrials.gov/study/NCT03945162","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7d00f5d7-c40b-4b96-9909-106940ce81e2"},{"id":"575da50a-6e6d-4df3-9155-c6a88320a7c6","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"TiumBio Co., Ltd.","ticker":null,"asset":"TU2218 + KEYTRUDA® (Pembrolizumab)","indication":"Solid Tumor","summary":"As of 30 March 2025, TiumBio Co. estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026.","as_of":"2025-03-30","source":"clinicaltrials","source_ref":"NCT05784688","source_url":"https://clinicaltrials.gov/study/NCT05784688","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-575da50a-6e6d-4df3-9155-c6a88320a7c6"},{"id":"e9661c09-bd27-4610-b4ba-27e4f9e76bd3","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"TolerogenixX GmbH","ticker":null,"asset":"MIC","indication":"Kidney Transplantation","summary":"As of 11 April 2025, TolerogenixX estimated primary completion of a Phase 2 trial in Kidney Transplantation, in December 2026.","as_of":"2025-04-11","source":"clinicaltrials","source_ref":"NCT05365672","source_url":"https://clinicaltrials.gov/study/NCT05365672","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e9661c09-bd27-4610-b4ba-27e4f9e76bd3"},{"id":"a90f826d-ea98-43f9-993d-5d41cdedb273","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Toll Biotech Co. Ltd. (Beijing)","ticker":null,"asset":"Group 1: TollB-001 100mg qd po; Group 2: TollB-001 200mg qd po; Group 3: TollB-001400mg qd po","indication":"Rheumatoid Arthritis (RA)","summary":"As of 17 February 2026, Toll Biotech Co. estimated primary completion of a Phase 2 trial in Rheumatoid Arthritis (RA), in December 2026.","as_of":"2026-02-17","source":"clinicaltrials","source_ref":"NCT07408024","source_url":"https://clinicaltrials.gov/study/NCT07408024","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a90f826d-ea98-43f9-993d-5d41cdedb273"},{"id":"5596eae5-e821-4f97-a56e-98d9966ffd3d","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"TransThera Sciences (Nanjing), Inc.","ticker":null,"asset":"Tinengotinib 8 mg","indication":"Cholangiocarcinoma","summary":"As of 6 July 2026, TransThera Sciences (Nanjing) estimated primary completion of a Phase 3 trial in cholangiocarcinoma, in December 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT05948475","source_url":"https://clinicaltrials.gov/study/NCT05948475","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5596eae5-e821-4f97-a56e-98d9966ffd3d"},{"id":"e9a5053e-3da6-4d67-84cc-97d4259e63cd","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Traws Pharma, Inc.","ticker":null,"asset":"TRX-100","indication":"Influenza","summary":"As of 27 March 2026, Traws Pharma estimated primary completion of a Phase 2 trial in influenza, in December 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT07371650","source_url":"https://clinicaltrials.gov/study/NCT07371650","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e9a5053e-3da6-4d67-84cc-97d4259e63cd"},{"id":"24dfea8c-4974-48b1-b252-e60a4b07c0d6","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"United Therapeutics","ticker":null,"asset":"Ralinepag","indication":"PAH","summary":"As of 20 February 2026, United Therapeutics estimated primary completion of a Phase 3 trial in pAH, in December 2026.","as_of":"2026-02-20","source":"clinicaltrials","source_ref":"NCT03683186","source_url":"https://clinicaltrials.gov/study/NCT03683186","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-24dfea8c-4974-48b1-b252-e60a4b07c0d6"},{"id":"b70d7c5f-f656-489a-a21d-cdf7529dfe05","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"VIS, Inc.","ticker":null,"asset":"Optimal laser keratoplasty","indication":"Presbyopia","summary":"As of 5 September 2024, VIS estimated primary completion of a Phase 3 trial in presbyopia, in December 2026.","as_of":"2024-09-05","source":"clinicaltrials","source_ref":"NCT06487897","source_url":"https://clinicaltrials.gov/study/NCT06487897","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b70d7c5f-f656-489a-a21d-cdf7529dfe05"},{"id":"3628b567-6bdf-4d64-a166-572eab3682f7","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Vanda Pharmaceuticals","ticker":null,"asset":"VQW-765","indication":"Social Anxiety Disorder (SAD)","summary":"As of 20 July 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 3 trial in Social Anxiety Disorder (SAD), in December 2026.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT07221578","source_url":"https://clinicaltrials.gov/study/NCT07221578","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3628b567-6bdf-4d64-a166-572eab3682f7"},{"id":"870fd06b-c7f7-44a9-9ad8-803b67af0223","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"day","confidence":"estimated","company":"Vanda Pharmaceuticals","ticker":null,"asset":"Tradipitant","indication":"Nausea and Vomiting","summary":"As of 20 April 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 3 trial in Nausea and Vomiting, on 1 December 2026.","as_of":"2026-04-20","source":"clinicaltrials","source_ref":"NCT07446439","source_url":"https://clinicaltrials.gov/study/NCT07446439","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-870fd06b-c7f7-44a9-9ad8-803b67af0223"},{"id":"0363d244-410e-4064-8a4b-8cbdb6fb2ab7","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Vantive Health LLC","ticker":null,"asset":"Prismocitrate 18","indication":"Regional Citrate Anticoagulation (RCA)","summary":"As of 27 July 2026, Vantive Health estimated primary completion of a Phase 3 trial in Regional Citrate Anticoagulation (RCA), in December 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT05399537","source_url":"https://clinicaltrials.gov/study/NCT05399537","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0363d244-410e-4064-8a4b-8cbdb6fb2ab7"},{"id":"9b277f47-13ed-4de9-b438-aef0cc609af4","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"VapeAway","ticker":null,"asset":"VapeAway filter system","indication":"Addiction Nicotine","summary":"As of 7 January 2026, VapeAway estimated primary completion of a Phase 2 trial in Addiction Nicotine, in December 2026.","as_of":"2026-01-07","source":"clinicaltrials","source_ref":"NCT07322432","source_url":"https://clinicaltrials.gov/study/NCT07322432","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b277f47-13ed-4de9-b438-aef0cc609af4"},{"id":"04a1c851-b5d5-435d-b940-9d4750f5fe1e","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Veradermics, Inc.","ticker":null,"asset":"VDPHL01","indication":"Androgenetic Alopecia","summary":"As of 12 February 2026, Veradermics estimated primary completion of a Phase 3 trial in Androgenetic Alopecia, in December 2026.","as_of":"2026-02-12","source":"clinicaltrials","source_ref":"NCT06972264","source_url":"https://clinicaltrials.gov/study/NCT06972264","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-04a1c851-b5d5-435d-b940-9d4750f5fe1e"},{"id":"715aaeaf-2806-40e9-8209-fa05fc43d0b0","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Vergent Bioscience, Inc.","ticker":null,"asset":"Abenacianine","indication":"Lung Cancer","summary":"As of 29 May 2026, Vergent Bioscience estimated primary completion of a Phase 3 trial in Lung Cancer, in December 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT07499674","source_url":"https://clinicaltrials.gov/study/NCT07499674","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-715aaeaf-2806-40e9-8209-fa05fc43d0b0"},{"id":"59e84151-3ddc-4792-8f83-2d0241fc7713","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA","ticker":null,"asset":"Ensifentrine","indication":"COPD","summary":"As of 13 May 2026, Verona Pharma estimated primary completion of a Phase 2 trial in cOPD, in December 2026.","as_of":"2026-05-13","source":"clinicaltrials","source_ref":"NCT05270525","source_url":"https://clinicaltrials.gov/study/NCT05270525","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-59e84151-3ddc-4792-8f83-2d0241fc7713"},{"id":"1eb9723e-7c59-4cec-b2a2-70c8b8b4042f","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Vir Biotechnology, Inc.","ticker":null,"asset":"Tobevibart","indication":"Viral Hepatitis","summary":"As of 13 July 2026, Vir Biotechnology estimated primary completion of a Phase 3 trial in Viral Hepatitis, in December 2026.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT07128550","source_url":"https://clinicaltrials.gov/study/NCT07128550","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1eb9723e-7c59-4cec-b2a2-70c8b8b4042f"},{"id":"2c8e34f9-8484-481b-a52e-050809f59afb","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Wuxi Cellular Biopharmaceutical Group Ltd.","ticker":null,"asset":"Mesenchymal Stem Cells","indication":"Knee Osteoarthritis","summary":"As of 16 July 2025, Wuxi Cellular Biopharmaceutical Group estimated primary completion of a Phase 3 trial in Knee Osteoarthritis, in December 2026.","as_of":"2025-07-16","source":"clinicaltrials","source_ref":"NCT06570291","source_url":"https://clinicaltrials.gov/study/NCT06570291","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2c8e34f9-8484-481b-a52e-050809f59afb"},{"id":"42d10add-f58a-4942-b009-df17a79b2cbb","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Xenothera SAS","ticker":null,"asset":"XON7","indication":"Advanced Solid Tumor","summary":"As of 22 June 2025, Xenothera estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in December 2026.","as_of":"2025-06-22","source":"clinicaltrials","source_ref":"NCT06154291","source_url":"https://clinicaltrials.gov/study/NCT06154291","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-42d10add-f58a-4942-b009-df17a79b2cbb"},{"id":"7d35cb09-7328-4dd2-8483-f40eb4c6ae5c","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Zenith Epigenetics","ticker":null,"asset":"ZEN003694","indication":"Metastatic Castration-Resistant Prostate Cancer","summary":"As of 8 May 2026, Zenith Epigenetics estimated primary completion of a Phase 2 trial in Metastatic Castration-Resistant Prostate Cancer, in December 2026.","as_of":"2026-05-08","source":"clinicaltrials","source_ref":"NCT04986423","source_url":"https://clinicaltrials.gov/study/NCT04986423","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7d35cb09-7328-4dd2-8483-f40eb4c6ae5c"},{"id":"1856f9f0-b25f-49cd-9aa8-6462b8ff1fce","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Zhejiang Haichang Biotech Co., Ltd.","ticker":null,"asset":"WGI-0301 at MTD/RP2D dose IV infusion, QW","indication":"Advanced Hepatocellular Carcinoma (HCC)","summary":"As of 19 March 2026, Zhejiang Haichang Biotech Co. estimated primary completion of a Phase 2 trial in Advanced Hepatocellular Carcinoma (HCC), in December 2026.","as_of":"2026-03-19","source":"clinicaltrials","source_ref":"NCT06309485","source_url":"https://clinicaltrials.gov/study/NCT06309485","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1856f9f0-b25f-49cd-9aa8-6462b8ff1fce"},{"id":"31a11610-fbdc-43b1-bc43-28d6674b1435","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"Zucara Therapeutics Inc.","ticker":null,"asset":"ZT-01, 7 mg","indication":"Type 1 Diabetes Mellitus With Hypoglycemia","summary":"As of 29 April 2026, Zucara Therapeutics estimated primary completion of a Phase 2 trial in Type 1 Diabetes Mellitus With Hypoglycemia, in December 2026.","as_of":"2026-04-29","source":"clinicaltrials","source_ref":"NCT05762107","source_url":"https://clinicaltrials.gov/study/NCT05762107","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-31a11610-fbdc-43b1-bc43-28d6674b1435"},{"id":"f092bc88-1178-4f1b-83f5-a787f87a98ce","lane":"clinical","event_type":"primary-completion","date":"2026-12-01","date_precision":"month","confidence":"estimated","company":"jCyte, Inc","ticker":null,"asset":"human retinal progenitor cells","indication":"Retinitis Pigmentosa","summary":"As of 30 July 2026, jCyte estimated primary completion of a Phase 2 trial in Retinitis Pigmentosa, in December 2026.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT06912633","source_url":"https://clinicaltrials.gov/study/NCT06912633","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f092bc88-1178-4f1b-83f5-a787f87a98ce"},{"id":"789986e5-5406-4408-b1f8-98f8ca7ad8c2","lane":"clinical","event_type":"primary-completion","date":"2026-12-02","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"PF-06821497","indication":"Metastatic Castration-Resistant Prostate Cancer","summary":"As of 29 July 2026, Pfizer estimated primary completion of a Phase 3 trial in Metastatic Castration-Resistant Prostate Cancer, on 2 December 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT06629779","source_url":"https://clinicaltrials.gov/study/NCT06629779","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-789986e5-5406-4408-b1f8-98f8ca7ad8c2"},{"id":"1084d8fc-cd17-4dbe-b57c-54034625fe72","lane":"clinical","event_type":"primary-completion","date":"2026-12-02","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"Ritlecitinib higher dose","indication":"Severe Alopecia Areata","summary":"As of 17 June 2026, Pfizer estimated primary completion of a Phase 3 trial in Severe Alopecia Areata, on 2 December 2026.","as_of":"2026-06-17","source":"clinicaltrials","source_ref":"NCT07029711","source_url":"https://clinicaltrials.gov/study/NCT07029711","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1084d8fc-cd17-4dbe-b57c-54034625fe72"},{"id":"8a05f109-434b-45a1-be84-ad9fc6c700de","lane":"clinical","event_type":"primary-completion","date":"2026-12-03","date_precision":"day","confidence":"estimated","company":"Eisai Inc.","ticker":null,"asset":"E2814","indication":"Alzheimer's Disease","summary":"As of 11 February 2026, Eisai estimated primary completion of a Phase 2 trial in Alzheimer's Disease, on 3 December 2026.","as_of":"2026-02-11","source":"clinicaltrials","source_ref":"NCT06602258","source_url":"https://clinicaltrials.gov/study/NCT06602258","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8a05f109-434b-45a1-be84-ad9fc6c700de"},{"id":"c4b536ad-6bd7-4d5d-980d-10d68b7dcd61","lane":"clinical","event_type":"primary-completion","date":"2026-12-03","date_precision":"day","confidence":"estimated","company":"Regeneron Pharmaceuticals","ticker":null,"asset":"REGN7999","indication":"Non-Transfusion Dependent Beta-Thalassemia (NTDT)","summary":"As of 1 July 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Non-Transfusion Dependent Beta-Thalassemia (NTDT), on 3 December 2026.","as_of":"2026-07-01","source":"clinicaltrials","source_ref":"NCT06421636","source_url":"https://clinicaltrials.gov/study/NCT06421636","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c4b536ad-6bd7-4d5d-980d-10d68b7dcd61"},{"id":"1d0d267b-7046-47c2-8980-61ce8bd0e977","lane":"clinical","event_type":"primary-completion","date":"2026-12-04","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"VLA15","indication":"Lyme Disease","summary":"As of 6 May 2026, Pfizer estimated primary completion of a Phase 3 trial in Lyme Disease, on 4 December 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT07500506","source_url":"https://clinicaltrials.gov/study/NCT07500506","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1d0d267b-7046-47c2-8980-61ce8bd0e977"},{"id":"d550d559-4ba1-4ccc-a126-4144a0e41fae","lane":"clinical","event_type":"primary-completion","date":"2026-12-05","date_precision":"day","confidence":"estimated","company":"Haisco Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"HSK39297 200mgQD","indication":"IgA Nephropathy (IgAN)","summary":"As of 1 June 2026, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in IgA Nephropathy (IgAN), on 5 December 2026.","as_of":"2026-06-01","source":"clinicaltrials","source_ref":"NCT07616700","source_url":"https://clinicaltrials.gov/study/NCT07616700","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d550d559-4ba1-4ccc-a126-4144a0e41fae"},{"id":"b5a65199-a6d9-43c8-b83c-e93120d24d1f","lane":"clinical","event_type":"primary-completion","date":"2026-12-05","date_precision":"day","confidence":"estimated","company":"Suzhou Forlong Biotechnology Co., Ltd","ticker":null,"asset":"FL115+PD-1","indication":"Advanced Solid Tumors","summary":"As of 8 January 2026, Suzhou Forlong Biotechnology Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 5 December 2026.","as_of":"2026-01-08","source":"clinicaltrials","source_ref":"NCT07131202","source_url":"https://clinicaltrials.gov/study/NCT07131202","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b5a65199-a6d9-43c8-b83c-e93120d24d1f"},{"id":"ff8cb29e-5b45-45c3-b34c-3b818f2dadab","lane":"clinical","event_type":"primary-completion","date":"2026-12-07","date_precision":"day","confidence":"estimated","company":"Alexion Pharmaceuticals, Inc.","ticker":null,"asset":"eculizumab","indication":"NMOSD","summary":"As of 19 December 2025, Alexion Pharmaceuticals estimated primary completion of a Phase 3 trial in nMOSD, on 7 December 2026.","as_of":"2025-12-19","source":"clinicaltrials","source_ref":"NCT06724809","source_url":"https://clinicaltrials.gov/study/NCT06724809","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ff8cb29e-5b45-45c3-b34c-3b818f2dadab"},{"id":"b7a0d958-5dfd-466b-a3fa-27a94b93e40e","lane":"clinical","event_type":"primary-completion","date":"2026-12-09","date_precision":"day","confidence":"estimated","company":"SK Bioscience Co., Ltd.","ticker":null,"asset":"Test Drug 1-1 (GBP511 low dose)","indication":"Healthy Participants","summary":"As of 14 May 2026, SK Bioscience Co. estimated primary completion of a Phase 2 trial in Healthy Participants, on 9 December 2026.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT07280858","source_url":"https://clinicaltrials.gov/study/NCT07280858","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b7a0d958-5dfd-466b-a3fa-27a94b93e40e"},{"id":"d9bd3e65-bf9f-4732-b8d6-afbcbdc2b317","lane":"clinical","event_type":"primary-completion","date":"2026-12-10","date_precision":"day","confidence":"estimated","company":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"asset":"LT3001 Drug:high dose","indication":"Acute Ischemic Stroke","summary":"As of 30 April 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 10 December 2026.","as_of":"2026-04-30","source":"clinicaltrials","source_ref":"NCT05686642","source_url":"https://clinicaltrials.gov/study/NCT05686642","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d9bd3e65-bf9f-4732-b8d6-afbcbdc2b317"},{"id":"bbf8a62c-aeb7-4b78-b605-9d1277a67457","lane":"clinical","event_type":"primary-completion","date":"2026-12-11","date_precision":"day","confidence":"estimated","company":"Gan & Lee Pharmaceuticals.","ticker":null,"asset":"GZR18","indication":"Type 2 Diabetes Mellitus (T2DM)","summary":"As of 25 November 2025, Gan & Lee Pharmaceuticals. estimated primary completion of a Phase 3 trial in Type 2 Diabetes Mellitus (T2DM), on 11 December 2026.","as_of":"2025-11-25","source":"clinicaltrials","source_ref":"NCT06778967","source_url":"https://clinicaltrials.gov/study/NCT06778967","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bbf8a62c-aeb7-4b78-b605-9d1277a67457"},{"id":"1de861ca-a6d9-4c98-b3a3-9d8565fea42c","lane":"clinical","event_type":"primary-completion","date":"2026-12-11","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"MMB","indication":"Neoplasms","summary":"As of 18 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in neoplasms, on 11 December 2026.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT03441113","source_url":"https://clinicaltrials.gov/study/NCT03441113","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1de861ca-a6d9-4c98-b3a3-9d8565fea42c"},{"id":"d7e34549-d48a-421d-a56c-e426a4aee192","lane":"clinical","event_type":"primary-completion","date":"2026-12-11","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"dTpa","indication":"Diphtheria-Tetanus-acellular Pertussis Vaccines","summary":"As of 28 July 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines, on 11 December 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT07596199","source_url":"https://clinicaltrials.gov/study/NCT07596199","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d7e34549-d48a-421d-a56c-e426a4aee192"},{"id":"2d0458a3-b37e-437f-a1d0-ca7d23fe9f59","lane":"clinical","event_type":"primary-completion","date":"2026-12-11","date_precision":"day","confidence":"estimated","company":"Seagen, a wholly owned subsidiary of Pfizer","ticker":null,"asset":"disitamab vedotin","indication":"Urothelial Carcinoma","summary":"As of 22 July 2026, Seagen estimated primary completion of a Phase 2 trial in Urothelial Carcinoma, on 11 December 2026.","as_of":"2026-07-22","source":"clinicaltrials","source_ref":"NCT04879329","source_url":"https://clinicaltrials.gov/study/NCT04879329","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2d0458a3-b37e-437f-a1d0-ca7d23fe9f59"},{"id":"130d9c68-6976-4e1a-8b46-718d56a874fb","lane":"clinical","event_type":"primary-completion","date":"2026-12-12","date_precision":"day","confidence":"estimated","company":"Ausper Biopharma Co., Ltd.","ticker":null,"asset":"AHB-137","indication":"Chronic Hepatitis B","summary":"As of 5 August 2026, Ausper Biopharma Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, on 12 December 2026.","as_of":"2026-08-05","source":"clinicaltrials","source_ref":"NCT07137910","source_url":"https://clinicaltrials.gov/study/NCT07137910","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-130d9c68-6976-4e1a-8b46-718d56a874fb"},{"id":"705612d4-e4b9-4cc6-a609-8f9a18a40458","lane":"clinical","event_type":"primary-completion","date":"2026-12-12","date_precision":"day","confidence":"estimated","company":"Beijing QL Biopharmaceutical Co.,Ltd","ticker":null,"asset":"ZT006","indication":"Overweight , Obesity","summary":"As of 12 June 2026, Beijing QL Biopharmaceutical Co. estimated primary completion of a Phase 2 trial in Overweight , Obesity, on 12 December 2026.","as_of":"2026-06-12","source":"clinicaltrials","source_ref":"NCT07230132","source_url":"https://clinicaltrials.gov/study/NCT07230132","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-705612d4-e4b9-4cc6-a609-8f9a18a40458"},{"id":"b047fa9a-98f2-4c0f-af55-24d881998880","lane":"clinical","event_type":"primary-completion","date":"2026-12-14","date_precision":"day","confidence":"estimated","company":"Amgen","ticker":null,"asset":"ABP 234","indication":"Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)","summary":"As of 1 April 2026, Amgen estimated primary completion of a Phase 3 trial in Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC), on 14 December 2026.","as_of":"2026-04-01","source":"clinicaltrials","source_ref":"NCT06430866","source_url":"https://clinicaltrials.gov/study/NCT06430866","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b047fa9a-98f2-4c0f-af55-24d881998880"},{"id":"73fc205d-51f2-456d-81ab-3030b9f18796","lane":"clinical","event_type":"primary-completion","date":"2026-12-14","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"BMS-986435","indication":"Heart Failure","summary":"As of 30 July 2026, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Heart Failure, on 14 December 2026.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT06122779","source_url":"https://clinicaltrials.gov/study/NCT06122779","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-73fc205d-51f2-456d-81ab-3030b9f18796"},{"id":"fb628899-4291-4c42-89d6-7f2f5ee85ccd","lane":"clinical","event_type":"primary-completion","date":"2026-12-14","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Investigational varicella vaccine","indication":"Chickenpox","summary":"As of 29 May 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in chickenpox, on 14 December 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT06806137","source_url":"https://clinicaltrials.gov/study/NCT06806137","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fb628899-4291-4c42-89d6-7f2f5ee85ccd"},{"id":"9f19e67c-534b-4765-9392-60288214c9d7","lane":"clinical","event_type":"primary-completion","date":"2026-12-14","date_precision":"day","confidence":"estimated","company":"LEO Pharma","ticker":null,"asset":"Delgocitinib cream","indication":"Palmoplantar Pustulosis","summary":"As of 21 July 2026, LEO Pharma estimated primary completion of a Phase 2 trial in Palmoplantar Pustulosis, on 14 December 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT07013201","source_url":"https://clinicaltrials.gov/study/NCT07013201","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9f19e67c-534b-4765-9392-60288214c9d7"},{"id":"0642ac76-26d1-451f-a8a2-0f8496fa64e6","lane":"clinical","event_type":"primary-completion","date":"2026-12-14","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"AAA617","indication":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","summary":"As of 10 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC), on 14 December 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT06004661","source_url":"https://clinicaltrials.gov/study/NCT06004661","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0642ac76-26d1-451f-a8a2-0f8496fa64e6"},{"id":"b03aee0a-d86d-4865-951c-fb396cb2b218","lane":"clinical","event_type":"primary-completion","date":"2026-12-14","date_precision":"day","confidence":"estimated","company":"Novo Nordisk A/S","ticker":null,"asset":"Ziltivekimab","indication":"Cardiovascular Risk","summary":"As of 14 April 2026, Novo Nordisk estimated primary completion of a Phase 3 trial in Cardiovascular Risk, on 14 December 2026.","as_of":"2026-04-14","source":"clinicaltrials","source_ref":"NCT06118281","source_url":"https://clinicaltrials.gov/study/NCT06118281","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b03aee0a-d86d-4865-951c-fb396cb2b218"},{"id":"15fb244f-054f-4725-b6e6-49c9dab9dc29","lane":"clinical","event_type":"primary-completion","date":"2026-12-14","date_precision":"day","confidence":"estimated","company":"Novo Nordisk A/S","ticker":null,"asset":"NNC0662-0419","indication":"Overweight","summary":"As of 7 May 2026, Novo Nordisk estimated primary completion of a Phase 2 trial in overweight, on 14 December 2026.","as_of":"2026-05-07","source":"clinicaltrials","source_ref":"NCT07184632","source_url":"https://clinicaltrials.gov/study/NCT07184632","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-15fb244f-054f-4725-b6e6-49c9dab9dc29"},{"id":"60292c9e-7721-4398-aae8-084b094744e6","lane":"clinical","event_type":"primary-completion","date":"2026-12-15","date_precision":"day","confidence":"estimated","company":"Alexion Pharmaceuticals, Inc.","ticker":null,"asset":"Gefurulimab","indication":"Generalized Myasthenia Gravis","summary":"As of 1 April 2026, Alexion Pharmaceuticals estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 15 December 2026.","as_of":"2026-04-01","source":"clinicaltrials","source_ref":"NCT06607627","source_url":"https://clinicaltrials.gov/study/NCT06607627","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-60292c9e-7721-4398-aae8-084b094744e6"},{"id":"032299d9-4a5b-4cdc-9033-64707c8fe7db","lane":"clinical","event_type":"primary-completion","date":"2026-12-15","date_precision":"day","confidence":"estimated","company":"EXACT Therapeutics AS","ticker":null,"asset":"Acoustic Cluster Therapy","indication":"Locally Advanced Pancreatic Adenocarcinoma","summary":"As of 3 April 2026, EXACT Therapeutics AS estimated primary completion of a Phase 2 trial in Locally Advanced Pancreatic Adenocarcinoma, on 15 December 2026.","as_of":"2026-04-03","source":"clinicaltrials","source_ref":"NCT06850623","source_url":"https://clinicaltrials.gov/study/NCT06850623","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-032299d9-4a5b-4cdc-9033-64707c8fe7db"},{"id":"6e687a12-9eb1-4a84-8146-3065cb016398","lane":"clinical","event_type":"primary-completion","date":"2026-12-15","date_precision":"day","confidence":"estimated","company":"Exelixis","ticker":null,"asset":"XL092","indication":"Non-Clear Cell Renal Cell Carcinoma","summary":"As of 29 July 2026, Exelixis estimated primary completion of a Phase 3 trial in Non-Clear Cell Renal Cell Carcinoma, on 15 December 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT05678673","source_url":"https://clinicaltrials.gov/study/NCT05678673","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6e687a12-9eb1-4a84-8146-3065cb016398"},{"id":"d0a9351c-50d6-47b0-aecb-1cdf5cdf9325","lane":"clinical","event_type":"primary-completion","date":"2026-12-15","date_precision":"day","confidence":"estimated","company":"GV20 Therapeutics","ticker":null,"asset":"GV20-0251","indication":"Solid Tumor, Adult","summary":"As of 13 February 2025, GV20 Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 15 December 2026.","as_of":"2025-02-13","source":"clinicaltrials","source_ref":"NCT05669430","source_url":"https://clinicaltrials.gov/study/NCT05669430","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d0a9351c-50d6-47b0-aecb-1cdf5cdf9325"},{"id":"672ffca5-968c-4da1-bb8f-a7e6ddfb9bfe","lane":"clinical","event_type":"primary-completion","date":"2026-12-15","date_precision":"day","confidence":"estimated","company":"Gedeon Richter Plc.","ticker":null,"asset":"Cariprazine","indication":"Schizophrenia","summary":"As of 8 October 2025, Gedeon Richter estimated primary completion of a Phase 3 trial in schizophrenia, on 15 December 2026.","as_of":"2025-10-08","source":"clinicaltrials","source_ref":"NCT03817502","source_url":"https://clinicaltrials.gov/study/NCT03817502","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-672ffca5-968c-4da1-bb8f-a7e6ddfb9bfe"},{"id":"ecdbf10d-57a5-4752-8835-37315d2aa34c","lane":"clinical","event_type":"primary-completion","date":"2026-12-15","date_precision":"day","confidence":"estimated","company":"Ipsen","ticker":null,"asset":"Corabotase","indication":"Moderate to Severe Glabellar Lines","summary":"As of 28 July 2026, Ipsen estimated primary completion of a Phase 3 trial in Moderate to Severe Glabellar Lines, on 15 December 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT07427797","source_url":"https://clinicaltrials.gov/study/NCT07427797","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ecdbf10d-57a5-4752-8835-37315d2aa34c"},{"id":"4b740617-654e-41cb-9702-db6430bc1512","lane":"clinical","event_type":"primary-completion","date":"2026-12-15","date_precision":"day","confidence":"estimated","company":"Ipsen","ticker":null,"asset":"Corabotase","indication":"Moderate to Severe Glabellar Lines","summary":"As of 28 July 2026, Ipsen estimated primary completion of a Phase 3 trial in Moderate to Severe Glabellar Lines, on 15 December 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT07435428","source_url":"https://clinicaltrials.gov/study/NCT07435428","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4b740617-654e-41cb-9702-db6430bc1512"},{"id":"5a8b864b-7575-4fef-a975-d7bcdda2e667","lane":"clinical","event_type":"primary-completion","date":"2026-12-16","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Satralizumab","indication":"NMDAR Autoimmune Encephalitis","summary":"As of 10 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in NMDAR Autoimmune Encephalitis, on 16 December 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT05503264","source_url":"https://clinicaltrials.gov/study/NCT05503264","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5a8b864b-7575-4fef-a975-d7bcdda2e667"},{"id":"821cbbf0-3a2f-4a83-8560-3b9d944c9d10","lane":"clinical","event_type":"primary-completion","date":"2026-12-16","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Posaconazole IV 6 mg/kg","indication":"Invasive Fungal Infection","summary":"As of 18 September 2025, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Invasive Fungal Infection, on 16 December 2026.","as_of":"2025-09-18","source":"clinicaltrials","source_ref":"NCT04665037","source_url":"https://clinicaltrials.gov/study/NCT04665037","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-821cbbf0-3a2f-4a83-8560-3b9d944c9d10"},{"id":"e951f644-571d-40cb-a505-9a0534f28170","lane":"clinical","event_type":"primary-completion","date":"2026-12-16","date_precision":"day","confidence":"estimated","company":"Shanghai JMT-Bio Inc.","ticker":null,"asset":"KN026","indication":"Early or Locally Advanced HER2-positive Breast Cancer","summary":"As of 7 July 2026, Shanghai JMT-Bio estimated primary completion of a Phase 3 trial in Early or Locally Advanced HER2-positive Breast Cancer, on 16 December 2026.","as_of":"2026-07-07","source":"clinicaltrials","source_ref":"NCT06747338","source_url":"https://clinicaltrials.gov/study/NCT06747338","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e951f644-571d-40cb-a505-9a0534f28170"},{"id":"6f256095-a7ec-4ee8-8499-5dfb18b47f05","lane":"clinical","event_type":"primary-completion","date":"2026-12-17","date_precision":"day","confidence":"estimated","company":"Ipsen","ticker":null,"asset":"Elafibranor","indication":"Primary Biliary Cholangitis","summary":"As of 3 August 2026, Ipsen estimated primary completion of a Phase 3 trial in Primary Biliary Cholangitis, on 17 December 2026.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT06730061","source_url":"https://clinicaltrials.gov/study/NCT06730061","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6f256095-a7ec-4ee8-8499-5dfb18b47f05"},{"id":"b6e5006c-cb08-4dfc-a455-ba40562de02c","lane":"clinical","event_type":"primary-completion","date":"2026-12-17","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"SAR442970","indication":"Ulcerative Colitis","summary":"As of 23 April 2026, Sanofi estimated primary completion of a Phase 2 trial in Ulcerative Colitis, on 17 December 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT06975722","source_url":"https://clinicaltrials.gov/study/NCT06975722","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b6e5006c-cb08-4dfc-a455-ba40562de02c"},{"id":"2e524f6d-3d5b-438b-bfa9-f93f8cbcee8d","lane":"clinical","event_type":"primary-completion","date":"2026-12-17","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"SAR442970","indication":"Crohn's Disease","summary":"As of 27 March 2026, Sanofi estimated primary completion of a Phase 2 trial in Crohn's Disease, on 17 December 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT06958536","source_url":"https://clinicaltrials.gov/study/NCT06958536","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2e524f6d-3d5b-438b-bfa9-f93f8cbcee8d"},{"id":"ce355ea1-3d32-42de-8003-cf7764a837b9","lane":"clinical","event_type":"primary-completion","date":"2026-12-18","date_precision":"day","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"MEDI0618","indication":"Migraine","summary":"As of 19 May 2026, AbbVie estimated primary completion of a Phase 2 trial in migraine, on 18 December 2026.","as_of":"2026-05-19","source":"clinicaltrials","source_ref":"NCT06602479","source_url":"https://clinicaltrials.gov/study/NCT06602479","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ce355ea1-3d32-42de-8003-cf7764a837b9"},{"id":"2859c600-4c82-43b1-b7b7-36ac37c1c5ca","lane":"clinical","event_type":"primary-completion","date":"2026-12-18","date_precision":"day","confidence":"estimated","company":"Ausper Biopharma Co., Ltd.","ticker":null,"asset":"AHB-137","indication":"Chronic Hepatitis B","summary":"As of 4 May 2026, Ausper Biopharma Co. estimated primary completion of a Phase 3 trial in Chronic Hepatitis B, on 18 December 2026.","as_of":"2026-05-04","source":"clinicaltrials","source_ref":"NCT07246889","source_url":"https://clinicaltrials.gov/study/NCT07246889","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2859c600-4c82-43b1-b7b7-36ac37c1c5ca"},{"id":"86e1c90a-6015-468e-b701-c65d806ca7f3","lane":"clinical","event_type":"primary-completion","date":"2026-12-18","date_precision":"day","confidence":"estimated","company":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","ticker":null,"asset":"Raloxifene - Usual","indication":"Breast Cancer","summary":"As of 23 April 2026, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair estimated primary completion of a Phase 3 trial in Breast Cancer, on 18 December 2026.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT06062810","source_url":"https://clinicaltrials.gov/study/NCT06062810","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-86e1c90a-6015-468e-b701-c65d806ca7f3"},{"id":"0436762c-06db-48b3-9855-cd0e5f0bf6b7","lane":"clinical","event_type":"primary-completion","date":"2026-12-20","date_precision":"day","confidence":"estimated","company":"TJ Biopharma Co., Ltd.","ticker":null,"asset":"Plonmarlimab","indication":"Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lympho...","summary":"As of 20 July 2026, TJ Biopharma Co. estimated primary completion of a Phase 3 trial in Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lympho, on 20 December 2026.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT07208058","source_url":"https://clinicaltrials.gov/study/NCT07208058","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0436762c-06db-48b3-9855-cd0e5f0bf6b7"},{"id":"9171c754-354d-4686-9313-f204c620c892","lane":"clinical","event_type":"primary-completion","date":"2026-12-21","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"Ritlecitinib 100 mg","indication":"Alopecia Areata","summary":"As of 13 May 2026, Pfizer estimated primary completion of a Phase 3 trial in Alopecia Areata, on 21 December 2026.","as_of":"2026-05-13","source":"clinicaltrials","source_ref":"NCT06873945","source_url":"https://clinicaltrials.gov/study/NCT06873945","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9171c754-354d-4686-9313-f204c620c892"},{"id":"92df3234-976b-421d-b827-a77a7e45064f","lane":"clinical","event_type":"primary-completion","date":"2026-12-21","date_precision":"day","confidence":"estimated","company":"UCB Biopharma SRL","ticker":null,"asset":"Bimekizumab","indication":"Hidradenitis Suppurativa","summary":"As of 31 July 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 21 December 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT06921850","source_url":"https://clinicaltrials.gov/study/NCT06921850","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-92df3234-976b-421d-b827-a77a7e45064f"},{"id":"329b325c-7a40-402c-8e0b-cf45fbbead1c","lane":"clinical","event_type":"primary-completion","date":"2026-12-22","date_precision":"day","confidence":"estimated","company":"Adverum Biotechnologies, Inc.","ticker":null,"asset":"Ixo-vec","indication":"Neovascular Age-Related Macular Degeneration (nAMD)","summary":"As of 22 May 2026, Adverum Biotechnologies estimated primary completion of a Phase 3 trial in Neovascular Age-Related Macular Degeneration (nAMD), on 22 December 2026.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT06856577","source_url":"https://clinicaltrials.gov/study/NCT06856577","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-329b325c-7a40-402c-8e0b-cf45fbbead1c"},{"id":"0ea0aab5-6db5-4e76-8190-0f2f4ca740bb","lane":"clinical","event_type":"primary-completion","date":"2026-12-22","date_precision":"day","confidence":"estimated","company":"Janssen Pharmaceutica N.V., Belgium","ticker":null,"asset":"JNJ-64042056","indication":"Alzheimer Disease","summary":"As of 31 July 2026, Janssen Pharmaceutica N.V., Belgium estimated primary completion of a Phase 2 trial in Alzheimer Disease, on 22 December 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT06544616","source_url":"https://clinicaltrials.gov/study/NCT06544616","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0ea0aab5-6db5-4e76-8190-0f2f4ca740bb"},{"id":"1996deff-779e-4ac0-8e7a-31c25acb7c7f","lane":"clinical","event_type":"primary-completion","date":"2026-12-22","date_precision":"day","confidence":"estimated","company":"Taisho Pharmaceutical Co., Ltd.","ticker":null,"asset":"TS-172 20~60 mg/day","indication":"Hyperphosphatemia Patients on Hemodialysis","summary":"As of 17 April 2026, Taisho Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Hyperphosphatemia Patients on Hemodialysis, on 22 December 2026.","as_of":"2026-04-17","source":"clinicaltrials","source_ref":"NCT07285291","source_url":"https://clinicaltrials.gov/study/NCT07285291","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1996deff-779e-4ac0-8e7a-31c25acb7c7f"},{"id":"6eaf0337-e4be-4c81-831c-05bfb20fd71a","lane":"clinical","event_type":"primary-completion","date":"2026-12-23","date_precision":"day","confidence":"estimated","company":"Changchun GeneScience Pharmaceutical Co., Ltd.","ticker":null,"asset":"PEG-rhGH Injection","indication":"Short Stature Children Born Small for Gestational Age (SGA)","summary":"As of 17 February 2026, Changchun GeneScience Pharmaceutical Co. estimated primary completion of a Phase 2 trial on 23 December 2026.","as_of":"2026-02-17","source":"clinicaltrials","source_ref":"NCT07260500","source_url":"https://clinicaltrials.gov/study/NCT07260500","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6eaf0337-e4be-4c81-831c-05bfb20fd71a"},{"id":"e8fae385-39b7-443f-9735-3d06464a142d","lane":"clinical","event_type":"primary-completion","date":"2026-12-23","date_precision":"day","confidence":"estimated","company":"Cho Pharma Inc.","ticker":null,"asset":"CHO-H01","indication":"Non-Hodgkin Lymphoma","summary":"As of 3 March 2026, Cho Pharma estimated primary completion of a Phase 2 trial in Non-Hodgkin Lymphoma, on 23 December 2026.","as_of":"2026-03-03","source":"clinicaltrials","source_ref":"NCT05950165","source_url":"https://clinicaltrials.gov/study/NCT05950165","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e8fae385-39b7-443f-9735-3d06464a142d"},{"id":"c92932d0-47f1-4563-81e9-8df39f0784b4","lane":"clinical","event_type":"primary-completion","date":"2026-12-23","date_precision":"day","confidence":"estimated","company":"Corxel Pharmaceuticals","ticker":null,"asset":"CX11","indication":"Type II Diabetes Mellitus","summary":"As of 28 May 2026, Corxel Pharmaceuticals estimated primary completion of a Phase 2 trial in Type II Diabetes Mellitus, on 23 December 2026.","as_of":"2026-05-28","source":"clinicaltrials","source_ref":"NCT07340320","source_url":"https://clinicaltrials.gov/study/NCT07340320","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c92932d0-47f1-4563-81e9-8df39f0784b4"},{"id":"b07e5c03-240d-4f0a-9a91-76c1a588c538","lane":"clinical","event_type":"primary-completion","date":"2026-12-23","date_precision":"day","confidence":"estimated","company":"Fusion Pharmaceuticals Inc.","ticker":null,"asset":"FPI-2265","indication":"Metastatic Castration-resistant Prostate Cancer","summary":"As of 8 April 2026, Fusion Pharmaceuticals estimated primary completion of a Phase 2 trial in Metastatic Castration-resistant Prostate Cancer, on 23 December 2026.","as_of":"2026-04-08","source":"clinicaltrials","source_ref":"NCT06402331","source_url":"https://clinicaltrials.gov/study/NCT06402331","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b07e5c03-240d-4f0a-9a91-76c1a588c538"},{"id":"74403865-4c52-48cd-97d8-28bd02bbe2fe","lane":"clinical","event_type":"primary-completion","date":"2026-12-23","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"AAA617","indication":"Prostatic Neoplasm","summary":"As of 17 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Prostatic Neoplasm, on 23 December 2026.","as_of":"2026-07-17","source":"clinicaltrials","source_ref":"NCT05849298","source_url":"https://clinicaltrials.gov/study/NCT05849298","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-74403865-4c52-48cd-97d8-28bd02bbe2fe"},{"id":"4e6bcb41-d0a0-44b3-ba12-a7351459dae4","lane":"clinical","event_type":"primary-completion","date":"2026-12-23","date_precision":"day","confidence":"estimated","company":"OncoZenge AB","ticker":null,"asset":"BupiZenge 25 mg","indication":"Head & Neck Cancer","summary":"As of 13 July 2026, OncoZenge estimated primary completion of a Phase 3 trial in Head & Neck Cancer, on 23 December 2026.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT07672236","source_url":"https://clinicaltrials.gov/study/NCT07672236","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4e6bcb41-d0a0-44b3-ba12-a7351459dae4"},{"id":"ead89d46-a910-4d4c-9203-a607352b60b7","lane":"clinical","event_type":"primary-completion","date":"2026-12-23","date_precision":"day","confidence":"estimated","company":"R-Bio","ticker":null,"asset":"JOINTSTEM","indication":"Knee Osteoarthritis","summary":"As of 10 July 2023, R-Bio estimated primary completion of a Phase 3 trial in Knee Osteoarthritis, on 23 December 2026.","as_of":"2023-07-10","source":"clinicaltrials","source_ref":"NCT04427930","source_url":"https://clinicaltrials.gov/study/NCT04427930","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ead89d46-a910-4d4c-9203-a607352b60b7"},{"id":"9d8eb846-e315-4580-86d4-e8ff0a349ddf","lane":"clinical","event_type":"primary-completion","date":"2026-12-23","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"frexalimab","indication":"Focal Segmental Glomerulosclerosis","summary":"As of 20 July 2026, Sanofi estimated primary completion of a Phase 2 trial in Focal Segmental Glomerulosclerosis, on 23 December 2026.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT06500702","source_url":"https://clinicaltrials.gov/study/NCT06500702","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9d8eb846-e315-4580-86d4-e8ff0a349ddf"},{"id":"7acb1340-f4e1-4541-8205-c948a892702d","lane":"clinical","event_type":"primary-completion","date":"2026-12-24","date_precision":"day","confidence":"estimated","company":"InxMed (Shanghai) Co., Ltd.","ticker":null,"asset":"IN10018","indication":"Ovarian Cancer Recurrent","summary":"As of 30 April 2025, InxMed (Shanghai) Co. estimated primary completion of a Phase 2 trial in Ovarian Cancer Recurrent, on 24 December 2026.","as_of":"2025-04-30","source":"clinicaltrials","source_ref":"NCT06014528","source_url":"https://clinicaltrials.gov/study/NCT06014528","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7acb1340-f4e1-4541-8205-c948a892702d"},{"id":"ba727d83-da9c-41ce-a4ac-a23f8f39db68","lane":"clinical","event_type":"primary-completion","date":"2026-12-24","date_precision":"day","confidence":"estimated","company":"Nanjing Leads Biolabs Co.,Ltd","ticker":null,"asset":"LBL-024 for Injection","indication":"Advanced Solid Tumour","summary":"As of 18 May 2026, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumour, on 24 December 2026.","as_of":"2026-05-18","source":"clinicaltrials","source_ref":"NCT06783647","source_url":"https://clinicaltrials.gov/study/NCT06783647","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ba727d83-da9c-41ce-a4ac-a23f8f39db68"},{"id":"80255472-fae2-4edd-8d84-7300e2c07e19","lane":"clinical","event_type":"primary-completion","date":"2026-12-24","date_precision":"day","confidence":"estimated","company":"Shanghai Kechow Pharma, Inc.","ticker":null,"asset":"Tunlametinib plus Vemurafenib","indication":"Colorectal Cancer Metastatic","summary":"As of 18 September 2025, Shanghai Kechow Pharma estimated primary completion of a Phase 3 trial in Colorectal Cancer Metastatic, on 24 December 2026.","as_of":"2025-09-18","source":"clinicaltrials","source_ref":"NCT06008119","source_url":"https://clinicaltrials.gov/study/NCT06008119","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-80255472-fae2-4edd-8d84-7300e2c07e19"},{"id":"07f87f10-5afb-4128-a5aa-ee1547fc6ba5","lane":"clinical","event_type":"primary-completion","date":"2026-12-25","date_precision":"day","confidence":"estimated","company":"Boehringer Ingelheim","ticker":null,"asset":"BI 1584862","indication":"Geographic Atrophy","summary":"As of 28 July 2026, Boehringer Ingelheim estimated primary completion of a Phase 2 trial in Geographic Atrophy, on 25 December 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT06769048","source_url":"https://clinicaltrials.gov/study/NCT06769048","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-07f87f10-5afb-4128-a5aa-ee1547fc6ba5"},{"id":"7f3b3fd5-d04e-4d75-a22c-23ca0e45b35a","lane":"clinical","event_type":"primary-completion","date":"2026-12-25","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Investigational varicella vaccine_Lot 1","indication":"Chickenpox","summary":"As of 29 May 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in chickenpox, on 25 December 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT06740630","source_url":"https://clinicaltrials.gov/study/NCT06740630","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7f3b3fd5-d04e-4d75-a22c-23ca0e45b35a"},{"id":"3c818ec6-1169-4f94-9a36-bf33e72ffa1f","lane":"clinical","event_type":"primary-completion","date":"2026-12-25","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"Ritlecitinib 50 mg","indication":"Chronic Spontaneous Urticaria","summary":"As of 17 June 2026, Pfizer estimated primary completion of a Phase 2 trial in Chronic Spontaneous Urticaria, on 25 December 2026.","as_of":"2026-06-17","source":"clinicaltrials","source_ref":"NCT07219615","source_url":"https://clinicaltrials.gov/study/NCT07219615","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3c818ec6-1169-4f94-9a36-bf33e72ffa1f"},{"id":"aaacebea-c0e2-4356-99e8-19828b4c44b5","lane":"clinical","event_type":"primary-completion","date":"2026-12-26","date_precision":"day","confidence":"estimated","company":"CanariaBio Inc.","ticker":null,"asset":"Oregovomab","indication":"Carcinoma, Ovarian Epithelial","summary":"As of 1 April 2026, CanariaBio estimated primary completion of a Phase 3 trial in Carcinoma, Ovarian Epithelial, on 26 December 2026.","as_of":"2026-04-01","source":"clinicaltrials","source_ref":"NCT04498117","source_url":"https://clinicaltrials.gov/study/NCT04498117","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-aaacebea-c0e2-4356-99e8-19828b4c44b5"},{"id":"e544e857-c529-407c-acf3-7e5f5257e58c","lane":"clinical","event_type":"primary-completion","date":"2026-12-26","date_precision":"day","confidence":"estimated","company":"Incyte Corporation","ticker":null,"asset":"Povorcitinib","indication":"Hidradenitis Suppurativa (HS)","summary":"As of 23 March 2026, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa (HS), on 26 December 2026.","as_of":"2026-03-23","source":"clinicaltrials","source_ref":"NCT06212999","source_url":"https://clinicaltrials.gov/study/NCT06212999","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e544e857-c529-407c-acf3-7e5f5257e58c"},{"id":"62c78072-3d92-402d-b182-beaaff59c2fd","lane":"clinical","event_type":"primary-completion","date":"2026-12-27","date_precision":"day","confidence":"estimated","company":"Amplexd Therapeutics, Inc.","ticker":null,"asset":"EGCG and Quinine Sulfate Vaginal Suppository","indication":"High-risk HPV (Any Strain)","summary":"As of 14 May 2026, Amplexd Therapeutics estimated primary completion of a Phase 2 trial in High-risk HPV (Any Strain), on 27 December 2026.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT07572396","source_url":"https://clinicaltrials.gov/study/NCT07572396","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-62c78072-3d92-402d-b182-beaaff59c2fd"},{"id":"f9a75594-c125-4573-87d3-fce1de597916","lane":"clinical","event_type":"primary-completion","date":"2026-12-27","date_precision":"day","confidence":"estimated","company":"Stemline Therapeutics, Inc.","ticker":null,"asset":"Elacestrant","indication":"Breast Cancer","summary":"As of 12 June 2026, Stemline Therapeutics estimated primary completion of a Phase 2 trial in Breast Cancer, on 27 December 2026.","as_of":"2026-06-12","source":"clinicaltrials","source_ref":"NCT05563220","source_url":"https://clinicaltrials.gov/study/NCT05563220","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f9a75594-c125-4573-87d3-fce1de597916"},{"id":"baeef214-c8e9-48a8-a791-dfdd323d65c1","lane":"clinical","event_type":"primary-completion","date":"2026-12-28","date_precision":"day","confidence":"estimated","company":"Beijing InnoCare Pharma Tech Co., Ltd.","ticker":null,"asset":"CM355","indication":"Hematoma","summary":"As of 27 January 2022, Beijing InnoCare Pharma Tech Co. estimated primary completion of a Phase 2 trial in hematoma, on 28 December 2026.","as_of":"2022-01-27","source":"clinicaltrials","source_ref":"NCT05210868","source_url":"https://clinicaltrials.gov/study/NCT05210868","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-baeef214-c8e9-48a8-a791-dfdd323d65c1"},{"id":"c518ad62-720b-44e2-8bea-134e136cb885","lane":"clinical","event_type":"primary-completion","date":"2026-12-28","date_precision":"day","confidence":"estimated","company":"Chengdu Origen Biotechnology Co., Ltd.","ticker":null,"asset":"KH631","indication":"Age-Related Macular Degeneration","summary":"As of 27 November 2024, Chengdu Origen Biotechnology Co. estimated primary completion of a Phase 2 trial in Age-Related Macular Degeneration, on 28 December 2026.","as_of":"2024-11-27","source":"clinicaltrials","source_ref":"NCT05672121","source_url":"https://clinicaltrials.gov/study/NCT05672121","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c518ad62-720b-44e2-8bea-134e136cb885"},{"id":"2455bedd-0e50-44fd-8dc7-d015693e38ef","lane":"clinical","event_type":"primary-completion","date":"2026-12-28","date_precision":"day","confidence":"estimated","company":"Frantz Viral Therapeutics, LLC","ticker":null,"asset":"Artesunate","indication":"Anal High Grade Squamous Intraepithelial Lesion","summary":"As of 18 May 2025, Frantz Viral Therapeutics estimated primary completion of a Phase 2 trial in Anal High Grade Squamous Intraepithelial Lesion, on 28 December 2026.","as_of":"2025-05-18","source":"clinicaltrials","source_ref":"NCT05555862","source_url":"https://clinicaltrials.gov/study/NCT05555862","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2455bedd-0e50-44fd-8dc7-d015693e38ef"},{"id":"a4030ac9-5016-4468-8879-eb1a201a5b19","lane":"clinical","event_type":"primary-completion","date":"2026-12-28","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Niraparib","indication":"Ovarian Neoplasms","summary":"As of 24 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Ovarian Neoplasms, on 28 December 2026.","as_of":"2026-06-24","source":"clinicaltrials","source_ref":"NCT04641247","source_url":"https://clinicaltrials.gov/study/NCT04641247","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a4030ac9-5016-4468-8879-eb1a201a5b19"},{"id":"d6f19ca3-2c71-4cd6-adda-15a44bc7cc97","lane":"clinical","event_type":"primary-completion","date":"2026-12-28","date_precision":"day","confidence":"estimated","company":"Jiangsu Topcel-KH Pharmaceutical Co., Ltd.","ticker":null,"asset":"Human TH-SC01 cell injection","indication":"Crohn's Disease","summary":"As of 13 April 2025, Jiangsu Topcel-KH Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Crohn's Disease, on 28 December 2026.","as_of":"2025-04-13","source":"clinicaltrials","source_ref":"NCT06925594","source_url":"https://clinicaltrials.gov/study/NCT06925594","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d6f19ca3-2c71-4cd6-adda-15a44bc7cc97"},{"id":"6d7af0e4-c473-4f3e-bbd4-7f9f62ab1046","lane":"clinical","event_type":"primary-completion","date":"2026-12-28","date_precision":"day","confidence":"estimated","company":"Nanjing Leads Biolabs Co.,Ltd","ticker":null,"asset":"LBL-024 for Injection","indication":"Advanced Neuroendocrine Carcinoma","summary":"As of 12 March 2026, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Advanced Neuroendocrine Carcinoma, on 28 December 2026.","as_of":"2026-03-12","source":"clinicaltrials","source_ref":"NCT06157827","source_url":"https://clinicaltrials.gov/study/NCT06157827","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6d7af0e4-c473-4f3e-bbd4-7f9f62ab1046"},{"id":"c7c05677-11c0-48bf-815f-80cb7690bab2","lane":"clinical","event_type":"primary-completion","date":"2026-12-28","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"PF-06821497","indication":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","summary":"As of 11 August 2026, Pfizer estimated primary completion of a Phase 3 trial in Metastatic Castrate Resistant Prostate Cancer (mCRPC), on 28 December 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT06551324","source_url":"https://clinicaltrials.gov/study/NCT06551324","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c7c05677-11c0-48bf-815f-80cb7690bab2"},{"id":"551d7dd7-f183-4496-a988-fb0e72183316","lane":"clinical","event_type":"primary-completion","date":"2026-12-29","date_precision":"day","confidence":"estimated","company":"Arctic Therapeutics","ticker":null,"asset":"NACA","indication":"Hereditary Cystatin C Amyloid Angiopathy (HCCAA)","summary":"As of 21 July 2026, Arctic Therapeutics estimated primary completion of a Phase 2 trial in Hereditary Cystatin C Amyloid Angiopathy (HCCAA), on 29 December 2026.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT07716865","source_url":"https://clinicaltrials.gov/study/NCT07716865","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-551d7dd7-f183-4496-a988-fb0e72183316"},{"id":"7e65e4e2-ca07-4d44-8b4b-d89c23fe7165","lane":"clinical","event_type":"primary-completion","date":"2026-12-29","date_precision":"day","confidence":"estimated","company":"Regeneron Pharmaceuticals","ticker":null,"asset":"Alirocumab","indication":"Hypercholesterolemia","summary":"As of 22 July 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in hypercholesterolemia, on 29 December 2026.","as_of":"2026-07-22","source":"clinicaltrials","source_ref":"NCT07477704","source_url":"https://clinicaltrials.gov/study/NCT07477704","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7e65e4e2-ca07-4d44-8b4b-d89c23fe7165"},{"id":"4f4b3b53-ee6f-453c-b641-be6a8b82a550","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"3D Medicines (Sichuan) Co., Ltd.","ticker":null,"asset":"KN035","indication":"Solid Tumor","summary":"As of 25 March 2026, 3D Medicines (Sichuan) Co. estimated primary completion of a Phase 2 trial in Solid Tumor, on 30 December 2026.","as_of":"2026-03-25","source":"clinicaltrials","source_ref":"NCT03667170","source_url":"https://clinicaltrials.gov/study/NCT03667170","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4f4b3b53-ee6f-453c-b641-be6a8b82a550"},{"id":"5058f798-a08c-4f5b-b5dd-e1cf65df911d","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"4TEEN4 Pharmaceuticals GmbH","ticker":null,"asset":"AK1967 (Invobenitug also known as Procizumab)","indication":"Shock, Cardiogenic","summary":"As of 9 July 2026, 4TEEN4 Pharmaceuticals estimated primary completion of a Phase 2 trial in Shock, Cardiogenic, on 30 December 2026.","as_of":"2026-07-09","source":"clinicaltrials","source_ref":"NCT06832722","source_url":"https://clinicaltrials.gov/study/NCT06832722","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5058f798-a08c-4f5b-b5dd-e1cf65df911d"},{"id":"619a2118-1d52-460a-86fd-3f531ba223fa","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Akeso","ticker":null,"asset":"AK117","indication":"Metastatic Triple-negative Breast Cancer","summary":"As of 16 March 2026, Akeso estimated primary completion of a Phase 2 trial in Metastatic Triple-negative Breast Cancer, on 30 December 2026.","as_of":"2026-03-16","source":"clinicaltrials","source_ref":"NCT05227664","source_url":"https://clinicaltrials.gov/study/NCT05227664","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-619a2118-1d52-460a-86fd-3f531ba223fa"},{"id":"823f6831-26b5-408e-8224-f3bd2aa53a5d","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Akeso","ticker":null,"asset":"AK112, Cadonilimab, nab-paclitaxel, gemcitabine","indication":"Metastatic Pancreatic Ductal Adenocarcinoma","summary":"As of 9 March 2026, Akeso estimated primary completion of a Phase 2 trial in Metastatic Pancreatic Ductal Adenocarcinoma, on 30 December 2026.","as_of":"2026-03-09","source":"clinicaltrials","source_ref":"NCT06646055","source_url":"https://clinicaltrials.gov/study/NCT06646055","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-823f6831-26b5-408e-8224-f3bd2aa53a5d"},{"id":"6fcf5c5b-ea05-493b-bc8c-40940ee6c8d8","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Allotera Therapeutics","ticker":null,"asset":"WU-CART-007","indication":"T-cell Acute Lymphoblastic Leukemia","summary":"As of 6 August 2026, Allotera Therapeutics estimated primary completion of a Phase 2 trial in T-cell Acute Lymphoblastic Leukemia, on 30 December 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT06514794","source_url":"https://clinicaltrials.gov/study/NCT06514794","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6fcf5c5b-ea05-493b-bc8c-40940ee6c8d8"},{"id":"909d7aea-4398-40a1-bad3-057fc8b8fb0b","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"AskGene Pharma, Inc.","ticker":null,"asset":"ASKB589","indication":"Gastroesophageal Junction Adenocarcinoma","summary":"As of 27 January 2026, AskGene Pharma estimated primary completion of a Phase 3 trial in Gastroesophageal Junction Adenocarcinoma, on 30 December 2026.","as_of":"2026-01-27","source":"clinicaltrials","source_ref":"NCT06206733","source_url":"https://clinicaltrials.gov/study/NCT06206733","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-909d7aea-4398-40a1-bad3-057fc8b8fb0b"},{"id":"db3905cb-4235-4a77-b9ce-2446a17571ae","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Astellas Pharma Global Development, Inc.","ticker":null,"asset":"XNW27011","indication":"Pancreatic Adenocarcinoma Metastatic","summary":"As of 11 August 2026, Astellas Pharma Global Development estimated primary completion of a Phase 2 trial in Pancreatic Adenocarcinoma Metastatic, on 30 December 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT06792435","source_url":"https://clinicaltrials.gov/study/NCT06792435","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-db3905cb-4235-4a77-b9ce-2446a17571ae"},{"id":"bc1f9367-eb73-4ef2-ac9f-09e5e0bd8ff5","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Beijing Continent Pharmaceutical Co, Ltd.","ticker":null,"asset":"Pirfenidone Capsules （400 mg）","indication":"Radiation-induced Lung Injury","summary":"As of 22 April 2026, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 3 trial in Radiation-induced Lung Injury, on 30 December 2026.","as_of":"2026-04-22","source":"clinicaltrials","source_ref":"NCT07388680","source_url":"https://clinicaltrials.gov/study/NCT07388680","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bc1f9367-eb73-4ef2-ac9f-09e5e0bd8ff5"},{"id":"268b04d5-b6ed-4738-a7ef-5ce60f3067f5","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Beijing Konruns Pharmaceutical Co., Ltd.","ticker":null,"asset":"KC1036","indication":"Esophageal Squamous Cell Carcinoma","summary":"As of 7 March 2024, Beijing Konruns Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Esophageal Squamous Cell Carcinoma, on 30 December 2026.","as_of":"2024-03-07","source":"clinicaltrials","source_ref":"NCT06194734","source_url":"https://clinicaltrials.gov/study/NCT06194734","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-268b04d5-b6ed-4738-a7ef-5ce60f3067f5"},{"id":"5b72e8f0-b04a-49e5-af99-4e1a797158c5","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Bionic Sight LLC","ticker":null,"asset":"BS01","indication":"Retinitis Pigmentosa","summary":"As of 23 January 2026, Bionic Sight estimated primary completion of a Phase 2 trial in Retinitis Pigmentosa, on 30 December 2026.","as_of":"2026-01-23","source":"clinicaltrials","source_ref":"NCT04278131","source_url":"https://clinicaltrials.gov/study/NCT04278131","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5b72e8f0-b04a-49e5-af99-4e1a797158c5"},{"id":"43abbf61-d98a-45ae-a78f-2b88a82a26f0","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"CanariaBio Inc.","ticker":null,"asset":"Oregovomab","indication":"Recurrent Ovarian Cancer","summary":"As of 3 April 2026, CanariaBio estimated primary completion of a Phase 2 trial in Recurrent Ovarian Cancer, on 30 December 2026.","as_of":"2026-04-03","source":"clinicaltrials","source_ref":"NCT05335993","source_url":"https://clinicaltrials.gov/study/NCT05335993","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-43abbf61-d98a-45ae-a78f-2b88a82a26f0"},{"id":"c61ff8eb-93a7-4d5c-bc74-c36888bffa34","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Chengdu Zenitar Biomedical Technology Co., Ltd","ticker":null,"asset":"PM 8.4 mg/m^2","indication":"Diffuse Large B Cell Lymphoma，DLBCL","summary":"As of 4 February 2026, Chengdu Zenitar Biomedical Technology Co. estimated primary completion of a Phase 2 trial in Diffuse Large B Cell Lymphoma，DLBCL, on 30 December 2026.","as_of":"2026-02-04","source":"clinicaltrials","source_ref":"NCT05563844","source_url":"https://clinicaltrials.gov/study/NCT05563844","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c61ff8eb-93a7-4d5c-bc74-c36888bffa34"},{"id":"904d5a57-de91-4ee4-abc2-6c65fdfac634","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Ever Supreme Bio Technology Co., Ltd.","ticker":null,"asset":"autologous dendritic cells","indication":"GBM","summary":"As of 19 September 2024, Ever Supreme Bio Technology Co. estimated primary completion of a Phase 2 trial in gBM, on 30 December 2026.","as_of":"2024-09-19","source":"clinicaltrials","source_ref":"NCT04115761","source_url":"https://clinicaltrials.gov/study/NCT04115761","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-904d5a57-de91-4ee4-abc2-6c65fdfac634"},{"id":"4b9e6d00-802d-42f7-a00f-063d32da7c37","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Ganzhou Hemay Pharmaceutical Co., Ltd","ticker":null,"asset":"Hemay005 tablets","indication":"Moderate to Severe Ulcerative Colitis","summary":"As of 3 April 2026, Ganzhou Hemay Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Moderate to Severe Ulcerative Colitis, on 30 December 2026.","as_of":"2026-04-03","source":"clinicaltrials","source_ref":"NCT05486104","source_url":"https://clinicaltrials.gov/study/NCT05486104","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4b9e6d00-802d-42f7-a00f-063d32da7c37"},{"id":"c5e6b84a-d933-4729-aadb-7e24b75abb99","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"HC Biopharma Inc.","ticker":null,"asset":"HC010","indication":"NSCLC","summary":"As of 17 December 2025, HC Biopharma estimated primary completion of a Phase 2 trial in nSCLC, on 30 December 2026.","as_of":"2025-12-17","source":"clinicaltrials","source_ref":"NCT07169552","source_url":"https://clinicaltrials.gov/study/NCT07169552","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c5e6b84a-d933-4729-aadb-7e24b75abb99"},{"id":"ce4b3760-63d0-496a-94d5-0a7699f1f660","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Janssen Research & Development, LLC","ticker":null,"asset":"Cetrelimab","indication":"Urinary Bladder Neoplasms","summary":"As of 31 July 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Urinary Bladder Neoplasms, on 30 December 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT04658862","source_url":"https://clinicaltrials.gov/study/NCT04658862","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ce4b3760-63d0-496a-94d5-0a7699f1f660"},{"id":"8b3c2686-9892-4e54-8eef-1a864d34ab36","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Janssen Research & Development, LLC","ticker":null,"asset":"Seltorexant","indication":"Depressive Disorder, Major","summary":"As of 31 July 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Depressive Disorder, Major, on 30 December 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT06559306","source_url":"https://clinicaltrials.gov/study/NCT06559306","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8b3c2686-9892-4e54-8eef-1a864d34ab36"},{"id":"0cdf8938-9231-476a-a08d-bf0335e07d19","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Jiangsu vcare pharmaceutical technology co., LTD","ticker":null,"asset":"VC004 Capsules","indication":"Locally Advanced Solid Tumor","summary":"As of 27 July 2026, Jiangsu vcare pharmaceutical technology co. estimated primary completion of a Phase 3 trial in Locally Advanced Solid Tumor, on 30 December 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT06658353","source_url":"https://clinicaltrials.gov/study/NCT06658353","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0cdf8938-9231-476a-a08d-bf0335e07d19"},{"id":"3f74fac2-6ccc-47dd-af9f-87f553ae08aa","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Jiangsu vcare pharmaceutical technology co., LTD","ticker":null,"asset":"Vicagrel","indication":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","summary":"As of 27 July 2026, Jiangsu vcare pharmaceutical technology co. estimated primary completion of a Phase 3 trial on 30 December 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT06577519","source_url":"https://clinicaltrials.gov/study/NCT06577519","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3f74fac2-6ccc-47dd-af9f-87f553ae08aa"},{"id":"888d2826-4551-4e1f-a9a4-8767365b4a49","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"L & L Bio Co., Ltd., Ningbo, China","ticker":null,"asset":"LB1410","indication":"Solid Tumor","summary":"As of 11 September 2025, L & L Bio Co., Ltd., Ningbo, China estimated primary completion of a Phase 2 trial in Solid Tumor, on 30 December 2026.","as_of":"2025-09-11","source":"clinicaltrials","source_ref":"NCT06468358","source_url":"https://clinicaltrials.gov/study/NCT06468358","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-888d2826-4551-4e1f-a9a4-8767365b4a49"},{"id":"474227c4-fa1f-4760-b0a8-052222de28b4","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Meribank Biotech Co., Ltd.","ticker":null,"asset":"UMC119-06-05","indication":"Chronic Obstructive Pulmonary Disease","summary":"As of 8 July 2024, Meribank Biotech Co. estimated primary completion of a Phase 2 trial in Chronic Obstructive Pulmonary Disease, on 30 December 2026.","as_of":"2024-07-08","source":"clinicaltrials","source_ref":"NCT06491043","source_url":"https://clinicaltrials.gov/study/NCT06491043","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-474227c4-fa1f-4760-b0a8-052222de28b4"},{"id":"2cc0ab98-d5c0-4f05-bfe5-90e742cc6c7c","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"NATCO Pharma Ltd.","ticker":null,"asset":"NRC-2694-A","indication":"Carcinoma","summary":"As of 23 January 2026, NATCO Pharma estimated primary completion of a Phase 2 trial in carcinoma, on 30 December 2026.","as_of":"2026-01-23","source":"clinicaltrials","source_ref":"NCT05283226","source_url":"https://clinicaltrials.gov/study/NCT05283226","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2cc0ab98-d5c0-4f05-bfe5-90e742cc6c7c"},{"id":"60d5585b-42a3-48e4-98a5-de3a516eb0f9","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Neonc Technologies, Inc.","ticker":null,"asset":"NEO100","indication":"Residual, Progressive or Recurrent Grade II or III Meningioma","summary":"As of 16 July 2026, Neonc Technologies estimated primary completion of a Phase 2 trial on 30 December 2026.","as_of":"2026-07-16","source":"clinicaltrials","source_ref":"NCT05023018","source_url":"https://clinicaltrials.gov/study/NCT05023018","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-60d5585b-42a3-48e4-98a5-de3a516eb0f9"},{"id":"9991f8c2-34cf-431a-97ad-33ec0278149a","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"Iptacopan","indication":"Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis","summary":"As of 23 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis, on 30 December 2026.","as_of":"2026-06-23","source":"clinicaltrials","source_ref":"NCT06388941","source_url":"https://clinicaltrials.gov/study/NCT06388941","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9991f8c2-34cf-431a-97ad-33ec0278149a"},{"id":"730fb6b6-8d53-4430-9524-916f499d0213","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"ARV-471","indication":"Breast Cancer","summary":"As of 9 March 2026, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 30 December 2026.","as_of":"2026-03-09","source":"clinicaltrials","source_ref":"NCT05573555","source_url":"https://clinicaltrials.gov/study/NCT05573555","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-730fb6b6-8d53-4430-9524-916f499d0213"},{"id":"85d67bb5-42fb-49c1-82b7-c6194bd253cd","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"Vepdegestrant (ARV-471/PF-07850327)","indication":"Breast Cancer","summary":"As of 10 February 2026, Pfizer estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 December 2026.","as_of":"2026-02-10","source":"clinicaltrials","source_ref":"NCT05909397","source_url":"https://clinicaltrials.gov/study/NCT05909397","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-85d67bb5-42fb-49c1-82b7-c6194bd253cd"},{"id":"c7a3c9bc-8157-4265-9f72-f24527cfb1ed","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Psyence Australia Pty Ltd","ticker":null,"asset":"Psilocybin therapy","indication":"Adjustment Disorder","summary":"As of 3 March 2026, Psyence Australia Pty estimated primary completion of a Phase 2 trial in Adjustment Disorder, on 30 December 2026.","as_of":"2026-03-03","source":"clinicaltrials","source_ref":"NCT07072728","source_url":"https://clinicaltrials.gov/study/NCT07072728","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c7a3c9bc-8157-4265-9f72-f24527cfb1ed"},{"id":"ec2bbff0-24c7-4004-8e6d-1733bdfd3518","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Sellas Life Sciences Group","ticker":null,"asset":"SLS009","indication":"Hematologic Malignancies","summary":"As of 29 July 2026, Sellas Life Sciences Group estimated primary completion of a Phase 2 trial in Hematologic Malignancies, on 30 December 2026.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT04588922","source_url":"https://clinicaltrials.gov/study/NCT04588922","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ec2bbff0-24c7-4004-8e6d-1733bdfd3518"},{"id":"4e3fe69e-51a3-4305-9df9-30115230bbc6","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Shanghai Hengrui Pharmaceutical Co., Ltd.","ticker":null,"asset":"SHR-1905","indication":"Asthma","summary":"As of 5 June 2026, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in asthma, on 30 December 2026.","as_of":"2026-06-05","source":"clinicaltrials","source_ref":"NCT05593250","source_url":"https://clinicaltrials.gov/study/NCT05593250","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4e3fe69e-51a3-4305-9df9-30115230bbc6"},{"id":"04be539d-11e9-4d0e-a3f9-7cf82451132d","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Shanghai Henlius Biotech","ticker":null,"asset":"HLX43 Dose 1;","indication":"Colorectal Cancer (CRC)","summary":"As of 17 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Colorectal Cancer (CRC), on 30 December 2026.","as_of":"2025-11-17","source":"clinicaltrials","source_ref":"NCT07106892","source_url":"https://clinicaltrials.gov/study/NCT07106892","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-04be539d-11e9-4d0e-a3f9-7cf82451132d"},{"id":"7be866dd-4194-4bdc-8d87-4940bba452b9","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Shionogi","ticker":null,"asset":"S-337395","indication":"Respiratory Syncytial Virus Infections","summary":"As of 11 August 2026, Shionogi estimated primary completion of a Phase 2 trial in Respiratory Syncytial Virus Infections, on 30 December 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT07214571","source_url":"https://clinicaltrials.gov/study/NCT07214571","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7be866dd-4194-4bdc-8d87-4940bba452b9"},{"id":"784ed264-900d-4161-b4eb-c41ff8fdfa14","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":null,"asset":"SKB264","indication":"Selected Subjects With Advanced Solid Tumors","summary":"As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 2 trial in Selected Subjects With Advanced Solid Tumors, on 30 December 2026.","as_of":"2026-05-08","source":"clinicaltrials","source_ref":"NCT05631262","source_url":"https://clinicaltrials.gov/study/NCT05631262","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-784ed264-900d-4161-b4eb-c41ff8fdfa14"},{"id":"6eeb0385-744f-494c-b74d-e4711a3bb232","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Sunshine Lake Pharma Co., Ltd.","ticker":null,"asset":"HEC169096","indication":"Advanced Solid Tumor","summary":"As of 28 April 2026, Sunshine Lake Pharma Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 30 December 2026.","as_of":"2026-04-28","source":"clinicaltrials","source_ref":"NCT05451602","source_url":"https://clinicaltrials.gov/study/NCT05451602","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6eeb0385-744f-494c-b74d-e4711a3bb232"},{"id":"c9ac93ef-4668-4dad-bfab-fe18c2596178","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Supernus Pharmaceuticals, Inc.","ticker":null,"asset":"BIS-001ER","indication":"Focal Impaired Awareness Seizures","summary":"As of 30 August 2022, Supernus Pharmaceuticals estimated primary completion of a Phase 2 trial in Focal Impaired Awareness Seizures, on 30 December 2026.","as_of":"2022-08-30","source":"clinicaltrials","source_ref":"NCT03474770","source_url":"https://clinicaltrials.gov/study/NCT03474770","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c9ac93ef-4668-4dad-bfab-fe18c2596178"},{"id":"25043bd6-c1c5-4a95-94e4-23dbdc526ef7","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Suzhou Abogen Biosciences Co., Ltd.","ticker":null,"asset":"ABO2011 Injection","indication":"Solid Tumor, Adult","summary":"As of 22 August 2025, Suzhou Abogen Biosciences Co. estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 30 December 2026.","as_of":"2025-08-22","source":"clinicaltrials","source_ref":"NCT06088004","source_url":"https://clinicaltrials.gov/study/NCT06088004","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-25043bd6-c1c5-4a95-94e4-23dbdc526ef7"},{"id":"e9742efe-0562-4d07-a1d4-14b76e431f9b","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"asset":"SHR-8068","indication":"Biliary Tract Cancer","summary":"As of 29 May 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Biliary Tract Cancer, on 30 December 2026.","as_of":"2026-05-29","source":"clinicaltrials","source_ref":"NCT06465563","source_url":"https://clinicaltrials.gov/study/NCT06465563","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e9742efe-0562-4d07-a1d4-14b76e431f9b"},{"id":"53336d8b-0b91-46e7-b76f-26ca50a93151","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Swedish Orphan Biovitrum","ticker":null,"asset":"Pacritinib","indication":"VEXAS","summary":"As of 24 April 2026, Swedish Orphan Biovitrum estimated primary completion of a Phase 2 trial in vEXAS, on 30 December 2026.","as_of":"2026-04-24","source":"clinicaltrials","source_ref":"NCT06782373","source_url":"https://clinicaltrials.gov/study/NCT06782373","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-53336d8b-0b91-46e7-b76f-26ca50a93151"},{"id":"b06b44ea-ddbe-4ee0-a461-593afe065923","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Teclison Ltd.","ticker":null,"asset":"Nivolumab Injectable Product","indication":"Hepatocellular Carcinoma","summary":"As of 16 April 2026, Teclison estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 30 December 2026.","as_of":"2026-04-16","source":"clinicaltrials","source_ref":"NCT03259867","source_url":"https://clinicaltrials.gov/study/NCT03259867","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b06b44ea-ddbe-4ee0-a461-593afe065923"},{"id":"38afb856-9278-4555-a005-0b95490113a7","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"ThromBio Pty. Ltd.","ticker":null,"asset":"TBO-309: 60 mg","indication":"Ischemic Stroke","summary":"As of 25 November 2025, ThromBio Pty. estimated primary completion of a Phase 2 trial in Ischemic Stroke, on 30 December 2026.","as_of":"2025-11-25","source":"clinicaltrials","source_ref":"NCT06813651","source_url":"https://clinicaltrials.gov/study/NCT06813651","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-38afb856-9278-4555-a005-0b95490113a7"},{"id":"a7c059ac-1a48-497a-b92f-975383c3f7d1","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Vertex Pharmaceuticals Incorporated","ticker":null,"asset":"Inaxaplin","indication":"Proteinuric Kidney Disease","summary":"As of 5 May 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 2 trial in Proteinuric Kidney Disease, on 30 December 2026.","as_of":"2026-05-05","source":"clinicaltrials","source_ref":"NCT06794996","source_url":"https://clinicaltrials.gov/study/NCT06794996","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a7c059ac-1a48-497a-b92f-975383c3f7d1"},{"id":"950f60a8-cabe-4199-8d45-c2c4bd8620b3","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Wuhan Createrna Science and Technology Co., Ltd","ticker":null,"asset":"MY008211A tablets","indication":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","summary":"As of 18 April 2025, Wuhan Createrna Science and Technology Co. estimated primary completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria (PNH), on 30 December 2026.","as_of":"2025-04-18","source":"clinicaltrials","source_ref":"NCT06933914","source_url":"https://clinicaltrials.gov/study/NCT06933914","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-950f60a8-cabe-4199-8d45-c2c4bd8620b3"},{"id":"50a94459-4cfa-41a3-af84-d122251dc4ef","lane":"clinical","event_type":"primary-completion","date":"2026-12-30","date_precision":"day","confidence":"estimated","company":"Xynomic Pharmaceuticals, Inc.","ticker":null,"asset":"Pazopanib","indication":"Renal Cell Carcinoma","summary":"As of 13 April 2025, Xynomic Pharmaceuticals estimated primary completion of a Phase 3 trial in Renal Cell Carcinoma, on 30 December 2026.","as_of":"2025-04-13","source":"clinicaltrials","source_ref":"NCT03592472","source_url":"https://clinicaltrials.gov/study/NCT03592472","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-50a94459-4cfa-41a3-af84-d122251dc4ef"},{"id":"d45ab580-d6e7-464a-abee-d329696a85b9","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"AMO Pharma Limited","ticker":null,"asset":"Tideglusib","indication":"Congenital Myotonic Dystrophy","summary":"As of 28 May 2025, AMO Pharma estimated primary completion of a Phase 3 trial in Congenital Myotonic Dystrophy, on 31 December 2026.","as_of":"2025-05-28","source":"clinicaltrials","source_ref":"NCT05004129","source_url":"https://clinicaltrials.gov/study/NCT05004129","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d45ab580-d6e7-464a-abee-d329696a85b9"},{"id":"19417d38-12dc-4218-90dd-a718fbf900d0","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"AUG Therapeutics","ticker":null,"asset":"AVTX-803","indication":"Leukocyte Adhesion Deficiency","summary":"As of 1 May 2026, AUG Therapeutics estimated primary completion of a Phase 3 trial in Leukocyte Adhesion Deficiency, on 31 December 2026.","as_of":"2026-05-01","source":"clinicaltrials","source_ref":"NCT05754450","source_url":"https://clinicaltrials.gov/study/NCT05754450","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-19417d38-12dc-4218-90dd-a718fbf900d0"},{"id":"892f3408-5830-458d-98e8-9a1be4b6e8e2","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Akeso","ticker":null,"asset":"AK112","indication":"Advanced Malignant Tumors","summary":"As of 9 March 2026, Akeso estimated primary completion of a Phase 2 trial in Advanced Malignant Tumors, on 31 December 2026.","as_of":"2026-03-09","source":"clinicaltrials","source_ref":"NCT05229497","source_url":"https://clinicaltrials.gov/study/NCT05229497","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-892f3408-5830-458d-98e8-9a1be4b6e8e2"},{"id":"a2711bfd-8933-4e8e-8d7e-7394e4b61de8","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Albireo, an Ipsen Company","ticker":null,"asset":"Odevixibat","indication":"Alagille Syndrome","summary":"As of 2 July 2026, Albireo, an Ipsen estimated primary completion of a Phase 3 trial in Alagille Syndrome, on 31 December 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT05035030","source_url":"https://clinicaltrials.gov/study/NCT05035030","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a2711bfd-8933-4e8e-8d7e-7394e4b61de8"},{"id":"9318804d-8f37-4d5c-b9cb-2c266381be92","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Allist Pharmaceuticals, Inc.","ticker":null,"asset":"JAB-21822","indication":"KRAS P.G12C","summary":"As of 13 March 2026, Allist Pharmaceuticals estimated primary completion of a Phase 2 trial in KRAS P.G12C, on 31 December 2026.","as_of":"2026-03-13","source":"clinicaltrials","source_ref":"NCT06008288","source_url":"https://clinicaltrials.gov/study/NCT06008288","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9318804d-8f37-4d5c-b9cb-2c266381be92"},{"id":"c562d7dd-1702-4d73-92a7-78c3084fa907","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Amicus Therapeutics","ticker":null,"asset":"migalastat HCl 150 mg","indication":"Fabry Disease","summary":"As of 6 July 2026, Amicus Therapeutics estimated primary completion of a Phase 3 trial in Fabry Disease, on 31 December 2026.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT04020055","source_url":"https://clinicaltrials.gov/study/NCT04020055","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c562d7dd-1702-4d73-92a7-78c3084fa907"},{"id":"45713dce-5e5b-4657-b153-bcd3097f4407","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Annexon, Inc.","ticker":null,"asset":"Tanruprubart","indication":"Guillain-Barre Syndrome","summary":"As of 28 May 2026, Annexon estimated primary completion of a Phase 3 trial in Guillain-Barre Syndrome, on 31 December 2026.","as_of":"2026-05-28","source":"clinicaltrials","source_ref":"NCT07020819","source_url":"https://clinicaltrials.gov/study/NCT07020819","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-45713dce-5e5b-4657-b153-bcd3097f4407"},{"id":"68c98cd9-8780-4075-a6ab-3471d5435145","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Ascentage Pharma Group Inc.","ticker":null,"asset":"lisaftoclax +BTK inhibitor","indication":"CLL/SLL","summary":"As of 18 June 2026, Ascentage Pharma Group estimated primary completion of a Phase 3 trial in cLL/SLL, on 31 December 2026.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT06104566","source_url":"https://clinicaltrials.gov/study/NCT06104566","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-68c98cd9-8780-4075-a6ab-3471d5435145"},{"id":"7a60de03-1212-4586-9473-ac7e99b81a69","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"AskGene Pharma, Inc.","ticker":null,"asset":"ASKG915","indication":"Advanced Solid Tumors","summary":"As of 27 January 2026, AskGene Pharma estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 31 December 2026.","as_of":"2026-01-27","source":"clinicaltrials","source_ref":"NCT05867420","source_url":"https://clinicaltrials.gov/study/NCT05867420","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7a60de03-1212-4586-9473-ac7e99b81a69"},{"id":"cd78af66-adbc-4981-a7ae-48f56d349f72","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Astellas Pharma Global Development, Inc.","ticker":null,"asset":"zolbetuximab","indication":"Pharmacokinetics of Zolbetuximab","summary":"As of 18 June 2026, Astellas Pharma Global Development estimated primary completion of a Phase 2 trial in Pharmacokinetics of Zolbetuximab, on 31 December 2026.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT03505320","source_url":"https://clinicaltrials.gov/study/NCT03505320","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cd78af66-adbc-4981-a7ae-48f56d349f72"},{"id":"7953d068-198c-4fd4-b2aa-d5217100b64e","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Durvalumab","indication":"Cancer","summary":"As of 11 August 2026, AstraZeneca estimated primary completion of a Phase 3 trial in cancer, on 31 December 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT05303532","source_url":"https://clinicaltrials.gov/study/NCT05303532","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7953d068-198c-4fd4-b2aa-d5217100b64e"},{"id":"5db56148-2a3b-4fc1-87e3-2cde789596c6","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Aveta Biomics, Inc.","ticker":null,"asset":"APG-157","indication":"Glioma","summary":"As of 8 June 2026, Aveta Biomics estimated primary completion of a Phase 2 trial in glioma, on 31 December 2026.","as_of":"2026-06-08","source":"clinicaltrials","source_ref":"NCT06011109","source_url":"https://clinicaltrials.gov/study/NCT06011109","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5db56148-2a3b-4fc1-87e3-2cde789596c6"},{"id":"957739ba-daf2-410c-bbf3-e1f629e24420","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Avistone Biotechnology Co., Ltd.","ticker":null,"asset":"Vebreltinib","indication":"Non-Small-Cell Lung Cancer","summary":"As of 21 May 2025, Avistone Biotechnology Co. estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer, on 31 December 2026.","as_of":"2025-05-21","source":"clinicaltrials","source_ref":"NCT06343064","source_url":"https://clinicaltrials.gov/study/NCT06343064","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-957739ba-daf2-410c-bbf3-e1f629e24420"},{"id":"2f3a4ddb-4640-4805-b409-ff63ef5378a6","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Azure Biotech Inc.","ticker":null,"asset":"Lasofoxifene Tartrate","indication":"Vulvo Vaginal Atrophy (VVA)","summary":"As of 22 May 2026, Azure Biotech estimated primary completion of a Phase 2 trial in Vulvo Vaginal Atrophy (VVA), on 31 December 2026.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT06197568","source_url":"https://clinicaltrials.gov/study/NCT06197568","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2f3a4ddb-4640-4805-b409-ff63ef5378a6"},{"id":"9d06b9c9-2843-4167-8fc4-f2167f56a131","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Beijing Tuohua Weiye Biotechnology Co., Ltd.","ticker":null,"asset":"Human Umbilical Cord Mesenchymal Stem Cells Injection","indication":"Decompensated Hepatitis B Cirrhosis","summary":"As of 17 February 2026, Beijing Tuohua Weiye Biotechnology Co. estimated primary completion of a Phase 2 trial in Decompensated Hepatitis B Cirrhosis, on 31 December 2026.","as_of":"2026-02-17","source":"clinicaltrials","source_ref":"NCT07413549","source_url":"https://clinicaltrials.gov/study/NCT07413549","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9d06b9c9-2843-4167-8fc4-f2167f56a131"},{"id":"ae093e94-471c-49fa-919b-201ae5936813","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"BioInvent International AB","ticker":null,"asset":"BI-1808","indication":"Advanced Malignancies","summary":"As of 18 February 2026, BioInvent International estimated primary completion of a Phase 2 trial in Advanced Malignancies, on 31 December 2026.","as_of":"2026-02-18","source":"clinicaltrials","source_ref":"NCT04752826","source_url":"https://clinicaltrials.gov/study/NCT04752826","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ae093e94-471c-49fa-919b-201ae5936813"},{"id":"3fad6e01-b3ad-489b-94f9-13427110af0e","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Biocity Biopharmaceutics Co., Ltd.","ticker":null,"asset":"SC0062 strength 10mg","indication":"IgA Nephropathy (IgAN)","summary":"As of 17 February 2025, Biocity Biopharmaceutics Co. estimated primary completion of a Phase 3 trial in IgA Nephropathy (IgAN), on 31 December 2026.","as_of":"2025-02-17","source":"clinicaltrials","source_ref":"NCT06819826","source_url":"https://clinicaltrials.gov/study/NCT06819826","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3fad6e01-b3ad-489b-94f9-13427110af0e"},{"id":"eb9e7266-9370-42da-bc09-481765cb82ee","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Blueprint Medicines Corporation","ticker":null,"asset":"BLU-808","indication":"Chronic Inducible Urticaria","summary":"As of 22 July 2026, Blueprint Medicines estimated primary completion of a Phase 2 trial in Chronic Inducible Urticaria, on 31 December 2026.","as_of":"2026-07-22","source":"clinicaltrials","source_ref":"NCT06931405","source_url":"https://clinicaltrials.gov/study/NCT06931405","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-eb9e7266-9370-42da-bc09-481765cb82ee"},{"id":"d04cdc1a-93d1-4f97-8538-6a9579c670a6","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Chongqing Precision Biotech Co., Ltd","ticker":null,"asset":"BCMA targeted prime CAR-T cells","indication":"Multiple Myeloma","summary":"As of 25 February 2025, Chongqing Precision Biotech Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 31 December 2026.","as_of":"2025-02-25","source":"clinicaltrials","source_ref":"NCT04776330","source_url":"https://clinicaltrials.gov/study/NCT04776330","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d04cdc1a-93d1-4f97-8538-6a9579c670a6"},{"id":"94f2351a-f629-41b5-a46f-b4655100c902","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Chongqing Precision Biotech Co., Ltd","ticker":null,"asset":"BCMA CAR-T cells","indication":"Multiple Myeloma","summary":"As of 25 February 2025, Chongqing Precision Biotech Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 31 December 2026.","as_of":"2025-02-25","source":"clinicaltrials","source_ref":"NCT04271644","source_url":"https://clinicaltrials.gov/study/NCT04271644","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-94f2351a-f629-41b5-a46f-b4655100c902"},{"id":"570b32dc-61a1-4d7c-a7ca-58f4a9bf9185","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Chongqing Precision Biotech Co., Ltd","ticker":null,"asset":"CD19 and CD22 targeted prime CAR-T cells","indication":"B-ALL","summary":"As of 25 February 2025, Chongqing Precision Biotech Co. estimated primary completion of a Phase 2 trial in b-ALL, on 31 December 2026.","as_of":"2025-02-25","source":"clinicaltrials","source_ref":"NCT04781634","source_url":"https://clinicaltrials.gov/study/NCT04781634","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-570b32dc-61a1-4d7c-a7ca-58f4a9bf9185"},{"id":"4a5f027a-6c22-4aa1-b7db-db626bad26f1","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Clarity Pharmaceuticals Ltd","ticker":null,"asset":"64Cu-SAR-bisPSMA","indication":"Prostate Cancer","summary":"As of 14 May 2026, Clarity Pharmaceuticals estimated primary completion of a Phase 3 trial in Prostate Cancer, on 31 December 2026.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT06970847","source_url":"https://clinicaltrials.gov/study/NCT06970847","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4a5f027a-6c22-4aa1-b7db-db626bad26f1"},{"id":"09bb6e07-f0f6-473e-bef2-5e57cee601c4","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Clearmind Medicine Inc.","ticker":null,"asset":"CMND-100","indication":"Alcohol Use Disorder","summary":"As of 31 March 2026, Clearmind Medicine estimated primary completion of a Phase 2 trial in Alcohol Use Disorder, on 31 December 2026.","as_of":"2026-03-31","source":"clinicaltrials","source_ref":"NCT05913752","source_url":"https://clinicaltrials.gov/study/NCT05913752","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-09bb6e07-f0f6-473e-bef2-5e57cee601c4"},{"id":"27823096-33ff-478b-b339-720906b44dbe","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Cloudbreak Therapeutics, LLC","ticker":null,"asset":"CBT-001","indication":"Pterygium","summary":"As of 24 September 2025, Cloudbreak Therapeutics estimated primary completion of a Phase 3 trial in pterygium, on 31 December 2026.","as_of":"2025-09-24","source":"clinicaltrials","source_ref":"NCT05456425","source_url":"https://clinicaltrials.gov/study/NCT05456425","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-27823096-33ff-478b-b339-720906b44dbe"},{"id":"4aa03e93-9cd5-4027-86b1-71a01623705f","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Corza Medical GmbH","ticker":null,"asset":"TachoSil","indication":"Hemorrhage","summary":"As of 30 June 2026, Corza Medical estimated primary completion of a Phase 3 trial in hemorrhage, on 31 December 2026.","as_of":"2026-06-30","source":"clinicaltrials","source_ref":"NCT06664775","source_url":"https://clinicaltrials.gov/study/NCT06664775","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4aa03e93-9cd5-4027-86b1-71a01623705f"},{"id":"6591156b-4994-4f08-a668-bbf60f185699","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.","ticker":null,"asset":"QY201 Tablets(5mg）","indication":"Adult Subjects With Non-Segmental Vitiligo","summary":"As of 17 July 2026, E-nitiate Biopharmaceuticals (Hangzhou) Co. estimated primary completion of a Phase 2 trial in Adult Subjects With Non-Segmental Vitiligo, on 31 December 2026.","as_of":"2026-07-17","source":"clinicaltrials","source_ref":"NCT07712523","source_url":"https://clinicaltrials.gov/study/NCT07712523","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6591156b-4994-4f08-a668-bbf60f185699"},{"id":"a310cdf7-1561-4c86-98a9-21a42bf9e808","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"ENCell","ticker":null,"asset":"EN001","indication":"Charcot-Marie-Tooth Disease Type 1A","summary":"As of 26 May 2026, ENCell estimated primary completion of a Phase 2 trial in Charcot-Marie-Tooth Disease Type 1A, on 31 December 2026.","as_of":"2026-05-26","source":"clinicaltrials","source_ref":"NCT06328712","source_url":"https://clinicaltrials.gov/study/NCT06328712","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a310cdf7-1561-4c86-98a9-21a42bf9e808"},{"id":"c442f20a-6bfa-4f6e-827c-30f2b2e853f4","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Elixiron Immunotherapeutics (Hong Kong) Ltd.","ticker":null,"asset":"EI-001","indication":"Non-segmental Vitiligo","summary":"As of 5 June 2026, Elixiron Immunotherapeutics (Hong Kong) estimated primary completion of a Phase 2 trial in Non-segmental Vitiligo, on 31 December 2026.","as_of":"2026-06-05","source":"clinicaltrials","source_ref":"NCT07223229","source_url":"https://clinicaltrials.gov/study/NCT07223229","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c442f20a-6bfa-4f6e-827c-30f2b2e853f4"},{"id":"b4928b95-f570-4544-8203-31422c5f6228","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Estrella Biopharma, Inc.","ticker":null,"asset":"EB103","indication":"B-Cell Non-Hodgkin's Lymphoma (NHL)","summary":"As of 7 August 2025, Estrella Biopharma estimated primary completion of a Phase 2 trial in B-Cell Non-Hodgkin's Lymphoma (NHL), on 31 December 2026.","as_of":"2025-08-07","source":"clinicaltrials","source_ref":"NCT06343311","source_url":"https://clinicaltrials.gov/study/NCT06343311","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b4928b95-f570-4544-8203-31422c5f6228"},{"id":"b9d47797-1530-48a7-9767-456b0899ebff","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Evopoint Biosciences Inc.","ticker":null,"asset":"XNW28012","indication":"Advanced Solid Tumors","summary":"As of 15 April 2026, Evopoint Biosciences estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 31 December 2026.","as_of":"2026-04-15","source":"clinicaltrials","source_ref":"NCT06799637","source_url":"https://clinicaltrials.gov/study/NCT06799637","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b9d47797-1530-48a7-9767-456b0899ebff"},{"id":"7d1ec24e-0bc7-4994-9d9d-d51ab9259dd9","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Excelsior","ticker":null,"asset":"EX039","indication":"Alzheimer Disease","summary":"As of 26 February 2025, Excelsior estimated primary completion of a Phase 2 trial in Alzheimer Disease, on 31 December 2026.","as_of":"2025-02-26","source":"clinicaltrials","source_ref":"NCT05413655","source_url":"https://clinicaltrials.gov/study/NCT05413655","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7d1ec24e-0bc7-4994-9d9d-d51ab9259dd9"},{"id":"145c1165-2b05-4b12-9b71-e97035e1e9a3","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Excyte Biopharma Ltd","ticker":null,"asset":"YK012","indication":"B-cell Acute Lymphoblastic Leukemia","summary":"As of 6 February 2026, Excyte Biopharma estimated primary completion of a Phase 2 trial in B-cell Acute Lymphoblastic Leukemia, on 31 December 2026.","as_of":"2026-02-06","source":"clinicaltrials","source_ref":"NCT06580301","source_url":"https://clinicaltrials.gov/study/NCT06580301","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-145c1165-2b05-4b12-9b71-e97035e1e9a3"},{"id":"89ecbedd-7317-45af-95cb-37d2d2c12524","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Frantz Viral Therapeutics, LLC","ticker":null,"asset":"Artesunate ointment","indication":"Anal High-grade Squamous Intraepithelial Lesion","summary":"As of 18 May 2025, Frantz Viral Therapeutics estimated primary completion of a Phase 2 trial in Anal High-grade Squamous Intraepithelial Lesion, on 31 December 2026.","as_of":"2025-05-18","source":"clinicaltrials","source_ref":"NCT06206564","source_url":"https://clinicaltrials.gov/study/NCT06206564","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-89ecbedd-7317-45af-95cb-37d2d2c12524"},{"id":"930d107d-0256-4e75-b2ff-30e9f542d70c","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Galderma R&D","ticker":null,"asset":"Trifarotene","indication":"Acne Vulgaris","summary":"As of 21 November 2025, Galderma R&D estimated primary completion of a Phase 3 trial in Acne Vulgaris, on 31 December 2026.","as_of":"2025-11-21","source":"clinicaltrials","source_ref":"NCT07186413","source_url":"https://clinicaltrials.gov/study/NCT07186413","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-930d107d-0256-4e75-b2ff-30e9f542d70c"},{"id":"06703282-6525-45bb-aaa7-d3de410142d3","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"GeneCradle Inc","ticker":null,"asset":"GC101 adeno-associated virus injection","indication":"SMA - Spinal Muscular Atrophy","summary":"As of 5 June 2025, GeneCradle estimated primary completion of a Phase 3 trial in SMA - Spinal Muscular Atrophy, on 31 December 2026.","as_of":"2025-06-05","source":"clinicaltrials","source_ref":"NCT06971094","source_url":"https://clinicaltrials.gov/study/NCT06971094","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-06703282-6525-45bb-aaa7-d3de410142d3"},{"id":"0c9b7b75-71c9-40cf-a08a-145933f1d199","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Genfleet Therapeutics (Shanghai) Inc.","ticker":null,"asset":"GFH009","indication":"Large B-cell Lymphoma","summary":"As of 12 August 2025, Genfleet Therapeutics (Shanghai) estimated primary completion of a Phase 2 trial in Large B-cell Lymphoma, on 31 December 2026.","as_of":"2025-08-12","source":"clinicaltrials","source_ref":"NCT06375733","source_url":"https://clinicaltrials.gov/study/NCT06375733","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0c9b7b75-71c9-40cf-a08a-145933f1d199"},{"id":"89ef54d4-7578-4619-9897-7ecc7667a72d","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"GeoVax, Inc.","ticker":null,"asset":"COVID-19 Vaccine","indication":"COVID-19 Infection","summary":"As of 11 February 2026, GeoVax estimated primary completion of a Phase 2 trial in COVID-19 Infection, on 31 December 2026.","as_of":"2026-02-11","source":"clinicaltrials","source_ref":"NCT04977024","source_url":"https://clinicaltrials.gov/study/NCT04977024","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-89ef54d4-7578-4619-9897-7ecc7667a72d"},{"id":"0dc8799e-a7a8-414b-a595-8cd22c5645fe","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Guangzhou Gloria Biosciences Co., Ltd.","ticker":null,"asset":"Motixafortide+G-CSF","indication":"Multiple Myeloma","summary":"As of 16 December 2025, Guangzhou Gloria Biosciences Co. estimated primary completion of a Phase 3 trial in Multiple Myeloma, on 31 December 2026.","as_of":"2025-12-16","source":"clinicaltrials","source_ref":"NCT06514508","source_url":"https://clinicaltrials.gov/study/NCT06514508","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0dc8799e-a7a8-414b-a595-8cd22c5645fe"},{"id":"21e0b680-d2d0-48f3-a076-f4dcb8516030","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Guangzhou JOYO Pharma Co., Ltd","ticker":null,"asset":"SC1011","indication":"Idiopathic Pulmonary Fibrosis","summary":"As of 19 November 2024, Guangzhou JOYO Pharma Co. estimated primary completion of a Phase 3 trial in Idiopathic Pulmonary Fibrosis, on 31 December 2026.","as_of":"2024-11-19","source":"clinicaltrials","source_ref":"NCT06125327","source_url":"https://clinicaltrials.gov/study/NCT06125327","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-21e0b680-d2d0-48f3-a076-f4dcb8516030"},{"id":"855d26eb-da67-48f4-8cee-a53dba15aba5","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Hangzhou Hanx Biopharmaceuticals, Ltd.","ticker":null,"asset":"HX301+/Temozolomide","indication":"Glioma","summary":"As of 15 January 2025, Hangzhou Hanx Biopharmaceuticals estimated primary completion of a Phase 2 trial in glioma, on 31 December 2026.","as_of":"2025-01-15","source":"clinicaltrials","source_ref":"NCT06703255","source_url":"https://clinicaltrials.gov/study/NCT06703255","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-855d26eb-da67-48f4-8cee-a53dba15aba5"},{"id":"c0630fe1-01ff-46bf-91de-77a8509f0aff","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Hangzhou Highlightll Pharmaceutical Co., Ltd","ticker":null,"asset":"TLL-018","indication":"Rheumatoid Arthritis","summary":"As of 20 May 2026, Hangzhou Highlightll Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Rheumatoid Arthritis, on 31 December 2026.","as_of":"2026-05-20","source":"clinicaltrials","source_ref":"NCT06887127","source_url":"https://clinicaltrials.gov/study/NCT06887127","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c0630fe1-01ff-46bf-91de-77a8509f0aff"},{"id":"5fbd0498-b621-4a87-a751-684c0aead222","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Hillhurst Biopharmaceuticals, Inc.","ticker":null,"asset":"HBI-002","indication":"Parkinson Disease","summary":"As of 10 August 2026, Hillhurst Biopharmaceuticals estimated primary completion of a Phase 2 trial in Parkinson Disease, on 31 December 2026.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT07005180","source_url":"https://clinicaltrials.gov/study/NCT07005180","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5fbd0498-b621-4a87-a751-684c0aead222"},{"id":"4dd40fca-9b40-472f-a038-ccc98ebdece9","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Inavolisib","indication":"Metastatic Breast Cancer","summary":"As of 27 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Metastatic Breast Cancer, on 31 December 2026.","as_of":"2026-07-27","source":"clinicaltrials","source_ref":"NCT05894239","source_url":"https://clinicaltrials.gov/study/NCT05894239","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4dd40fca-9b40-472f-a038-ccc98ebdece9"},{"id":"c7ec1d6d-1708-4381-aa7e-391fb59178e9","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Atezolizumab","indication":"Cancer","summary":"As of 10 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in cancer, on 31 December 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT03148418","source_url":"https://clinicaltrials.gov/study/NCT03148418","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c7ec1d6d-1708-4381-aa7e-391fb59178e9"},{"id":"b4c8fb59-1e13-485c-9fa9-9b45e2aaaa51","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Atezolizumab","indication":"Urothelial Cancer","summary":"As of 28 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Urothelial Cancer, on 31 December 2026.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT05645692","source_url":"https://clinicaltrials.gov/study/NCT05645692","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b4c8fb59-1e13-485c-9fa9-9b45e2aaaa51"},{"id":"e920edb4-bc5c-4c42-a630-44bfcd88a867","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Afimkibart","indication":"Crohns Disease","summary":"As of 23 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Crohns Disease, on 31 December 2026.","as_of":"2026-06-23","source":"clinicaltrials","source_ref":"NCT05910528","source_url":"https://clinicaltrials.gov/study/NCT05910528","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e920edb4-bc5c-4c42-a630-44bfcd88a867"},{"id":"da31f7d8-914f-451c-932f-74bd63bac2de","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Pertuzumab","indication":"Solid Tumors","summary":"As of 11 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Solid Tumors, on 31 December 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT02320435","source_url":"https://clinicaltrials.gov/study/NCT02320435","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-da31f7d8-914f-451c-932f-74bd63bac2de"},{"id":"fd3aa78e-3f97-4dfc-8069-9a18a4d2a48c","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","ticker":null,"asset":"IBR854","indication":"Renal Cell Carcinoma (RCC)","summary":"As of 2 July 2026, Imbioray (Hangzhou) Biomedicine Co. estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma (RCC), on 31 December 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT07087158","source_url":"https://clinicaltrials.gov/study/NCT07087158","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fd3aa78e-3f97-4dfc-8069-9a18a4d2a48c"},{"id":"a4201c38-6152-4999-acb5-e787a1b97ed2","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Impact Therapeutics, Inc.","ticker":null,"asset":"IMP9064","indication":"Solid Tumor","summary":"As of 1 April 2025, Impact Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, on 31 December 2026.","as_of":"2025-04-01","source":"clinicaltrials","source_ref":"NCT05269316","source_url":"https://clinicaltrials.gov/study/NCT05269316","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a4201c38-6152-4999-acb5-e787a1b97ed2"},{"id":"9b3190bf-73f9-4a94-a453-89cbaa734e88","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"asset":"IBI311","indication":"Thyroid Eye Disease","summary":"As of 17 November 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in Thyroid Eye Disease, on 31 December 2026.","as_of":"2025-11-17","source":"clinicaltrials","source_ref":"NCT07113262","source_url":"https://clinicaltrials.gov/study/NCT07113262","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b3190bf-73f9-4a94-a453-89cbaa734e88"},{"id":"48dffd0d-e799-42ce-9a82-8ee24ad719d9","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Innovent Biologics (Suzhou) Co. Ltd.","ticker":null,"asset":"IBI362","indication":"Overweight","summary":"As of 12 May 2026, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in overweight, on 31 December 2026.","as_of":"2026-05-12","source":"clinicaltrials","source_ref":"NCT06884293","source_url":"https://clinicaltrials.gov/study/NCT06884293","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-48dffd0d-e799-42ce-9a82-8ee24ad719d9"},{"id":"15dca72b-0023-43f4-bc85-06ed5f027086","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Innovent Biologics Technology Limited (Shanghai R&D Center)","ticker":null,"asset":"IBI302","indication":"Diabetic Macular Oedema","summary":"As of 27 May 2026, Innovent Biologics Technology estimated primary completion of a Phase 2 trial in Diabetic Macular Oedema, on 31 December 2026.","as_of":"2026-05-27","source":"clinicaltrials","source_ref":"NCT06908876","source_url":"https://clinicaltrials.gov/study/NCT06908876","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-15dca72b-0023-43f4-bc85-06ed5f027086"},{"id":"818f01a6-21be-41be-a62c-716375bd82db","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Inovio Pharmaceuticals","ticker":null,"asset":"INO-5401","indication":"Glioblastoma","summary":"As of 4 May 2026, Inovio Pharmaceuticals estimated primary completion of a Phase 2 trial in glioblastoma, on 31 December 2026.","as_of":"2026-05-04","source":"clinicaltrials","source_ref":"NCT03491683","source_url":"https://clinicaltrials.gov/study/NCT03491683","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-818f01a6-21be-41be-a62c-716375bd82db"},{"id":"a5b4fe84-3e9c-49e2-bb29-dff9437fb9cb","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Insmed Incorporated","ticker":null,"asset":"Treprostinil Palmitil","indication":"Pulmonary Arterial Hypertension","summary":"As of 8 July 2026, Insmed Incorporated estimated primary completion of a Phase 3 trial in Pulmonary Arterial Hypertension, on 31 December 2026.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT05649748","source_url":"https://clinicaltrials.gov/study/NCT05649748","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a5b4fe84-3e9c-49e2-bb29-dff9437fb9cb"},{"id":"3163948f-01c3-4038-a64f-eb174c60b9d2","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Iperboreal Pharma Srl","ticker":null,"asset":"XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght","indication":"End Stage Renal Disease","summary":"As of 24 March 2026, Iperboreal Pharma Srl estimated primary completion of a Phase 3 trial in End Stage Renal Disease, on 31 December 2026.","as_of":"2026-03-24","source":"clinicaltrials","source_ref":"NCT03994471","source_url":"https://clinicaltrials.gov/study/NCT03994471","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3163948f-01c3-4038-a64f-eb174c60b9d2"},{"id":"7767161a-b5ac-47f2-bf84-cbac6e16c841","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"JCR Pharmaceuticals Co., Ltd.","ticker":null,"asset":"JR-141","indication":"Mucopolysaccharidosis II","summary":"As of 24 July 2025, JCR Pharmaceuticals Co. estimated primary completion of a Phase 2 trial in Mucopolysaccharidosis II, on 31 December 2026.","as_of":"2025-07-24","source":"clinicaltrials","source_ref":"NCT03708965","source_url":"https://clinicaltrials.gov/study/NCT03708965","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7767161a-b5ac-47f2-bf84-cbac6e16c841"},{"id":"6dea7e64-ec27-441b-8aeb-2fad67dd9d5a","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Jacobio Pharmaceuticals Co., Ltd.","ticker":null,"asset":"JAB-23E73","indication":"Advanced Solid Tumor","summary":"As of 20 January 2026, Jacobio Pharmaceuticals Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 31 December 2026.","as_of":"2026-01-20","source":"clinicaltrials","source_ref":"NCT06959615","source_url":"https://clinicaltrials.gov/study/NCT06959615","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6dea7e64-ec27-441b-8aeb-2fad67dd9d5a"},{"id":"f726bddd-db30-4fed-bda9-59f2354d369b","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Janssen Research & Development, LLC","ticker":null,"asset":"Ibrutinib","indication":"Chronic Lymphocytic Leukemia","summary":"As of 31 July 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Chronic Lymphocytic Leukemia, on 31 December 2026.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT01804686","source_url":"https://clinicaltrials.gov/study/NCT01804686","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f726bddd-db30-4fed-bda9-59f2354d369b"},{"id":"bbb987b2-54c0-4100-9401-a4a1a6c60a3a","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Jazz Pharmaceuticals","ticker":null,"asset":"Zanidatamab","indication":"Breast Cancer","summary":"As of 10 July 2026, Jazz Pharmaceuticals estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 December 2026.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT06695845","source_url":"https://clinicaltrials.gov/study/NCT06695845","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bbb987b2-54c0-4100-9401-a4a1a6c60a3a"},{"id":"90f5f9f9-6c26-4dcd-aa8e-172e663d792e","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"SHR-A1811","indication":"HER2 Expression / Amplification in Patients With Biliary Tract Cancer","summary":"As of 17 July 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial on 31 December 2026.","as_of":"2026-07-17","source":"clinicaltrials","source_ref":"NCT06413745","source_url":"https://clinicaltrials.gov/study/NCT06413745","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-90f5f9f9-6c26-4dcd-aa8e-172e663d792e"},{"id":"efea8c38-b891-47e3-a216-44bfc47a66ad","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"Fuzuloparib , Abiraterone acetate and Prednisone","indication":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","summary":"As of 31 December 2024, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC), on 31 December 2026.","as_of":"2024-12-31","source":"clinicaltrials","source_ref":"NCT04691804","source_url":"https://clinicaltrials.gov/study/NCT04691804","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-efea8c38-b891-47e3-a216-44bfc47a66ad"},{"id":"665a3338-8d14-4a7e-85e7-575ba623a032","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Jiangsu HengRui Medicine Co., Ltd.","ticker":null,"asset":"SHR-A1811","indication":"HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated...","summary":"As of 22 August 2025, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial on 31 December 2026.","as_of":"2025-08-22","source":"clinicaltrials","source_ref":"NCT05424835","source_url":"https://clinicaltrials.gov/study/NCT05424835","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-665a3338-8d14-4a7e-85e7-575ba623a032"},{"id":"059796ca-58ab-4121-8be3-fe98b56798fd","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Kamau Therapeutics","ticker":null,"asset":"nula-cel Drug Product","indication":"Sickle Cell Disease","summary":"As of 2 July 2026, Kamau Therapeutics estimated primary completion of a Phase 2 trial in Sickle Cell Disease, on 31 December 2026.","as_of":"2026-07-02","source":"clinicaltrials","source_ref":"NCT04819841","source_url":"https://clinicaltrials.gov/study/NCT04819841","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-059796ca-58ab-4121-8be3-fe98b56798fd"},{"id":"c9a58cc2-8f29-4a5d-b2ff-6d8b2a1bd2d5","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Kartos Therapeutics, Inc.","ticker":null,"asset":"Navtemadlin","indication":"Myelofibrosis","summary":"As of 25 September 2025, Kartos Therapeutics estimated primary completion of a Phase 3 trial in myelofibrosis, on 31 December 2026.","as_of":"2025-09-25","source":"clinicaltrials","source_ref":"NCT06479135","source_url":"https://clinicaltrials.gov/study/NCT06479135","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c9a58cc2-8f29-4a5d-b2ff-6d8b2a1bd2d5"},{"id":"18c575fb-816a-44de-b107-73e5fbccb62e","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Klus Pharma Inc.","ticker":null,"asset":"SKB264","indication":"Epithelial Ovarian Cancer","summary":"As of 11 May 2026, Klus Pharma estimated primary completion of a Phase 2 trial in Epithelial Ovarian Cancer, on 31 December 2026.","as_of":"2026-05-11","source":"clinicaltrials","source_ref":"NCT04152499","source_url":"https://clinicaltrials.gov/study/NCT04152499","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-18c575fb-816a-44de-b107-73e5fbccb62e"},{"id":"ba40ce3e-25e3-4bdb-b024-f025790696dc","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Laboratorios Silanes S.A. de C.V.","ticker":null,"asset":"Etoricoxib + Betamethasone fixed dose","indication":"Gout Arthritis","summary":"As of 3 April 2025, Laboratorios Silanes S.A. de C.V. estimated primary completion of a Phase 3 trial in Gout Arthritis, on 31 December 2026.","as_of":"2025-04-03","source":"clinicaltrials","source_ref":"NCT06863701","source_url":"https://clinicaltrials.gov/study/NCT06863701","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ba40ce3e-25e3-4bdb-b024-f025790696dc"},{"id":"5d3965ce-84de-4755-af77-bde74939f5e7","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Lin BioScience, Inc","ticker":null,"asset":"LBS-007","indication":"Relapsed or Resistant Acute Leukaemias","summary":"As of 27 March 2026, Lin BioScience estimated primary completion of a Phase 2 trial in Relapsed or Resistant Acute Leukaemias, on 31 December 2026.","as_of":"2026-03-27","source":"clinicaltrials","source_ref":"NCT05756322","source_url":"https://clinicaltrials.gov/study/NCT05756322","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5d3965ce-84de-4755-af77-bde74939f5e7"},{"id":"6fa20c7a-e6d5-40f7-8170-667814f2f470","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Lukas Biomedical Inc.","ticker":null,"asset":"ATL administration","indication":"Hepatocellular Carcinoma","summary":"As of 6 March 2025, Lukas Biomedical estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 31 December 2026.","as_of":"2025-03-06","source":"clinicaltrials","source_ref":"NCT05304481","source_url":"https://clinicaltrials.gov/study/NCT05304481","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6fa20c7a-e6d5-40f7-8170-667814f2f470"},{"id":"7e967bd3-f977-4e8d-94ad-e7389874b97a","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Mabwell (Shanghai) Bioscience Co., Ltd.","ticker":null,"asset":"9MW2821","indication":"Advanced Urothelial Carcinoma","summary":"As of 19 September 2024, Mabwell (Shanghai) Bioscience Co. estimated primary completion of a Phase 2 trial in Advanced Urothelial Carcinoma, on 31 December 2026.","as_of":"2024-09-19","source":"clinicaltrials","source_ref":"NCT06079112","source_url":"https://clinicaltrials.gov/study/NCT06079112","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7e967bd3-f977-4e8d-94ad-e7389874b97a"},{"id":"c8efb1ec-5cb4-4bfd-9453-db0361940b14","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Mapi Pharma Ltd.","ticker":null,"asset":"Cariprazine Depot","indication":"Schizophrenia","summary":"As of 1 May 2026, Mapi Pharma estimated primary completion of a Phase 2 trial in schizophrenia, on 31 December 2026.","as_of":"2026-05-01","source":"clinicaltrials","source_ref":"NCT07185815","source_url":"https://clinicaltrials.gov/study/NCT07185815","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c8efb1ec-5cb4-4bfd-9453-db0361940b14"},{"id":"13f36aa9-cf00-4170-b348-e327ca7e3d9e","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Materia Medica Holding","ticker":null,"asset":"Raphamin","indication":"Cystitis Chronic","summary":"As of 13 February 2026, Materia Medica Holding estimated primary completion of a Phase 3 trial in Cystitis Chronic, on 31 December 2026.","as_of":"2026-02-13","source":"clinicaltrials","source_ref":"NCT06284265","source_url":"https://clinicaltrials.gov/study/NCT06284265","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-13f36aa9-cf00-4170-b348-e327ca7e3d9e"},{"id":"156070e3-d1f5-4d63-8b07-f5c08284419a","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"MediciNova","ticker":null,"asset":"MN-001","indication":"Diabetes Mellitus, Type 2","summary":"As of 5 February 2026, MediciNova estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, on 31 December 2026.","as_of":"2026-02-05","source":"clinicaltrials","source_ref":"NCT05464784","source_url":"https://clinicaltrials.gov/study/NCT05464784","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-156070e3-d1f5-4d63-8b07-f5c08284419a"},{"id":"beec55b8-a68f-4d99-b25a-8560d4284498","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Miltenyi Biomedicine GmbH","ticker":null,"asset":"zamtocabtagene autoleucel (MB-CART2019.1)","indication":"Refractory Diffuse Large B Cell Lymphoma (DLBCL)","summary":"As of 13 July 2026, Miltenyi Biomedicine estimated primary completion of a Phase 2 trial in Refractory Diffuse Large B Cell Lymphoma (DLBCL), on 31 December 2026.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT04792489","source_url":"https://clinicaltrials.gov/study/NCT04792489","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-beec55b8-a68f-4d99-b25a-8560d4284498"},{"id":"32e9a027-4e26-47c8-bf39-cb567f413e4c","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"NaviFUS Corporation","ticker":null,"asset":"Bevacizumab","indication":"Glioblastoma Multiforme","summary":"As of 9 April 2026, NaviFUS estimated primary completion of a Phase 3 trial in Glioblastoma Multiforme, on 31 December 2026.","as_of":"2026-04-09","source":"clinicaltrials","source_ref":"NCT06496971","source_url":"https://clinicaltrials.gov/study/NCT06496971","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-32e9a027-4e26-47c8-bf39-cb567f413e4c"},{"id":"1e62fbdc-9756-4db5-abee-df54ef4dc45f","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"NaviFUS Corporation","ticker":null,"asset":"NaviFUS System","indication":"Drug Resistant Epilepsy","summary":"As of 9 April 2026, NaviFUS estimated primary completion of a Phase 2 trial in Drug Resistant Epilepsy, on 31 December 2026.","as_of":"2026-04-09","source":"clinicaltrials","source_ref":"NCT06388707","source_url":"https://clinicaltrials.gov/study/NCT06388707","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1e62fbdc-9756-4db5-abee-df54ef4dc45f"},{"id":"4026e87d-47e4-4338-a930-74929ee5aeda","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Newron Pharmaceuticals SPA","ticker":null,"asset":"Evenamide 15 mg bid","indication":"Treatment-resistant Schizophrenia","summary":"As of 30 July 2026, Newron Pharmaceuticals SPA estimated primary completion of a Phase 3 trial in Treatment-resistant Schizophrenia, on 31 December 2026.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT07184619","source_url":"https://clinicaltrials.gov/study/NCT07184619","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4026e87d-47e4-4338-a930-74929ee5aeda"},{"id":"e00b904d-4622-4bca-8ae4-a7d391736c21","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Olatec Therapeutics, Inc.","ticker":null,"asset":"Dapansutrile","indication":"Acute Gout Flare","summary":"As of 11 March 2026, Olatec Therapeutics estimated primary completion of a Phase 3 trial in Acute Gout Flare, on 31 December 2026.","as_of":"2026-03-11","source":"clinicaltrials","source_ref":"NCT05658575","source_url":"https://clinicaltrials.gov/study/NCT05658575","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e00b904d-4622-4bca-8ae4-a7d391736c21"},{"id":"1eb01fe2-2f7a-41a0-910c-aad472d62f82","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Ono Pharmaceutical Co., Ltd.","ticker":null,"asset":"ONO-4538","indication":"Pan-tumor","summary":"As of 3 June 2025, Ono Pharmaceutical Co. estimated primary completion of a Phase 2 trial in pan-tumor, on 31 December 2026.","as_of":"2025-06-03","source":"clinicaltrials","source_ref":"NCT04566380","source_url":"https://clinicaltrials.gov/study/NCT04566380","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1eb01fe2-2f7a-41a0-910c-aad472d62f82"},{"id":"8402b991-79af-4559-b214-07022a127d2f","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Ono Pharmaceutical Co., Ltd.","ticker":null,"asset":"ONO-2020","indication":"Agitation Associated With Alzheimer's Disease Dementia","summary":"As of 12 May 2026, Ono Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Agitation Associated With Alzheimer's Disease Dementia, on 31 December 2026.","as_of":"2026-05-12","source":"clinicaltrials","source_ref":"NCT06803823","source_url":"https://clinicaltrials.gov/study/NCT06803823","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8402b991-79af-4559-b214-07022a127d2f"},{"id":"972b46b2-b509-4c53-9ac5-9110bc8e4c22","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Partner Therapeutics, Inc.","ticker":null,"asset":"zenocutuzumab (MCLA-128)","indication":"Solid Tumours Harboring NRG1 Fusion","summary":"As of 29 April 2025, Partner Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumours Harboring NRG1 Fusion, on 31 December 2026.","as_of":"2025-04-29","source":"clinicaltrials","source_ref":"NCT02912949","source_url":"https://clinicaltrials.gov/study/NCT02912949","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-972b46b2-b509-4c53-9ac5-9110bc8e4c22"},{"id":"83312d41-68ed-457c-93cc-3c516ce5e55c","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Pell Bio-Med Technology Co., Ltd.","ticker":null,"asset":"CD19-targeted chimeric antigen receptor T-cell","indication":"Diffuse Large B Cell Lymphoma","summary":"As of 13 May 2025, Pell Bio-Med Technology Co. estimated primary completion of a Phase 2 trial in Diffuse Large B Cell Lymphoma, on 31 December 2026.","as_of":"2025-05-13","source":"clinicaltrials","source_ref":"NCT05326243","source_url":"https://clinicaltrials.gov/study/NCT05326243","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-83312d41-68ed-457c-93cc-3c516ce5e55c"},{"id":"664d79fc-3c89-4f67-abec-0b128aca98d5","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"Avelumab","indication":"Advanced Malignancies","summary":"As of 22 June 2026, Pfizer estimated primary completion of a Phase 3 trial in Advanced Malignancies, on 31 December 2026.","as_of":"2026-06-22","source":"clinicaltrials","source_ref":"NCT05059522","source_url":"https://clinicaltrials.gov/study/NCT05059522","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-664d79fc-3c89-4f67-abec-0b128aca98d5"},{"id":"503d2225-2195-4467-8d0a-35fac3f40ab0","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"PF-07104091 monotherapy dose escalation","indication":"Small Cell Lung Cancer","summary":"As of 6 May 2026, Pfizer estimated primary completion of a Phase 2 trial in Small Cell Lung Cancer, on 31 December 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT04553133","source_url":"https://clinicaltrials.gov/study/NCT04553133","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-503d2225-2195-4467-8d0a-35fac3f40ab0"},{"id":"3ffddcb9-f6b1-4f46-8b13-bb5da4a5c60f","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"Palbociclib","indication":"Breast Cancer","summary":"As of 25 November 2025, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 December 2026.","as_of":"2025-11-25","source":"clinicaltrials","source_ref":"NCT05226871","source_url":"https://clinicaltrials.gov/study/NCT05226871","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3ffddcb9-f6b1-4f46-8b13-bb5da4a5c60f"},{"id":"b7e3f026-095d-4697-93fe-96b219a23406","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"vepdegestrant","indication":"Breast Cancer","summary":"As of 6 May 2026, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 December 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT06125522","source_url":"https://clinicaltrials.gov/study/NCT06125522","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b7e3f026-095d-4697-93fe-96b219a23406"},{"id":"9f44b4d9-8366-4d1a-a068-1806c276f146","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"RemeGen Co., Ltd.","ticker":null,"asset":"Telitacicept","indication":"Myasthenia Gravis, Ocular","summary":"As of 9 April 2026, RemeGen Co. estimated primary completion of a Phase 3 trial in Myasthenia Gravis, Ocular, on 31 December 2026.","as_of":"2026-04-09","source":"clinicaltrials","source_ref":"NCT07249632","source_url":"https://clinicaltrials.gov/study/NCT07249632","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9f44b4d9-8366-4d1a-a068-1806c276f146"},{"id":"d6e583be-387f-4dc4-9562-f7c27e3361e4","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"RemeGen Co., Ltd.","ticker":null,"asset":"RC48-ADC","indication":"Urothelial Carcinoma","summary":"As of 18 December 2023, RemeGen Co. estimated primary completion of a Phase 3 trial in Urothelial Carcinoma, on 31 December 2026.","as_of":"2023-12-18","source":"clinicaltrials","source_ref":"NCT05302284","source_url":"https://clinicaltrials.gov/study/NCT05302284","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d6e583be-387f-4dc4-9562-f7c27e3361e4"},{"id":"94d5661c-784a-4b2e-b056-4e25a4a60047","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Remedy","ticker":null,"asset":"MDMA assisted psychotherapy","indication":"Post Traumatic Stress Disorder","summary":"As of 26 November 2024, Remedy estimated primary completion of a Phase 2 trial in Post Traumatic Stress Disorder, on 31 December 2026.","as_of":"2024-11-26","source":"clinicaltrials","source_ref":"NCT06044675","source_url":"https://clinicaltrials.gov/study/NCT06044675","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-94d5661c-784a-4b2e-b056-4e25a4a60047"},{"id":"2fecb9e6-30b3-4060-8051-97de116ebca1","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Rhizen Pharmaceuticals SA","ticker":null,"asset":"Tenalisib","indication":"Triple Negative Breast Cancer (TNBC)","summary":"As of 2 December 2025, Rhizen Pharmaceuticals SA estimated primary completion of a Phase 2 trial in Triple Negative Breast Cancer (TNBC), on 31 December 2026.","as_of":"2025-12-02","source":"clinicaltrials","source_ref":"NCT06189209","source_url":"https://clinicaltrials.gov/study/NCT06189209","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2fecb9e6-30b3-4060-8051-97de116ebca1"},{"id":"c7feb2eb-e405-45ca-94c2-0fac821a1eeb","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Sano Chemicals Inc","ticker":null,"asset":"OCF001 Intravaginal Gel","indication":"Candidiasis, Vulvovaginal","summary":"As of 15 June 2026, Sano Chemicals estimated primary completion of a Phase 2 trial in Candidiasis, Vulvovaginal, on 31 December 2026.","as_of":"2026-06-15","source":"clinicaltrials","source_ref":"NCT07521137","source_url":"https://clinicaltrials.gov/study/NCT07521137","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c7feb2eb-e405-45ca-94c2-0fac821a1eeb"},{"id":"d18a3956-f539-4831-8964-5d6c265f29b2","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Sarepta Therapeutics, Inc.","ticker":null,"asset":"SRP-1003 IV Infusion","indication":"Myotonic Dystrophy 1","summary":"As of 11 August 2026, Sarepta Therapeutics estimated primary completion of a Phase 2 trial in Myotonic Dystrophy 1, on 31 December 2026.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT06138743","source_url":"https://clinicaltrials.gov/study/NCT06138743","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d18a3956-f539-4831-8964-5d6c265f29b2"},{"id":"a2356f11-a683-40fc-94c1-6685d627b918","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"ScinnoHub Pharmaceutical Co., Ltd.","ticker":null,"asset":"Low-dose BT-114143","indication":"Total Knee Arthroplasty","summary":"As of 15 December 2025, ScinnoHub Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Total Knee Arthroplasty, on 31 December 2026.","as_of":"2025-12-15","source":"clinicaltrials","source_ref":"NCT07127042","source_url":"https://clinicaltrials.gov/study/NCT07127042","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a2356f11-a683-40fc-94c1-6685d627b918"},{"id":"325dc972-3120-4de5-aae9-43e1a332906d","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Serum Institute of India Pvt. Ltd.","ticker":null,"asset":"Cervavac as three dose regimen","indication":"Human Papillomavirus Infection","summary":"As of 29 June 2026, Serum Institute of India Pvt. estimated primary completion of a Phase 3 trial in Human Papillomavirus Infection, on 31 December 2026.","as_of":"2026-06-29","source":"clinicaltrials","source_ref":"NCT06281119","source_url":"https://clinicaltrials.gov/study/NCT06281119","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-325dc972-3120-4de5-aae9-43e1a332906d"},{"id":"5d3f61b9-263f-47c5-b06b-b49b4ff2c132","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shanghai Cell Therapy Group Co.,Ltd","ticker":null,"asset":"Super DC Vaccine","indication":"Solid Tumor Cancer","summary":"As of 28 August 2025, Shanghai Cell Therapy Group Co. estimated primary completion of a Phase 2 trial in Solid Tumor Cancer, on 31 December 2026.","as_of":"2025-08-28","source":"clinicaltrials","source_ref":"NCT07146672","source_url":"https://clinicaltrials.gov/study/NCT07146672","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5d3f61b9-263f-47c5-b06b-b49b4ff2c132"},{"id":"91f0cb71-b0b8-417f-82c7-b6fc27456964","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shanghai Henlius Biotech","ticker":null,"asset":"HLX43","indication":"Cervical Cancer","summary":"As of 22 April 2026, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Cervical Cancer, on 31 December 2026.","as_of":"2026-04-22","source":"clinicaltrials","source_ref":"NCT06769152","source_url":"https://clinicaltrials.gov/study/NCT06769152","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-91f0cb71-b0b8-417f-82c7-b6fc27456964"},{"id":"a7e01604-e7ff-4a9d-937e-ae86ef718fc6","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shanghai Jiaolian Drug Research and Development Co., Ltd","ticker":null,"asset":"B007","indication":"Pemphigus","summary":"As of 5 May 2026, Shanghai Jiaolian Drug Research and Development Co. estimated primary completion of a Phase 3 trial in pemphigus, on 31 December 2026.","as_of":"2026-05-05","source":"clinicaltrials","source_ref":"NCT06454357","source_url":"https://clinicaltrials.gov/study/NCT06454357","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a7e01604-e7ff-4a9d-937e-ae86ef718fc6"},{"id":"8e5ef4be-8837-45d7-bad5-6e6d72e32597","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shanghai Jiaolian Drug Research and Development Co., Ltd","ticker":null,"asset":"B007","indication":"Primary Membranous Nephropathy","summary":"As of 5 May 2026, Shanghai Jiaolian Drug Research and Development Co. estimated primary completion of a Phase 3 trial in Primary Membranous Nephropathy, on 31 December 2026.","as_of":"2026-05-05","source":"clinicaltrials","source_ref":"NCT06470191","source_url":"https://clinicaltrials.gov/study/NCT06470191","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8e5ef4be-8837-45d7-bad5-6e6d72e32597"},{"id":"14bb04f5-aa07-41df-aa95-1cc486021e0f","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"asset":"SPH4336 Tablets","indication":"Breast Cancer Brain Metastases","summary":"As of 5 May 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Breast Cancer Brain Metastases, on 31 December 2026.","as_of":"2026-05-05","source":"clinicaltrials","source_ref":"NCT05872347","source_url":"https://clinicaltrials.gov/study/NCT05872347","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-14bb04f5-aa07-41df-aa95-1cc486021e0f"},{"id":"f48ed01b-8880-4823-bc48-eb195f43a0e2","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"asset":"SPH4336","indication":"Advanced Solid Tumors","summary":"As of 6 August 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 31 December 2026.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT05944224","source_url":"https://clinicaltrials.gov/study/NCT05944224","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f48ed01b-8880-4823-bc48-eb195f43a0e2"},{"id":"c126af58-7ed0-4110-9725-b17c52bf2407","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shanghai Pharmaceuticals Holding Co., Ltd","ticker":null,"asset":"T3011 high dose","indication":"Advanced Solid Tumors","summary":"As of 5 May 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 31 December 2026.","as_of":"2026-05-05","source":"clinicaltrials","source_ref":"NCT06214143","source_url":"https://clinicaltrials.gov/study/NCT06214143","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c126af58-7ed0-4110-9725-b17c52bf2407"},{"id":"ee77b483-3a32-4a21-8cf3-4e149b186da8","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shanghai RAAS Blood Products Co., Ltd.","ticker":null,"asset":"SR604","indication":"Hemophilia A","summary":"As of 12 June 2026, Shanghai RAAS Blood Products Co. estimated primary completion of a Phase 2 trial in Hemophilia A, on 31 December 2026.","as_of":"2026-06-12","source":"clinicaltrials","source_ref":"NCT07644832","source_url":"https://clinicaltrials.gov/study/NCT07644832","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ee77b483-3a32-4a21-8cf3-4e149b186da8"},{"id":"9583e7ce-414e-46ee-9cfb-f46bc4e25df4","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shanghai Synvida Biotechnology Co.,Ltd.","ticker":null,"asset":"SV001","indication":"Idiopathic Pulmonary Fibrosis(IPF)","summary":"As of 11 February 2026, Shanghai Synvida Biotechnology Co. estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis(IPF), on 31 December 2026.","as_of":"2026-02-11","source":"clinicaltrials","source_ref":"NCT07121413","source_url":"https://clinicaltrials.gov/study/NCT07121413","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9583e7ce-414e-46ee-9cfb-f46bc4e25df4"},{"id":"8cc6a108-26b7-43f0-87ab-1b42a7e5f3f3","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shenyang Sunshine Pharmaceutical Co., LTD.","ticker":null,"asset":"SSGJ-705","indication":"Locally Advanced, Recurrent or Metastatic Malignancies","summary":"As of 3 August 2025, Shenyang Sunshine Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Locally Advanced, Recurrent or Metastatic Malignancies, on 31 December 2026.","as_of":"2025-08-03","source":"clinicaltrials","source_ref":"NCT07022002","source_url":"https://clinicaltrials.gov/study/NCT07022002","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8cc6a108-26b7-43f0-87ab-1b42a7e5f3f3"},{"id":"3ebe8e03-7ddf-4c5a-880c-4454f4acfa47","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Shionogi","ticker":null,"asset":"Sivopixant","indication":"Sleep Apnea","summary":"As of 6 May 2026, Shionogi estimated primary completion of a Phase 2 trial in Sleep Apnea, on 31 December 2026.","as_of":"2026-05-06","source":"clinicaltrials","source_ref":"NCT06776432","source_url":"https://clinicaltrials.gov/study/NCT06776432","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3ebe8e03-7ddf-4c5a-880c-4454f4acfa47"},{"id":"7bee1bb7-79de-4697-9b16-3d70a4c529ed","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":null,"asset":"KL590586 Capsule","indication":"Advanced Solid Tumor","summary":"As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 31 December 2026.","as_of":"2026-05-08","source":"clinicaltrials","source_ref":"NCT05265091","source_url":"https://clinicaltrials.gov/study/NCT05265091","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7bee1bb7-79de-4697-9b16-3d70a4c529ed"},{"id":"9b5df16a-d43b-4691-acf4-783749e48fe0","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":null,"asset":"SKB264","indication":"Metastatic Breast Cancer","summary":"As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Metastatic Breast Cancer, on 31 December 2026.","as_of":"2026-05-08","source":"clinicaltrials","source_ref":"NCT06081959","source_url":"https://clinicaltrials.gov/study/NCT06081959","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b5df16a-d43b-4691-acf4-783749e48fe0"},{"id":"149fd98d-e021-415b-ad1b-cf162ab9cebb","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Skingenix, Inc.","ticker":null,"asset":"Investigational Drug, MW-III","indication":"Burns","summary":"As of 16 March 2026, Skingenix estimated primary completion of a Phase 2 trial in burns, on 31 December 2026.","as_of":"2026-03-16","source":"clinicaltrials","source_ref":"NCT01297400","source_url":"https://clinicaltrials.gov/study/NCT01297400","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-149fd98d-e021-415b-ad1b-cf162ab9cebb"},{"id":"3daac669-93fb-4b08-b9a2-fd1fefb49090","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Spirovant Sciences, Inc.","ticker":null,"asset":"SP-101 and doxorubicin Cohort 1","indication":"Cystic Fibrosis","summary":"As of 25 November 2024, Spirovant Sciences estimated primary completion of a Phase 2 trial in Cystic Fibrosis, on 31 December 2026.","as_of":"2024-11-25","source":"clinicaltrials","source_ref":"NCT06526923","source_url":"https://clinicaltrials.gov/study/NCT06526923","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3daac669-93fb-4b08-b9a2-fd1fefb49090"},{"id":"38783e0a-abc4-4d55-a5cd-dc218b6665bb","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Supergene, LLC","ticker":null,"asset":"Recombinant non-immunogenic staphylokinase (Fortelyzin®)","indication":"Acute Limb Ischemia","summary":"As of 1 December 2025, Supergene estimated primary completion of a Phase 3 trial in Acute Limb Ischemia, on 31 December 2026.","as_of":"2025-12-01","source":"clinicaltrials","source_ref":"NCT05372718","source_url":"https://clinicaltrials.gov/study/NCT05372718","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-38783e0a-abc4-4d55-a5cd-dc218b6665bb"},{"id":"fbb24760-7065-48f7-b674-4175b1541056","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Supernus Pharmaceuticals, Inc.","ticker":null,"asset":"SPN-821 2400 mg","indication":"Major Depressive Disorder (MDD)","summary":"As of 24 March 2026, Supernus Pharmaceuticals estimated primary completion of a Phase 2 trial in Major Depressive Disorder (MDD), on 31 December 2026.","as_of":"2026-03-24","source":"clinicaltrials","source_ref":"NCT07226661","source_url":"https://clinicaltrials.gov/study/NCT07226661","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fbb24760-7065-48f7-b674-4175b1541056"},{"id":"429a328c-7329-46b8-bf0e-566c4fa3edde","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"TRB Chemedica","ticker":null,"asset":"Artrodar","indication":"Knee Osteoarthritis","summary":"As of 22 November 2024, TRB Chemedica estimated primary completion of a Phase 3 trial in Knee Osteoarthritis, on 31 December 2026.","as_of":"2024-11-22","source":"clinicaltrials","source_ref":"NCT04318041","source_url":"https://clinicaltrials.gov/study/NCT04318041","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-429a328c-7329-46b8-bf0e-566c4fa3edde"},{"id":"d00d2ef9-814e-45ae-90d5-5541f013540b","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"TaiRx, Inc.","ticker":null,"asset":"Nivolumab Injection [Opdivo]","indication":"Hepatocellular Carcinoma","summary":"As of 13 April 2026, TaiRx estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 31 December 2026.","as_of":"2026-04-13","source":"clinicaltrials","source_ref":"NCT05257590","source_url":"https://clinicaltrials.gov/study/NCT05257590","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d00d2ef9-814e-45ae-90d5-5541f013540b"},{"id":"1e242845-1c1d-454f-a68a-8c1e512cc80f","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Takeda","ticker":null,"asset":"Maribavir","indication":"Cytomegalovirus (CMV)","summary":"As of 2 March 2026, Takeda estimated primary completion of a Phase 3 trial in cytomegalovirus (CMV), on 31 December 2026.","as_of":"2026-03-02","source":"clinicaltrials","source_ref":"NCT06439342","source_url":"https://clinicaltrials.gov/study/NCT06439342","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1e242845-1c1d-454f-a68a-8c1e512cc80f"},{"id":"fe59441d-9a94-4621-86e4-4779c70ea72f","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Tarsus Pharmaceuticals, Inc.","ticker":null,"asset":"lotilaner","indication":"Ocular Rosacea","summary":"As of 2 March 2026, Tarsus Pharmaceuticals estimated primary completion of a Phase 2 trial in Ocular Rosacea, on 31 December 2026.","as_of":"2026-03-02","source":"clinicaltrials","source_ref":"NCT07443202","source_url":"https://clinicaltrials.gov/study/NCT07443202","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fe59441d-9a94-4621-86e4-4779c70ea72f"},{"id":"b564e7d9-5fb4-4147-9dba-f9349bb751a0","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Tasly Pharmaceutical Group Co., Ltd","ticker":null,"asset":"Mesenchymal stem cells(HucMSCs)","indication":"Coronary Artery Bypass Grafting (CABG)","summary":"As of 9 January 2026, Tasly Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Coronary Artery Bypass Grafting (CABG), on 31 December 2026.","as_of":"2026-01-09","source":"clinicaltrials","source_ref":"NCT07265349","source_url":"https://clinicaltrials.gov/study/NCT07265349","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b564e7d9-5fb4-4147-9dba-f9349bb751a0"},{"id":"959995a2-3a72-40f7-8de1-eac62e168938","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Tasly Pharmaceutical Group Co., Ltd","ticker":null,"asset":"Lianxiaxiaopi Granules","indication":"Postprandial Distress Syndrome","summary":"As of 20 January 2026, Tasly Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Postprandial Distress Syndrome, on 31 December 2026.","as_of":"2026-01-20","source":"clinicaltrials","source_ref":"NCT06696261","source_url":"https://clinicaltrials.gov/study/NCT06696261","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-959995a2-3a72-40f7-8de1-eac62e168938"},{"id":"ba8cf631-d0b2-4ea1-9e47-6f9c273e7450","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"TheiaNova Ltd.","ticker":null,"asset":"Low-dose TGF-B3 and Dexamethasone Sodium Phosphate","indication":"Keratoconus","summary":"As of 4 February 2026, TheiaNova estimated primary completion of a Phase 2 trial in keratoconus, on 31 December 2026.","as_of":"2026-02-04","source":"clinicaltrials","source_ref":"NCT07388069","source_url":"https://clinicaltrials.gov/study/NCT07388069","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ba8cf631-d0b2-4ea1-9e47-6f9c273e7450"},{"id":"9239a498-af88-4b62-b271-c92386f14077","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Tioga Pharmaceuticals","ticker":null,"asset":"Asimadoline","indication":"Vasomotor Symptoms","summary":"As of 9 September 2025, Tioga Pharmaceuticals estimated primary completion of a Phase 2 trial in Vasomotor Symptoms, on 31 December 2026.","as_of":"2025-09-09","source":"clinicaltrials","source_ref":"NCT07042516","source_url":"https://clinicaltrials.gov/study/NCT07042516","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9239a498-af88-4b62-b271-c92386f14077"},{"id":"e5ec3ef2-5e66-4215-a9f8-511df9aab890","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Valenta Pharm JSC","ticker":null,"asset":"Grammidin with anesthetic","indication":"Pharyngitis Acute","summary":"As of 10 July 2025, Valenta Pharm JSC estimated primary completion of a Phase 2 trial in Pharyngitis Acute, on 31 December 2026.","as_of":"2025-07-10","source":"clinicaltrials","source_ref":"NCT06843018","source_url":"https://clinicaltrials.gov/study/NCT06843018","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e5ec3ef2-5e66-4215-a9f8-511df9aab890"},{"id":"79208b3e-cb2b-40b1-8757-0c51079dbe5d","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Valenta Pharm JSC","ticker":null,"asset":"4-MUST","indication":"Chronic Cholecystitis","summary":"As of 11 July 2025, Valenta Pharm JSC estimated primary completion of a Phase 2 trial in Chronic Cholecystitis, on 31 December 2026.","as_of":"2025-07-11","source":"clinicaltrials","source_ref":"NCT06842966","source_url":"https://clinicaltrials.gov/study/NCT06842966","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-79208b3e-cb2b-40b1-8757-0c51079dbe5d"},{"id":"dc7f453e-7f87-4db0-b34f-eeb419056b5a","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Vir Biotechnology, Inc.","ticker":null,"asset":"Tobevibart","indication":"Viral Hepatitis","summary":"As of 8 April 2026, Vir Biotechnology estimated primary completion of a Phase 3 trial in Viral Hepatitis, on 31 December 2026.","as_of":"2026-04-08","source":"clinicaltrials","source_ref":"NCT06903338","source_url":"https://clinicaltrials.gov/study/NCT06903338","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dc7f453e-7f87-4db0-b34f-eeb419056b5a"},{"id":"09efa084-c7c5-4572-b1e3-e4dc24ea604a","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"XyloCor Therapeutics, Inc.","ticker":null,"asset":"XC001","indication":"Refractory Angina","summary":"As of 3 August 2025, XyloCor Therapeutics estimated primary completion of a Phase 2 trial in Refractory Angina, on 31 December 2026.","as_of":"2025-08-03","source":"clinicaltrials","source_ref":"NCT07048808","source_url":"https://clinicaltrials.gov/study/NCT07048808","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-09efa084-c7c5-4572-b1e3-e4dc24ea604a"},{"id":"2fa53ae1-a57e-4ebe-83f3-290073c05c01","lane":"clinical","event_type":"primary-completion","date":"2026-12-31","date_precision":"day","confidence":"estimated","company":"Zhejiang ACEA Pharmaceutical Co. Ltd.","ticker":null,"asset":"STI-6129","indication":"Relapsed or Refractory Multiple Myeloma","summary":"As of 15 August 2025, Zhejiang ACEA Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Relapsed or Refractory Multiple Myeloma, on 31 December 2026.","as_of":"2025-08-15","source":"clinicaltrials","source_ref":"NCT05565807","source_url":"https://clinicaltrials.gov/study/NCT05565807","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2fa53ae1-a57e-4ebe-83f3-290073c05c01"},{"id":"b04f40b0-f05b-448c-98c0-e1138bdeede2","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"A. Menarini International Licensing S.A.","ticker":null,"asset":"Obicetrapib 10 mg/Bempedoic Acid Placebo","indication":"Mixed Dyslipidemia","summary":"As of 9 June 2026, A. Menarini International Licensing estimated primary completion of a Phase 3 trial in Mixed Dyslipidemia, in January 2027.","as_of":"2026-06-09","source":"clinicaltrials","source_ref":"NCT07614958","source_url":"https://clinicaltrials.gov/study/NCT07614958","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b04f40b0-f05b-448c-98c0-e1138bdeede2"},{"id":"5911cfa0-a2e8-41da-ae39-b35aeeb56ec2","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"AION Healthspan, Inc.","ticker":null,"asset":"AION-301","indication":"Chronic Kidney Disease Stage 3","summary":"As of 1 April 2026, AION Healthspan estimated primary completion of a Phase 2 trial in Chronic Kidney Disease Stage 3, in January 2027.","as_of":"2026-04-01","source":"clinicaltrials","source_ref":"NCT06721143","source_url":"https://clinicaltrials.gov/study/NCT06721143","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5911cfa0-a2e8-41da-ae39-b35aeeb56ec2"},{"id":"e599cacd-3963-4bde-b5e2-6e387b6e5029","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"Upadacitinib","indication":"Atopic Dermatitis","summary":"As of 23 February 2026, AbbVie estimated primary completion of a Phase 3 trial in Atopic Dermatitis, in January 2027.","as_of":"2026-02-23","source":"clinicaltrials","source_ref":"NCT06701331","source_url":"https://clinicaltrials.gov/study/NCT06701331","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e599cacd-3963-4bde-b5e2-6e387b6e5029"},{"id":"9b3e1c1d-b805-4458-8c92-f205f548014c","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Actio Biosciences, Inc.","ticker":null,"asset":"ABS-1230","indication":"KCNT1-Related Epilepsy","summary":"As of 7 August 2026, Actio Biosciences estimated primary completion of a Phase 2 trial in KCNT1-Related Epilepsy, in January 2027.","as_of":"2026-08-07","source":"clinicaltrials","source_ref":"NCT07600736","source_url":"https://clinicaltrials.gov/study/NCT07600736","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b3e1c1d-b805-4458-8c92-f205f548014c"},{"id":"ca55ca63-edb2-45dc-b9f5-75bd2dca4ca1","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Akeso","ticker":null,"asset":"AK117 in combination with AK112","indication":"Head and Neck Squamous Cell Carcinoma","summary":"As of 14 November 2024, Akeso estimated primary completion of a Phase 3 trial in Head and Neck Squamous Cell Carcinoma, in January 2027.","as_of":"2024-11-14","source":"clinicaltrials","source_ref":"NCT06601335","source_url":"https://clinicaltrials.gov/study/NCT06601335","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ca55ca63-edb2-45dc-b9f5-75bd2dca4ca1"},{"id":"22ae085c-fb6d-4b36-bcba-d363571f8e7e","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Alesta Therapeutics","ticker":null,"asset":"ALE1","indication":"Hypophosphatasia (HPP)","summary":"As of 3 August 2026, Alesta Therapeutics estimated primary completion of a Phase 2 trial in hypophosphatasia (HPP), in January 2027.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT07179640","source_url":"https://clinicaltrials.gov/study/NCT07179640","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-22ae085c-fb6d-4b36-bcba-d363571f8e7e"},{"id":"ed80f883-362b-43ae-a823-238c1d6fd6b4","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Arcus Biosciences, Inc.","ticker":null,"asset":"Domvanalimab","indication":"Gastrointestinal Tract Malignancies","summary":"As of 29 July 2026, Arcus Biosciences estimated primary completion of a Phase 2 trial in Gastrointestinal Tract Malignancies, in January 2027.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT05329766","source_url":"https://clinicaltrials.gov/study/NCT05329766","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ed80f883-362b-43ae-a823-238c1d6fd6b4"},{"id":"a8f1e042-902d-4a03-bd5a-adf7951066f0","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Biocad","ticker":null,"asset":"BCD-217","indication":"Melanoma Stage III","summary":"As of 8 July 2025, Biocad estimated primary completion of a Phase 3 trial in Melanoma Stage III, in January 2027.","as_of":"2025-07-08","source":"clinicaltrials","source_ref":"NCT05751928","source_url":"https://clinicaltrials.gov/study/NCT05751928","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a8f1e042-902d-4a03-bd5a-adf7951066f0"},{"id":"9a7fcc73-efc9-4109-b417-9c1b5821bd30","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Biocad","ticker":null,"asset":"anti-TL1A monoclonal antibody, low dose","indication":"Ulcerative Colitis (UC)","summary":"As of 19 September 2025, Biocad estimated primary completion of a Phase 2 trial in Ulcerative Colitis (UC), in January 2027.","as_of":"2025-09-19","source":"clinicaltrials","source_ref":"NCT07080034","source_url":"https://clinicaltrials.gov/study/NCT07080034","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9a7fcc73-efc9-4109-b417-9c1b5821bd30"},{"id":"827e5bbb-eb3e-49b9-8f07-6a75bf55e9b3","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"day","confidence":"estimated","company":"Biotheus Inc.","ticker":null,"asset":"PM8002","indication":"Neuroendocrine Neoplasm","summary":"As of 9 July 2026, Biotheus estimated primary completion of a Phase 2 trial in Neuroendocrine Neoplasm, on 1 January 2027.","as_of":"2026-07-09","source":"clinicaltrials","source_ref":"NCT05879055","source_url":"https://clinicaltrials.gov/study/NCT05879055","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-827e5bbb-eb3e-49b9-8f07-6a75bf55e9b3"},{"id":"b67fe943-6200-4ae7-b961-2281fe60b4ec","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"CStone Pharmaceuticals","ticker":null,"asset":"CS2009","indication":"Advanced Solid Tumors","summary":"As of 9 July 2026, CStone Pharmaceuticals estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, in January 2027.","as_of":"2026-07-09","source":"clinicaltrials","source_ref":"NCT06741644","source_url":"https://clinicaltrials.gov/study/NCT06741644","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b67fe943-6200-4ae7-b961-2281fe60b4ec"},{"id":"75c4bdd5-e421-4dc1-905c-fdfc451f1e61","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Caravel Oculus Pty Ltd","ticker":null,"asset":"Ophthalmic solution (matching formulation without ascorbic acid)","indication":"Corneal Endothelial Cell Loss","summary":"As of 6 August 2026, Caravel Oculus Pty estimated primary completion of a Phase 2 trial in Corneal Endothelial Cell Loss, in January 2027.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT07694375","source_url":"https://clinicaltrials.gov/study/NCT07694375","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-75c4bdd5-e421-4dc1-905c-fdfc451f1e61"},{"id":"09e1c15e-03ac-4dc8-a090-928d89e5cb83","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","ticker":null,"asset":"AL2846 Capsules","indication":"Thyroid Cancer","summary":"As of 31 December 2025, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Thyroid Cancer, in January 2027.","as_of":"2025-12-31","source":"clinicaltrials","source_ref":"NCT06860971","source_url":"https://clinicaltrials.gov/study/NCT06860971","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-09e1c15e-03ac-4dc8-a090-928d89e5cb83"},{"id":"4d9ed5d7-7c9f-47e9-ae66-b4e7df58f62b","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Coya Therapeutics","ticker":null,"asset":"COYA 302","indication":"Amyotrophic Lateral Sclerosis (ALS)","summary":"As of 6 August 2026, Coya Therapeutics estimated primary completion of a Phase 3 trial in Amyotrophic Lateral Sclerosis (ALS), in January 2027.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT07161999","source_url":"https://clinicaltrials.gov/study/NCT07161999","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4d9ed5d7-7c9f-47e9-ae66-b4e7df58f62b"},{"id":"39a6d045-2697-47ee-b930-f42130cf5964","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Cumberland Pharmaceuticals","ticker":null,"asset":"Ifetroban Sodium","indication":"Idiopathic Pulmonary Fibrosis","summary":"As of 5 March 2026, Cumberland Pharmaceuticals estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in January 2027.","as_of":"2026-03-05","source":"clinicaltrials","source_ref":"NCT05571059","source_url":"https://clinicaltrials.gov/study/NCT05571059","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-39a6d045-2697-47ee-b930-f42130cf5964"},{"id":"1c77e52f-7804-4557-8140-75dddb633f02","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Dr. F. Köhler Chemie GmbH","ticker":null,"asset":"Custodiol-N","indication":"Heart Transplantation","summary":"As of 30 January 2026, Dr. F. Köhler Chemie estimated primary completion of a Phase 2 trial in Heart Transplantation, in January 2027.","as_of":"2026-01-30","source":"clinicaltrials","source_ref":"NCT06032195","source_url":"https://clinicaltrials.gov/study/NCT06032195","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1c77e52f-7804-4557-8140-75dddb633f02"},{"id":"6c977cc2-989a-4937-bf79-c65ae02ebc5e","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Edgewise Therapeutics, Inc.","ticker":null,"asset":"Sevasemten Dose 1","indication":"Duchenne Muscular Dystrophy","summary":"As of 12 November 2025, Edgewise Therapeutics estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, in January 2027.","as_of":"2025-11-12","source":"clinicaltrials","source_ref":"NCT05540860","source_url":"https://clinicaltrials.gov/study/NCT05540860","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6c977cc2-989a-4937-bf79-c65ae02ebc5e"},{"id":"76c23d9c-7b80-4dee-9896-554f2f21840e","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Eledon Pharmaceuticals","ticker":null,"asset":"AT-1501","indication":"Prevention of Rejection in Kidney Transplant","summary":"As of 29 June 2025, Eledon Pharmaceuticals estimated primary completion of a Phase 2 trial in Prevention of Rejection in Kidney Transplant, in January 2027.","as_of":"2025-06-29","source":"clinicaltrials","source_ref":"NCT05027906","source_url":"https://clinicaltrials.gov/study/NCT05027906","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-76c23d9c-7b80-4dee-9896-554f2f21840e"},{"id":"688fca2d-ed44-4bce-858a-86eec237b8b5","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"EyeD Pharma","ticker":null,"asset":"TimoD implant","indication":"Glaucoma","summary":"As of 30 July 2026, EyeD Pharma estimated primary completion of a Phase 2 trial in glaucoma, in January 2027.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT07036510","source_url":"https://clinicaltrials.gov/study/NCT07036510","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-688fca2d-ed44-4bce-858a-86eec237b8b5"},{"id":"3442c9fd-adb7-4b76-9b1d-92fcd2fb8b44","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Gilead Sciences","ticker":null,"asset":"Tilpisertib Fosmecarbil","indication":"Ulcerative Colitis","summary":"As of 11 February 2026, Gilead Sciences estimated primary completion of a Phase 2 trial in Ulcerative Colitis, in January 2027.","as_of":"2026-02-11","source":"clinicaltrials","source_ref":"NCT06029972","source_url":"https://clinicaltrials.gov/study/NCT06029972","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3442c9fd-adb7-4b76-9b1d-92fcd2fb8b44"},{"id":"98a6ff34-7169-4eff-8a82-18b74b706a15","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Hanmi Pharmaceutical Company Limited","ticker":null,"asset":"HM15275","indication":"Obese","summary":"As of 8 April 2026, Hanmi Pharmaceutical Company estimated primary completion of a Phase 2 trial in obese, in January 2027.","as_of":"2026-04-08","source":"clinicaltrials","source_ref":"NCT07205900","source_url":"https://clinicaltrials.gov/study/NCT07205900","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-98a6ff34-7169-4eff-8a82-18b74b706a15"},{"id":"c7af94fb-94d8-485e-bd49-bd5b05e1213b","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Hope Biosciences Research Foundation","ticker":null,"asset":"Autologous HB-adMSCs","indication":"Relapsing Remitting Multiple Sclerosis (RRMS)","summary":"As of 20 November 2025, Hope Biosciences Research Foundation estimated primary completion of a Phase 2 trial in Relapsing Remitting Multiple Sclerosis (RRMS), in January 2027.","as_of":"2025-11-20","source":"clinicaltrials","source_ref":"NCT06800404","source_url":"https://clinicaltrials.gov/study/NCT06800404","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c7af94fb-94d8-485e-bd49-bd5b05e1213b"},{"id":"f9e1515b-1e27-44c0-b279-8df25510a7f7","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Hyundai Bioscience Co., Ltd.","ticker":null,"asset":"CP-COV03","indication":"Dengue","summary":"As of 10 July 2026, Hyundai Bioscience Co. estimated primary completion of a Phase 3 trial in dengue, in January 2027.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT07576868","source_url":"https://clinicaltrials.gov/study/NCT07576868","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f9e1515b-1e27-44c0-b279-8df25510a7f7"},{"id":"5032f105-75b6-4615-bbcf-7e7a2cade3ac","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Imvax","ticker":null,"asset":"IGV-001 Cell Immunotherapy","indication":"Glioblastoma","summary":"As of 9 July 2026, Imvax estimated primary completion of a Phase 2 trial in glioblastoma, in January 2027.","as_of":"2026-07-09","source":"clinicaltrials","source_ref":"NCT04485949","source_url":"https://clinicaltrials.gov/study/NCT04485949","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5032f105-75b6-4615-bbcf-7e7a2cade3ac"},{"id":"0b5fd01e-4415-4ae4-99a0-5d0d8ceababa","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Jacobio Pharmaceuticals Co., Ltd.","ticker":null,"asset":"JAB-30355","indication":"Solid Tumors","summary":"As of 22 May 2026, Jacobio Pharmaceuticals Co. estimated primary completion of a Phase 2 trial in Solid Tumors, in January 2027.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT06386146","source_url":"https://clinicaltrials.gov/study/NCT06386146","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0b5fd01e-4415-4ae4-99a0-5d0d8ceababa"},{"id":"bc5c5cc8-9332-405b-98c6-f1d6a3c59dc6","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Larimar Therapeutics, Inc.","ticker":null,"asset":"CTI-1601","indication":"Friedreich Ataxia","summary":"As of 13 May 2026, Larimar Therapeutics estimated primary completion of a Phase 2 trial in Friedreich Ataxia, in January 2027.","as_of":"2026-05-13","source":"clinicaltrials","source_ref":"NCT06447025","source_url":"https://clinicaltrials.gov/study/NCT06447025","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bc5c5cc8-9332-405b-98c6-f1d6a3c59dc6"},{"id":"8824c6b7-3c9c-4ee1-b1f1-7e28cd3b3020","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"LigaChem Biosciences, Inc.","ticker":null,"asset":"LCB84","indication":"Advanced Solid Tumors","summary":"As of 24 September 2025, LigaChem Biosciences estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, in January 2027.","as_of":"2025-09-24","source":"clinicaltrials","source_ref":"NCT05941507","source_url":"https://clinicaltrials.gov/study/NCT05941507","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8824c6b7-3c9c-4ee1-b1f1-7e28cd3b3020"},{"id":"828df6dd-1711-4a8c-a3cc-5d109a66c4b5","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Loxo Oncology, Inc.","ticker":null,"asset":"Pirtobrutinib","indication":"Lymphoma, Mantle-Cell","summary":"As of 15 May 2026, Loxo Oncology estimated primary completion of a Phase 3 trial in Lymphoma, Mantle-Cell, in January 2027.","as_of":"2026-05-15","source":"clinicaltrials","source_ref":"NCT04662255","source_url":"https://clinicaltrials.gov/study/NCT04662255","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-828df6dd-1711-4a8c-a3cc-5d109a66c4b5"},{"id":"e0194794-9b37-4768-bd6b-e46b5b566fc3","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Marengo Therapeutics, Inc.","ticker":null,"asset":"STAR0602","indication":"Triple Negative Locally Advanced Non-resectable Breast Cancer","summary":"As of 24 September 2025, Marengo Therapeutics estimated primary completion of a Phase 2 trial in Triple Negative Locally Advanced Non-resectable Breast Cancer, in January 2027.","as_of":"2025-09-24","source":"clinicaltrials","source_ref":"NCT06827613","source_url":"https://clinicaltrials.gov/study/NCT06827613","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e0194794-9b37-4768-bd6b-e46b5b566fc3"},{"id":"47052d07-eb87-4c24-96c4-5f634082f63a","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"MediLink Therapeutics (Suzhou) Co., Ltd.","ticker":null,"asset":"YL201","indication":"Advanced Solid Tumors","summary":"As of 18 June 2026, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, in January 2027.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT07208773","source_url":"https://clinicaltrials.gov/study/NCT07208773","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-47052d07-eb87-4c24-96c4-5f634082f63a"},{"id":"ac088a30-a296-4b03-92f5-aca72bf10a3e","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Merz Aesthetics GmbH","ticker":null,"asset":"NT 201","indication":"Neuromuscular Agents","summary":"As of 23 July 2026, Merz Aesthetics estimated primary completion of a Phase 3 trial in Neuromuscular Agents, in January 2027.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT07210463","source_url":"https://clinicaltrials.gov/study/NCT07210463","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ac088a30-a296-4b03-92f5-aca72bf10a3e"},{"id":"d67b30c3-4083-4650-8a6b-ca96fb676857","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Newleos Therapeutics, Inc.","ticker":null,"asset":"NTX-1472","indication":"Social Anxiety Disorder (SAD)","summary":"As of 9 July 2026, Newleos Therapeutics estimated primary completion of a Phase 2 trial in Social Anxiety Disorder (SAD), in January 2027.","as_of":"2026-07-09","source":"clinicaltrials","source_ref":"NCT07323784","source_url":"https://clinicaltrials.gov/study/NCT07323784","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d67b30c3-4083-4650-8a6b-ca96fb676857"},{"id":"a4009c72-3a47-4449-a639-d236b2e8d9dc","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"OncoVerity, Inc.","ticker":null,"asset":"Cusatuzumab","indication":"Leukemia, Myeloid, Acute","summary":"As of 11 May 2026, OncoVerity estimated primary completion of a Phase 2 trial in Leukemia, Myeloid, Acute, in January 2027.","as_of":"2026-05-11","source":"clinicaltrials","source_ref":"NCT06384261","source_url":"https://clinicaltrials.gov/study/NCT06384261","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a4009c72-3a47-4449-a639-d236b2e8d9dc"},{"id":"92f78f57-478a-4e4d-8b2a-d325e4c08fe9","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Praxis Precision Medicines","ticker":null,"asset":"40 mg/day vormatrogine for 12 weeks","indication":"Focal Epilepsy","summary":"As of 3 August 2026, Praxis Precision Medicines estimated primary completion of a Phase 3 trial in Focal Epilepsy, in January 2027.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT07505004","source_url":"https://clinicaltrials.gov/study/NCT07505004","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-92f78f57-478a-4e4d-8b2a-d325e4c08fe9"},{"id":"e32d3321-1cc6-4870-ac5b-0ee815672011","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Prolium Bioscience, Inc","ticker":null,"asset":"PRO-203","indication":"Healthy Volunteers","summary":"As of 18 June 2026, Prolium Bioscience estimated primary completion of a Phase 2 trial in Healthy Volunteers, in January 2027.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT07641634","source_url":"https://clinicaltrials.gov/study/NCT07641634","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e32d3321-1cc6-4870-ac5b-0ee815672011"},{"id":"be43e2ed-26fc-4357-b48b-8cebac5f50f7","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"QBiotics Group Limited","ticker":null,"asset":"Tigilanol Tiglate","indication":"Soft Tissue Sarcoma","summary":"As of 12 March 2026, QBiotics Group estimated primary completion of a Phase 2 trial in Soft Tissue Sarcoma, in January 2027.","as_of":"2026-03-12","source":"clinicaltrials","source_ref":"NCT05755113","source_url":"https://clinicaltrials.gov/study/NCT05755113","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-be43e2ed-26fc-4357-b48b-8cebac5f50f7"},{"id":"9388050a-c4e3-46fd-baa1-a2e7f77091ad","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"QED Therapeutics, a BridgeBio company","ticker":null,"asset":"infigratinib 0.128 mg/kg/day","indication":"Hypochondroplasia","summary":"As of 16 July 2026, QED Therapeutics, a BridgeBio estimated primary completion of a Phase 3 trial in hypochondroplasia, in January 2027.","as_of":"2026-07-16","source":"clinicaltrials","source_ref":"NCT06873035","source_url":"https://clinicaltrials.gov/study/NCT06873035","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9388050a-c4e3-46fd-baa1-a2e7f77091ad"},{"id":"32eddd7c-d9e2-411d-8792-65df72ef7c6f","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Qilu Pharmaceutical Co., Ltd.","ticker":null,"asset":"QL1206","indication":"Postmenopausal Women With Osteoporosis at High Risk of Fracture","summary":"As of 14 July 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in January 2027.","as_of":"2025-07-14","source":"clinicaltrials","source_ref":"NCT07062978","source_url":"https://clinicaltrials.gov/study/NCT07062978","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-32eddd7c-d9e2-411d-8792-65df72ef7c6f"},{"id":"d1fdcce6-94d6-4710-b90c-298987005da1","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)","ticker":null,"asset":"Meropenem-Vaborbactam","indication":"Acute Pyelonephritis","summary":"As of 3 June 2026, Rempex estimated primary completion of a Phase 2 trial in Acute Pyelonephritis, in January 2027.","as_of":"2026-06-03","source":"clinicaltrials","source_ref":"NCT06672978","source_url":"https://clinicaltrials.gov/study/NCT06672978","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d1fdcce6-94d6-4710-b90c-298987005da1"},{"id":"cda2eda6-daa0-46e3-b8a9-e2e37ade66b0","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Resilience","ticker":null,"asset":"Resilience PRO","indication":"Cancer","summary":"As of 3 April 2026, Resilience estimated primary completion of a Phase 3 trial in cancer, in January 2027.","as_of":"2026-04-03","source":"clinicaltrials","source_ref":"NCT06867705","source_url":"https://clinicaltrials.gov/study/NCT06867705","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cda2eda6-daa0-46e3-b8a9-e2e37ade66b0"},{"id":"e240b14c-7c84-4449-a427-8c731e7e843d","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"day","confidence":"estimated","company":"SIGA Technologies","ticker":null,"asset":"Tecovirimat","indication":"Smallpox","summary":"As of 2 April 2026, SIGA Technologies estimated primary completion of a Phase 2 trial in smallpox, on 1 January 2027.","as_of":"2026-04-02","source":"clinicaltrials","source_ref":"NCT04957485","source_url":"https://clinicaltrials.gov/study/NCT04957485","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e240b14c-7c84-4449-a427-8c731e7e843d"},{"id":"3d271f4f-cc28-47b6-94f6-e4cb5c0251e6","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"day","confidence":"estimated","company":"Second Life Therapeutics","ticker":null,"asset":"SL-28","indication":"Head & Neck Cancer","summary":"As of 10 July 2026, Second Life Therapeutics estimated primary completion of a Phase 2 trial in Head & Neck Cancer, on 1 January 2027.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT07341737","source_url":"https://clinicaltrials.gov/study/NCT07341737","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3d271f4f-cc28-47b6-94f6-e4cb5c0251e6"},{"id":"f0ba70c1-ecbe-47dd-b563-860e16cf1d48","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","ticker":null,"asset":"Hemopfin+Green Light","indication":"Port-wine Birthmarks","summary":"As of 3 March 2026, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Port-wine Birthmarks, in January 2027.","as_of":"2026-03-03","source":"clinicaltrials","source_ref":"NCT05171894","source_url":"https://clinicaltrials.gov/study/NCT05171894","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f0ba70c1-ecbe-47dd-b563-860e16cf1d48"},{"id":"ccd20027-97c8-4d6a-8956-494eb9abe0b9","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Shanghai Henlius Biotech","ticker":null,"asset":"HLX79 10mg/kg/Placebo+HLX01","indication":"Membranous Nephropathy","summary":"As of 18 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Membranous Nephropathy, in January 2027.","as_of":"2025-11-18","source":"clinicaltrials","source_ref":"NCT07038382","source_url":"https://clinicaltrials.gov/study/NCT07038382","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ccd20027-97c8-4d6a-8956-494eb9abe0b9"},{"id":"6084477d-d010-491e-b9cd-98ab5619dac6","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Sinovac Biotech Co., Ltd","ticker":null,"asset":"experimental vaccine","indication":"Epidemic Meningitis","summary":"As of 10 August 2026, Sinovac Biotech Co. estimated primary completion of a Phase 3 trial in Epidemic Meningitis, in January 2027.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT07505836","source_url":"https://clinicaltrials.gov/study/NCT07505836","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6084477d-d010-491e-b9cd-98ab5619dac6"},{"id":"7e6a2f12-30af-4bfd-bd89-f693da3a30fb","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Sun Pharmaceutical Industries, Inc.","ticker":null,"asset":"Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%","indication":"Actinic Keratosis","summary":"As of 22 April 2026, Sun Pharmaceutical Industries estimated primary completion of a Phase 3 trial in Actinic Keratosis, in January 2027.","as_of":"2026-04-22","source":"clinicaltrials","source_ref":"NCT07144345","source_url":"https://clinicaltrials.gov/study/NCT07144345","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7e6a2f12-30af-4bfd-bd89-f693da3a30fb"},{"id":"a9c8d7eb-01f3-40de-8835-716c979c2517","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Sun Pharmaceutical Industries, Inc.","ticker":null,"asset":"Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%","indication":"Actinic Keratosis","summary":"As of 22 April 2026, Sun Pharmaceutical Industries estimated primary completion of a Phase 3 trial in Actinic Keratosis, in January 2027.","as_of":"2026-04-22","source":"clinicaltrials","source_ref":"NCT07144852","source_url":"https://clinicaltrials.gov/study/NCT07144852","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a9c8d7eb-01f3-40de-8835-716c979c2517"},{"id":"b11f8740-718b-42d4-b5b6-c810ffbe3af6","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","ticker":null,"asset":"SHR-4375 Injection","indication":"Advanced Solid Tumor","summary":"As of 1 May 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in January 2027.","as_of":"2026-05-01","source":"clinicaltrials","source_ref":"NCT07298772","source_url":"https://clinicaltrials.gov/study/NCT07298772","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b11f8740-718b-42d4-b5b6-c810ffbe3af6"},{"id":"9d695873-7342-441c-840a-6fa4f1ef02c8","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Synendos Therapeutics AG","ticker":null,"asset":"SYT-510","indication":"Generalized Anxiety Disorder","summary":"As of 18 June 2026, Synendos Therapeutics estimated primary completion of a Phase 2 trial in Generalized Anxiety Disorder, in January 2027.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT07478744","source_url":"https://clinicaltrials.gov/study/NCT07478744","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9d695873-7342-441c-840a-6fa4f1ef02c8"},{"id":"8e4920d6-7632-4943-acc6-ca90127544ad","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Telix Pharmaceuticals (Innovations) Pty Limited","ticker":null,"asset":"68Ga-PSMA-11","indication":"PCA","summary":"As of 23 July 2026, Telix Pharmaceuticals (Innovations) Pty estimated primary completion of a Phase 3 trial in pCA, in January 2027.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT07052214","source_url":"https://clinicaltrials.gov/study/NCT07052214","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8e4920d6-7632-4943-acc6-ca90127544ad"},{"id":"25bbe1c6-ca4b-4d2a-9562-5927b4d67156","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Ultragenyx Pharmaceutical Inc","ticker":null,"asset":"setrusumab","indication":"Osteogenesis Imperfecta","summary":"As of 15 June 2026, Ultragenyx Pharmaceutical estimated primary completion of a Phase 3 trial in Osteogenesis Imperfecta, in January 2027.","as_of":"2026-06-15","source":"clinicaltrials","source_ref":"NCT06636071","source_url":"https://clinicaltrials.gov/study/NCT06636071","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-25bbe1c6-ca4b-4d2a-9562-5927b4d67156"},{"id":"d26cdae9-84c6-4fd0-a314-56ef9e356bd2","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Vaderis Therapeutics AG","ticker":null,"asset":"VAD044 Part I","indication":"Hereditary Hemorrhagic Telangiectasia (HHT)","summary":"As of 17 March 2026, Vaderis Therapeutics estimated primary completion of a Phase 2 trial in Hereditary Hemorrhagic Telangiectasia (HHT), in January 2027.","as_of":"2026-03-17","source":"clinicaltrials","source_ref":"NCT05406362","source_url":"https://clinicaltrials.gov/study/NCT05406362","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d26cdae9-84c6-4fd0-a314-56ef9e356bd2"},{"id":"a0bae348-d913-4483-bd9c-6328b136077a","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Vaxcyte, Inc.","ticker":null,"asset":"31 valent pneumococcal conjugate vaccine","indication":"Pneumococcal Vaccines","summary":"As of 15 May 2026, Vaxcyte estimated primary completion of a Phase 3 trial in Pneumococcal Vaccines, in January 2027.","as_of":"2026-05-15","source":"clinicaltrials","source_ref":"NCT07284654","source_url":"https://clinicaltrials.gov/study/NCT07284654","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a0bae348-d913-4483-bd9c-6328b136077a"},{"id":"0e8206fa-d3ae-4aa3-bbbf-c4e1b58c627e","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"Xenon Pharmaceuticals Inc.","ticker":null,"asset":"Azetukalner","indication":"Major Depressive Disorder","summary":"As of 3 August 2026, Xenon Pharmaceuticals estimated primary completion of a Phase 3 trial in Major Depressive Disorder, in January 2027.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT06922110","source_url":"https://clinicaltrials.gov/study/NCT06922110","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0e8206fa-d3ae-4aa3-bbbf-c4e1b58c627e"},{"id":"99bda922-fb1c-440a-ad85-2f8d49bd6f48","lane":"clinical","event_type":"primary-completion","date":"2027-01-01","date_precision":"month","confidence":"estimated","company":"iOnctura","ticker":null,"asset":"roginolisib","indication":"Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","summary":"As of 16 January 2026, iOnctura estimated primary completion of a Phase 2 trial in Non-Squamous Non-Small Cell Lung Cancer (NSCLC), in January 2027.","as_of":"2026-01-16","source":"clinicaltrials","source_ref":"NCT06879717","source_url":"https://clinicaltrials.gov/study/NCT06879717","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-99bda922-fb1c-440a-ad85-2f8d49bd6f48"},{"id":"3331dd0a-cca9-4b08-a81c-f7fbf289551e","lane":"clinical","event_type":"primary-completion","date":"2027-01-03","date_precision":"day","confidence":"estimated","company":"Shenzhen Kangzhe Biotechnology Co., Ltd.","ticker":null,"asset":"CMS-D002 Capsules 10 mg","indication":"Uterine Fibroids With Menorrhagia","summary":"As of 11 March 2026, Shenzhen Kangzhe Biotechnology Co. estimated primary completion of a Phase 2 trial in Uterine Fibroids With Menorrhagia, on 3 January 2027.","as_of":"2026-03-11","source":"clinicaltrials","source_ref":"NCT07402369","source_url":"https://clinicaltrials.gov/study/NCT07402369","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3331dd0a-cca9-4b08-a81c-f7fbf289551e"},{"id":"7ef3bf82-0eca-4acc-a875-8f4d566bbaa8","lane":"clinical","event_type":"primary-completion","date":"2027-01-04","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD0780","indication":"Heterozygous Familial Hypercholesterolaemia","summary":"As of 16 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Heterozygous Familial Hypercholesterolaemia, on 4 January 2027.","as_of":"2026-07-16","source":"clinicaltrials","source_ref":"NCT07000136","source_url":"https://clinicaltrials.gov/study/NCT07000136","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-7ef3bf82-0eca-4acc-a875-8f4d566bbaa8"},{"id":"cc2f183f-f6da-40bc-b936-beeb0b6865cd","lane":"clinical","event_type":"primary-completion","date":"2027-01-04","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Sacituzumab tirumotecan","indication":"Gastroesophageal Cancer","summary":"As of 27 February 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Gastroesophageal Cancer, on 4 January 2027.","as_of":"2026-02-27","source":"clinicaltrials","source_ref":"NCT06356311","source_url":"https://clinicaltrials.gov/study/NCT06356311","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cc2f183f-f6da-40bc-b936-beeb0b6865cd"},{"id":"caeeeefd-aeac-46ac-acf3-ebd69e2c72e8","lane":"clinical","event_type":"primary-completion","date":"2027-01-06","date_precision":"day","confidence":"estimated","company":"Amgen","ticker":null,"asset":"AMG 732","indication":"Thyroid Eye Disease","summary":"As of 10 August 2026, Amgen estimated primary completion of a Phase 2 trial in Thyroid Eye Disease, on 6 January 2027.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT06401044","source_url":"https://clinicaltrials.gov/study/NCT06401044","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-caeeeefd-aeac-46ac-acf3-ebd69e2c72e8"},{"id":"d846597d-710c-4eb4-b489-e0edc26db95c","lane":"clinical","event_type":"primary-completion","date":"2027-01-06","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Anifrolumab (blinded)","indication":"Systemic Sclerosis","summary":"As of 23 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Systemic Sclerosis, on 6 January 2027.","as_of":"2026-07-23","source":"clinicaltrials","source_ref":"NCT05925803","source_url":"https://clinicaltrials.gov/study/NCT05925803","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d846597d-710c-4eb4-b489-e0edc26db95c"},{"id":"84acdb99-58ea-480b-bd1c-f994e3cd00c6","lane":"clinical","event_type":"primary-completion","date":"2027-01-06","date_precision":"day","confidence":"estimated","company":"Incyte Corporation","ticker":null,"asset":"INCA034176","indication":"Chronic Graft-versus-host-disease","summary":"As of 10 August 2026, Incyte estimated primary completion of a Phase 2 trial in Chronic Graft-versus-host-disease, on 6 January 2027.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT06843408","source_url":"https://clinicaltrials.gov/study/NCT06843408","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-84acdb99-58ea-480b-bd1c-f994e3cd00c6"},{"id":"f56d83c3-aac2-4611-812a-6f0a37705bed","lane":"clinical","event_type":"primary-completion","date":"2027-01-06","date_precision":"day","confidence":"estimated","company":"Norgine","ticker":null,"asset":"PLENVU®","indication":"Bowel Cleansing Prior to Clinical Procedures","summary":"As of 27 May 2026, Norgine estimated primary completion of a Phase 3 trial in Bowel Cleansing Prior to Clinical Procedures, on 6 January 2027.","as_of":"2026-05-27","source":"clinicaltrials","source_ref":"NCT07218523","source_url":"https://clinicaltrials.gov/study/NCT07218523","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f56d83c3-aac2-4611-812a-6f0a37705bed"},{"id":"1ab5297a-a8f9-4d9f-8798-92cb20b82b84","lane":"clinical","event_type":"primary-completion","date":"2027-01-07","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"PCV21","indication":"Sickle Cell Disease","summary":"As of 15 April 2026, Sanofi estimated primary completion of a Phase 3 trial in Sickle Cell Disease, on 7 January 2027.","as_of":"2026-04-15","source":"clinicaltrials","source_ref":"NCT07247188","source_url":"https://clinicaltrials.gov/study/NCT07247188","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1ab5297a-a8f9-4d9f-8798-92cb20b82b84"},{"id":"176a88a5-3d86-497c-846d-bac48851b0a0","lane":"clinical","event_type":"primary-completion","date":"2027-01-08","date_precision":"day","confidence":"estimated","company":"Ocular Therapeutix, Inc.","ticker":null,"asset":"OTX-TKI","indication":"Neovascular Age-related Macular Degeneration","summary":"As of 17 June 2025, Ocular Therapeutix estimated primary completion of a Phase 3 trial in Neovascular Age-related Macular Degeneration, on 8 January 2027.","as_of":"2025-06-17","source":"clinicaltrials","source_ref":"NCT06495918","source_url":"https://clinicaltrials.gov/study/NCT06495918","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-176a88a5-3d86-497c-846d-bac48851b0a0"},{"id":"08c9bf16-6474-4997-b9f5-2bee88af5090","lane":"clinical","event_type":"primary-completion","date":"2027-01-08","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"Isatuximab SC-OBDS","indication":"Plasma Cell Myeloma Refractory","summary":"As of 23 February 2026, Sanofi estimated primary completion of a Phase 2 trial in Plasma Cell Myeloma Refractory, on 8 January 2027.","as_of":"2026-02-23","source":"clinicaltrials","source_ref":"NCT06356571","source_url":"https://clinicaltrials.gov/study/NCT06356571","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-08c9bf16-6474-4997-b9f5-2bee88af5090"},{"id":"c5593776-1e35-4c8d-af6f-a15ecb7930cf","lane":"clinical","event_type":"primary-completion","date":"2027-01-09","date_precision":"day","confidence":"estimated","company":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","ticker":null,"asset":"GQ1005","indication":"HER2-positive Breast Cancer","summary":"As of 29 June 2026, GeneQuantum Healthcare (Suzhou) Co. estimated primary completion of a Phase 3 trial in HER2-positive Breast Cancer, on 9 January 2027.","as_of":"2026-06-29","source":"clinicaltrials","source_ref":"NCT07673029","source_url":"https://clinicaltrials.gov/study/NCT07673029","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c5593776-1e35-4c8d-af6f-a15ecb7930cf"},{"id":"b4c92ae4-90f8-4770-bdcc-b8d98f39a5c8","lane":"clinical","event_type":"primary-completion","date":"2027-01-10","date_precision":"day","confidence":"estimated","company":"Celgene","ticker":null,"asset":"mezigdomide","indication":"Relapsed or Refractory Multiple Myeloma","summary":"As of 29 July 2026, Celgene estimated primary completion of a Phase 3 trial in Relapsed or Refractory Multiple Myeloma, on 10 January 2027.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT05519085","source_url":"https://clinicaltrials.gov/study/NCT05519085","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b4c92ae4-90f8-4770-bdcc-b8d98f39a5c8"},{"id":"c5c6927c-ce13-47ae-84b2-bb0f3f3b1bfd","lane":"clinical","event_type":"primary-completion","date":"2027-01-11","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD0780","indication":"Cardiovascular Disease","summary":"As of 11 August 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Cardiovascular Disease, on 11 January 2027.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT07000123","source_url":"https://clinicaltrials.gov/study/NCT07000123","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c5c6927c-ce13-47ae-84b2-bb0f3f3b1bfd"},{"id":"07bc667d-e313-4716-bbda-dcf8b248d9e8","lane":"clinical","event_type":"primary-completion","date":"2027-01-11","date_precision":"day","confidence":"estimated","company":"LaNova Medicines Limited","ticker":null,"asset":"LM101","indication":"Malignant Tumors","summary":"As of 19 December 2024, LaNova Medicines estimated primary completion of a Phase 2 trial in Malignant Tumors, on 11 January 2027.","as_of":"2024-12-19","source":"clinicaltrials","source_ref":"NCT05615974","source_url":"https://clinicaltrials.gov/study/NCT05615974","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-07bc667d-e313-4716-bbda-dcf8b248d9e8"},{"id":"645b0a0e-6750-4d29-92e9-866f6a4b181d","lane":"clinical","event_type":"primary-completion","date":"2027-01-12","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"Adjuvanted RSVPreF3 vaccine","indication":"Respiratory Syncytial Virus Infections","summary":"As of 30 July 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Respiratory Syncytial Virus Infections, on 12 January 2027.","as_of":"2026-07-30","source":"clinicaltrials","source_ref":"NCT07092865","source_url":"https://clinicaltrials.gov/study/NCT07092865","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-645b0a0e-6750-4d29-92e9-866f6a4b181d"},{"id":"80bb46ac-332a-42e7-a7a4-6ca995f8646d","lane":"clinical","event_type":"primary-completion","date":"2027-01-12","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Sacituzumab Govitecan","indication":"Carcinoma, Non-Small-Cell Lung","summary":"As of 24 December 2025, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Carcinoma, Non-Small-Cell Lung, on 12 January 2027.","as_of":"2025-12-24","source":"clinicaltrials","source_ref":"NCT05609968","source_url":"https://clinicaltrials.gov/study/NCT05609968","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-80bb46ac-332a-42e7-a7a4-6ca995f8646d"},{"id":"75a9c049-cd94-471c-87e1-eef5f5ed68d6","lane":"clinical","event_type":"primary-completion","date":"2027-01-13","date_precision":"day","confidence":"estimated","company":"Akeso","ticker":null,"asset":"AK112","indication":"Colorectal Adenocarcinoma","summary":"As of 4 March 2026, Akeso estimated primary completion of a Phase 3 trial in Colorectal Adenocarcinoma, on 13 January 2027.","as_of":"2026-03-04","source":"clinicaltrials","source_ref":"NCT06951503","source_url":"https://clinicaltrials.gov/study/NCT06951503","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-75a9c049-cd94-471c-87e1-eef5f5ed68d6"},{"id":"e85f2ab9-f38a-4cbf-aaf6-df31d6aa8fb2","lane":"clinical","event_type":"primary-completion","date":"2027-01-13","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Tezepelumab","indication":"Chronic Rhinosinusitis With Nasal Polyps","summary":"As of 5 August 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Chronic Rhinosinusitis With Nasal Polyps, on 13 January 2027.","as_of":"2026-08-05","source":"clinicaltrials","source_ref":"NCT06706817","source_url":"https://clinicaltrials.gov/study/NCT06706817","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e85f2ab9-f38a-4cbf-aaf6-df31d6aa8fb2"},{"id":"9b268ed8-e577-4ae9-94ad-2b138f2e5dd7","lane":"clinical","event_type":"primary-completion","date":"2027-01-13","date_precision":"day","confidence":"estimated","company":"Avirmax Biopharma Inc","ticker":null,"asset":"ABI-110 Low Dose","indication":"Neovascular (Wet) AMD","summary":"As of 12 February 2026, Avirmax Biopharma estimated primary completion of a Phase 2 trial in Neovascular (Wet) AMD, on 13 January 2027.","as_of":"2026-02-12","source":"clinicaltrials","source_ref":"NCT06550011","source_url":"https://clinicaltrials.gov/study/NCT06550011","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9b268ed8-e577-4ae9-94ad-2b138f2e5dd7"},{"id":"ceb67cf8-d373-44d0-ae9a-01dde4df0c63","lane":"clinical","event_type":"primary-completion","date":"2027-01-13","date_precision":"day","confidence":"estimated","company":"iVascular S.L.U.","ticker":null,"asset":"Angiolite: Sirolimus-eluting stent","indication":"Coronary Artery Disease","summary":"As of 15 May 2026, iVascular S.L.U. estimated primary completion of a Phase 3 trial in Coronary Artery Disease, on 13 January 2027.","as_of":"2026-05-15","source":"clinicaltrials","source_ref":"NCT05952206","source_url":"https://clinicaltrials.gov/study/NCT05952206","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ceb67cf8-d373-44d0-ae9a-01dde4df0c63"},{"id":"e718e183-9da0-45f2-93f8-3cfffd467ec3","lane":"clinical","event_type":"primary-completion","date":"2027-01-14","date_precision":"day","confidence":"estimated","company":"Novo Nordisk A/S","ticker":null,"asset":"UBT251","indication":"Overweight","summary":"As of 21 April 2026, Novo Nordisk estimated primary completion of a Phase 2 trial in overweight, on 14 January 2027.","as_of":"2026-04-21","source":"clinicaltrials","source_ref":"NCT07395687","source_url":"https://clinicaltrials.gov/study/NCT07395687","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e718e183-9da0-45f2-93f8-3cfffd467ec3"},{"id":"27485e38-5fa1-4b4d-962f-e83dfb578a6a","lane":"clinical","event_type":"primary-completion","date":"2027-01-14","date_precision":"day","confidence":"estimated","company":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","ticker":null,"asset":"608 dose","indication":"Ankylosing Spondylitis","summary":"As of 10 December 2025, Sunshine Guojian Pharmaceutical (Shanghai) Co. estimated primary completion of a Phase 3 trial in Ankylosing Spondylitis, on 14 January 2027.","as_of":"2025-12-10","source":"clinicaltrials","source_ref":"NCT07261644","source_url":"https://clinicaltrials.gov/study/NCT07261644","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-27485e38-5fa1-4b4d-962f-e83dfb578a6a"},{"id":"4e89e67d-696e-48df-9aa7-e2a64d2e39f7","lane":"clinical","event_type":"primary-completion","date":"2027-01-15","date_precision":"day","confidence":"estimated","company":"Azitra Inc.","ticker":null,"asset":"ATR04-484","indication":"EGFR Inhibitor-associated Rash","summary":"As of 11 February 2026, Azitra estimated primary completion of a Phase 2 trial in EGFR Inhibitor-associated Rash, on 15 January 2027.","as_of":"2026-02-11","source":"clinicaltrials","source_ref":"NCT06830863","source_url":"https://clinicaltrials.gov/study/NCT06830863","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4e89e67d-696e-48df-9aa7-e2a64d2e39f7"},{"id":"0d9b2485-8480-4320-a56a-38a1e1a0caf4","lane":"clinical","event_type":"primary-completion","date":"2027-01-15","date_precision":"day","confidence":"estimated","company":"Biostar Pharma, Inc.","ticker":null,"asset":"Utidelone","indication":"HER2-negative Breast Cancer Patients With Brain Metastases","summary":"As of 28 November 2025, Biostar Pharma estimated primary completion of a Phase 2 trial in HER2-negative Breast Cancer Patients With Brain Metastases, on 15 January 2027.","as_of":"2025-11-28","source":"clinicaltrials","source_ref":"NCT06764940","source_url":"https://clinicaltrials.gov/study/NCT06764940","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0d9b2485-8480-4320-a56a-38a1e1a0caf4"},{"id":"fc6743a9-aa82-4df8-9958-332e49ef1671","lane":"clinical","event_type":"primary-completion","date":"2027-01-15","date_precision":"day","confidence":"estimated","company":"Bioverativ, a Sanofi company","ticker":null,"asset":"efanesoctocog alfa (BIVV001)","indication":"Hemophilia A","summary":"As of 28 July 2026, Bioverativ, a Sanofi estimated primary completion of a Phase 3 trial in Hemophilia A, on 15 January 2027.","as_of":"2026-07-28","source":"clinicaltrials","source_ref":"NCT04644575","source_url":"https://clinicaltrials.gov/study/NCT04644575","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fc6743a9-aa82-4df8-9958-332e49ef1671"},{"id":"adffa175-1f58-4018-bfa6-5ebb53caede7","lane":"clinical","event_type":"primary-completion","date":"2027-01-15","date_precision":"day","confidence":"estimated","company":"Huabo Biopharm Co., Ltd.","ticker":null,"asset":"HB0025 20 mg/kg plus nab-paclitaxel","indication":"TNBC","summary":"As of 29 January 2026, Huabo Biopharm Co. estimated primary completion of a Phase 2 trial in tNBC, on 15 January 2027.","as_of":"2026-01-29","source":"clinicaltrials","source_ref":"NCT07376629","source_url":"https://clinicaltrials.gov/study/NCT07376629","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-adffa175-1f58-4018-bfa6-5ebb53caede7"},{"id":"a2b2e739-96ac-4e8c-9efd-4be8153c1493","lane":"clinical","event_type":"primary-completion","date":"2027-01-15","date_precision":"day","confidence":"estimated","company":"IDEAYA Biosciences","ticker":null,"asset":"IDE196","indication":"Metastatic Uveal Melanoma","summary":"As of 17 February 2026, IDEAYA Biosciences estimated primary completion of a Phase 3 trial in Metastatic Uveal Melanoma, on 15 January 2027.","as_of":"2026-02-17","source":"clinicaltrials","source_ref":"NCT05987332","source_url":"https://clinicaltrials.gov/study/NCT05987332","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a2b2e739-96ac-4e8c-9efd-4be8153c1493"},{"id":"e473cf43-205f-4914-aca1-0d11cff3cb52","lane":"clinical","event_type":"primary-completion","date":"2027-01-15","date_precision":"day","confidence":"estimated","company":"MoonLake Immunotherapeutics AG","ticker":null,"asset":"Sonelokimab","indication":"Arthritis, Psoriatic","summary":"As of 13 July 2026, MoonLake Immunotherapeutics estimated primary completion of a Phase 3 trial in Arthritis, Psoriatic, on 15 January 2027.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT06641089","source_url":"https://clinicaltrials.gov/study/NCT06641089","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e473cf43-205f-4914-aca1-0d11cff3cb52"},{"id":"35b78f23-2b8a-49c2-bf46-257090ffd465","lane":"clinical","event_type":"primary-completion","date":"2027-01-16","date_precision":"day","confidence":"estimated","company":"Corbus Pharmaceuticals Inc.","ticker":null,"asset":"CRB-701","indication":"Solid Tumor, Adult","summary":"As of 8 January 2026, Corbus Pharmaceuticals estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 16 January 2027.","as_of":"2026-01-08","source":"clinicaltrials","source_ref":"NCT06265727","source_url":"https://clinicaltrials.gov/study/NCT06265727","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-35b78f23-2b8a-49c2-bf46-257090ffd465"},{"id":"a7d2b3b0-5ec3-42ed-9657-f37f327459a7","lane":"clinical","event_type":"primary-completion","date":"2027-01-18","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"Savolitinib","indication":"Lung Cancer","summary":"As of 14 May 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Lung Cancer, on 18 January 2027.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT05374603","source_url":"https://clinicaltrials.gov/study/NCT05374603","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a7d2b3b0-5ec3-42ed-9657-f37f327459a7"},{"id":"8ca14279-83a6-4039-85c3-0bcd52f083fa","lane":"clinical","event_type":"primary-completion","date":"2027-01-18","date_precision":"day","confidence":"estimated","company":"Centre for Neuro Skills","ticker":null,"asset":"Aerobic Exercise (AER)","indication":"Traumatic Brain Injury","summary":"As of 28 March 2023, Centre for Neuro Skills estimated primary completion of a Phase 2 trial in Traumatic Brain Injury, on 18 January 2027.","as_of":"2023-03-28","source":"clinicaltrials","source_ref":"NCT05786729","source_url":"https://clinicaltrials.gov/study/NCT05786729","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8ca14279-83a6-4039-85c3-0bcd52f083fa"},{"id":"ba37658c-10cb-4a94-b36e-15efaeaaca9f","lane":"clinical","event_type":"primary-completion","date":"2027-01-18","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"RSVpreF","indication":"Lower Respiratory Tract Illness","summary":"As of 28 January 2026, Pfizer estimated primary completion of a Phase 3 trial in Lower Respiratory Tract Illness, on 18 January 2027.","as_of":"2026-01-28","source":"clinicaltrials","source_ref":"NCT05035212","source_url":"https://clinicaltrials.gov/study/NCT05035212","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ba37658c-10cb-4a94-b36e-15efaeaaca9f"},{"id":"4d966392-c8da-4311-bb4a-f67c727f12f6","lane":"clinical","event_type":"primary-completion","date":"2027-01-18","date_precision":"day","confidence":"estimated","company":"Sanofi Pasteur, a Sanofi Company","ticker":null,"asset":"Investigational hMPV/RSV vaccine","indication":"Human Metapneumovirus Immunization","summary":"As of 11 December 2025, Sanofi Pasteur, a Sanofi estimated primary completion of a Phase 2 trial in Human Metapneumovirus Immunization, on 18 January 2027.","as_of":"2025-12-11","source":"clinicaltrials","source_ref":"NCT06686654","source_url":"https://clinicaltrials.gov/study/NCT06686654","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4d966392-c8da-4311-bb4a-f67c727f12f6"},{"id":"62d66cc6-d72c-4f3c-8d7b-e915096ea231","lane":"clinical","event_type":"primary-completion","date":"2027-01-18","date_precision":"day","confidence":"estimated","company":"Takeda","ticker":null,"asset":"Maribavir","indication":"Cytomegalovirus (CMV)","summary":"As of 22 May 2026, Takeda estimated primary completion of a Phase 3 trial in cytomegalovirus (CMV), on 18 January 2027.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT05319353","source_url":"https://clinicaltrials.gov/study/NCT05319353","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-62d66cc6-d72c-4f3c-8d7b-e915096ea231"},{"id":"f763fd02-61fb-454d-b07d-a4d78e8df567","lane":"clinical","event_type":"primary-completion","date":"2027-01-19","date_precision":"day","confidence":"estimated","company":"Sanofi","ticker":null,"asset":"SAR445877","indication":"Solid Tumor","summary":"As of 23 June 2026, Sanofi estimated primary completion of a Phase 2 trial in Solid Tumor, on 19 January 2027.","as_of":"2026-06-23","source":"clinicaltrials","source_ref":"NCT05584670","source_url":"https://clinicaltrials.gov/study/NCT05584670","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f763fd02-61fb-454d-b07d-a4d78e8df567"},{"id":"db1c52df-ff4a-4c97-9562-46c05b5b6817","lane":"clinical","event_type":"primary-completion","date":"2027-01-20","date_precision":"day","confidence":"estimated","company":"Acepodia Biotech, Inc.","ticker":null,"asset":"ACE1831","indication":"IgG4 Related Disease","summary":"As of 13 February 2026, Acepodia Biotech estimated primary completion of a Phase 2 trial in IgG4 Related Disease, on 20 January 2027.","as_of":"2026-02-13","source":"clinicaltrials","source_ref":"NCT07061938","source_url":"https://clinicaltrials.gov/study/NCT07061938","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-db1c52df-ff4a-4c97-9562-46c05b5b6817"},{"id":"d5e64ce9-8207-434b-945c-77d90c0db66a","lane":"clinical","event_type":"primary-completion","date":"2027-01-21","date_precision":"day","confidence":"estimated","company":"Amgen","ticker":null,"asset":"Maridebart Cafraglutide","indication":"Obesity","summary":"As of 20 October 2025, Amgen estimated primary completion of a Phase 3 trial in obesity, on 21 January 2027.","as_of":"2025-10-20","source":"clinicaltrials","source_ref":"NCT06858839","source_url":"https://clinicaltrials.gov/study/NCT06858839","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d5e64ce9-8207-434b-945c-77d90c0db66a"},{"id":"6f32f672-103d-44a4-b0b2-538a7d384c86","lane":"clinical","event_type":"primary-completion","date":"2027-01-21","date_precision":"day","confidence":"estimated","company":"Amgen","ticker":null,"asset":"Maridebart cafraglutide","indication":"Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight","summary":"As of 31 December 2025, Amgen estimated primary completion of a Phase 3 trial in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, on 21 January 2027.","as_of":"2025-12-31","source":"clinicaltrials","source_ref":"NCT06858878","source_url":"https://clinicaltrials.gov/study/NCT06858878","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6f32f672-103d-44a4-b0b2-538a7d384c86"},{"id":"4d4b6d3a-a1ca-45eb-b9b7-311eb2cdecda","lane":"clinical","event_type":"primary-completion","date":"2027-01-21","date_precision":"day","confidence":"estimated","company":"Laboratoires Thea","ticker":null,"asset":"Slit Lamp Examination","indication":"Moderate to Severe Vernal Keratoconjunctivitis","summary":"As of 22 April 2026, Laboratoires Thea estimated primary completion of a Phase 2 trial in Moderate to Severe Vernal Keratoconjunctivitis, on 21 January 2027.","as_of":"2026-04-22","source":"clinicaltrials","source_ref":"NCT07169695","source_url":"https://clinicaltrials.gov/study/NCT07169695","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4d4b6d3a-a1ca-45eb-b9b7-311eb2cdecda"},{"id":"fdb5937c-40c3-472e-abcd-1e84b07f91c3","lane":"clinical","event_type":"primary-completion","date":"2027-01-22","date_precision":"day","confidence":"estimated","company":"GlaxoSmithKline","ticker":null,"asset":"FF/UMEC/VI","indication":"Asthma","summary":"As of 16 July 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in asthma, on 22 January 2027.","as_of":"2026-07-16","source":"clinicaltrials","source_ref":"NCT05757102","source_url":"https://clinicaltrials.gov/study/NCT05757102","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fdb5937c-40c3-472e-abcd-1e84b07f91c3"},{"id":"27661a29-cd5e-4866-9ad6-f21e83474c99","lane":"clinical","event_type":"primary-completion","date":"2027-01-22","date_precision":"day","confidence":"estimated","company":"Lupin Ltd.","ticker":null,"asset":"Granular powder in unit dose foil-lined sachet Mexiletine (PR)","indication":"Myotonia","summary":"As of 22 December 2025, Lupin estimated primary completion of a Phase 3 trial in myotonia, on 22 January 2027.","as_of":"2025-12-22","source":"clinicaltrials","source_ref":"NCT07097701","source_url":"https://clinicaltrials.gov/study/NCT07097701","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-27661a29-cd5e-4866-9ad6-f21e83474c99"},{"id":"cbf9952e-c7d2-44d9-8dac-8968b46fda84","lane":"clinical","event_type":"primary-completion","date":"2027-01-23","date_precision":"day","confidence":"estimated","company":"Egle Therapeutics","ticker":null,"asset":"EGL-001","indication":"Solid Tumor, Adult","summary":"As of 7 November 2024, Egle Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 23 January 2027.","as_of":"2024-11-07","source":"clinicaltrials","source_ref":"NCT06622486","source_url":"https://clinicaltrials.gov/study/NCT06622486","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-cbf9952e-c7d2-44d9-8dac-8968b46fda84"},{"id":"4b3f6efc-8146-4e96-a3d0-f0c3b6fe780b","lane":"clinical","event_type":"primary-completion","date":"2027-01-24","date_precision":"day","confidence":"estimated","company":"Dompé Farmaceutici S.p.A","ticker":null,"asset":"DFL24498","indication":"Dry Eye Disease (DED)","summary":"As of 26 June 2026, Dompé Farmaceutici S.p.A estimated primary completion of a Phase 2 trial in Dry Eye Disease (DED), on 24 January 2027.","as_of":"2026-06-26","source":"clinicaltrials","source_ref":"NCT07503886","source_url":"https://clinicaltrials.gov/study/NCT07503886","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-4b3f6efc-8146-4e96-a3d0-f0c3b6fe780b"},{"id":"115c2da6-1fea-4951-91ef-2d53e08236ef","lane":"clinical","event_type":"primary-completion","date":"2027-01-25","date_precision":"day","confidence":"estimated","company":"Biotheus Inc.","ticker":null,"asset":"PM8002","indication":"SCLC","summary":"As of 22 May 2026, Biotheus estimated primary completion of a Phase 3 trial in sCLC, on 25 January 2027.","as_of":"2026-05-22","source":"clinicaltrials","source_ref":"NCT06616532","source_url":"https://clinicaltrials.gov/study/NCT06616532","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-115c2da6-1fea-4951-91ef-2d53e08236ef"},{"id":"a71eb952-99f7-4308-84bc-d9f57914f961","lane":"clinical","event_type":"primary-completion","date":"2027-01-25","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"JDQ443","indication":"KRAS G12C Mutant Solid Tumors","summary":"As of 18 March 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in KRAS G12C Mutant Solid Tumors, on 25 January 2027.","as_of":"2026-03-18","source":"clinicaltrials","source_ref":"NCT04699188","source_url":"https://clinicaltrials.gov/study/NCT04699188","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a71eb952-99f7-4308-84bc-d9f57914f961"},{"id":"0eb1acfc-74cb-404e-b395-4f92ea1aaec6","lane":"clinical","event_type":"primary-completion","date":"2027-01-25","date_precision":"day","confidence":"estimated","company":"Novo Nordisk A/S","ticker":null,"asset":"Insulin icodec","indication":"Diabetes Mellitus, Type 1","summary":"As of 29 June 2026, Novo Nordisk estimated primary completion of a Phase 3 trial in Diabetes Mellitus, Type 1, on 25 January 2027.","as_of":"2026-06-29","source":"clinicaltrials","source_ref":"NCT07076199","source_url":"https://clinicaltrials.gov/study/NCT07076199","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0eb1acfc-74cb-404e-b395-4f92ea1aaec6"},{"id":"fc0c8abc-7bdd-40c8-87f2-2bca490d760a","lane":"clinical","event_type":"primary-completion","date":"2027-01-25","date_precision":"day","confidence":"estimated","company":"Pfizer","ticker":null,"asset":"RSVpreF","indication":"Respiratory Syncytial Virus (RSV)","summary":"As of 29 July 2026, Pfizer estimated primary completion of a Phase 3 trial in Respiratory Syncytial Virus (RSV), on 25 January 2027.","as_of":"2026-07-29","source":"clinicaltrials","source_ref":"NCT07653100","source_url":"https://clinicaltrials.gov/study/NCT07653100","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-fc0c8abc-7bdd-40c8-87f2-2bca490d760a"},{"id":"5ba16311-afd8-4d48-ba2e-f8da6b4091e8","lane":"clinical","event_type":"primary-completion","date":"2027-01-25","date_precision":"day","confidence":"estimated","company":"Vertex Pharmaceuticals Incorporated","ticker":null,"asset":"Suzetrigine","indication":"Diabetic Peripheral Neuropathic Pain","summary":"As of 18 May 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 3 trial in Diabetic Peripheral Neuropathic Pain, on 25 January 2027.","as_of":"2026-05-18","source":"clinicaltrials","source_ref":"NCT06696443","source_url":"https://clinicaltrials.gov/study/NCT06696443","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5ba16311-afd8-4d48-ba2e-f8da6b4091e8"},{"id":"25ebd658-9b8e-407b-a9c5-9edef67c899d","lane":"clinical","event_type":"primary-completion","date":"2027-01-28","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD0901","indication":"Gastroesophageal Adenocarcinoma","summary":"As of 10 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Gastroesophageal Adenocarcinoma, on 28 January 2027.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT07069712","source_url":"https://clinicaltrials.gov/study/NCT07069712","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-25ebd658-9b8e-407b-a9c5-9edef67c899d"},{"id":"e0b3c00b-9897-4e59-b950-7a8097301646","lane":"clinical","event_type":"primary-completion","date":"2027-01-28","date_precision":"day","confidence":"estimated","company":"ModernaTX, Inc.","ticker":null,"asset":"mRNA-1018-H5","indication":"Influenza","summary":"As of 11 August 2026, ModernaTX estimated primary completion of a Phase 3 trial in influenza, on 28 January 2027.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT07496450","source_url":"https://clinicaltrials.gov/study/NCT07496450","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e0b3c00b-9897-4e59-b950-7a8097301646"},{"id":"1d808dab-4dd9-4e8a-8040-2df071c5268c","lane":"clinical","event_type":"primary-completion","date":"2027-01-28","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"Alpelisib","indication":"Breast Cancer","summary":"As of 14 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Breast Cancer, on 28 January 2027.","as_of":"2026-07-14","source":"clinicaltrials","source_ref":"NCT05038735","source_url":"https://clinicaltrials.gov/study/NCT05038735","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1d808dab-4dd9-4e8a-8040-2df071c5268c"},{"id":"b100c473-3de8-45ae-89d0-bf56a751040b","lane":"clinical","event_type":"primary-completion","date":"2027-01-29","date_precision":"day","confidence":"estimated","company":"AstraZeneca","ticker":null,"asset":"AZD9550","indication":"Overweight and Obesity","summary":"As of 23 June 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Overweight and Obesity, on 29 January 2027.","as_of":"2026-06-23","source":"clinicaltrials","source_ref":"NCT06151964","source_url":"https://clinicaltrials.gov/study/NCT06151964","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b100c473-3de8-45ae-89d0-bf56a751040b"},{"id":"ec77d23f-93b5-443c-973e-dda833eb78d8","lane":"clinical","event_type":"primary-completion","date":"2027-01-29","date_precision":"day","confidence":"estimated","company":"Dynavax Technologies Corporation","ticker":null,"asset":"rF1V-1018","indication":"Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis","summary":"As of 18 June 2026, Dynavax Technologies estimated primary completion of a Phase 2 trial on 29 January 2027.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT07207408","source_url":"https://clinicaltrials.gov/study/NCT07207408","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ec77d23f-93b5-443c-973e-dda833eb78d8"},{"id":"ac9c804a-49a5-400c-8d4e-581f87871a27","lane":"clinical","event_type":"primary-completion","date":"2027-01-29","date_precision":"day","confidence":"estimated","company":"IDEAYA Biosciences","ticker":null,"asset":"IDE196","indication":"Metastatic Uveal Melanoma","summary":"As of 8 June 2026, IDEAYA Biosciences estimated primary completion of a Phase 2 trial in Metastatic Uveal Melanoma, on 29 January 2027.","as_of":"2026-06-08","source":"clinicaltrials","source_ref":"NCT03947385","source_url":"https://clinicaltrials.gov/study/NCT03947385","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ac9c804a-49a5-400c-8d4e-581f87871a27"},{"id":"251914e5-1abc-4f9b-9054-77d2119a41db","lane":"clinical","event_type":"primary-completion","date":"2027-01-29","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"Alpelisib","indication":"Breast Neoplasms","summary":"As of 11 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Breast Neoplasms, on 29 January 2027.","as_of":"2026-06-11","source":"clinicaltrials","source_ref":"NCT04544189","source_url":"https://clinicaltrials.gov/study/NCT04544189","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-251914e5-1abc-4f9b-9054-77d2119a41db"},{"id":"00d9c630-5fd4-46d1-94d6-43f1abdf65fc","lane":"clinical","event_type":"primary-completion","date":"2027-01-29","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"QCZ484","indication":"Hypertension","summary":"As of 6 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in hypertension, on 29 January 2027.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT06857955","source_url":"https://clinicaltrials.gov/study/NCT06857955","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-00d9c630-5fd4-46d1-94d6-43f1abdf65fc"},{"id":"06b4b055-46d2-43a2-ad10-5cb48f4336fc","lane":"clinical","event_type":"primary-completion","date":"2027-01-29","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"iptacopan","indication":"C3G","summary":"As of 13 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in c3G, on 29 January 2027.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT04817618","source_url":"https://clinicaltrials.gov/study/NCT04817618","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-06b4b055-46d2-43a2-ad10-5cb48f4336fc"},{"id":"dc64869d-55a7-4d49-b97a-8282e490396f","lane":"clinical","event_type":"primary-completion","date":"2027-01-29","date_precision":"day","confidence":"estimated","company":"Seagen, a wholly owned subsidiary of Pfizer","ticker":null,"asset":"disitamab vedotin","indication":"Urothelial Carcinoma","summary":"As of 22 July 2026, Seagen estimated primary completion of a Phase 3 trial in Urothelial Carcinoma, on 29 January 2027.","as_of":"2026-07-22","source":"clinicaltrials","source_ref":"NCT05911295","source_url":"https://clinicaltrials.gov/study/NCT05911295","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dc64869d-55a7-4d49-b97a-8282e490396f"},{"id":"19dcc2a2-4a88-4d47-aeeb-d6dbd97bdcf0","lane":"clinical","event_type":"primary-completion","date":"2027-01-30","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"BMS-986369","indication":"Relapsed or Refractory T-cell Lymphomas","summary":"As of 1 May 2026, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Relapsed or Refractory T-cell Lymphomas, on 30 January 2027.","as_of":"2026-05-01","source":"clinicaltrials","source_ref":"NCT06035497","source_url":"https://clinicaltrials.gov/study/NCT06035497","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-19dcc2a2-4a88-4d47-aeeb-d6dbd97bdcf0"},{"id":"ea274b5d-59ee-4cd4-986f-d131e348654f","lane":"clinical","event_type":"primary-completion","date":"2027-01-30","date_precision":"day","confidence":"estimated","company":"Curasight","ticker":null,"asset":"64Cu-DOTA-AE105","indication":"Prostate Cancer","summary":"As of 1 June 2026, Curasight estimated primary completion of a Phase 2 trial in Prostate Cancer, on 30 January 2027.","as_of":"2026-06-01","source":"clinicaltrials","source_ref":"NCT06474806","source_url":"https://clinicaltrials.gov/study/NCT06474806","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ea274b5d-59ee-4cd4-986f-d131e348654f"},{"id":"05afcfd6-9c32-439a-bbaa-dbd23eba8e23","lane":"clinical","event_type":"primary-completion","date":"2027-01-30","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Afimkibart","indication":"Moderately to Severely Active Ulcerative Colitis","summary":"As of 18 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Moderately to Severely Active Ulcerative Colitis, on 30 January 2027.","as_of":"2026-06-18","source":"clinicaltrials","source_ref":"NCT06589986","source_url":"https://clinicaltrials.gov/study/NCT06589986","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-05afcfd6-9c32-439a-bbaa-dbd23eba8e23"},{"id":"6e4ffaa7-58bf-44b7-92b0-9f879fb50bc1","lane":"clinical","event_type":"primary-completion","date":"2027-01-30","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Afimkibart","indication":"Moderately to Severely Active Ulcerative Colitis","summary":"As of 5 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Moderately to Severely Active Ulcerative Colitis, on 30 January 2027.","as_of":"2026-08-05","source":"clinicaltrials","source_ref":"NCT06588855","source_url":"https://clinicaltrials.gov/study/NCT06588855","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6e4ffaa7-58bf-44b7-92b0-9f879fb50bc1"},{"id":"b49bdc58-f721-41ac-908b-1a631e0c2e60","lane":"clinical","event_type":"primary-completion","date":"2027-01-30","date_precision":"day","confidence":"estimated","company":"Psivac Ltd","ticker":null,"asset":"Ixovex-1","indication":"Solid Tumor","summary":"As of 30 January 2025, Psivac estimated primary completion of a Phase 2 trial in Solid Tumor, on 30 January 2027.","as_of":"2025-01-30","source":"clinicaltrials","source_ref":"NCT06549946","source_url":"https://clinicaltrials.gov/study/NCT06549946","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b49bdc58-f721-41ac-908b-1a631e0c2e60"},{"id":"146364ea-9e80-41a1-859b-c948471845c0","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Acerta Pharma BV","ticker":null,"asset":"Acalabrutinib","indication":"Chronic Lymphocytic Leukemia","summary":"As of 27 December 2024, Acerta Pharma BV estimated primary completion of a Phase 3 trial in Chronic Lymphocytic Leukemia, on 31 January 2027.","as_of":"2024-12-27","source":"clinicaltrials","source_ref":"NCT03836261","source_url":"https://clinicaltrials.gov/study/NCT03836261","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-146364ea-9e80-41a1-859b-c948471845c0"},{"id":"8431e67d-4b09-433a-99da-5629e35aed97","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Actelion","ticker":null,"asset":"Macitentan","indication":"Hypertension, Pulmonary","summary":"As of 31 July 2026, Actelion estimated primary completion of a Phase 3 trial in Hypertension, Pulmonary, on 31 January 2027.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT05179876","source_url":"https://clinicaltrials.gov/study/NCT05179876","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8431e67d-4b09-433a-99da-5629e35aed97"},{"id":"876e9b81-d617-4355-815e-6c6a998e1c38","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Creative Medical Technology Holdings Inc","ticker":null,"asset":"CELZ-201 Administration","indication":"Type 1 Diabetes","summary":"As of 19 February 2026, Creative Medical Technology Holdings estimated primary completion of a Phase 2 trial in Type 1 Diabetes, on 31 January 2027.","as_of":"2026-02-19","source":"clinicaltrials","source_ref":"NCT05626712","source_url":"https://clinicaltrials.gov/study/NCT05626712","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-876e9b81-d617-4355-815e-6c6a998e1c38"},{"id":"38fa05fe-d44f-4632-99dd-309247d1e3e9","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Daiichi Sankyo Co., Ltd.","ticker":null,"asset":"DS-5141b","indication":"Duchenne Muscular Dystrophy","summary":"As of 19 September 2025, Daiichi Sankyo Co. estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 31 January 2027.","as_of":"2025-09-19","source":"clinicaltrials","source_ref":"NCT04433234","source_url":"https://clinicaltrials.gov/study/NCT04433234","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-38fa05fe-d44f-4632-99dd-309247d1e3e9"},{"id":"2cd353b1-3dc5-4890-86ff-242ef32b12d1","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"EXO Biologics S.A.","ticker":null,"asset":"Endotracheopulmonary Instillation, Suspension","indication":"Bronchopulmonary Dysplasia","summary":"As of 19 September 2024, EXO Biologics estimated primary completion of a Phase 2 trial in Bronchopulmonary Dysplasia, on 31 January 2027.","as_of":"2024-09-19","source":"clinicaltrials","source_ref":"NCT06279741","source_url":"https://clinicaltrials.gov/study/NCT06279741","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-2cd353b1-3dc5-4890-86ff-242ef32b12d1"},{"id":"0195aa8d-8354-4959-853f-94e81fccfd39","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Grit Biotechnology","ticker":null,"asset":"GT101 injection","indication":"Adult","summary":"As of 15 April 2026, Grit Biotechnology estimated primary completion of a Phase 2 trial in adult, on 31 January 2027.","as_of":"2026-04-15","source":"clinicaltrials","source_ref":"NCT06241781","source_url":"https://clinicaltrials.gov/study/NCT06241781","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0195aa8d-8354-4959-853f-94e81fccfd39"},{"id":"9a8fa614-3957-44c2-8091-50cf0e0ec84c","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Obinutuzumab","indication":"B-Cell Non-Hodgkins Lymphoma","summary":"As of 20 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in B-Cell Non-Hodgkins Lymphoma, on 31 January 2027.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT06806033","source_url":"https://clinicaltrials.gov/study/NCT06806033","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9a8fa614-3957-44c2-8091-50cf0e0ec84c"},{"id":"317090d7-91d3-4c92-82ab-c501924bd755","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Janssen Research & Development, LLC","ticker":null,"asset":"Cetrelimab","indication":"Carcinoma, Non-Small-Cell Lung","summary":"As of 6 July 2026, Janssen Research & Development estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung, on 31 January 2027.","as_of":"2026-07-06","source":"clinicaltrials","source_ref":"NCT05908734","source_url":"https://clinicaltrials.gov/study/NCT05908734","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-317090d7-91d3-4c92-82ab-c501924bd755"},{"id":"9d339f10-30f8-4c90-b8dc-c3a023fc8d7e","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Merck Sharp & Dohme LLC","ticker":null,"asset":"Pembrolizumab","indication":"Urinary Bladder Neoplasms","summary":"As of 1 May 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Urinary Bladder Neoplasms, on 31 January 2027.","as_of":"2026-05-01","source":"clinicaltrials","source_ref":"NCT04241185","source_url":"https://clinicaltrials.gov/study/NCT04241185","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9d339f10-30f8-4c90-b8dc-c3a023fc8d7e"},{"id":"edf49938-596e-4300-96a2-fad510454b0e","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Miltenyi Biomedicine GmbH","ticker":null,"asset":"MB-CART2019.1","indication":"DLBCL - Diffuse Large B Cell Lymphoma","summary":"As of 8 January 2026, Miltenyi Biomedicine estimated primary completion of a Phase 2 trial in DLBCL - Diffuse Large B Cell Lymphoma, on 31 January 2027.","as_of":"2026-01-08","source":"clinicaltrials","source_ref":"NCT07288879","source_url":"https://clinicaltrials.gov/study/NCT07288879","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-edf49938-596e-4300-96a2-fad510454b0e"},{"id":"23d70801-52ee-4152-ab1b-4eff8a407325","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"NeuroBiogen Co., Ltd","ticker":null,"asset":"KDS2010","indication":"Overweight","summary":"As of 24 June 2026, NeuroBiogen Co. estimated primary completion of a Phase 2 trial in overweight, on 31 January 2027.","as_of":"2026-06-24","source":"clinicaltrials","source_ref":"NCT07009171","source_url":"https://clinicaltrials.gov/study/NCT07009171","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-23d70801-52ee-4152-ab1b-4eff8a407325"},{"id":"bbfe4cca-4195-491d-9bb6-7213206d1f8c","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Ono Pharmaceutical Co., Ltd.","ticker":null,"asset":"Cenobamate","indication":"Epilepsies, Partial","summary":"As of 3 June 2025, Ono Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Epilepsies, Partial, on 31 January 2027.","as_of":"2025-06-03","source":"clinicaltrials","source_ref":"NCT06590896","source_url":"https://clinicaltrials.gov/study/NCT06590896","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bbfe4cca-4195-491d-9bb6-7213206d1f8c"},{"id":"6d75406c-372c-41e7-aaa6-f3bae0750098","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Ono Pharmaceutical Co., Ltd.","ticker":null,"asset":"Cenobamate","indication":"Epilepsy, Generalized","summary":"As of 17 June 2025, Ono Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Epilepsy, Generalized, on 31 January 2027.","as_of":"2025-06-17","source":"clinicaltrials","source_ref":"NCT06579573","source_url":"https://clinicaltrials.gov/study/NCT06579573","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6d75406c-372c-41e7-aaa6-f3bae0750098"},{"id":"93f31f93-d66c-41e4-a926-ca3da1c6f98e","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Quoin Pharmaceuticals","ticker":null,"asset":"QRX003","indication":"Netherton Syndrome","summary":"As of 21 April 2026, Quoin Pharmaceuticals estimated primary completion of a Phase 3 trial in Netherton Syndrome, on 31 January 2027.","as_of":"2026-04-21","source":"clinicaltrials","source_ref":"NCT07538583","source_url":"https://clinicaltrials.gov/study/NCT07538583","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-93f31f93-d66c-41e4-a926-ca3da1c6f98e"},{"id":"e2440e5b-a902-48a3-be96-15e767d9b5ac","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Scancell Ltd","ticker":null,"asset":"SCIB1 or iSCIB1+ DNA vaccine","indication":"Malignant Melanoma","summary":"As of 19 December 2025, Scancell estimated primary completion of a Phase 2 trial in Malignant Melanoma, on 31 January 2027.","as_of":"2025-12-19","source":"clinicaltrials","source_ref":"NCT04079166","source_url":"https://clinicaltrials.gov/study/NCT04079166","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-e2440e5b-a902-48a3-be96-15e767d9b5ac"},{"id":"bec53899-3ce9-4009-b367-d2fcd3a801d2","lane":"clinical","event_type":"primary-completion","date":"2027-01-31","date_precision":"day","confidence":"estimated","company":"Tiohundra AB","ticker":null,"asset":"Vasopressin; Methylprednisolone; Hydrocortisone","indication":"Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline...","summary":"As of 20 January 2022, Tiohundra estimated primary completion of a Phase 3 trial in Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline, on 31 January 2027.","as_of":"2022-01-20","source":"clinicaltrials","source_ref":"NCT05139849","source_url":"https://clinicaltrials.gov/study/NCT05139849","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bec53899-3ce9-4009-b367-d2fcd3a801d2"},{"id":"9bde3726-3de5-4d8a-b690-963980b1fdcd","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"60 Degrees Pharmaceuticals LLC","ticker":null,"asset":"Tafenoquine 100mg","indication":"Chronic Babesiosis","summary":"As of 21 November 2025, 60 Degrees Pharmaceuticals estimated primary completion of a Phase 2 trial in Chronic Babesiosis, in February 2027.","as_of":"2025-11-21","source":"clinicaltrials","source_ref":"NCT06656351","source_url":"https://clinicaltrials.gov/study/NCT06656351","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-9bde3726-3de5-4d8a-b690-963980b1fdcd"},{"id":"1f70a6d7-a774-436d-bb65-130fcbc7cd54","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"day","confidence":"estimated","company":"AB Biotics, SA","ticker":null,"asset":"Lactiplantibacillus plantarum Probiotic Mixture","indication":"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","summary":"As of 30 April 2026, AB Biotics, SA estimated primary completion of a Phase 2 trial in MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, on 1 February 2027.","as_of":"2026-04-30","source":"clinicaltrials","source_ref":"NCT07193927","source_url":"https://clinicaltrials.gov/study/NCT07193927","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1f70a6d7-a774-436d-bb65-130fcbc7cd54"},{"id":"df7e4730-e48f-4062-8ceb-3ce32226b2ea","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"AbCellera Biologics Inc.","ticker":null,"asset":"ABCL635","indication":"Vasomotor Symptoms Associated With Menopause","summary":"As of 15 June 2026, AbCellera Biologics estimated primary completion of a Phase 2 trial in Vasomotor Symptoms Associated With Menopause, in February 2027.","as_of":"2026-06-15","source":"clinicaltrials","source_ref":"NCT07118891","source_url":"https://clinicaltrials.gov/study/NCT07118891","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-df7e4730-e48f-4062-8ceb-3ce32226b2ea"},{"id":"339df390-1686-47a8-bc1c-57a5e47db3d3","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"Lutikizumab","indication":"Rheumatoid Arthritis","summary":"As of 10 July 2026, AbbVie estimated primary completion of a Phase 2 trial in Rheumatoid Arthritis, in February 2027.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT06972446","source_url":"https://clinicaltrials.gov/study/NCT06972446","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-339df390-1686-47a8-bc1c-57a5e47db3d3"},{"id":"dd97b12a-cb80-4f5d-9093-be981c3ba0b4","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"Lutikizumab","indication":"Hidradenitis Suppurativa","summary":"As of 24 January 2025, AbbVie estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa, in February 2027.","as_of":"2025-01-24","source":"clinicaltrials","source_ref":"NCT06524635","source_url":"https://clinicaltrials.gov/study/NCT06524635","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dd97b12a-cb80-4f5d-9093-be981c3ba0b4"},{"id":"c47f70cf-8469-4049-b3e7-16b6d6e71d01","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"AbbVie","ticker":null,"asset":"Azacitidine","indication":"Acute Myeloid Leukemia","summary":"As of 14 August 2025, AbbVie estimated primary completion of a Phase 2 trial in Acute Myeloid Leukemia, in February 2027.","as_of":"2025-08-14","source":"clinicaltrials","source_ref":"NCT04086264","source_url":"https://clinicaltrials.gov/study/NCT04086264","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c47f70cf-8469-4049-b3e7-16b6d6e71d01"},{"id":"d194e05e-0692-4912-bb38-4ac113350375","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"day","confidence":"estimated","company":"Amplia Therapeutics Limited","ticker":null,"asset":"AMP945 ascending doses","indication":"Pancreatic Cancer","summary":"As of 10 July 2026, Amplia Therapeutics estimated primary completion of a Phase 2 trial in Pancreatic Cancer, on 1 February 2027.","as_of":"2026-07-10","source":"clinicaltrials","source_ref":"NCT05355298","source_url":"https://clinicaltrials.gov/study/NCT05355298","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d194e05e-0692-4912-bb38-4ac113350375"},{"id":"ef41aa66-a5f2-4ffd-97fc-d5beff87928e","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Antag Therapeutics","ticker":null,"asset":"AT673 low dose","indication":"Adults With Overweight/Obesity and Type 2 Diabetes","summary":"As of 24 July 2026, Antag Therapeutics estimated primary completion of a Phase 2 trial in Adults With Overweight/Obesity and Type 2 Diabetes, in February 2027.","as_of":"2026-07-24","source":"clinicaltrials","source_ref":"NCT07724340","source_url":"https://clinicaltrials.gov/study/NCT07724340","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ef41aa66-a5f2-4ffd-97fc-d5beff87928e"},{"id":"243f0985-592c-4b55-ac0f-bbffdcc63448","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Arrowhead Pharmaceuticals","ticker":null,"asset":"ARO-ALK7","indication":"Obesity","summary":"As of 8 July 2026, Arrowhead Pharmaceuticals estimated primary completion of a Phase 2 trial in obesity, in February 2027.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT06937203","source_url":"https://clinicaltrials.gov/study/NCT06937203","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-243f0985-592c-4b55-ac0f-bbffdcc63448"},{"id":"ae6fd4ba-5360-4f7f-8379-84975012f69f","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Bavarian Nordic","ticker":null,"asset":"MVA-BN-WEV","indication":"Encephalitis","summary":"As of 1 October 2025, Bavarian Nordic estimated primary completion of a Phase 2 trial in encephalitis, in February 2027.","as_of":"2025-10-01","source":"clinicaltrials","source_ref":"NCT06899802","source_url":"https://clinicaltrials.gov/study/NCT06899802","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ae6fd4ba-5360-4f7f-8379-84975012f69f"},{"id":"5f7559b9-b105-4cdf-901c-42fb85efa4ae","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Bond Biosciences","ticker":null,"asset":"BBI-001","indication":"Hereditary Hemochromatosis","summary":"As of 13 May 2026, Bond Biosciences estimated primary completion of a Phase 2 trial in Hereditary Hemochromatosis, in February 2027.","as_of":"2026-05-13","source":"clinicaltrials","source_ref":"NCT07371793","source_url":"https://clinicaltrials.gov/study/NCT07371793","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5f7559b9-b105-4cdf-901c-42fb85efa4ae"},{"id":"86d7a0fc-ee7a-41f8-8d9c-7b4659b33530","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Celltrion","ticker":null,"asset":"CT-P53","indication":"Relapsing-remitting Multiple Sclerosis","summary":"As of 22 May 2024, Celltrion estimated primary completion of a Phase 3 trial in Relapsing-remitting Multiple Sclerosis, in February 2027.","as_of":"2024-05-22","source":"clinicaltrials","source_ref":"NCT05906992","source_url":"https://clinicaltrials.gov/study/NCT05906992","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-86d7a0fc-ee7a-41f8-8d9c-7b4659b33530"},{"id":"93ff931e-3ca4-4c3e-9d62-2230e3e15ef0","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Celltrion","ticker":null,"asset":"CT-P51","indication":"Non Squamous Non Small Cell Lung Cancer","summary":"As of 8 July 2026, Celltrion estimated primary completion of a Phase 3 trial in Non Squamous Non Small Cell Lung Cancer, in February 2027.","as_of":"2026-07-08","source":"clinicaltrials","source_ref":"NCT06939595","source_url":"https://clinicaltrials.gov/study/NCT06939595","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-93ff931e-3ca4-4c3e-9d62-2230e3e15ef0"},{"id":"f7a9707c-f13a-410a-a51b-c4a7fd6ef40a","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Day One Biopharmaceuticals, Inc.","ticker":null,"asset":"Emi-Le","indication":"Triple Negative Breast Cancer","summary":"As of 29 June 2026, Day One Biopharmaceuticals estimated primary completion of a Phase 2 trial in Triple Negative Breast Cancer, in February 2027.","as_of":"2026-06-29","source":"clinicaltrials","source_ref":"NCT05377996","source_url":"https://clinicaltrials.gov/study/NCT05377996","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-f7a9707c-f13a-410a-a51b-c4a7fd6ef40a"},{"id":"b10e0950-565b-462f-8b3a-0aca59f53a08","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Disc Medicine, Inc","ticker":null,"asset":"DISC-3405","indication":"Polycythemia Vera (PV)","summary":"As of 31 July 2026, Disc Medicine estimated primary completion of a Phase 2 trial in Polycythemia Vera (PV), in February 2027.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT06985147","source_url":"https://clinicaltrials.gov/study/NCT06985147","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b10e0950-565b-462f-8b3a-0aca59f53a08"},{"id":"84d82b43-a0a0-476f-be8b-ba6fe385fe71","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"DualityBio Inc.","ticker":null,"asset":"DB-1419","indication":"Solid Tumor, Adult","summary":"As of 5 June 2026, DualityBio estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, in February 2027.","as_of":"2026-06-05","source":"clinicaltrials","source_ref":"NCT06554795","source_url":"https://clinicaltrials.gov/study/NCT06554795","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-84d82b43-a0a0-476f-be8b-ba6fe385fe71"},{"id":"d2ad8115-a33c-4a19-9e82-d73d9f2bdbe2","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"Orforglipron","indication":"Obesity","summary":"As of 20 July 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in obesity, in February 2027.","as_of":"2026-07-20","source":"clinicaltrials","source_ref":"NCT06672549","source_url":"https://clinicaltrials.gov/study/NCT06672549","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d2ad8115-a33c-4a19-9e82-d73d9f2bdbe2"},{"id":"dff225cf-2834-4669-b169-7ab653958940","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"Abemaciclib","indication":"Glioma","summary":"As of 17 July 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in glioma, in February 2027.","as_of":"2026-07-17","source":"clinicaltrials","source_ref":"NCT06413706","source_url":"https://clinicaltrials.gov/study/NCT06413706","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dff225cf-2834-4669-b169-7ab653958940"},{"id":"457ea95c-d16f-460d-b169-e109e3b6bbe0","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Eli Lilly and Company","ticker":null,"asset":"Brenipatide","indication":"Smoking","summary":"As of 6 August 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in smoking, in February 2027.","as_of":"2026-08-06","source":"clinicaltrials","source_ref":"NCT07223840","source_url":"https://clinicaltrials.gov/study/NCT07223840","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-457ea95c-d16f-460d-b169-e109e3b6bbe0"},{"id":"bc4e30b5-25d9-494c-ac96-dd4605f49232","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Enlivex Therapeutics Ltd.","ticker":null,"asset":"Allocetra","indication":"Primary Knee Osteoarthritis","summary":"As of 17 June 2026, Enlivex Therapeutics estimated primary completion of a Phase 2 trial in Primary Knee Osteoarthritis, in February 2027.","as_of":"2026-06-17","source":"clinicaltrials","source_ref":"NCT07580716","source_url":"https://clinicaltrials.gov/study/NCT07580716","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-bc4e30b5-25d9-494c-ac96-dd4605f49232"},{"id":"61be79db-bb47-4673-8d88-7457aeb7239b","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Fujian Shengdi Pharmaceutical Co., Ltd.","ticker":null,"asset":"HRS9531","indication":"Type 2 Diabetes","summary":"As of 2 January 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Type 2 Diabetes, in February 2027.","as_of":"2026-01-02","source":"clinicaltrials","source_ref":"NCT07060456","source_url":"https://clinicaltrials.gov/study/NCT07060456","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-61be79db-bb47-4673-8d88-7457aeb7239b"},{"id":"1bc4f8c8-17c1-457f-b1b5-1fc710860de2","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"GI Innovation, Inc.","ticker":null,"asset":"GI-108","indication":"Advanced Solid Tumor","summary":"As of 15 September 2025, GI Innovation estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in February 2027.","as_of":"2025-09-15","source":"clinicaltrials","source_ref":"NCT07172802","source_url":"https://clinicaltrials.gov/study/NCT07172802","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1bc4f8c8-17c1-457f-b1b5-1fc710860de2"},{"id":"6a932414-e103-4d34-bb90-b1103fde7909","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Genelux Corporation","ticker":null,"asset":"Olvimulogene nanivacirepvec","indication":"Advanced Non-squamous Non-small-cell Lung Cancer","summary":"As of 4 June 2026, Genelux estimated primary completion of a Phase 2 trial in Advanced Non-squamous Non-small-cell Lung Cancer, in February 2027.","as_of":"2026-06-04","source":"clinicaltrials","source_ref":"NCT06463665","source_url":"https://clinicaltrials.gov/study/NCT06463665","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6a932414-e103-4d34-bb90-b1103fde7909"},{"id":"60d1a1ce-7e18-435a-89bd-5f4f98e198fa","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Genmab","ticker":null,"asset":"Rina-S","indication":"Platinum-resistant Ovarian Cancer","summary":"As of 7 July 2026, Genm estimated primary completion of a Phase 3 trial in Platinum-resistant Ovarian Cancer, in February 2027.","as_of":"2026-07-07","source":"clinicaltrials","source_ref":"NCT06619236","source_url":"https://clinicaltrials.gov/study/NCT06619236","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-60d1a1ce-7e18-435a-89bd-5f4f98e198fa"},{"id":"a19cde8d-6415-4132-aada-fce59bb8b872","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Gilead Sciences","ticker":null,"asset":"Sacituzumab Govitecan-hziy","indication":"Triple Negative Breast Cancer","summary":"As of 18 September 2025, Gilead Sciences estimated primary completion of a Phase 3 trial in Triple Negative Breast Cancer, in February 2027.","as_of":"2025-09-18","source":"clinicaltrials","source_ref":"NCT05382286","source_url":"https://clinicaltrials.gov/study/NCT05382286","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-a19cde8d-6415-4132-aada-fce59bb8b872"},{"id":"8fc9761d-3476-4d6c-97d5-a24440b40a42","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"day","confidence":"estimated","company":"Gracell Biotechnologies (Shanghai) Co., Ltd.","ticker":null,"asset":"GC012F Injection","indication":"Refractory Systemic Lupus Erythematosus","summary":"As of 9 June 2026, Gracell Biotechnologies (Shanghai) Co. estimated primary completion of a Phase 2 trial in Refractory Systemic Lupus Erythematosus, on 1 February 2027.","as_of":"2026-06-09","source":"clinicaltrials","source_ref":"NCT06530849","source_url":"https://clinicaltrials.gov/study/NCT06530849","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8fc9761d-3476-4d6c-97d5-a24440b40a42"},{"id":"6a5810e7-7f2f-47d4-93fe-40a4aca0e9d4","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Hangzhou Gensciences Biopharmaceutical Co., Ltd.","ticker":null,"asset":"FRSW107","indication":"Severe Hemophilia A","summary":"As of 23 June 2026, Hangzhou Gensciences Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Severe Hemophilia A, in February 2027.","as_of":"2026-06-23","source":"clinicaltrials","source_ref":"NCT07663903","source_url":"https://clinicaltrials.gov/study/NCT07663903","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6a5810e7-7f2f-47d4-93fe-40a4aca0e9d4"},{"id":"152041ff-0bfd-42b2-a309-97dbde3a74e8","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Ionis Pharmaceuticals, Inc.","ticker":null,"asset":"ION717","indication":"Prion Disease","summary":"As of 5 August 2026, Ionis Pharmaceuticals estimated primary completion of a Phase 2 trial in Prion Disease, in February 2027.","as_of":"2026-08-05","source":"clinicaltrials","source_ref":"NCT06153966","source_url":"https://clinicaltrials.gov/study/NCT06153966","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-152041ff-0bfd-42b2-a309-97dbde3a74e8"},{"id":"5d64aa3f-9132-4af3-94a0-ae651522f788","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Kallyope Inc.","ticker":null,"asset":"Elismetrep","indication":"Migraine","summary":"As of 5 August 2026, Kallyope estimated primary completion of a Phase 3 trial in migraine, in February 2027.","as_of":"2026-08-05","source":"clinicaltrials","source_ref":"NCT07645924","source_url":"https://clinicaltrials.gov/study/NCT07645924","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-5d64aa3f-9132-4af3-94a0-ae651522f788"},{"id":"646bb6ea-5124-4842-82e4-07363740994e","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Kodiak Sciences Inc","ticker":null,"asset":"KSI-101","indication":"Macular Edema Secondary to Inflammation","summary":"As of 18 May 2026, Kodiak Sciences estimated primary completion of a Phase 3 trial in Macular Edema Secondary to Inflammation, in February 2027.","as_of":"2026-05-18","source":"clinicaltrials","source_ref":"NCT06996080","source_url":"https://clinicaltrials.gov/study/NCT06996080","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-646bb6ea-5124-4842-82e4-07363740994e"},{"id":"dd86a01c-dd4c-41eb-9d8f-e6dcbf627d06","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Krystal Biotech, Inc.","ticker":null,"asset":"KB707","indication":"Lung Cancer, Non-small Cell","summary":"As of 24 October 2025, Krystal Biotech estimated primary completion of a Phase 2 trial in Lung Cancer, Non-small Cell, in February 2027.","as_of":"2025-10-24","source":"clinicaltrials","source_ref":"NCT06228326","source_url":"https://clinicaltrials.gov/study/NCT06228326","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-dd86a01c-dd4c-41eb-9d8f-e6dcbf627d06"},{"id":"8b41bb76-3e4b-49e9-b240-fe6d282b46a9","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"MediLink Therapeutics (Suzhou) Co., Ltd.","ticker":null,"asset":"YL201 for Injection","indication":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","summary":"As of 27 August 2025, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Metastatic Castration-resistant Prostate Cancer (mCRPC), in February 2027.","as_of":"2025-08-27","source":"clinicaltrials","source_ref":"NCT06241846","source_url":"https://clinicaltrials.gov/study/NCT06241846","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-8b41bb76-3e4b-49e9-b240-fe6d282b46a9"},{"id":"187bc054-5348-4045-957a-ef40d5abf063","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Neurocrine Biosciences","ticker":null,"asset":"NBI-1065890","indication":"Tardive Dyskinesia","summary":"As of 23 June 2026, Neurocrine Biosciences estimated primary completion of a Phase 2 trial in Tardive Dyskinesia, in February 2027.","as_of":"2026-06-23","source":"clinicaltrials","source_ref":"NCT07365462","source_url":"https://clinicaltrials.gov/study/NCT07365462","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-187bc054-5348-4045-957a-ef40d5abf063"},{"id":"71ba417d-bc02-4b8b-bee0-7fd7fe241e6a","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"LEE011","indication":"Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump...","summary":"As of 16 April 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial on 1 February 2027.","as_of":"2026-04-16","source":"clinicaltrials","source_ref":"NCT02934568","source_url":"https://clinicaltrials.gov/study/NCT02934568","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-71ba417d-bc02-4b8b-bee0-7fd7fe241e6a"},{"id":"95b5c93d-5e3f-4e89-8926-b2ce5f32fe6d","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.","ticker":null,"asset":"0.4% ZOC2017217","indication":"Age Related Cataracts","summary":"As of 11 August 2026, Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co. estimated primary completion of a Phase 2 trial in Age Related Cataracts, in February 2027.","as_of":"2026-08-11","source":"clinicaltrials","source_ref":"NCT07395986","source_url":"https://clinicaltrials.gov/study/NCT07395986","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-95b5c93d-5e3f-4e89-8926-b2ce5f32fe6d"},{"id":"1eea268f-0cd8-4caa-87b9-71a153e95dfd","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"RDC Clinical Pty Ltd","ticker":null,"asset":"Lavender Oil","indication":"Sleep Disorder (Disorder)","summary":"As of 23 April 2026, RDC Clinical Pty estimated primary completion of a Phase 2 trial in Sleep Disorder (Disorder), in February 2027.","as_of":"2026-04-23","source":"clinicaltrials","source_ref":"NCT07315516","source_url":"https://clinicaltrials.gov/study/NCT07315516","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-1eea268f-0cd8-4caa-87b9-71a153e95dfd"},{"id":"d01a00e1-5696-4a50-a988-41ed018a1727","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"RIGImmune Inc.","ticker":null,"asset":"RIG-101","indication":"Healthy Adult Participants","summary":"As of 23 March 2026, RIGImmune estimated primary completion of a Phase 2 trial in Healthy Adult Participants, in February 2027.","as_of":"2026-03-23","source":"clinicaltrials","source_ref":"NCT07488897","source_url":"https://clinicaltrials.gov/study/NCT07488897","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d01a00e1-5696-4a50-a988-41ed018a1727"},{"id":"ef6d2f7c-cf9a-49e6-95d1-11dbfe28252f","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Reunion Neuroscience Inc","ticker":null,"asset":"RE104 for Injection","indication":"Generalized Anxiety Disorder","summary":"As of 26 June 2026, Reunion Neuroscience estimated primary completion of a Phase 2 trial in Generalized Anxiety Disorder, in February 2027.","as_of":"2026-06-26","source":"clinicaltrials","source_ref":"NCT07489651","source_url":"https://clinicaltrials.gov/study/NCT07489651","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ef6d2f7c-cf9a-49e6-95d1-11dbfe28252f"},{"id":"84ab574d-e2b3-48ee-8c26-f69b5ecd95dd","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Rivus Pharmaceuticals, Inc.","ticker":null,"asset":"HU6","indication":"MASH - Metabolic Dysfunction-Associated Steatohepatitis","summary":"As of 18 May 2026, Rivus Pharmaceuticals estimated primary completion of a Phase 2 trial in MASH - Metabolic Dysfunction-Associated Steatohepatitis, in February 2027.","as_of":"2026-05-18","source":"clinicaltrials","source_ref":"NCT07491458","source_url":"https://clinicaltrials.gov/study/NCT07491458","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-84ab574d-e2b3-48ee-8c26-f69b5ecd95dd"},{"id":"44b51d97-0cb1-4c05-be81-8b313a5b6f8e","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"SK Life Science, Inc.","ticker":null,"asset":"Carisbamate","indication":"Seizures","summary":"As of 24 July 2025, SK Life Science estimated primary completion of a Phase 3 trial in seizures, in February 2027.","as_of":"2025-07-24","source":"clinicaltrials","source_ref":"NCT05219617","source_url":"https://clinicaltrials.gov/study/NCT05219617","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-44b51d97-0cb1-4c05-be81-8b313a5b6f8e"},{"id":"22218c72-dae8-4e26-94b9-6301003707b6","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Sanaria Inc.","ticker":null,"asset":"Genetically attenuated PfSPZ Vaccine","indication":"Malaria (Plasmodium Falciparum)","summary":"As of 1 June 2026, Sanaria estimated primary completion of a Phase 2 trial in Malaria (Plasmodium Falciparum), in February 2027.","as_of":"2026-06-01","source":"clinicaltrials","source_ref":"NCT07385287","source_url":"https://clinicaltrials.gov/study/NCT07385287","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-22218c72-dae8-4e26-94b9-6301003707b6"},{"id":"b33acdce-4855-40a8-8887-decaa344a012","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Sovargen","ticker":null,"asset":"SVG103","indication":"Focal Cortical Dysplasia","summary":"As of 10 August 2026, Sovargen estimated primary completion of a Phase 2 trial in Focal Cortical Dysplasia, in February 2027.","as_of":"2026-08-10","source":"clinicaltrials","source_ref":"NCT07287202","source_url":"https://clinicaltrials.gov/study/NCT07287202","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b33acdce-4855-40a8-8887-decaa344a012"},{"id":"b4189e09-2dc3-402d-ad3c-976eed9129c1","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"SparingVision","ticker":null,"asset":"SPVN06","indication":"Retinitis Pigmentosa","summary":"As of 15 May 2026, SparingVision estimated primary completion of a Phase 2 trial in Retinitis Pigmentosa, in February 2027.","as_of":"2026-05-15","source":"clinicaltrials","source_ref":"NCT05748873","source_url":"https://clinicaltrials.gov/study/NCT05748873","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b4189e09-2dc3-402d-ad3c-976eed9129c1"},{"id":"6634bb40-8f3a-4bc3-8980-9ef7cc97b859","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","ticker":null,"asset":"610","indication":"Asthma","summary":"As of 7 January 2026, Sunshine Guojian Pharmaceutical (Shanghai) Co. estimated primary completion of a Phase 3 trial in asthma, in February 2027.","as_of":"2026-01-07","source":"clinicaltrials","source_ref":"NCT06323213","source_url":"https://clinicaltrials.gov/study/NCT06323213","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-6634bb40-8f3a-4bc3-8980-9ef7cc97b859"},{"id":"277972bd-e6f3-4d3d-8db4-13edd9b8d761","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","ticker":null,"asset":"610","indication":"Asthma","summary":"As of 29 January 2026, Sunshine Guojian Pharmaceutical (Shanghai) Co. estimated primary completion of a Phase 2 trial in asthma, in February 2027.","as_of":"2026-01-29","source":"clinicaltrials","source_ref":"NCT06680947","source_url":"https://clinicaltrials.gov/study/NCT06680947","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-277972bd-e6f3-4d3d-8db4-13edd9b8d761"},{"id":"74ba6fae-5dc1-46f6-b8a5-7425c760f9e3","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Suzhou HepaThera Biotech Co., Ltd.","ticker":null,"asset":"HT-101","indication":"Chronic Hepatitis B","summary":"As of 24 November 2025, Suzhou HepaThera Biotech Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, in February 2027.","as_of":"2025-11-24","source":"clinicaltrials","source_ref":"NCT07245953","source_url":"https://clinicaltrials.gov/study/NCT07245953","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-74ba6fae-5dc1-46f6-b8a5-7425c760f9e3"},{"id":"c07b8aec-3471-4327-a128-efd2773d7bc4","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"TearSolutions, Inc.","ticker":null,"asset":"Lacripep","indication":"Neurotrophic Keratitis","summary":"As of 11 May 2026, TearSolutions estimated primary completion of a Phase 2 trial in Neurotrophic Keratitis, in February 2027.","as_of":"2026-05-11","source":"clinicaltrials","source_ref":"NCT07568730","source_url":"https://clinicaltrials.gov/study/NCT07568730","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c07b8aec-3471-4327-a128-efd2773d7bc4"},{"id":"b970e2b4-0425-48c5-a684-fa94f533bdd9","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Theravia","ticker":null,"asset":"Hydroxycarbamid","indication":"Sickle Cell Disease","summary":"As of 17 September 2025, Theravia estimated primary completion of a Phase 2 trial in Sickle Cell Disease, in February 2027.","as_of":"2025-09-17","source":"clinicaltrials","source_ref":"NCT06578507","source_url":"https://clinicaltrials.gov/study/NCT06578507","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b970e2b4-0425-48c5-a684-fa94f533bdd9"},{"id":"3ced22ee-e6d1-42c7-b24f-fc7d77681d98","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"Trust Bio-sonics, Inc.","ticker":null,"asset":"NH002 (Perflutren Lipid Microspheres) Injectable Suspension","indication":"Cardiac Diseases","summary":"As of 9 July 2026, Trust Bio-sonics estimated primary completion of a Phase 3 trial in Cardiac Diseases, in February 2027.","as_of":"2026-07-09","source":"clinicaltrials","source_ref":"NCT06815627","source_url":"https://clinicaltrials.gov/study/NCT06815627","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3ced22ee-e6d1-42c7-b24f-fc7d77681d98"},{"id":"50b52e06-fdb1-413d-85b1-bc264e93898d","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"day","confidence":"estimated","company":"Tvardi Therapeutics, Incorporated","ticker":null,"asset":"TTI-101","indication":"Hepatocellular Carcinoma","summary":"As of 27 April 2026, Tvardi Therapeutics, Incorporated estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 1 February 2027.","as_of":"2026-04-27","source":"clinicaltrials","source_ref":"NCT05440708","source_url":"https://clinicaltrials.gov/study/NCT05440708","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-50b52e06-fdb1-413d-85b1-bc264e93898d"},{"id":"ecdba3f7-693a-49cc-bf78-34a99e0bed7b","lane":"clinical","event_type":"primary-completion","date":"2027-02-01","date_precision":"month","confidence":"estimated","company":"argenx","ticker":null,"asset":"Efgartigimod PH20 SC","indication":"Systemic Sclerosis (SSc)","summary":"As of 21 July 2026, argenx estimated primary completion of a Phase 2 trial in Systemic Sclerosis (SSc), in February 2027.","as_of":"2026-07-21","source":"clinicaltrials","source_ref":"NCT06655155","source_url":"https://clinicaltrials.gov/study/NCT06655155","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-ecdba3f7-693a-49cc-bf78-34a99e0bed7b"},{"id":"0c598125-b3a8-4cfa-a416-7ffd4c7ef559","lane":"clinical","event_type":"primary-completion","date":"2027-02-02","date_precision":"day","confidence":"estimated","company":"Cellvax Therapeutics Inc","ticker":null,"asset":"FK-PC101","indication":"Prostate Cancer (Adenocarcinoma)","summary":"As of 21 October 2024, Cellvax Therapeutics estimated primary completion of a Phase 2 trial in Prostate Cancer (Adenocarcinoma), on 2 February 2027.","as_of":"2024-10-21","source":"clinicaltrials","source_ref":"NCT06636682","source_url":"https://clinicaltrials.gov/study/NCT06636682","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-0c598125-b3a8-4cfa-a416-7ffd4c7ef559"},{"id":"37581582-0fe4-44b9-ab4f-cf79c9eb052a","lane":"clinical","event_type":"primary-completion","date":"2027-02-02","date_precision":"day","confidence":"estimated","company":"Noema Pharma AG","ticker":null,"asset":"Basimglurant","indication":"Trigeminal Neuralgia","summary":"As of 23 January 2026, Noema Pharma estimated primary completion of a Phase 3 trial in Trigeminal Neuralgia, on 2 February 2027.","as_of":"2026-01-23","source":"clinicaltrials","source_ref":"NCT05217628","source_url":"https://clinicaltrials.gov/study/NCT05217628","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-37581582-0fe4-44b9-ab4f-cf79c9eb052a"},{"id":"3b13ed3c-a5fd-43ff-bce3-78ef3bf2103c","lane":"clinical","event_type":"primary-completion","date":"2027-02-02","date_precision":"day","confidence":"estimated","company":"Novartis Pharmaceuticals","ticker":null,"asset":"LXH254","indication":"Melanoma","summary":"As of 12 March 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in melanoma, on 2 February 2027.","as_of":"2026-03-12","source":"clinicaltrials","source_ref":"NCT04417621","source_url":"https://clinicaltrials.gov/study/NCT04417621","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-3b13ed3c-a5fd-43ff-bce3-78ef3bf2103c"},{"id":"c0576d08-b4cb-4587-81c7-b083e0471575","lane":"clinical","event_type":"primary-completion","date":"2027-02-02","date_precision":"day","confidence":"estimated","company":"Vertex Pharmaceuticals Incorporated","ticker":null,"asset":"VX-670","indication":"Myotonic Dystrophy Type 1 (DM1)","summary":"As of 8 June 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 2 trial in Myotonic Dystrophy Type 1 (DM1), on 2 February 2027.","as_of":"2026-06-08","source":"clinicaltrials","source_ref":"NCT06185764","source_url":"https://clinicaltrials.gov/study/NCT06185764","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-c0576d08-b4cb-4587-81c7-b083e0471575"},{"id":"aee47b5f-f775-4688-8d3f-74adbf1d83b9","lane":"clinical","event_type":"primary-completion","date":"2027-02-03","date_precision":"day","confidence":"estimated","company":"Bayer","ticker":null,"asset":"BAY2927088","indication":"Advanced Solid Tumors","summary":"As of 7 July 2026, Bayer estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 3 February 2027.","as_of":"2026-07-07","source":"clinicaltrials","source_ref":"NCT06760819","source_url":"https://clinicaltrials.gov/study/NCT06760819","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-aee47b5f-f775-4688-8d3f-74adbf1d83b9"},{"id":"34137257-e241-4e26-862e-4030373f0da5","lane":"clinical","event_type":"primary-completion","date":"2027-02-03","date_precision":"day","confidence":"estimated","company":"InventVacc Biologicals Inc.","ticker":null,"asset":"Haemophilus influenzae serotype a vaccine candidate","indication":"Haemophilus Influenzae","summary":"As of 3 August 2026, InventVacc Biologicals estimated primary completion of a Phase 2 trial in Haemophilus Influenzae, on 3 February 2027.","as_of":"2026-08-03","source":"clinicaltrials","source_ref":"NCT07743008","source_url":"https://clinicaltrials.gov/study/NCT07743008","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-34137257-e241-4e26-862e-4030373f0da5"},{"id":"b75077e8-07bf-4607-843b-81c828529251","lane":"clinical","event_type":"primary-completion","date":"2027-02-04","date_precision":"day","confidence":"estimated","company":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","ticker":null,"asset":"HDM1005 dose level 1","indication":"Obesity","summary":"As of 13 April 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 2 trial in obesity, on 4 February 2027.","as_of":"2026-04-13","source":"clinicaltrials","source_ref":"NCT07521631","source_url":"https://clinicaltrials.gov/study/NCT07521631","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b75077e8-07bf-4607-843b-81c828529251"},{"id":"60218990-181a-4ba9-a688-a582a00d04f5","lane":"clinical","event_type":"primary-completion","date":"2027-02-04","date_precision":"day","confidence":"estimated","company":"Hoffmann-La Roche","ticker":null,"asset":"Ranibizumab","indication":"Neovascular Age-related Macular Degeneration (nAMD)","summary":"As of 31 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Neovascular Age-related Macular Degeneration (nAMD), on 4 February 2027.","as_of":"2026-07-31","source":"clinicaltrials","source_ref":"NCT04657289","source_url":"https://clinicaltrials.gov/study/NCT04657289","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-60218990-181a-4ba9-a688-a582a00d04f5"},{"id":"aed67b3e-d9f1-4964-93ed-86daeacb8a2f","lane":"clinical","event_type":"primary-completion","date":"2027-02-04","date_precision":"day","confidence":"estimated","company":"MoonLake Immunotherapeutics AG","ticker":null,"asset":"Sonelokimab","indication":"Arthritis, Psoriatic","summary":"As of 13 July 2026, MoonLake Immunotherapeutics estimated primary completion of a Phase 3 trial in Arthritis, Psoriatic, on 4 February 2027.","as_of":"2026-07-13","source":"clinicaltrials","source_ref":"NCT06641076","source_url":"https://clinicaltrials.gov/study/NCT06641076","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-aed67b3e-d9f1-4964-93ed-86daeacb8a2f"},{"id":"b38c9157-2674-48a2-9a92-a7cd5621cdda","lane":"clinical","event_type":"primary-completion","date":"2027-02-05","date_precision":"day","confidence":"estimated","company":"Bristol-Myers Squibb","ticker":null,"asset":"Nivolumab","indication":"Non-Small Cell Lung Cancer","summary":"As of 14 May 2026, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Non-Small Cell Lung Cancer, on 5 February 2027.","as_of":"2026-05-14","source":"clinicaltrials","source_ref":"NCT06946797","source_url":"https://clinicaltrials.gov/study/NCT06946797","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b38c9157-2674-48a2-9a92-a7cd5621cdda"},{"id":"d75a83ef-35ed-4917-9f44-4c9330a87e88","lane":"clinical","event_type":"primary-completion","date":"2027-02-07","date_precision":"day","confidence":"estimated","company":"Intra-IMMUSG Pte Ltd","ticker":null,"asset":"PRL3-ZUMAB","indication":"Neovascular Age Related Macular Degeneration","summary":"As of 29 April 2026, Intra-IMMUSG Pte estimated primary completion of a Phase 2 trial in Neovascular Age Related Macular Degeneration, on 7 February 2027.","as_of":"2026-04-29","source":"clinicaltrials","source_ref":"NCT07547228","source_url":"https://clinicaltrials.gov/study/NCT07547228","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-d75a83ef-35ed-4917-9f44-4c9330a87e88"},{"id":"b2a1ec5d-3aeb-4ef9-8353-a5f53994e59c","lane":"clinical","event_type":"primary-completion","date":"2027-02-08","date_precision":"day","confidence":"estimated","company":"Abcentra","ticker":null,"asset":"Orticumab","indication":"Acute Coronary Syndromes","summary":"As of 27 January 2026, Abcentra estimated primary completion of a Phase 2 trial in Acute Coronary Syndromes, on 8 February 2027.","as_of":"2026-01-27","source":"clinicaltrials","source_ref":"NCT06927739","source_url":"https://clinicaltrials.gov/study/NCT06927739","previous_date":null,"retracted":false,"url":"https://julienwillard.com/calendar/clinical#e-b2a1ec5d-3aeb-4ef9-8353-a5f53994e59c"}]}